0001200375-24-000027.txt : 20241031 0001200375-24-000027.hdr.sgml : 20241031 20241031161857 ACCESSION NUMBER: 0001200375-24-000027 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241031 DATE AS OF CHANGE: 20241031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CODEXIS, INC. CENTRAL INDEX KEY: 0001200375 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 710872999 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34705 FILM NUMBER: 241415500 BUSINESS ADDRESS: STREET 1: 200 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-421-8100 MAIL ADDRESS: STREET 1: 200 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 FORMER COMPANY: FORMER CONFORMED NAME: CODEXIS INC DATE OF NAME CHANGE: 20021022 10-Q 1 cdxs-20240930.htm 10-Q cdxs-20240930
0001200375false2024Q312/31311http://fasb.org/us-gaap/2024#PrimeRateMemberhttp://fasb.org/us-gaap/2024#PrimeRateMemberxbrli:sharesiso4217:USDiso4217:USDxbrli:sharescdxs:segmentxbrli:purecdxs:tranche00012003752024-01-012024-09-3000012003752024-10-2800012003752024-09-3000012003752023-12-310001200375us-gaap:ProductMember2024-07-012024-09-300001200375us-gaap:ProductMember2023-07-012023-09-300001200375us-gaap:ProductMember2024-01-012024-09-300001200375us-gaap:ProductMember2023-01-012023-09-300001200375cdxs:ResearchandDevelopmentRevenueMember2024-07-012024-09-300001200375cdxs:ResearchandDevelopmentRevenueMember2023-07-012023-09-300001200375cdxs:ResearchandDevelopmentRevenueMember2024-01-012024-09-300001200375cdxs:ResearchandDevelopmentRevenueMember2023-01-012023-09-3000012003752024-07-012024-09-3000012003752023-07-012023-09-3000012003752023-01-012023-09-300001200375us-gaap:CommonStockMember2024-06-300001200375us-gaap:AdditionalPaidInCapitalMember2024-06-300001200375us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001200375us-gaap:RetainedEarningsMember2024-06-3000012003752024-06-300001200375us-gaap:CommonStockMember2024-07-012024-09-300001200375us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001200375us-gaap:RetainedEarningsMember2024-07-012024-09-300001200375us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001200375us-gaap:CommonStockMember2024-09-300001200375us-gaap:AdditionalPaidInCapitalMember2024-09-300001200375us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001200375us-gaap:RetainedEarningsMember2024-09-300001200375us-gaap:CommonStockMember2023-06-300001200375us-gaap:AdditionalPaidInCapitalMember2023-06-300001200375us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001200375us-gaap:RetainedEarningsMember2023-06-3000012003752023-06-300001200375us-gaap:CommonStockMember2023-07-012023-09-300001200375us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001200375us-gaap:RetainedEarningsMember2023-07-012023-09-300001200375us-gaap:CommonStockMember2023-09-300001200375us-gaap:AdditionalPaidInCapitalMember2023-09-300001200375us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001200375us-gaap:RetainedEarningsMember2023-09-3000012003752023-09-300001200375us-gaap:CommonStockMember2023-12-310001200375us-gaap:AdditionalPaidInCapitalMember2023-12-310001200375us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001200375us-gaap:RetainedEarningsMember2023-12-310001200375us-gaap:CommonStockMember2024-01-012024-09-300001200375us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001200375us-gaap:RetainedEarningsMember2024-01-012024-09-300001200375us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001200375us-gaap:CommonStockMember2022-12-310001200375us-gaap:AdditionalPaidInCapitalMember2022-12-310001200375us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001200375us-gaap:RetainedEarningsMember2022-12-3100012003752022-12-310001200375us-gaap:CommonStockMember2023-01-012023-09-300001200375us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001200375us-gaap:RetainedEarningsMember2023-01-012023-09-3000012003752022-01-012022-12-3100012003752023-01-012023-12-310001200375srt:AmericasMember2024-07-012024-09-300001200375srt:AmericasMember2023-07-012023-09-300001200375srt:AmericasMember2024-01-012024-09-300001200375srt:AmericasMember2023-01-012023-09-300001200375us-gaap:EMEAMember2024-07-012024-09-300001200375us-gaap:EMEAMember2023-07-012023-09-300001200375us-gaap:EMEAMember2024-01-012024-09-300001200375us-gaap:EMEAMember2023-01-012023-09-300001200375cdxs:APACMember2024-07-012024-09-300001200375cdxs:APACMember2023-07-012023-09-300001200375cdxs:APACMember2024-01-012024-09-300001200375cdxs:APACMember2023-01-012023-09-300001200375cdxs:ShortTermUnbilledReceivablesMember2024-09-300001200375cdxs:LongTermUnbilledReceivablesMember2024-09-300001200375cdxs:ShortTermUnbilledReceivablesMember2023-12-310001200375cdxs:LongTermUnbilledReceivablesMember2023-12-3100012003752024-10-01us-gaap:ProductMember2024-09-3000012003752025-01-01us-gaap:ProductMember2024-09-3000012003752026-01-01us-gaap:ProductMember2024-09-3000012003752027-01-01us-gaap:ProductMember2024-09-300001200375us-gaap:ProductMember2024-09-300001200375us-gaap:StockCompensationPlanMember2024-07-012024-09-300001200375us-gaap:StockCompensationPlanMember2023-07-012023-09-300001200375us-gaap:StockCompensationPlanMember2024-01-012024-09-300001200375us-gaap:StockCompensationPlanMember2023-01-012023-09-300001200375us-gaap:WarrantMember2024-07-012024-09-300001200375us-gaap:WarrantMember2023-07-012023-09-300001200375us-gaap:WarrantMember2024-01-012024-09-300001200375us-gaap:WarrantMember2023-01-012023-09-300001200375cdxs:SeqWellMember2023-07-012023-09-300001200375cdxs:SeqWellMember2023-01-012023-09-300001200375cdxs:ArzedaMember2023-01-012023-09-300001200375cdxs:ArzedaMember2023-07-012023-09-300001200375cdxs:MolecularAssembliesIncMember2024-09-300001200375cdxs:MolecularAssembliesIncMember2023-12-310001200375cdxs:SeqWellMember2024-09-300001200375cdxs:SeqWellMember2023-12-310001200375us-gaap:OtherAggregatedInvestmentsMember2024-09-300001200375us-gaap:OtherAggregatedInvestmentsMember2023-12-310001200375us-gaap:CashAndCashEquivalentsMember2024-09-300001200375us-gaap:ShortTermInvestmentsMember2024-09-300001200375us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-09-300001200375us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2024-09-300001200375us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:MoneyMarketFundsMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:CommercialPaperMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasurySecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2024-09-300001200375us-gaap:FairValueInputsLevel2Member2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2024-09-300001200375us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2024-09-300001200375us-gaap:CashAndCashEquivalentsMember2023-12-310001200375us-gaap:ShortTermInvestmentsMember2023-12-310001200375us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001200375us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-12-310001200375us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:MoneyMarketFundsMember2023-12-310001200375us-gaap:ConvertibleDebtMember2023-01-012023-09-300001200375us-gaap:ConvertibleDebtMember2024-01-012024-09-300001200375us-gaap:ConvertibleDebtMember2023-07-012023-09-300001200375us-gaap:ConvertibleDebtMember2024-07-012024-09-300001200375cdxs:LaboratoryEquipmentMember2024-09-300001200375cdxs:LaboratoryEquipmentMember2023-12-310001200375us-gaap:LeaseholdImprovementsMember2024-09-300001200375us-gaap:LeaseholdImprovementsMember2023-12-310001200375us-gaap:ComputerEquipmentMember2024-09-300001200375us-gaap:ComputerEquipmentMember2023-12-310001200375cdxs:OfficeEquipmentAndFurnitureMember2024-09-300001200375cdxs:OfficeEquipmentAndFurnitureMember2023-12-310001200375us-gaap:ConstructionInProgressMember2024-09-300001200375us-gaap:ConstructionInProgressMember2023-12-310001200375us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001200375us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001200375us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001200375us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001200375us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001200375us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001200375us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001200375us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001200375cdxs:A2024InducementPlanMember2024-08-310001200375us-gaap:EmployeeStockMember2023-06-012023-06-300001200375us-gaap:EmployeeStockMember2023-06-300001200375us-gaap:EmployeeStockMember2024-07-012024-09-300001200375us-gaap:EmployeeStockMember2024-01-012024-09-300001200375us-gaap:EmployeeStockMember2024-09-300001200375us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001200375us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001200375us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001200375us-gaap:EmployeeStockOptionMember2024-01-012024-01-310001200375us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-01-310001200375us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-01-310001200375us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001200375us-gaap:CostOfSalesMember2024-07-012024-09-300001200375us-gaap:CostOfSalesMember2023-07-012023-09-300001200375us-gaap:CostOfSalesMember2024-01-012024-09-300001200375us-gaap:CostOfSalesMember2023-01-012023-09-300001200375us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001200375us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001200375us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001200375cdxs:RSAsandRSUsMember2024-07-012024-09-300001200375cdxs:RSAsandRSUsMember2023-07-012023-09-300001200375cdxs:RSAsandRSUsMember2024-01-012024-09-300001200375cdxs:RSAsandRSUsMember2023-01-012023-09-300001200375cdxs:PerformanceContingentRestrictedStockUnitsPSUMember2024-07-012024-09-300001200375cdxs:PerformanceContingentRestrictedStockUnitsPSUMember2023-07-012023-09-300001200375cdxs:PerformanceContingentRestrictedStockUnitsPSUMember2024-01-012024-09-300001200375cdxs:PerformanceContingentRestrictedStockUnitsPSUMember2023-01-012023-09-300001200375cdxs:PerformanceBasedOptionsPBOsMember2024-07-012024-09-300001200375cdxs:PerformanceBasedOptionsPBOsMember2023-07-012023-09-300001200375cdxs:PerformanceBasedOptionsPBOsMember2024-01-012024-09-300001200375cdxs:PerformanceBasedOptionsPBOsMember2023-01-012023-09-300001200375us-gaap:EmployeeStockMember2023-07-012023-09-300001200375us-gaap:EmployeeStockMember2023-01-012023-09-300001200375us-gaap:EmployeeStockOptionMember2024-09-300001200375cdxs:RSAsandRSUsMember2024-09-3000012003752023-02-270001200375cdxs:PiperSandlerCoMember2021-05-012021-05-310001200375cdxs:PiperSandlerCoMembersrt:MaximumMember2021-05-310001200375cdxs:PiperSandlerCoMember2024-07-012024-09-300001200375cdxs:PiperSandlerCoMember2024-01-012024-09-300001200375cdxs:PiperSandlerCoMember2023-07-012023-09-300001200375cdxs:PiperSandlerCoMember2023-01-012023-09-300001200375cdxs:CantorSalesAgreementMember2024-05-022024-05-020001200375cdxs:CantorSalesAgreementMember2024-05-020001200375cdxs:CantorMember2024-07-012024-09-300001200375cdxs:CantorMember2024-01-012024-09-300001200375cdxs:CantorMember2024-09-300001200375cdxs:SanCarlosMember2023-10-010001200375cdxs:SanCarlosMember2023-10-012023-10-010001200375cdxs:SanCarlosMember2023-07-012023-09-300001200375cdxs:SanCarlosMember2023-10-012023-12-310001200375cdxs:FacilityMaintenanceAgreementMember2024-09-300001200375us-gaap:IndemnificationGuaranteeMember2024-09-300001200375cdxs:InnovatusLoanMemberus-gaap:SecuredDebtMember2024-02-132024-02-130001200375cdxs:InnovatusLoanMemberus-gaap:SecuredDebtMember2024-02-130001200375cdxs:InnovatusLoanFirstTrancheMemberus-gaap:SecuredDebtMember2024-02-130001200375cdxs:InnovatusLoanSecondTrancheMemberus-gaap:SecuredDebtMember2024-02-1300012003752024-02-130001200375cdxs:InnovatusLoanMemberus-gaap:SecuredDebtMembersrt:MaximumMember2024-02-130001200375cdxs:InnovatusLoanMemberus-gaap:SecuredDebtMembersrt:MinimumMember2024-02-130001200375cdxs:InnovatusLoanMemberus-gaap:SecuredDebtMember2024-07-012024-09-300001200375cdxs:InnovatusLoanMemberus-gaap:SecuredDebtMember2024-01-012024-09-300001200375cdxs:InnovatusLoanMemberus-gaap:SecuredDebtMember2024-09-300001200375cdxs:InnovatusLoanWarrantsMemberus-gaap:SecuredDebtMember2024-02-130001200375cdxs:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001200375cdxs:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001200375cdxs:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001200375cdxs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001200375cdxs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001200375cdxs:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001200375cdxs:CustomerDMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001200375cdxs:CustomerEMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001200375cdxs:CustomerFMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-07-012023-09-300001200375cdxs:CustomerGMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001200375cdxs:CustomerHMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001200375cdxs:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001200375cdxs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001200375cdxs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001200375cdxs:CustomerDMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001200375cdxs:CustomerDMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001200375cdxs:CustomerIMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001200375cdxs:CustomerJMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001200375cdxs:CustomerKMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001200375country:US2024-09-300001200375country:US2023-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission file number: 001-34705
___________________________
Codexis, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________
Delaware 71-0872999
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
200 Penobscot Drive, Redwood City, California
 94063
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (650) 421-8100

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTradingName of Each Exchange on Which Registered
Symbol(s)
Common Stock, par value $0.0001 per shareCDXSThe Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒   No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☒
Non-accelerated filer☐Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of October 28, 2024, there were 81,377,855 shares of the registrant’s Common Stock, par value $0.0001 per share, outstanding.
1



Codexis, Inc.
Quarterly Report on Form 10-Q
For the Quarter Ended September 30, 2024


TABLE OF CONTENTS
 PAGE
NUMBER
PART I. FINANCIAL INFORMATION
ITEM 1.
ITEM 2.
ITEM 3.
ITEM 4.
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 3.
ITEM 4.
ITEM 5.
ITEM 6.

2


PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Codexis, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In Thousands, Except Per Share Amounts)
September 30, 2024December 31, 2023
Assets
Current assets:
Cash and cash equivalents$37,452 $65,116 
Restricted cash, current514 519 
Short-term investments52,803 — 
Financial assets:
Accounts receivable9,721 10,036 
Contract assets3,424 815 
Unbilled receivables3,460 9,142 
Total financial assets16,605 19,993 
Less: allowances(65)(65)
Total financial assets, net16,540 19,928 
Inventories2,103 2,685 
Prepaid expenses and other current assets3,490 5,218 
Total current assets112,902 93,466 
Restricted cash1,062 1,062 
Investment in non-marketable equity securities5,790 9,700 
Right-of-use assets - Operating leases, net10,772 13,137 
Property and equipment, net13,266 15,487 
Goodwill2,463 2,463 
Other non-current assets1,928 1,246 
Total assets$148,183 $136,561 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$4,212 $5,947 
Accrued compensation10,320 11,246 
Other accrued liabilities6,505 4,735 
Current portion of lease obligations - Operating leases4,081 3,781 
Deferred revenue10,011 10,121 
Total current liabilities35,129 35,830 
Deferred revenue, net of current portion610 640 
Long-term lease obligations - Operating leases9,134 12,243 
Long-term debt28,631 — 
Other long-term liabilities1,279 1,233 
Total liabilities74,783 49,946 
Commitments and Contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding
— — 
Common stock, $0.0001 par value per share; 200,000 shares authorized;
81,376 shares and 69,905 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively
8 7 
Additional paid-in capital625,696 584,138 
Accumulated other comprehensive income
126 — 
Accumulated deficit(552,430)(497,530)
Total stockholders' equity73,400 86,615 
Total liabilities and stockholders' equity$148,183 $136,561 

See accompanying notes to the unaudited condensed consolidated financial statements.
3


Codexis, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In Thousands, Except Per Share Amounts)
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Revenues:
Product revenue$11,158 $5,395 $26,968 $24,807 
Research and development revenue1,675 3,882 10,917 18,775 
Total revenues12,833 9,277 37,885 43,582 
Costs and operating expenses:
Cost of product revenue4,317 2,249 12,634 9,947 
Research and development11,505 13,662 34,164 47,651 
Selling, general and administrative13,568 12,302 42,100 41,066 
Restructuring charges— 3,140 — 3,284 
Asset impairment and other charges— 9,984 165 9,984 
Total costs and operating expenses29,390 41,337 89,063 111,932 
Loss from operations(16,557)(32,060)(51,178)(68,350)
Interest income849 1,056 2,730 3,266 
Interest and other expense, net
(4,922)(3,895)(6,421)(3,930)
Loss before income taxes(20,630)(34,899)(54,869)(69,014)
Provision for income taxes10 9 31 34 
Net loss$(20,640)$(34,908)$(54,900)$(69,048)
Net loss per share, basic and diluted$(0.29)$(0.50)$(0.78)$(1.02)
Weighted average common stock shares used in computing net loss per share, basic and diluted72,032 69,466 70,759 67,670 
See accompanying notes to the unaudited condensed consolidated financial statements.
4


Codexis, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
(In Thousands)
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Net loss$(20,640)$(34,908)$(54,900)$(69,048)
Other comprehensive gain:
Unrealized gain on available-for-sale short-term investments, net of tax
149 — 126 — 
Comprehensive loss$(20,491)$(34,908)$(54,774)$(69,048)
See accompanying notes to the unaudited condensed consolidated financial statements.
5


Codexis, Inc.
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)
(In Thousands)
Common StockAdditional
Paid-in
Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated DeficitTotal Stockholders' Equity
Three Months Ended September 30, 2024SharesAmount
Balance as of July 1, 2024
70,914 $7 $593,253 $(23)$(531,790)$61,447 
Issuance of common stock upon release of stock awards22 — — — — — 
Issuance of common stock in connection with an equity sales agreement, net of issuance costs of $1,584
10,440 1 29,735 — — 29,736 
Stock-based compensation— — 2,708 — — 2,708 
Net Loss— — — — (20,640)(20,640)
Other comprehensive gain
— — — 149 — 149 
Balance as of September 30, 2024
81,376 $8 $625,696 $126 $(552,430)$73,400 

Common StockAdditional
Paid-in
Capital
Accumulated Other Comprehensive Income
Accumulated DeficitTotal Stockholders' Equity
Three Months Ended September 30, 2023SharesAmount
Balance as of July 1, 2023
69,804 $6 $579,555 $— $(455,430)$124,131 
Issuance of common stock upon release of stock awards23 — — — — — 
Stock-based compensation— — 2,283 — — 2,283 
Net Loss— — — — (34,908)(34,908)
Balance as of September 30, 2023
69,827 $6 $581,838 $— $(490,338)$91,506 

See accompanying notes to the unaudited condensed consolidated financial statements.
6


Codexis, Inc.
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)
(In Thousands)
Common StockAdditional
Paid-in
Capital
Accumulated Other Comprehensive Income
Accumulated DeficitTotal Stockholders' Equity
Nine Months Ended September 30, 2024SharesAmount
Balance as of January 1, 2024
69,905 $7 $584,138 $— $(497,530)$86,615 
Issuance of common stock upon exercise of stock options73 — 143 — — 143 
Issuance of common stock upon release of stock awards834 — — — — — 
Issuance of common stock warrants in connection with debt issuance— — 859 — — 859 
Issuance of common stock under employee stock purchase plan124 — 260 — — 260 
Issuance of common stock in connection with an equity sales agreement, net of issuance costs of $1,584
10,440 1 29,735 — — 29,736 
Stock-based compensation— — 10,561 — — 10,561 
Net Loss— — — (54,900)(54,900)
Other comprehensive gain
— — — 126 — 126 
Balance as of September 30, 2024
81,376 $8 $625,696 $126 $(552,430)$73,400 

Common StockAdditional
Paid-in
Capital
Accumulated Other Comprehensive Income
Accumulated DeficitTotal Stockholders' Equity
Nine Months Ended September 30, 2023SharesAmount
Balance as of January 1, 2023
65,811 $6 $566,081 $— $(421,290)$144,797 
Issuance of common stock upon exercise of stock options214 — 422 — — 422 
Issuance of common stock upon release of stock awards787 — — — — — 
Issuance of common stock in connection with an equity sales agreement, net of issuance costs of $721
3,080 — 7,931 — — 7,931 
Stock-based compensation— — 7,808 — — 7,808 
Taxes paid related to net share settlement of equity awards(65)— (404)— — (404)
Net Loss— — — — (69,048)(69,048)
Balance as of September 30, 2023
69,827 $6 $581,838 $— $(490,338)$91,506 

See accompanying notes to the unaudited condensed consolidated financial statements.
7


Codexis, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In Thousands)
Nine Months Ended September 30,
 20242023
Operating activities:
Net loss$(54,900)$(69,048)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization3,737 4,302 
Reduction in the carrying amount of right-of-use assets2,364 3,647 
Stock-based compensation10,561 7,808 
Asset impairment and other charges165 9,984 
Impairment of investment in non-marketable equity securities3,910 3,875 
Equity securities earned from research and development activities— (187)
Non-cash interest expense611 — 
Amortization of discount on short-term investments(1,009)— 
Other non-cash items11 (3)
Changes in operating assets and liabilities:
Financial assets2,818 21,580 
Inventories582 (276)
Prepaid expenses and other assets1,417 (252)
Accounts payable(1,339)(105)
Accrued compensation and other accrued liabilities1,334 (7,269)
Other long-term liabilities(3,064)(4,384)
Deferred revenue(140)(11,273)
Net cash used in operating activities(32,942)(41,601)
Investing activities:
Purchase of property and equipment(2,531)(4,798)
Proceeds from sale of property and equipment84 27 
Purchases of short-term investments
(72,643)— 
Proceeds from maturity of short-term investments19,000 — 
Proceeds from sale of short-term investments
1,973 — 
Investment in non-marketable securities— (1,191)
Net cash used in investing activities(54,117)(5,962)
Financing activities:
Proceeds from exercises of stock options281 422 
Proceeds from issuance of stock under employee stock purchase plan525 — 
Proceeds from issuance of common stock in connection with equity sales agreements
31,320 8,652 
Costs incurred in connection with equity sales agreements(1,615)(503)
Proceeds from long-term debt29,521 — 
Payment of debt issuance costs(642)— 
Taxes paid related to net share settlement of equity awards— (404)
Net cash provided by financing activities59,390 8,167 
Net decrease in cash, cash equivalents and restricted cash(27,669)(39,396)
Cash, cash equivalents and restricted cash at the beginning of the period66,697 116,026 
Cash, cash equivalents and restricted cash at the end of the period$39,028 $76,630 
8


Supplemental disclosure of cash flow information:
Interest paid$1,633 $28 
Income taxes paid$17 $193 
Supplemental non-cash investing and financing activities:
Capital expenditures incurred but not yet paid$249 $159 

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets as of September 30, 2024 and 2023 to the total of the same such amounts shown above in the unaudited condensed consolidated statements of cash flows:
 September 30,
 20242023
Cash and cash equivalents$37,452 $74,577 
Restricted cash, current and non-current 1,576 2,053 
Total cash, cash equivalents and restricted cash$39,028 $76,630 

This table excludes short-term investments of $52.8 million as of September 30, 2024. Total cash, cash equivalents, and short-term investments as of September 30, 2024 were $90.3 million.

See accompanying notes to the unaudited condensed consolidated financial statements.
9


Codexis Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Description of Business
In these notes to the unaudited condensed consolidated financial statements, the “Company,” “Codexis,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.
We discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins leveraging our proprietary CodeEvolver® directed evolution technology platform.
We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our Chief Executive Officer (“CEO”), our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment. Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocates resources based on the consolidated results of operations. We believe that these changes better align internal resources to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of December 31, 2023. Comparative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.
Note 2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024 and 2023, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2023.
The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2024 and results of operations for the interim periods presented. The interim results are not necessarily indicative of the results for any future interim period or for the entire year.
The unaudited condensed consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.
10

Short-term Investments
We classify all marketable debt securities that have effective maturities of three months or less from the date of purchase as cash equivalents and those with effective maturities of greater than three months as short-term investment securities in the condensed consolidated balance sheets. We determine the appropriate classification of our short-term investments at the time of purchase and reevaluate such designation at each balance sheet date. We have classified and accounted for our short-term investments as available-for-sale. After consideration of our risk versus reward objectives, as well as our liquidity requirements, we may sell these debt securities prior to their effective maturities.
We carry these short-term investments at fair value, and report the unrealized gains and losses, net of taxes, as a component of stockholders’ equity, except for the changes in allowance for expected credit losses, which are included in “Interest and other expense, net” in the unaudited condensed consolidated statements of operations. We determine any realized gains or losses on the sale of short-term investments on a specific identification method, and we record such gains and losses as a component of interest income.
Short-term investments are reviewed periodically for allowances for credit losses and impairment. When evaluating the investments, the Company reviews factors such as the extent to which the fair value of the security is less than the amortized cost basis, adverse conditions specifically related to the security, the financial condition of the issuer, the Company’s intent to sell, and whether it would be more likely than not that the Company would be required to sell the investments before the recovery of the amortized cost basis.
Impairment of Long-Lived Assets
We evaluate the carrying values of long-lived assets, which include property and equipment and right-of-use assets, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with the future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Assets Held For Sale
The Company classifies assets as held for sale when the following conditions are met: (i) management has committed to a plan to sell, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to identify a buyer, (iv) it is probable that a sale will occur within one year, (v) the assets are actively marketed for sale at a reasonable price in relation to their current fair value, and (vi) there is a low likelihood of significant changes to the plan or that the plan will be withdrawn. If all of the criteria are met as of the balance sheet date, the assets are presented separately in the consolidated balance sheet as held for sale at the lower of the carrying amount or fair value less costs to sell. The assets are then no longer depreciated or amortized while classified as held for sale. There were no assets classified as held for sale as of September 30, 2024 and December 31, 2023.
Accounting Pronouncements
Recently adopted accounting pronouncements
There were no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2024, that are of significance or potential significance to us.
Recently issued accounting pronouncements not yet adopted
In March 2024, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2024-02, Codification Improvements - Amendments to Remove References to the Concepts Statements. This ASU amends the FASB Accounting Standard Codification (the “ASC”) to remove references to various concepts statements and impacts a variety of topics in the ASC. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
11

In December 2023, FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in the ASU require public companies, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in the ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The standard should be applied retrospectively to all prior periods presented in the financial statements. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
In October 2023, FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. The amendments in the ASU are intended to amend certain disclosure and presentation requirements for a variety of topics within the ASC. These amendments align the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, as announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
Note 3. Revenue Recognition
Disaggregation of Revenue
The following table provides information about disaggregated revenue from contracts with customers by geographic regions. The geographic regions that are tracked are the Americas (United States, Canada, and Latin America), EMEA (Europe, Middle East, and Africa), and APAC (Australia, New Zealand, Southeast Asia, and China).
Disaggregated information is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Primary geographical markets:
Americas$1,534 $4,278 $9,823 $10,798 
EMEA2,229 3,191 6,768 14,630 
APAC9,070 1,808 21,294 18,154 
Total revenues$12,833 $9,277 $37,885 $43,582 
Contract Balances
The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):
September 30, 2024December 31, 2023
Contract assets$3,424 $815 
Unbilled receivables$4,793 $9,904 
Contract liabilities: deferred revenue$10,621 $10,761 
We had no asset impairment charges related to financial assets in the three and nine months ended September 30, 2024 and 2023.
The increase in contract assets was primarily due to increases in product revenue from contracts subject to over time revenue recognition. The decrease in unbilled receivables was primarily due to the timing of billings. The decrease in deferred revenue was primarily due to the timing of recognition of revenue.
12

As of September 30, 2024, we have $3.5 million of short-term unbilled receivables presented as unbilled receivables within current assets and $1.3 million of long-term unbilled receivables that is included within the other non-current assets line item in the condensed consolidated balance sheets. As of December 31, 2023, we had $9.1 million of short-term unbilled receivables presented as unbilled receivables within current assets and $0.8 million of long-term unbilled receivables that is included within the other non-current assets line item in the condensed consolidated balance sheets.
We recognized the following revenues (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
Revenue recognized in the period for:2024202320242023
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied$— $1,303 $475 $9,111 
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods146 1,018 (446)4,238 
Performance obligations satisfied from new activities in the period - contract revenue12,687 6,956 37,856 30,233 
Total revenues$12,833 $9,277 $37,885 $43,582 
Performance Obligations
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2024.
The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2024 (in thousands):
Remainder of 2024
20252026
2027 and Thereafter
Total
Product revenue$9,981 $140 $140 $360 $10,621 
Note 4. Net Loss per Share
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding, less restricted stock awards (“RSAs”) subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock shares outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common stock shares had been issued for other dilutive securities. For all periods presented, diluted and basic net loss per share are identical since potential common stock shares are excluded from the calculation, as their effect was anti-dilutive.
Anti-Dilutive Securities
In periods of net loss, the weighted average number of shares outstanding, prior to the application of the treasury stock method, excludes potentially dilutive securities from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect.
The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Shares issuable under the Equity Incentive Plan and ESPP12,9318,87312,9318,873
Warrants(1)
424—424—
Total potentially dilutive securities13,3558,87313,3558,873
(1) Pertains to the warrants issued in connection with the Innovatus Loan. For additional information, see Note 11, “Debt.”
13

Note 5. Investments in Non-Marketable Securities
Non-Marketable Equity Securities
Our non-marketable equity securities are investments in privately held companies without readily determinable market value and primarily relate to our investments in Molecular Assemblies, Inc. (“MAI”) and seqWell, Inc. (“seqWell”). These investments are accounted for under the measurement alternative and are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes for identical or similar securities of the same issuer. Non-marketable equity securities are measured at fair value on a non-recurring basis and classified within Level 2 in the fair value hierarchy when we estimate the fair value of these investments using the observable transaction price paid by third party investors for the same or similar security of the same issuers. The fair value of non-marketable equity securities are classified within Level 3 when we estimate fair value using unobservable inputs such as when we remeasure due to impairment and we use discount rates, market data of comparable companies, and rights and obligations of the securities the Company holds, among others. We adjust the carrying value of non-marketable equity securities which have been remeasured during the period and recognize resulting gains or losses as a component of interest and other expense, net in the unaudited condensed consolidated statements of operations.
For the three and nine months ended September 30, 2024, we recognized an impairment charge of $3.9 million which is presented within interest and other expense, net in the condensed consolidated statements of operations. This adjustment is related to the write-down of our investment in MAI to its related fair value as determined based on valuation methods using the latest observed transaction price of MAI’s preferred stock securities to be issued during the fourth quarter of 2024 and adjusted for the rights and obligations of the preferred stock securities the Company holds. There was no remeasurement event for our investments in seqWell and other non-marketable equity securities that occurred during the three and nine months ended September 30, 2024.
For the three and nine months ended September 30, 2023, we recognized an impairment charge of $3.9 million and included this as an adjustment to the carrying value of our investments in seqWell and Arzeda Corp. (“Arzeda”). This adjustment, which is presented within interest and other expense, net in the condensed consolidated statements of operations, is related to the write-down of the carrying value of our investments in seqWell by $3.0 million and in Arzeda by $0.9 million to their estimated fair values as determined based on valuation methods using the recent transaction price of similar preferred stock securities issued by the investees and adjusted for the rights and obligations of the preferred stock securities the Company holds. We recognized no realized gains or losses during the three and nine months ended September 30, 2024 and 2023.
The following table presents the carrying value of our non-marketable equity securities (in thousands):
 September 30, 2024December 31, 2023
MAI
$2,783 $6,693 
seqWell2,625 2,625 
Other investments in non-marketable equity securities382 382 
Total non-marketable equity securities$5,790 $9,700 
14

Note 6. Fair Value Measurements
The following tables show the Company’s cash, cash equivalents, and short-term investments by significant investment category as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Amortized CostUnrealized GainsUnrealized LossesFair ValueCash and Cash Equivalents
Short-term Investments
Cash$7,359 $— $— $7,359 $7,359 $— 
Level 1:
Money market funds
30,093 — — 30,093 30,093 — 
Level 2(1):
Commercial paper8,416 7 — 8,423 — 8,423 
Corporate debt8,723 14 (2)8,735 — 8,735 
U.S. agency securities1,983 9 — 1,992 — 1,992 
U.S. treasury securities33,555 98 — 33,653 — 33,653 
Subtotal52,677 128 (2)52,803 — 52,803 
Total$90,129 $128 $(2)$90,255 $37,452 $52,803 
(1) The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments uses inputs that are either directly or indirectly observable for the asset through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
December 31, 2023
Amortized CostUnrealized GainsUnrealized LossesFair ValueCash and Cash Equivalents
Short-term Investments
Cash$8,742 $— $— $8,742 $8,742 $— 
Level 1:
Money market funds
56,374 — — 56,374 56,374 — 
Total$65,116 $— $— $65,116 $65,116 $— 
We limit the credit risk associated with our cash equivalents and short-term investments by placing them with banks and institutions we believe are highly credit-worthy and investing in highly-rated investments. As of September 30, 2024, and December 31, 2023, the contractual maturity of all investments held was less than one year.
During the three and nine months ended September 30, 2024 and 2023, we did not recognize any significant credit losses nor other-than-temporary impairment losses on our short-term investments.
Note 7. Balance Sheets Details
Inventories
Inventories consisted of the following (in thousands):
September 30, 2024December 31, 2023
Raw materials$— $108 
Work-in-process36 7 
Finished goods2,067 2,570 
Total Inventories$2,103 $2,685 
Prepaid expenses and other current assets
As of September 30, 2024, prepaid expenses and other current assets consisted of prepaid expenses of $3.2 million and other current assets of $0.3 million. As of December 31, 2023, prepaid expenses and other current assets consisted of prepaid expenses of $4.6 million and other current assets of $0.6 million.
15

Property and Equipment, net
Property and equipment, net consisted of the following (in thousands):
September 30, 2024December 31, 2023
Laboratory equipment$36,468 $37,216 
Leasehold improvements12,086 11,912 
Computer equipment and software2,675 2,565 
Office equipment and furniture1,131 1,469 
Construction in progress1,629 1,636 
Property and equipment53,989 54,798 
Less: accumulated depreciation and amortization(40,723)(39,311)
Property and equipment, net$13,266 $15,487 
Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the unaudited condensed consolidated statements of operations was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Research and development$965 $1,121 $3,017 $3,606 
Selling, general and administrative219 236 658 696 
Total depreciation expense$1,184 $1,357 $3,675 $4,302 
Other Accrued Liabilities
Other accrued liabilities consisted of the following (in thousands):
September 30, 2024December 31, 2023
Accrued purchases $3,291 $1,402 
Accrued professional and outside service fees2,810 2,330 
Other404 1,003 
Total other accrued liabilities$6,505 $4,735 
Note 8. Stock-based Compensation
Equity Incentive Plans
In August 2024, our board of directors (the “Board”) approved the 2024 Employment Inducement Award Plan (the “2024 Inducement Plan”) which provides for the grant of non-qualified stock options, RSAs, restricted stock units (“RSUs”), and performance awards to eligible employees with respect to an aggregate of up to 1,000,000 shares of our common stock.
Employee Stock Purchase Plan
In April 2023, the Board approved an employee stock purchase plan (as may be amended from time to time, the “ESPP”) which became effective upon approval at the Annual Meeting in June 2023. The ESPP allows eligible employees of the Company to purchase shares of our common stock through payroll deductions. Offering periods are generally over a 24-month period and begin in May and November of each year. The per share purchase price will be the lower of 85% of the closing trading price per share of our common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date. Participant purchases are limited to a maximum of $25,000 of fair value of our stock per calendar year. The Company is authorized to grant up to 2,000,000 shares of common stock under the ESPP. The first offering period of the ESPP commenced in December 2023.
16

For the three and nine months ended September 30, 2024, nil and 123,889 shares of our common stock were purchased under the ESPP, respectively. As of September 30, 2024, 1,876,111 shares of common stock were available for future issuance under the ESPP. We recognized $0.1 million and $0.2 million of stock-based compensation expenses related to the ESPP for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the total unrecognized stock-based compensation expense, net of expected forfeitures, related to the ESPP was $0.6 million and is expected to be recognized over the remaining offering period.
Stock Options
Stock options granted to employees generally have a maximum term of ten years and vest over four years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. In January 2024, the Board approved the grants of stock options with a vesting term over three years from the date of grant, of which 33% vest at the end of one year, and 67% vest monthly over the remaining two years.
Restricted Stock Units (“RSUs”)
We also grant employees RSUs, which generally vest over either a period with 33% of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. We may grant RSUs with different vesting terms from time to time.
Stock-Based Compensation Expense
Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Cost of product revenue$93 $60 $309 $272 
Research and development 690 450 2,151 1,978 
Selling, general and administrative1,925 1,773 8,101 5,558 
Total$2,708 $2,283 $10,561 $7,808 
The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Stock options$1,506 $1,017 $5,137 $3,035 
RSUs and RSAs1,109 942 3,578 3,441 
Performance-contingent restricted stock units (“PSUs”)— 292 247 1,408 
Performance based options (“PBOs”)— 32 1,357 (76)
ESPP93 — 242 — 
Total$2,708 $2,283 $10,561 $7,808 
On June 29, 2024, we entered into an Advisory Services Agreement with a former executive of the Company. Pursuant to the advisory agreement, the exercise period for the former executive’s vested stock options and performance-based options was also extended. The modification resulted in a stock-based compensation expense of $2.0 million recognized in selling, general and administrative expenses during the nine months ended September 30, 2024.
As of September 30, 2024, unrecognized stock-based compensation expense, net of expected forfeitures, was $12.0 million related to unvested stock options, and $5.0 million related to unvested RSUs and RSAs. Stock-based compensation expense for these awards will be recognized through 2028.
17

Note 9. Capital Stock
Exercise of Options
For the nine months ended September 30, 2024 and September 30, 2023, we issued 72,856 and 214,284 shares, respectively, upon option exercises at a weighted-average exercise price of $1.97 per share, with net cash proceeds of $0.1 million and $0.4 million, respectively.
Sales Agreements
In May 2021, we filed a Registration Statement on Form S-3 with the SEC (the “2021 Registration Statement”), that automatically became effective upon its filing, under which we were permitted to sell common stock, preferred stock, debt securities, warrants, purchase contracts, and units from time to time in one or more offerings. On February 27, 2023, we filed a post-effective amendment to the 2021 Registration Statement. Pursuant to that post-effective amendment, we registered an aggregate $200.0 million of securities. In May 2021, we entered into an Equity Distribution Agreement (“EDA”) with Piper Sandler & Co (“PSC”), under which PSC, as our exclusive agent, at our discretion and at such times that we determined from time to time, may have sold over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock. Under the terms of the EDA, PSC was permitted to sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”).
We were not required to sell any shares at any time during the term of the EDA. On April 24, 2024, we terminated the EDA.
No shares of our common stock were issued and sold pursuant to the EDA during the three and nine months ended September 30, 2024. During the three and nine months ended September 30, 2023, nil and 3,079,421 shares of our common stock, respectively, were issued and sold pursuant to the EDA and we received gross proceeds of nil and $8.7 million, or nil and $7.9 million in net proceeds after PSC's commissions and direct offering expenses of nil and $0.7 million, respectively.
On May 2, 2024, we entered into a Controlled Equity Offering℠ Sales Agreement (the “Cantor Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), under which Cantor, at our discretion and at such times that we may determine from time to time, may sell up to a maximum of $75.0 million of shares of our common stock. Under the terms of the Cantor Sales Agreement, Cantor may sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act. On May 2, 2024, we filed a registration statement on Form S-3 registering the offer and sale of these shares under the Securities Act which became effective on May 14, 2024. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the Cantor Sales Agreement.
During the three and nine months ended September 30, 2024, 10,440,000 shares of our common stock were issued and sold pursuant to the Cantor Sales Agreement and we received gross proceeds of $31.3 million, or $29.7 million in net proceeds after Cantor’s commissions and direct offering expenses of $1.6 million. As of September 30, 2024, $43.7 million remained available for sale under the Cantor Sales Agreement.
Note 10. Commitments and Contingencies
Lease and other information
The Company has entered into operating leases primarily for office and laboratory space. Lease cost amounts included in the measurement of lease obligations and other information related to non-cancellable operating leases were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Operating lease costs(1)
$1,032 $1,618 $3,097 $5,278 
(1) The Company had no variable lease costs.
Other information:Operating Leases
Weighted-average remaining lease term (in years)3.1 years
Weighted-average discount rate6.6 %
18

Nine Months Ended September 30,
Cash paid (in thousands):
20242023
Operating cash flows from operating leases$3,542 $5,668 
As of September 30, 2024, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands):
Years Ending December 31,Operating Leases
2024 (remaining 3 months)$1,184 
20254,868 
20265,014 
20272,533 
2028760 
Thereafter318 
Total minimum lease payments14,677 
Less: imputed interest1,462 
Lease obligations$13,215 
Reconciliation of operating lease liabilities as shown within the unaudited condensed consolidated balance sheets (in thousands):
Current portion of lease obligations - Operating leases$4,081 
Long-term lease obligations - Operating leases9,134 
Total operating lease liabilities$13,215 
In July 2023, we announced our plan to consolidate operations from our previous San Carlos facility to our headquarters in Redwood City. On September 1, 2023, the Company entered into an Assignment and Assumption of Lease (the “Assignment Agreement”) with Vaxcyte, Inc. (“Vaxcyte”) to assign to Vaxcyte all of the Company’s right, title and interest in, under and to the San Carlos facility and the Lease Agreement, dated as of January 29, 2021. On September 6, 2023, the Company, Vaxcyte and ARE-San Francisco No. 63, LLC (“ARE”) entered into a Consent to Assignment and First Amendment pursuant to which ARE consented to the Assignment Agreement and the assignment by the Company and the assumption by Vaxcyte of the Company’s interest as tenant in the lease. The effective date of the assignment was October 1, 2023.
As a result of the Assignment Agreement, the Company remeasured the lease obligation for the San Carlos facility to its present value of $3.1 million and wrote off the remaining lease liability of $19.6 million and the corresponding right of use asset balance. Simultaneously, the Company determined that indicators of impairment existed because the lease assignment impacts the utilization of the related right of use assets and leasehold improvements in the San Carlos facility, and therefore performed a recoverability test by estimating future undiscounted net cash flows expected to be generated from the use of these assets. As there were no substantial future cash inflows associated with these assets, the carrying values of these assets were deemed unrecoverable. As a result, during the third quarter of 2023, the Company recognized a non-cash impairment charge of $7.7 million, of which $4.7 million was related to leasehold improvements and $3.0 million for the right of use assets, presented within the asset impairment and other charges line item in the condensed consolidated statements of operations, for the three and nine months ended September 30, 2023.
As part of the plan, the Company entered into agreements to sell certain laboratory equipment previously located in the San Carlos facility through an asset auction and as part of the lease assignment of the San Carlos facility to Vaxcyte. These certain items of laboratory equipment met the assets held for sale criteria and were sold during the fourth quarter of 2023. Using a fair value estimate based of Level 3 inputs in the fair value hierarchy, the Company determined that the carrying value of these assets exceeds fair value less costs to sell, which resulted in a write-down of $1.5 million, presented within the asset impairment and other charges line item in the consolidated statements of operations for the three and nine months ended September 30, 2023.
19

Other Commitments
We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes. Commitments under service agreements are typically subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work.
The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):
Payments Due by Period
Total2024 (Remaining 3 Months)2025 and Thereafter
Facility maintenance agreement$281 $281 $— 
Legal Proceedings
We may be involved in legal actions in the ordinary course of business, including inquiries and proceedings concerning business practices and intellectual property infringement, employee relations and other claims. We will recognize a loss contingency in the condensed consolidated financial statements when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. We will disclose any loss contingencies that do not meet both conditions if there is a reasonable possibility that a material loss may have been incurred. Gain contingencies are not recorded until they are realized. We are not currently a party to any material pending litigation or other material legal proceedings that management believes could have a material adverse effect on our financial statements.
Indemnifications
We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented.
Note 11. Debt
Innovatus Loan Agreement
On February 13, 2024 (the “Closing Date”), we entered into a five-year term loan and security agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP (“Innovatus”), an affiliate of Innovatus Capital Partners, LLC, for an aggregate principal amount of up to $40.0 million and with a maturity date of February 13, 2029 (the “Innovatus Loan”). The Innovatus Loan consists of two tranches, of which the first tranche of $30.0 million was funded on February 13, 2024. We will be eligible to draw down the second tranche of $10.0 million upon achievement of certain milestones including pre-specified revenue thresholds.
The floating per annum interest rate of the Innovatus Loan is equal to the sum of (a) the greater of (i) prime rate published in the Money Rates section of the Wall Street Journal and (ii) 7.50%, plus (b) 3.25%; provided that, at the election of the Company, up to 2.0% of such rate shall be payable in-kind until the third anniversary of the closing date. The Company is required to make monthly interest-only payments through February 1, 2027, after which the Company is required to make monthly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. 2.0% of the interest is payable in-kind for the first three years of the term by increasing the principal balance. Prepayments of the loan, in whole or in part, will be subject to an early prepayment fee which ranges between 3.0% and 1.0% and declines each year until the third anniversary date of the Closing Date, after which no prepayment fee is required. The Company is also required to pay an exit fee upon any payment or prepayment equal to 3.0% of the aggregate principal amount of the tranches funded under the Innovatus Loan.
The Innovatus Loan contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and net product revenue, with the latter beginning with the period ended September 30, 2024. The Innovatus Loan is secured by perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company's intellectual property.
20

In connection with the issuance of the Innovatus Loan, we recorded a debt discount of $1.3 million and capitalized debt issuance costs of $0.6 million. The discount and issuance costs will be amortized over the life of the Innovatus Loan. Interest expense for the Innovatus Loan for the three and nine months ended September 30, 2024 was $1.0 million and $2.5 million respectively, and is inclusive of non-cash amortization of the debt discount, debt issuance costs, payable in-kind interest, and accretion of final payment. The carrying amount of the Innovatus Loan approximates fair value given its recent issuance and the interest rate is based on the current prime rate. The effective interest rate for the Innovatus Loan was 13.5% as of September 30, 2024.
Additionally, in connection with entering into the Innovatus Loan, we entered into a Warrant Agreement with Innovatus on February 13, 2024 and issued to Innovatus a warrant to purchase an aggregate of 424,028 shares of the Company’s common stock at an exercise price of $2.83 per share. The warrants may be exercised on a cashless basis, and are immediately exercisable through the 10th anniversary of the issuance date. At the time of issuance, the Company determined the estimated fair value of the warrants of $0.9 million using the Black-Scholes model. As the warrants represent a freestanding equity instrument, the Company recorded the fair value of the warrants in additional paid-in capital during the first quarter of 2024.
The Company accounts for the amortization of the debt discount and issuance costs utilizing the effective interest method. Long-term debt consisted of the following at September 30, 2024 (in thousands):
September 30, 2024
Face value of debt$30,000 
Add: payment in-kind interest332 
Add: amortized exit fee87 
Less: unamortized debt discount(1,208)
Less: unamortized debt issuance costs(580)
Total long-term debt$28,631 
The future principal payments under the Innovatus Loan are as follows (in thousands):
Years Ending December 31,
2024$— 
2025— 
2026— 
202713,264 
202815,917 
20292,653 
Total principal payments31,834 
Add: amortized exit fee87 
Less: uncapitalized payment in-kind interest(1,502)
Less: unamortized debt issuance fee(1,208)
Less: unamortized debt issuance costs(580)
Total long-term debt$28,631 
Note 12. Segment, Geographical and Other Revenue Information
Segment Information
We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our CEO, our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment.
21

Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocated resources based on the consolidated results of operations. We believe that these changes better align internal resources and external go to market activities in order to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of December 31, 2023. Comparative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.
As a result of the restructuring of our business, the Company determined that a triggering event had occurred that required an interim goodwill impairment test during the third quarter of 2023. The fair value estimate used in the interim goodwill impairment test was primarily based on Level 3 inputs in the fair value hierarchy. Based on the results of the impairment evaluation, the Company determined that the goodwill within the Novel Biotherapeutics reporting unit was impaired, which resulted in a non-cash impairment charge of $0.8 million to write off all of the associated goodwill. The impairment charge is recorded within asset impairment and other charges in the condensed consolidated statements of operation for the three and nine months ended September 30, 2023.
Significant Customers
Customers that each accounted for 10% or more of our total revenues were as follows:
Percentage of Total Revenues for the
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Customer A
18 %*17 %10 %
Customer B
17 %*10 %*
Customer C
11 %***
Customer D
11 %***
Customer E
***15 %
Customer F
*20 %**
Customer G
**16 %*
Customer H
***10 %
* Percentage was less than 10%
Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:
Percentage of Accounts Receivables as of
September 30, 2024December 31, 2023
Customer A
*12 %
Customer B
21 %12 %
Customer D
15 %13 %
Customer I
15 %*
Customer J
12 %*
Customer K
*21 %
* Percentage was less than 10%
Identifiable long-lived assets by location was as follows (in thousands):
September 30, 2024December 31, 2023
United States$24,277 $28,624 
22

ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following management's discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management's discussion and analysis of financial condition and results of operations for the year ended December 31, 2023 included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 28, 2024 (the “Annual Report”). This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include, but are not limited to, expectations regarding our strategy, business plans, financial performance and developments relating to our industry. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part II, Item 1A: “Risk Factors” of this Quarterly Report on Form 10-Q and Part I, Item 1A: “Risk Factors” of our Annual Report, as incorporated herein and referenced in Part II, Item 1A: “Risk Factors” of this Quarterly Report on Form 10-Q and elsewhere in this report. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.
Business Overview
We are a leading enzyme engineering company leveraging our proprietary CodeEvolver® directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. Enzymes are naturally occurring biological molecules critical to almost all biochemical reactions that sustain life. They can be precisely engineered and optimized for specific functions, and to have particular characteristics, such as an ability to survive environments in which natural enzymes cannot, or to perform (bio)chemical transformations different than those for which they naturally evolved. We focus on leveraging our capacity to enhance the properties and performance of enzymes to drive pivotal improvements across two key focus areas: our foundational, revenue-generating pharmaceutical manufacturing business and our Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ (“ECO Synthesis™”) manufacturing platform, which is currently in development to enable the commercial scale manufacture of RNA interference (“RNAi”) and other RNA-based therapeutics. Our unique enzymes drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, and improved efficiency in manufacturing. In July 2023, we announced that we discontinued investment in certain development programs, primarily in our novel biotherapeutics business segment and that we are actively exploring options to drive value by potentially monetizing non-core assets within our Biotherapeutics and Life Science portfolios.
Within the pharmaceutical manufacturing business, we utilize our CodeEvolver® technology platform to develop optimized enzymes that are used by some of the world’s largest pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. We also use the CodeEvolver® technology platform to develop enzymes for the synthesis of nucleic acids such as DNA/RNA, including enzymes utilized in our ECO Synthesis™ manufacturing platform. We demonstrated gram-scale synthesis with the ECO Synthesis™ manufacturing platform in December 2023 and expect to begin pre-commercial customer testing in 2024. We anticipate that this will be followed by early commercial licenses to the ECO Synthesis™ manufacturing platform in 2025 and a full commercial launch in 2026.
As of September 30, 2024, we manage our business as one business segment. For additional information, see Note 12, “Segment, Geographical and Other Revenue Information” in the Notes to Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report.
23

Recent Developments
Entered into licensing agreement for genomics life science enzyme portfolio with Alphazyme LLC
On October 1, 2024, we announced that we entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences, for multiple enzymes in Codexis’ life science enzyme portfolio. The agreement includes licenses for certain commercially available enzymes and certain enzymes that were in development directed towards genomics and diagnostics applications prior to the Company’s strategic shift announced in July 2023. Under the terms of the agreement, Codexis is eligible to receive sales-based royalties.
Strengthened management team with new appointments
On October 2, 2024, we announced the appointment of Georgia Erbez as our new Chief Financial Officer, replacing Sriram Ryali in such role, effective September 30, 2024. We also announced the appointment of Alison Moore, Ph.D., to the newly created role of Chief Technical Officer effective September 30, 2024. In connection with her appointment as Chief Technical Officer, Dr. Moore resigned from the Board and its committees, effective September 30, 2024. On October 22, 2024, we announced that we entered into a separation and consulting agreement with Mr. Ryali, pursuant to which Mr. Ryali will provide transitional consulting services on an as-needed basis until February 28, 2025.
Significant Collaborative Arrangements Update
Acquisition Agreement
In December 2023, we entered into an acquisition agreement (the “Acquisition Agreement”) with Nestlé Health Science, pursuant to which we agreed to assign our interests in CDX-7108 (including associated agreements and intellectual property rights) to Nestlé Health Science. Under the terms of the Acquisition Agreement, Nestlé Health Science will be solely responsible for the continued development and commercialization of CDX-7108, including all associated costs, and Codexis received an upfront payment, and will receive future potential milestone payments and net-sales based royalties. We recognized $5.0 million in research and development revenue during the fourth quarter of 2023 related to the Acquisition Agreement, with the $5.0 million upfront fee received in January 2024.
Pfizer Enzyme Supply Agreement
We are a party to an Enzyme Supply Agreement (the “Pfizer Supply Agreement”), with Pfizer Ireland Pharmaceuticals, a subsidiary of Pfizer, Inc. (“Pfizer”), covering the manufacture, sale and purchase of CDX-616 for use by Pfizer in the manufacture of nirmatrelvir. Under the terms of the Pfizer Supply Agreement, Pfizer paid us a fee of $25.9 million in August 2022 which was recorded as deferred revenue. Pursuant to the agreement, 90% of the fee ($23.3 million) is creditable against (i) future orders of CDX-616 used to manufacture its PAXLOVID™ with shipment dates prior to December 31, 2023, and (ii) fees associated with any new development and licensing agreements with Pfizer entered into prior to April 4, 2023. On March 31, 2023, we entered into a license agreement whereby Pfizer utilized a portion of the $23.3 million credit towards a license to develop future product candidates, for which we recognized $5.0 million as non-cash research and development revenue in the second quarter of 2023. Pfizer's ability to utilize the credit under item (i) above expired on December 31, 2023, and under item (ii) above expired on April 4, 2023. Up to 50% of any portion of the $25.9 million which has not been credited under items (i) and (ii) is creditable against future orders of CDX-616 used to manufacture PAXLOVID™ with shipment dates in 2024.
No product revenue was recognized from the Pfizer Supply Agreement during the three and nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, we had $9.5 million in deferred revenue related to the $25.9 million fee received from Pfizer.
Strategic Collaboration Agreement
In October 2017, we entered into the Nestlé Strategic Collaboration Agreement (the “Nestlé SCA”) pursuant to which we and Nestlé Health Science have collaborated to leverage the CodeEvolver® protein engineering technology platform to develop novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas.
In January 2020, we entered into a development agreement with Nestlé Health Science pursuant to which we and Nestlé Health Science have collaborated to advance a lead candidate discovered through our Nestlé SCA, CDX-7108, targeting exocrine pancreatic insufficiency, into preclinical and early clinical studies. We, together with Nestlé Health Science, initiated a Phase 1 clinical trial of CDX-7108 in the fourth quarter of 2021, and on February 23, 2023, we and Nestlé Health Science announced interim results. In July 2023, we announced plans to discontinue our development support of CDX-7108. Both the Nestlé SCA and development agreement were terminated under the terms of the CDX-7108 Acquisition Agreement with Nestlé Health Science.
24

Both the Nestlé SCA and the development agreement were terminated under the Nestlé Acquisition Agreement. Under the Nestlé SCA and the development agreement, we recognized nil in research and development fees for the three and nine months ended September 30, 2024, compared to $0.6 million and $4.1 million for the three and nine months ended September 30, 2023, respectively.
License Agreement
In February 2024, we entered into an agreement with Roche Sequencing Solutions, Inc. (“Roche”) for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase. Under the terms of the deal, Codexis received upfront and technical milestone payments. This deal superseded the prior exclusive license on the EvoT4™ DNA ligase. We recognized research and development revenue of $6.0 million during the first quarter of 2024 related to the license agreement.
Results of Operations
The following table shows the amounts from our unaudited condensed consolidated statements of operations for the periods presented (in thousands, except percentages):
 Three Months Ended September 30,ChangeNine Months Ended September 30,Change
 20242023$%20242023$%
Revenues:
Product revenue$11,158 $5,395 $5,763 107 %$26,968 $24,807 $2,161 9 %
Research and development revenue1,675 3,882 (2,207)(57)%10,917 18,775 (7,858)(42)%
Total revenues12,833 9,277 3,556 38 %37,885 43,582 (5,697)(13)%
Costs and operating expenses:
Cost of product revenue4,317 2,249 2,068 92 %12,634 9,947 2,687 27 %
Research and development11,505 13,662 (2,157)(16)%34,164 47,651 (13,487)(28)%
Selling, general and administrative13,568 12,302 1,266 10 %42,100 41,066 1,034 3 %
Restructuring charges— 3,140 (3,140)(100)%— 3,284 (3,284)(100)%
Asset impairment and other charges— 9,984 (9,984)(100)%165 9,984 (9,819)(98)%
Total costs and operating expenses29,390 41,337 (11,947)(29)%89,063 111,932 (22,869)(20)%
Loss from operations(16,557)(32,060)15,503 (48)%(51,178)(68,350)17,172 (25)%
Interest income849 1,056 (207)(20)%2,730 3,266 (536)(16)%
Interest and other expense, net
(4,922)(3,895)(1,027)26 %(6,421)(3,930)(2,491)63 %
Loss before income taxes(20,630)(34,899)14,269 (41)%(54,869)(69,014)14,145 (20)%
Provision for income taxes10 9 1 11 %31 34 (3)(9)%
Net loss$(20,640)$(34,908)$14,268 (41)%$(54,900)$(69,048)$14,148 (20)%
Revenues
Our revenues consisted of product revenue, research and development revenue, and royalties and license revenue as follows:
•Product revenue consist of sales of biocatalysts, pharmaceutical intermediates, and Codex® biocatalyst panels and kits.
•Research and development revenue include license, technology access and exclusivity fees, research services fees, milestone payments, royalties, optimization and screening fees.
25

Revenues are as follows (in thousands, except percentages):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Product revenue$11,158 $5,395 $5,763 107 %$26,968 $24,807 $2,161 9 %
Research and development revenue1,675 3,882 (2,207)(57)%10,917 18,775 (7,858)(42)%
Total revenues$12,833 $9,277 $3,556 38 %$37,885 $43,582 $(5,697)(13)%
Revenues typically fluctuate on a quarterly basis due to the variability in our customers' manufacturing schedules and the timing of our customers' clinical trials. In addition, we have limited internal capacity to manufacture enzymes. As a result, we are dependent upon the performance and capacity of third-party manufacturers for the commercial scale manufacturing of the enzymes used in our pharmaceutical and fine chemicals business.
We accept purchase orders for deliveries covering periods from one day up to 14 months from the date on which the order is placed. However, some of our purchase orders can be revised or cancelled by the customer without penalty. Considering these industry practices and our experience, we do not believe the total of customer purchase orders outstanding (backlog) provides meaningful information that can be relied on to predict actual sales for future periods.
Total revenues increased by $3.6 million in the three months ended September 30, 2024 compared to the same period in 2023 primarily due to higher product revenue, which was partially offset by lower research and development revenue. Total revenues decreased by $5.7 million in the nine months ended September 30, 2024 compared to the same period in 2023 primarily due to lower research and development revenue.
Product revenue increased by $5.8 million and $2.2 million in the three and nine months ended September 30, 2024, respectively, compared to the same periods in 2023, primarily due to higher sales of branded pharmaceutical products. This increase was partially offset with the prior year benefiting from the $2.9 million release of prior periods' product revenue deferrals during the second quarter of 2023 due to early termination of the enzyme supply obligations to a customer for a deprioritized asset related to a prior restructuring of our business, and $1.3 million of product revenue recognized during the third quarter of 2023 as a settlement fee pursuant to the enzyme supply agreement with the same customer.
Research and development revenue decreased by $2.2 million in the three months ended September 30, 2024 compared to the same period in 2023 primarily due to the recognition of $0.7 million in non-cash revenue related to our master service agreement with Pfizer in the third quarter of 2023, $0.6 million lower research and development fees from Nestlé Health Science under the Nestlé SCA and development agreement and $0.9 million lower revenue from both legacy and existing collaboration agreements being recognized in 2024 as compared to the same period in the prior year.
Research and development revenue decreased by $7.9 million in the nine months ended September 30, 2024 compared to the same period in 2023, primarily due to the recognition of $6.3 million in non-cash revenue related to our license and our master service agreements with Pfizer in the nine months ended September 30, 2023, $4.1 million lower research and development fees from Nestlé Health Science, $1.6 million lower revenue from Takeda Pharmaceutical Co. Ltd. under a Strategic Collaboration and License Agreement and $2.8 million lower revenue from other legacy collaboration agreements being recognized in 2024 as compared to the same period in 2023. This was offset by $6.0 million higher revenue from our licensing agreement with Roche entered into in February 2024 and $0.9 million higher revenue from existing collaboration agreements recognized in the current year.
26

Cost and Operating Expenses
The following table shows the amounts of our cost of product revenue, research and development expense, selling, general and administrative expense, and restructuring charges from our unaudited condensed consolidated statements of operations for the periods presented (in thousands, except percentages):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Cost of product revenue$4,317 $2,249 $2,068 92 %$12,634 $9,947 $2,687 27 %
Research and development11,505 13,662 (2,157)(16)%34,164 47,651 (13,487)(28)%
Selling, general and administrative13,568 12,302 1,266 10 %42,100 41,066 1,034 3 %
Restructuring charges— 3,140 (3,140)(100)%— 3,284 (3,284)(100)%
Asset impairment and other charges— 9,984 (9,984)(100)%165 9,984 (9,819)(98)%
Total costs and operating expenses$29,390 $41,337 $(11,947)(29)%$89,063 $111,932 $(22,869)(20)%
Cost of Product Revenue and Product Gross Margin
The following table shows the amounts of our product revenue, cost of product revenue, product gross profit and product gross margin from our unaudited condensed consolidated statements of operations for the periods presented (in thousands, except percentages):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Product revenue$11,158$5,395$5,763 107 %$26,968$24,807$2,161 9 %
Cost of product revenue(1)
4,3172,2492,068 92 %12,6349,9472,687 27 %
Product gross profit$6,841$3,146$3,695 117 %$14,334$14,860$(526)(4)%
Product gross margin (%)(2)
61 %58 %53 %60 %
(1) Cost of product revenue consists of both internal and third-party fixed and variable costs, including materials and supplies, labor, facilities and other overhead costs associated with our product revenue.
(2) Product gross margin is used as a performance measure to provide additional information regarding our results of operations on a consolidated basis.
Cost of product revenue increased by $2.1 million and $2.7 million in the three and nine months ended September 30, 2024, respectively, compared to the same periods in 2023, primarily due to a higher volume of product sales.
Product gross margins were 61% and 53% in the three and nine months ended September 30, 2024, respectively, compared to 58% and 60% in the corresponding periods in 2023 due to variability in the product mix and with 2023 benefiting from revenue recognized with no related cost in the second and third quarters of 2023 related to the early termination of an enzyme supply agreement with a customer for a deprioritized asset related to a prior restructuring of our business.
Research and Development Expenses
Research and development expenses consist of costs incurred for internal projects as well as collaborative research and development activities. These costs primarily consist of (i) employee-related costs, which include salaries and other personnel-related expenses (including stock-based compensation), (ii) various allocable expenses, which include occupancy-related costs, supplies, depreciation of facilities and laboratory equipment, and (iii) external costs. Research and development expenses are expensed when incurred.
Research and development expenses decreased by $2.2 million, or 16%, in the three months ended September 30, 2024 compared to the same period in 2023 primarily due to a $1.3 million decrease from lower use of outside services related to Chemistry, Manufacturing and Controls (“CMC”) and lower regulatory expenses and $0.9 million decrease in lease and facilities costs due to the assignment of our San Carlos facility lease during the fourth quarter of 2023, partially offset by a $0.2 million increase in costs associated with headcount. The decrease in research and development expenses of $13.5 million, or 28%, in the nine months ended September 30, 2024, compared to the same period in 2023, was primarily due to a $4.8 million decrease in CMC and outside services, $4.6 million decrease in costs associated with lower headcount, $3.7 million decrease from lower lease and facilities associated costs, $0.4 million lower lab supply, and a $0.2 million decrease in depreciation costs.
27

Selling, General and Administrative Expenses
Selling, general and administrative expenses consist of employee-related costs, which include salaries and other personnel-related expenses (including stock-based compensation), hiring and training costs, consulting and outside services expenses (including audit and legal counsel related costs), marketing costs, building lease costs, and depreciation expenses and amortization expenses.
Selling, general and administrative expenses increased by $1.3 million, or 10%, during the three months ended September 30, 2024, compared to the same period in 2023 primarily due to $1.2 million in higher consulting and outside services and a $0.3 million higher legal expense. Selling, general and administrative expenses increased by $1.0 million, or 3%, during the nine months ended September 30, 2024 as compared to the same period in 2023 primarily due to a $2.6 million higher stock-based compensation expense, a $1.1 million increase in legal costs, and a $0.7 million increase in consulting and outside services, partially offset by $2.8 million decrease in payroll-related expenses, and a $0.5 million decrease in facility associated costs.
Restructuring Charges
Restructuring charges consist of one-time employee severance and other termination benefits due to workforce reduction plans that were initiated in the prior years. There were no restructuring charges recognized in the three and nine months ended September 30, 2024. Restructuring charges were $3.1 million and $3.3 million for the three and nine months ended September 30, 2023, respectively.
Asset Impairment and Other Charges

Asset impairment and other charges were nil and $0.2 million for the three and nine months ended September 30, 2024, respectively, related to a long-lived asset impairment charge in the second quarter of 2024. Asset impairment and other charges for the three and nine months ended September 30, 2023 were $10.0 million, consisting of a $9.2 million long-lived asset impairment charge and a $0.8 million goodwill impairment charge, all of which are non-cash charges.
Interest Income and Interest and Other Expense, net (in thousands, except percentages):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Interest income$849 $1,056 $(207)(20)%$2,730 $3,266 $(536)(16)%
Interest and other expense, net
(4,922)(3,895)(1,027)26 %(6,421)(3,930)(2,491)63 %
Total other income (expense), net
$(4,073)$(2,839)$(1,234)43 %$(3,691)$(664)$(3,027)456 %
Interest Income
Interest income decreased by $0.2 million and $0.5 million in the three and nine months ended September 30, 2024, respectively, compared to the same periods in 2023, primarily due to lower average cash balances.
Interest and Other Expense, net
Interest and other expense, net increased by $1.0 million and $2.5 million in the three and nine months ended September 30, 2024, respectively, compared to the same periods in 2023, primarily due to the impairment of our investment in MAI during the third quarter of 2024 and interest related to long-term debt in the current year, partially offset by the impairment of our investments in seqWell and Arzeda recognized in 2023.
Provision for Income Taxes (in thousands, except percentages):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Provision for income taxes$10 $9 $1 11 %$31 $34 $(3)(9)%
The provision for income taxes for the three and nine months ended September 30, 2024 and 2023, was primarily due to the accrual of interest and penalties on historic uncertain tax positions.
28

Net Loss
Net loss for the three months ended September 30, 2024 was $20.6 million, or a net loss per basic and diluted share of $0.29. This compared to a net loss of $34.9 million, or a net loss per basic and diluted share of $0.50, for the three months ended September 30, 2023. Net loss for the nine months ended September 30, 2024 was $54.9 million, or a net loss per basic and diluted share of $0.78. This compared to a net loss of $69.0 million, or a net loss per basic and diluted share of $1.02, for the nine months ended September 30, 2023. The decrease in net loss for both the three and nine months ended September 30, 2024, was primarily related to higher product revenue and lower operating expenses in 2024.
LIQUIDITY AND CAPITAL RESOURCES
Liquidity is the measurement of our ability to meet working capital needs and to fund capital expenditures. We have historically funded our operations primarily through cash generated from operations, stock option exercises and public and private offerings of our common stock. In addition, pursuant to our five-year term loan and security agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP (“Innovatus”), an affiliate of Innovatus Capital Partners, LLC, we borrowed $30.0 million from Innovatus, as Lender, on February 13, 2024 and may become eligible to borrow up to an additional $10.0 million upon the achievement of certain financial milestones. The Loan Agreement provides for an aggregate principal amount of up to $40.0 million and with a maturity date of February 13, 2029 (the “Innovatus Loan”). We actively manage our cash usage and investment of liquid cash to ensure the maintenance of sufficient funds to meet our working capital needs. Our cash and cash equivalents are held in U.S. banks.
Our primary uses of capital for the foreseeable future, including the next 12 months, are for compensation and related expenses, research and development expenses including manufacturing costs, laboratory and related supplies, legal and other regulatory expenses, and general overhead costs.
The following summarizes our cash and cash equivalents and short-term investments balances and working capital as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024December 31, 2023
Cash and cash equivalents$37,452 $65,116 
Short-term investments$52,803 $— 
Working capital$77,773 $57,636 
Sources of Capital
In addition to our existing cash and cash equivalents, short-term investments and revenue generated through our existing operations, we are eligible to earn milestone and other contingent payments for the achievement of defined collaboration objectives under our collaboration agreements. Our ability to earn these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators’ research and development activities and is uncertain at this time.
We have historically experienced negative cash flows from operations as we continue to invest in key technology development projects and improvements to our CodeEvolver® technology platform, develop and commercialize new and existing products including our ECO Synthesis™ manufacturing platform and expand our business development and collaboration with new customers. Our cash flows from operations will continue to be affected principally by product sales and product gross margins, sales from licensing our technology to major pharmaceutical companies, and collaborative research and development services provided to customers, as well as our headcount costs, primarily in research and development. Our primary source of cash flows from operating activities is cash receipts from our customers for purchases of products, collaborative research and development services, and licensing our technology to major pharmaceutical companies. Our largest uses of cash from operating activities are for employee-related expenditures, rent payments, inventory purchases to support our product sales and non-payroll research and development costs.
Loan Agreement and Term Loans
On February 13, 2024, we entered into the Loan Agreement with Innovatus consisting of two tranches, of which the first tranche of $30.0 million was completed upon execution of the Loan Agreement. We will be eligible to draw on the second tranche of $10.0 million upon achievement of certain milestones including certain pre-specified revenue thresholds. The Loan Agreement carries an interest-only period of 36 months and will bear an interest at a floating rate of the sum of (a) the greater of (i) prime rate and (ii) 7.50%, plus (b) 3.25%. The Company believes it is in compliance with the terms included within the Innovatus Loan as of September 30, 2024.
29

Sales Agreements
In May 2021, we entered into an Equity Distribution Agreement (“EDA”) with Piper Sandler & Co (“PSC”), under which PSC, as our exclusive agent, at our discretion and at such times that we may determine from time to time, may sell over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock. In 2023, 3,079,421 shares of our common stock were issued and sold pursuant to the EDA, all during the first half of 2023, and we received net proceeds of $7.9 million. On April 24, 2024, we terminated the EDA.
On May 2, 2024, we entered into a Controlled Equity Offering℠ Sales Agreement (the “Cantor Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), under which Cantor, at our discretion and at such times that we may determine from time to time, may sell up to a maximum of $75.0 million of shares of our common stock. Under the terms of the Cantor Sales Agreement, Cantor may sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act. On May 2, 2024, we filed a registration statement on Form S-3 registering the offer and sale of these shares under the Securities Act which became effective on May 14, 2024. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the Cantor Sales Agreement. During the three and nine months ended September 30, 2024, 10,440,000 shares of our common stock were issued and sold pursuant to the Cantor Sales Agreement and we received gross proceeds of $31.3 million, or $29.7 million in net proceeds after Cantor’s commissions and direct offering expenses of $1.6 million. As of September 30, 2024, $43.7 million of shares remained available for sale under the Cantor Sales Agreement.
Sales of our common stock under the Cantor Sales Agreement could be subject to business, economic or competitive uncertainties and contingencies, many of which may be beyond our control, and which could cause actual results from the sale of our common stock to differ materially from expectations.
Liquidity
We believe that our existing cash and cash equivalents, combined with our future expectations for product revenues, research and development revenue, and expense management will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our capital resources sooner than we expect.
However, we may need additional capital if our current plans and assumptions change. In addition, we may choose to seek other sources of capital even if we believe we have generated sufficient cash flows to support our operating needs. Our need for additional capital will depend on many factors, including the financial success of our business, the spending required to develop and commercialize new and existing products including our ECO Synthesis™ manufacturing platform, the effect of any acquisitions of other businesses, technologies or facilities that we may make or develop in the future, our spending on new market opportunities, and the potential costs for the filing, prosecution, enforcement and defense of patent claims, if necessary. If our capital resources are insufficient to meet our capital requirements, and we are unable to enter into or maintain collaborations with partners that are able or willing to fund our development efforts or commercialize any products that we develop or enable, we will have to raise additional funds to continue the development of our technology and products and complete the commercialization of products, if any, resulting from our technologies. If future financings involve the issuance of equity securities, our existing stockholders would suffer dilution. In addition, under the Loan Agreement, we are subject to restrictive covenants that limit our ability to conduct our business and could be subject to additional covenants to the extent we seek other debt financing in the future. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and fail to generate sufficient revenues to achieve planned gross margins and to control operating costs, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate development of new products or services, such as our ECO Synthesis™ manufacturing platform, or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.
30

Cash Flows
The following is a summary of cash flows for the nine months ended September 30, 2024 and 2023 (in thousands):
 Nine Months Ended September 30,
20242023
Net cash used in operating activities$(32,942)$(41,601)
Net cash used in investing activities(54,117)(5,962)
Net cash provided by financing activities59,390 8,167 
Net decrease in cash, cash equivalents and restricted cash$(27,669)$(39,396)
Cash Flows from Operating Activities
The $8.7 million decrease in net cash used in operating activities for the nine months ended September 30, 2024 as compared to the same period in 2023, was primarily due to the net effect of decreases in cash paid for operating expenses, primarily driven by the restructuring of our business in 2023 which included the assignment of our San Carlos facility lease in the fourth quarter of 2023, and changes in operating assets and liabilities.
Cash Flows from Investing Activities
The $48.2 million increase in net cash used in investing activities for the nine months ended September 30, 2024 as compared to the same period in 2023, was primarily due to higher cash utilized for purchases of short-term investments, partially offset by lower purchases of property and equipment during the period.
Cash Flows from Financing Activities
The $51.2 million increase in net cash provided by financing activities for the nine months ended September 30, 2024 as compared to the same period in 2023 was primarily due to proceeds from the Innovatus Loan in February 2024 and proceeds from issuance of common stock under the Cantor Sales Agreement, partially offset by proceeds from issuance of common stock under the EDA during the nine months ended September 30, 2023.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes. Actual results could differ from those estimates. There have been no material changes to our critical accounting policies or estimates during the three and nine months ended September 30, 2024 from those discussed in our Annual Report.
31

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market Risk Management
Our cash flows and earnings are subject to fluctuations due to changes in foreign currency exchange rates, interest rates and other factors. These market risk exposures are disclosed in Part II, Item 7A of our Annual Report.
Interest Rate Sensitivity
Our unrestricted cash, cash equivalents, and short-term investments in marketable securities total $90.3 million as of September 30, 2024. We primarily invest these amounts in money market funds and short-term debt which are held for working capital purposes. We do not enter into investments for trading or speculative purposes. As of September 30, 2024, the effect of a hypothetical 10% decrease in market interest rates would have a $0.4 million impact on a potential loss in future interest income and cash flows.
We are also exposed to market risk from changes in interest rates as a result of our indebtedness under the Innovatus Loan. At September 30, 2024, we had $30.0 million principal amount outstanding under the Innovatus Loan. The floating per annum interest rate of the Innovatus Loan is equal to the sum of (a) the greater of (i) prime rate published in the Money Rates section of the Wall Street Journal and (ii) 7.50%, plus (b) 3.25%; provided that, at the election of the Company, up to 2.00% of such rate shall be payable in-kind until the third anniversary of the closing date. An immediate 10% change in the prime interest rate would result in a $0.2 million impact on our results of operations over the next twelve months from September 30, 2024.
Foreign Currency Risk
Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. In periods when the United States dollar (“USD”) declines in value as compared to the foreign currencies in which we incur expenses, our foreign-currency based expenses increase when translated into USD. Although substantially all of our sales are denominated in USD, future fluctuations in the value of the USD may affect the price competitiveness of our products outside the United States. Our most significant foreign currency exposure is due to non-functional currency denominated monetary assets, primarily currencies denominated in other than their functional currency. These non-functional currency denominated monetary assets are subject to re-measurement which may create fluctuations in interest and other expense, net, a component in our consolidated statement of operations and in the fair value of the assets in the consolidated balance sheets. As of September 30, 2024, the effect of a hypothetical 10% unfavorable change in exchange rates on currencies denominated in other than their functional currency would result in a potential loss in future earnings in our consolidated statement of operations and a reduction in the fair value of the assets of approximately $41 thousand.
Investment in Non-Marketable Equity Securities
We own investments in non-marketable equity securities without readily determinable fair values. We may value these equity securities based on significant recent arms-length equity transactions with sophisticated non-strategic unrelated investors, providing the terms of these security transactions are substantially similar to the security transactions terms between the investors and us. The impact of the difference in transaction terms on the market value of the portfolio company may be difficult or impossible to quantify.
32

ITEM 4.CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures and internal controls that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer and with the participation of our disclosure committee, evaluated the effectiveness of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this review, our Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective as of September 30, 2024 at a reasonable assurance level.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, even if determined effective and no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives to prevent or detect misstatements. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

33

PART II. OTHER INFORMATION
ITEM 1.
LEGAL PROCEEDINGS
We are not currently a party to any material pending litigation or other material legal proceedings.
ITEM 1A.RISK FACTORS
You should carefully consider the risks described below together with the other information set forth in this Quarterly Report, which could materially affect our business, financial condition or future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Additional discussion of the material risks and uncertainties summarized in this risk factor summary, as well as certain other risks and uncertainties that we face, can be found in this section.
RISK FACTORS SUMMARY
The following is a summary of the principal factors that cause an investment in the Company to be speculative or risky:
•We have a history of net losses and we may not achieve or maintain profitability.
•Biotherapeutic programs are highly regulated and expensive.
•We are dependent on a limited number of customers.
•Our product supply agreements with customers have finite duration and may not be extended or renewed.
•The demand for our product depends in part on our customers' research and development and the clinical and market success of their products.
•With respect to customers purchasing our products for the manufacture of API, the termination or expiration of such patent protection may materially and adversely affect our revenues, financial condition or results of operations.
•We are dependent on a limited number of contract manufacturers for large scale production of substantially all of our enzymes.
•We are dependent on our collaborators, and our failure to successfully manage these relationships could prevent us from developing and commercializing many of our products.
•If we are unable to develop and commercialize new products for the target markets, our business and prospects will be harmed.
•We have invested significant resources to enable enzymatic nucleic acid synthesis, which is based on novel ideas and technologies that are largely unproven.
•Future revenues from our sales of CDX-616 to Pfizer are subject to a number of factors which are outside of our control and may not materialize.
•Ethical, legal and social concerns about genetically engineered products and processes could limit or prevent the use of our products, processes, and technologies and limit our revenues.
•We have recently enhanced our strategic focus to concentrate on certain programs and business lines. As a result of this refined focus on returning the foundational, revenue-generating pharmaceutical manufacturing business and the ECO Synthesis™ manufacturing platform, we may fail to capitalize on other opportunities that may be more profitable or for which there is a greater likelihood of success.
•Given our recent change in strategic direction, we may receive limited revenue or no future value from certain of our existing license agreements.
•We use hazardous materials in our business, and we must comply with environmental laws and regulations.
34

•As a public reporting company, we are subject to rules and regulations established from time to time by the SEC and Nasdaq regarding our internal controls over financial reporting. We may not complete needed improvements to our internal controls over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may adversely affect investor confidence in our company and, as a result, the value of our common stock and your investment.
•We may need additional capital in the future in order to expand our business.
•We may not be able to comply with the terms of our Loan Agreement with Innovatus.
•Our ongoing efforts to deploy our technology in the life science tools market may fail.
•Even if our customers or collaborators obtain regulatory approval for any products utilizing our enzymes, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.
•If we or our customers fail to comply with certain healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.
•Our efforts to prosecute, maintain, protect and/or defend our intellectual property rights may not be successful.
•Our ability to compete may decline if we do not adequately prosecute, maintain, protect and/or defend our proprietary technology, products or services or our intellectual property rights.
•Third parties may claim that we are infringing, violating or misappropriating their intellectual property rights, which may subject us to costly and time-consuming litigation and prevent us from developing or commercializing our technology, products or services.
•We may be involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful.
•We may not be able to enforce our intellectual property rights throughout the world.
•If our biocatalysts are stolen, misappropriated or reverse engineered, others could use these biocatalysts to produce competing products.
•We are subject to anti-takeover provisions in our certificate of incorporation and bylaws and under Delaware law that could delay or prevent an acquisition of our company.
•Market and economic conditions may negatively impact our business, financial condition, and share price.
•Business interruptions resulting from disasters or other disturbances could delay us in the process of developing our products and could disrupt our sales.
•Evolving expectations around environmental, social and governance matters may expose us to reputational and other risks.
35

Risks Related to Our Business and Strategy
We have a history of net losses and we may not achieve or maintain profitability.
We have incurred net losses since our inception, including losses of $76.2 million, $33.6 million, and $21.3 million for the years ended December 31, 2023, 2022, and 2021, respectively, and $54.9 million and $69.0 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and December 31, 2023, we had an accumulated deficit of $552.4 million and $497.5 million, respectively. If we are unable to continue to successfully develop and commercialize products in our pharmaceutical manufacturing business, increase sales of existing products and services, develop and commercialize our ECO Synthesis™ manufacturing platform, and or develop new products or services, or otherwise expand our business, whether through new or expanded collaborations or other products and services, our net losses may increase and we may never achieve profitability. In addition, some of our agreements, including the agreements with GSK, Merck, Novartis, Nestlé Health Science, Aldevron, Roche, Crosswalk Therapeutics and Alphazyme provide for milestone payments, usage payments, and/or future royalty or other payments, which we will only receive if we and/or our collaborators develop and commercialize products or achieve technical milestones. We also intend to continue to fund the development of additional proprietary performance enzyme products and advance new technologies like our ECO Synthesis™ manufacturing platform. There can be no assurance that any of these products or services will become commercially viable or that we will ever achieve profitability on a quarterly or annual basis. If we fail to achieve profitability, or if the time required to achieve profitability is longer than we anticipate, we may not be able to continue our business. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.
Biotherapeutic programs are highly regulated and expensive, and our enzyme products are complex and subject to quality control requirements. The ability of our customers, future customers or collaborators, including any company developing RNAi and other RNA-based therapeutics, to advance product candidates utilizing our products to clinical trials and to ultimately receive regulatory approvals is highly uncertain.
Although we are no longer developing our own portfolio of biotherapeutics product candidates, we continue to develop enzyme products, including our ECO Synthesis™ manufacturing platform, that may be used by our customers, future customers or collaborators in connection with their biotherapeutic product candidates. The successful development of biotherapeutic candidates involves many risks and uncertainties, requires long timelines and may lead to uncertain results.
Our customers are subject to extensive regulations by the FDA and similar regulatory authorities in other countries for conducting clinical trials and commercializing products for therapeutic, vaccine or diagnostic use. These regulations result in our customers imposing quality requirements on us for the manufacture of our enzyme products through supplier qualification processes and customer contracts and specifications.
In order to market a biologic or drug product in the United States, our customers, future customers or collaborators must undergo the following process required by the FDA:
•completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA's Good Laboratory Practice requirements;
•submission to the FDA of an Investigational New Drug Application (“IND”), which must become effective before human clinical studies may begin in the United States;
•approval by an independent institutional review board (“IRB”) representing each clinical site before the clinical study may be initiated at the site;
•performance of adequate and well-controlled human clinical studies in accordance with Good Clinical Practice (“GCP”) requirements to establish the safety, purity and potency (or efficacy) of the product candidate for each proposed indication;
•preparation of and submission to the FDA of a Biologics License Application (“BLA”) or New Drug Application (“NDA”)after completion of all clinical studies;
•potential review of the product candidate by an FDA advisory committee;
•satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities where the product candidate is produced to assess compliance with current Good Manufacturing Practice (“cGMP”) requirements;
•FDA review and approval of a BLA or NDA prior to any commercial marketing or sale of the product in the United States; and
36

•any post-approval requirements, if applicable.
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and the results are inherently unpredictable. If our customers, future customers or collaborators are ultimately unable to obtain regulatory approval for their biotherapeutic product candidates utilizing our enzyme products, our business may be harmed. In addition, if our customers, future customers or collaborators fail to comply with applicable FDA or other regulatory requirements at any time during the drug development process, clinical testing, the approval process or after approval, they may become subject to administrative or judicial penalties, including the FDA’s refusal to approve a pending application, withdrawal of an approval, warning letters, product recalls and additional enforcement actions, any of which may have an adverse effect on our financial condition.
We believe our enzyme products are exempt from compliance with the Food, Drug, and Cosmetic Act (“FDCA”) and the current GMP (“cGMP”) regulations of the FDA, as our products are further processed and incorporated into final drug or biologic products by our customers and we do not make claims related to their safety or effectiveness. Our products are manufactured following the voluntary quality standards of ISO 9001:2015. In the event we, or our suppliers, produce products that fail to comply with required quality standards, we may incur delays in fulfilling orders, write-downs, damages resulting from product liability claims and harm to our reputation.
In the future, our products could become subject to more onerous regulation, or the FDA could disagree with our assessment that our enzyme products are exempt from current GMP regulations. In addition, the FDA could conclude that the products we provide to our customers are actually subject to the pharmaceutical, drug or biologic quality-related regulations for manufacturing, processing, packing or holding of drugs, biologics, or finished pharmaceuticals, and could take enforcement action against us, including requiring us to stop distribution of our products until we are in compliance with applicable regulations, which would reduce our revenue, increase our costs and adversely affect our business, prospects, results of operations and financial condition.
We are dependent on a limited number of customers.
Although we continue to expand our customer base, our current revenues are derived from a limited number of key customers. For the nine months ended September 30, 2024 and 2023, customers that each individually contributed 10% or more of our total revenue accounted for 43% and 35% of our total revenues, respectively. We expect a limited number of customers to continue to account for a significant portion of our revenues for the foreseeable future. This customer concentration increases the risk of quarterly fluctuations in our revenues and operating results. The loss or reduction of business from one or a combination of our significant customers could, materially adversely affect our revenues, financial condition and results of operations.
Our product supply agreements with customers have finite duration, may not be extended or renewed and generally do not require the customer to purchase any particular quantity or quantities of our products.
Our product supply agreements with customers generally have a finite duration, may not be extended or renewed and generally do not require the customer to purchase any particular quantity or quantities of our products. While our products are not considered commodities and may not be easily substituted for by our customers, particularly when our products are used in the manufacture of active pharmaceutical ingredients, our customers may nevertheless terminate or fail to renew their product supply agreements with us or significantly curtail their purchases thereunder under certain circumstances. We are working to develop new relationships with existing or new customers, but despite these efforts we may not, at the time that any of our existing product supply agreements expire or are terminated, or purchases thereunder curtailed, have other contracts in place generating similar or material revenue. Any such expiration, termination or reduction could materially adversely affect our revenues, financial condition and results of operations. For the nine months ended September 30, 2024, we derived a majority of our product revenue from these product supply agreements.
The demand for our products depends in part on our customers’ research and development and the clinical and market success of their products. Our business, financial condition, and results of operations may be harmed if our customers spend less on, or are less successful in, these activities. In addition, customer spending may be affected by, among other things, general market and economic conditions beyond our control.
37

Our customers are engaged in research, development, production, and marketing of pharmaceutical products and intermediates. The amount our customers spend on research, development, production, and marketing, as well as the outcomes of such research, development, and marketing activities, have a large impact on our sales and profitability, particularly the amount our customers choose to spend on our offerings. Available resources, the need to develop new products, and consolidation in the industries in which our customers operate may have an impact on such spending. Our customers and potential customers finance their research and development spending from private and public sources. A reduction in available financing for and spending by our customers, for these reasons or because of continued unstable or unpredictable economic and marketplace conditions, could have a material adverse effect on our business, financial condition, and results of operations. If our customers are not successful in attaining or retaining product sales due to market conditions, reimbursement issues, or other factors, our results of operations may be materially adversely affected.
With respect to customers purchasing our products for the manufacture of APIs for which they have exclusivity due to patent protection, the termination or expiration of such patent protection and any resulting generic competition may materially and adversely affect our revenues, financial condition or results of operations.
With respect to customers purchasing our products for the manufacture of API, or lead to the manufacture of API, for which exclusivity due to patent protection has or is about to expire, we can expect that the quantity of our products sold to such customers for such products may decline as generic competition for the API increases. While we anticipate that we may, in some cases, also be able to sell products to these generic competitors for the manufacture of these APIs, or lead to the manufacture of these APIs, the overall effect on our revenues, financial condition and results of operations could be materially adverse.
We are dependent on a limited number of contract manufacturers for large scale production of substantially all of our enzymes. We are working to qualify new contract manufacturers to produce certain of our enzymes, however those efforts may not be successful and therefore we may experience limitations on our ability to supply our enzymes to customers.
Manufacturing of our enzymes is conducted primarily in four locations: our in-house facility in Redwood City, California, and at three third-party contract manufacturing organizations, Lactosan in Kapfenberg, Austria, ACSD in Anagni, Italy, and Sekisui in Maidstone, United Kingdom. Generally, we perform smaller scale manufacturing in-house and outsource the larger scale manufacturing to these contract manufacturers. We have limited internal capacity to manufacture enzymes. As a result, we are dependent upon the performance and capacity of third-party manufacturers for the larger scale manufacturing of the enzymes used in our pharmaceutical and life sciences businesses.
Accordingly, we face risks of difficulties with, and interruptions in, performance by third party manufacturers, the occurrence of which could adversely impact the availability, launch and/or sales of our enzymes in the future. Enzyme manufacturing capacity limitations at our third-party manufacturers and manufacturing delays could negatively affect our business, reputation, results of operations and financial condition. The failure of any contract manufacturer to supply us our required volumes of enzyme on a timely basis, or to manufacture our enzymes in compliance with our specifications or applicable quality requirements or in volumes sufficient to meet demand, would adversely affect our ability to sell pharmaceutical and complex chemicals products, could harm our relationships with our customers or collaborators and could negatively affect our revenues and operating results. We may be forced to secure alternative sources of supply, which may be unavailable on commercially acceptable terms, and could cause delays in our ability to deliver products to our customers, increase our costs and decrease our profit margins.
We currently have supply agreements in place with Lactosan, ACSD and Sekisui. In the absence of a supply agreement, a contract manufacturer will be under no obligation to manufacture our enzymes and could elect to discontinue their manufacture at any time. If we require additional manufacturing capacity and are unable to obtain it in sufficient quantity, we may not be able to increase our product sales, or we may be required to make substantial capital investments to build that capacity or to contract with other manufacturers on terms that may be less favorable than the terms we currently have with our suppliers. If we choose to build our own additional manufacturing facility, it could take several years or longer before our facility is able to produce commercial volumes of our enzymes. Any resources we expend on acquiring or building internal manufacturing capabilities could be at the expense of other potentially more profitable opportunities. In addition, if we contract with other manufacturers, we may experience delays of several months in qualifying them, which could harm our relationships with our customers or collaborators and could negatively affect our revenues or operating results.
38

We are dependent on our collaborators, and our failure to successfully manage these relationships could prevent us from developing and commercializing many of our products and achieving or sustaining profitability, and could lead to disagreements with our current or former collaborators.
Our ability to maintain and manage collaborations in our markets is fundamental to the success of our business. We currently have license agreements, research and development agreements, supply agreements and/or distribution agreements with various collaborators. For example, we have ongoing collaborations and agreements with GSK, Merck, Novartis, Roche, Aldevron and Alphazyme that are important to our business and financial results. We may have limited or no control over the amount or timing of resources that any collaborator is able or willing to devote to our partnered products or collaborative efforts. Any of our collaborators may fail to perform its obligations. These collaborators may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully and in a timely manner. Further, our collaborators may not develop products arising out of our collaborative arrangements or devote sufficient resources to the development, manufacture, marketing or sale of these products. Moreover, disagreements with a collaborator could develop, and any conflict with a collaborator could lead to litigation, reduce our ability to enter into future collaboration agreements and negatively impact our relationships with one or more existing collaborators. If any of these events occur, especially if they occur in our collaborations with GSK, Merck or Novartis, or if we fail to maintain our agreements with our collaborators, we may not be able to commercialize our existing and potential products or grow our business or generate sufficient revenues to support our operations, we may not receive contemplated milestone payments and royalties under the collaboration, and we may be involved in litigation. Our collaboration opportunities could be harmed and our financial condition and results of operations could be negatively affected if:
•we do not achieve our research and development objectives under our collaboration agreements in a timely manner or at all;
•we develop products and processes or enter into additional collaborations that conflict with the business objectives of our other collaborators;
•our collaborators and/or our contract manufacturers do not receive the required regulatory and other approvals necessary for the commercialization of the applicable product;
•we disagree with our collaborators as to rights to intellectual property that are developed during the collaboration, or their research programs or commercialization activities;
•we are unable to manage multiple simultaneous collaborations;
•our collaborators or licensees are unable or unwilling to implement or use the technology or products that we provide or license to them;
•our collaborators become competitors of ours or enter into agreements with our competitors;
•our collaborators become unable or less willing to expend their resources on research and development or commercialization efforts due to general market conditions, their financial condition or other circumstances beyond our control; or
•our collaborators experience business difficulties, which could eliminate or impair their ability to effectively perform under our agreements.
Even after collaboration relationships expire or terminate, some elements of the collaboration may survive. For instance, certain rights, licenses and obligations of each party with respect to intellectual property and program materials may survive the expiration or termination of the collaboration. Disagreements or conflicts between and among the parties could develop even though the collaboration has ended. These disagreements or conflicts could result in expensive arbitration or litigation, which may not be resolved in our favor.
Finally, our business could be negatively affected if any of our collaborators or suppliers undergoes a change of control or were to otherwise assign the rights or obligations under any of our agreements.
If we are unable to develop and commercialize new products for the pharmaceutical, biotherapeutics, diagnostics and life science tools markets, our business and prospects will be harmed.
We plan to launch new products for the pharmaceutical, biotherapeutics, diagnostics and other life science tools markets such as our ECO Synthesis™ manufacturing platform. These efforts are subject to numerous risks, including the following:
39

•customers in these markets may be reluctant to adopt new manufacturing processes that use our enzymes;
•we may be unable to successfully develop the enzymes or manufacturing processes for our products in a timely and cost-effective manner, if at all;
•we may face difficulties in transferring the developed technologies to our customers and the contract manufacturers that we may use for commercial scale production of intermediates and enzymes in these markets;
•the biotherapeutics products that use our tools may not receive regulatory approval or be commercially viable;
•the contract manufacturers that we may use may be unable to scale their manufacturing operations to meet the demand for these products and we may be unable to secure additional manufacturing capacity;
•customers may not be willing to purchase these products for these markets from us on favorable terms, if at all;
•we may face product liability litigation, unexpected safety or efficacy concerns and product recalls or withdrawals;
•our customers’ products may experience adverse events or face competition from new products, which would reduce demand for our products;
•we may face pressure from existing or new competitive products; and
•we may face pricing pressures from existing or new competitors, some of which may benefit from government subsidies or other incentives.
We have invested significant resources to enable enzymatic nucleic acid synthesis, which is based on novel ideas and technologies that are largely unproven.

Our ECO Synthesis™ manufacturing platform is currently in development to enable the commercial-scale manufacture of RNAi and other RNA-based therapeutics through an enzymatic route. While we believe enzymatic nucleic acid synthesis will offer certain improvements over phosphoramidite chemistry, including with respect to required infrastructure investments, batch size limitations and waste disposal challenges, the enzymatic route is novel and has not yet been commercialized. As such, we may be faced with unforeseen results, delays and setbacks, in addition to the other foreseeable risks and uncertainties associated with the ongoing development of the ECO Synthesis™ manufacturing platform and other products.

Other challenges with a new technology such as our ECO Synthesis™ manufacturing platform include having an unknown and unproven development and regulatory path, uncertainly around the value that we can realize from the technology, uncertainty around the timeline for adoption of the technology by customers, and uncertainly around our ability to secure supply of necessary materials or to manufacture at GMP scale and partner with customers on manufacturing and utilizing the technology. We may also be unable to achieve the expected benefits of the ECO Synthesis™ manufacturing platform in a timely manner or at all.

There can be no assurance that these events we may experience in the future related to enzymatic synthesis will not cause significant delays or unanticipated costs, or that such development problems can be solved. Any delay or difficulties in developing and commercializing our ECO Synthesis™ manufacturing platform or any of our other current or future products could adversely affect our business and operations.
Competitors and potential competitors who have greater resources and experience than we do may develop products and technologies that make ours obsolete or may use their greater resources to gain market share at our expense.
The biocatalysis and performance enzyme industries and each of our target markets are characterized by rapid technological change. Our future success will depend on our ability to maintain a competitive position with respect to technological advances. In addition, as we enter new markets, we will face new competition and will need to adapt to competitive factors that may be different from those we face today.
We are aware that other companies, including DSM, BASF, Bayer and Novozymes have alternative methods for obtaining and generating genetic diversity or use mutagenesis techniques to produce genetic diversity. Academic institutions such as the California Institute of Technology, the Max Planck Institute and the Austrian Centre of Industrial Biotechnology are also working in this field. Technological development by others may result in our technology, products and services, as well as products developed by our customers using our biocatalysts, becoming obsolete.
40

Our primary competitors in the performance enzymes for the pharmaceutical products markets include (i) companies marketing either conventional, non-enzymatic processes or biocatalytic enzymes; (ii) manufacturers of pharmaceutical intermediates and APIs; and (iii) existing in-house technologies (both biocatalysts and conventional catalysts) within our client and potential client companies. The principal methods of competition and competitive differentiation in this market are price, product quality and performance, including manufacturing yield, safety and environmental benefits, and speed of delivery of product. Pharmaceutical manufacturers that use biocatalytic processes can face increased competition from manufacturers that use more conventional processes and/or manufacturers that are based in regions (such as India and China) with lower regulatory, safety and environmental costs.
The market for the manufacture and supply of APIs and intermediates is large with many established companies. These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer, Bristol-Myers, Kyorin, Urovant, and Teva which have significant internal research and development efforts directed at developing processes to manufacture APIs and intermediates. The processes used by these companies include classical conventional organic chemistry reactions, chemo catalytic reactions, biocatalytic reactions or combinations thereof. Our biocatalytic based manufacturing processes must compete with these internally developed routes. Additionally, we also face competition from companies developing and marketing conventional catalysts such as Solvias Inc., BASF and Takasago International Corporation.
The market for supplying enzymes for use in pharmaceutical manufacturing is quite fragmented. There is competition from large industrial enzyme companies, such as Novozymes and DuPont, as well as subsidiaries of larger contract research/contract manufacturing organizations, such as DSM, Cambrex Corporation, Lonza, WuXi STA and Almac Group Ltd. Some fermentation pathway design companies, like Ginkgo Bioworks (who recently acquired Zymergen), whose traditional focus has been to design microorganisms that express small molecule chemicals, could extend into designing organisms that express enzymes. There is also competition in the enzyme customization and optimization area from several smaller companies, such as BRAIN AG, Arzeda, c-LEcta GmbH and Evocatal GmbH.
We face competitive challenges related to our ECO Synthesis™ manufacturing platform. Phosphoramidite chemistry is the current and long-established industry standard for the manufacture of RNA therapeutics. Primary competitors in this space include CDMOs, such as Agilent Technologies, which has made significant capital investment to expand their RNA manufacturing capabilities using phosphoramidite chemistry. In addition, CDMOs and large pharmaceutical companies are seeking to make incremental improvements to phosphoramidite chemistry, including the development of ligation-based approaches, liquid-phase synthesis, and solvent recycling. There are also multiple early-stage competitors who are pursuing fully enzymatic approaches to the manufacture of RNA, including EnPlusOne, a private startup company, and a UK-based consortium led by CPI and consisting of multiple academic and research organizations, including The University of Manchester and large pharmaceutical companies, including AstraZeneca plc and Novartis.
Our ability to compete successfully in any of these markets will depend on our ability to develop proprietary products that reach the market in a timely manner and are technologically superior to and/or are less expensive than other products on the market. Many of our competitors have substantially greater production, financial, research and development, personnel and marketing resources than we do. They also started developing products earlier than we did, which may allow them to establish blocking intellectual property positions or bring products to market before we can. In addition, certain of our competitors may also benefit from local government subsidies and other incentives that are not available to us. As a result, our competitors may be able to develop competing and/or superior technologies and processes and compete more aggressively and sustain that competition over a longer period of time than we could. Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors. We cannot be certain that any products we develop in the future will compare favorably to products offered by our competitors or that our existing or future products will compare favorably to any new products that are developed by our competitors. As more companies develop new intellectual property in our markets, the possibility of a competitor acquiring patent or other rights that may limit our products or potential products increases, and could additionally lead to litigation.
Our limited resources relative to many of our competitors may cause us to fail to anticipate or respond adequately to new developments and other competitive pressures. This failure could reduce our competitiveness and market share, adversely affect our results of operations and financial position, and prevent us from obtaining or maintaining profitability.
41

Revenues in future years from our sales of CDX-616 to Pfizer are subject to a number of factors which are outside of our control and may not materialize.
Starting the first and second quarters of 2021, we began to receive purchase orders from Pfizer for large quantities of our proprietary enzyme product, CDX-616, for use by Pfizer in the manufacture of a critical intermediate for its proprietary active pharmaceutical ingredient, nirmatrelvir. Pfizer markets, sells and distributes nirmatrelvir, in combination with the active pharmaceutical ingredient ritonavir, as its PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) product, which received FDA approval in May 2023 for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Potential revenues in future years from our sales of CDX-616 to Pfizer and other potential customers (including sublicensees of Pfizer technology from The Medicines Patent Pool (the “MPP”)) are subject to a number of factors which are outside of our control, including, without limitation, the following, all of which could reduce or eliminate our sales of CDX-616, and therefore materially and adversely affect our business, results of operations and financial condition:
•Pfizer has no future binding commitment to purchase any particular quantity or quantities of CDX-616 from us, and we are dependent upon Pfizer continuing to place orders with us (whether on a spot basis or under a long-term agreement, when and if executed) for their requirements, if any, for CDX-616;
•to our knowledge, sublicensees of Pfizer technology from the MPP have no obligation to purchase CDX-616 from us under their sublicenses with the MPP;
•future vaccine development and usage and the development and usage of other new therapies for the treatment or elimination of COVID-19 may eliminate or reduce demand for PAXLOVID™;
•new variants of COVID-19 may emerge which PAXLOVID™ is not effective in treating;
•Pfizer could reformulate or make changes in the manufacturing process for nirmatrelvir which would eliminate or reduce demand for the use of CDX-616 in its manufacture;
•sublicensees of Pfizer technology for the manufacture, sale and distribution of PAXLOVID™ from the MPP may not utilize CDX-616 in the manufacture of nirmatrelvir;
•national and regional governmental authorities (including those of the United States government) may mandate that raw materials and intermediates used in the manufacture of PAXLOVID™ to be marketed, sold and distributed within the borders of that country be domestically produced, which could eliminate or reduce demand for the use of CDX-616 in such country; and
•we may be unable (because of lack of available manufacturing capacity at our contract manufacturers, supply chain disruptions or an inability to obtain applicable regulatory approvals) to manufacture the quantities of CDX-616 that Pfizer may desire to purchase from us.
We have investments in non-marketable securities, which may subject us to significant impairment charges.
We have investments in illiquid or non-marketable equity securities acquired in private transactions. As of September 30, 2024, 3.9% of our consolidated assets consisted of investment securities, which are illiquid investments. Investments in non-marketable, securities are inherently risky and difficult to value. We account for our non-marketable equity securities under the measurement alternative. Under the measurement alternative, the carrying value of our non-marketable equity investments is adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. We evaluate our investment in non-marketable securities when circumstances indicate that we may not be able to recover the carrying value. We may impair these securities and establish an allowance for a credit loss when we determine that there has been an “other-than-temporary” decline in estimated fair value of the equity security compared to its carrying value. The impairment analysis requires significant judgment to identify events or circumstances that would likely have a material adverse effect on the fair value of the investment. Future impairment charges from the write down in value of these securities could have a material adverse effect on our financial condition or results of operations.
42

Ethical, legal and social concerns about genetically engineered products and processes could limit or prevent the use of our technology, products and processes and limit our revenues.
Some of our technology, products and services, such as our ECO Synthesis™ manufacturing platform, are genetically engineered or involve the use of genetically engineered products or genetic engineering technologies. If we and/or our collaborators are not able to overcome the ethical, legal, and social concerns relating to genetic engineering, our technology, products and services may not be accepted. Any of the risks discussed below could result in increased expenses, delays, or other impediments to our programs or the public acceptance and commercialization of products and processes dependent on our technologies or inventions. Our ability to develop and commercialize one or more of our technologies, products, or processes could be limited by the following factors:
•public attitudes about the safety and environmental hazards of, and ethical concerns over, genetic research and genetically engineered products and processes, which could influence public acceptance of our technologies, products and processes;
•public attitudes regarding, and potential changes to laws governing ownership of, genetic material, which could harm our intellectual property rights with respect to our genetic material and/or discourage collaborators from supporting, developing, or commercializing our technology, products and services; and
•governmental reaction to negative publicity concerning genetically modified organisms, which could result in greater government regulation of genetic research and derivative products.
The subject of genetically modified organisms has received negative publicity, which has aroused public debate. This adverse publicity could lead to greater regulation and trade restrictions on imports of genetically altered products. The biocatalysts that we develop have significantly enhanced characteristics compared to those found in naturally occurring enzymes or microbes. While we produce our biocatalysts only for use in a controlled industrial environment, the release of such biocatalysts into uncontrolled environments could have unintended consequences. Any adverse effect resulting from such a release could have a material adverse effect on our business and financial condition, damage our reputation, and/or expose us to liability for any resulting harm.
We have recently enhanced our strategic focus to concentrate on certain programs and business lines. As a result of this refined focus, we may fail to capitalize on other opportunities that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we have recently focused our efforts on developing certain programs and business lines. As a result, we may forego or delay pursuit of business opportunities that later prove to have greater commercial potential. Further our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, our spending on current and future research and development programs, such as ECO Synthesis™ manufacturing platform that is in development, may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular program or business line, our business and results of operations could be harmed.
Given our recent change in strategic direction, we may receive limited revenue or no future value from certain of our existing license agreements.
While we have historically invested significant time and financial resources in the development of biotherapeutics assets, we announced we are terminating investment in our biotherapeutics business and in other programs. As a result, we are renegotiating some of these, along with other license agreements for product candidates in our biotherapeutics, food and feed, and non-core life science assets. For example, we entered into the Acquisition Agreement with Nestlé Health Science under which they acquired rights to our co-developed lipase enzyme CDX-7108 and we received an upfront payment and the right to downstream milestones and royalties, terminating our prior SCA and development agreement with Nestlé Health Science. While we are working to amend or terminate some of our agreements and enter into new agreements in such a way that we may be able to receive future revenue or other benefits, we may be unsuccessful in doing so. As a result, it remains uncertain as to whether we will receive any value or benefit from these license agreements going forward. Further, renegotiating these agreements may be costly and could divert management attention, which could have an adverse impact on our business and results of operations.
43

Our efforts to deploy our technology in the life science tools markets may fail.
We have used our CodeEvolver® directed evolution technology platform to develop new products for customers using NGS and PCR/qPCR for in vitro molecular diagnostic applications. While we have entered into license agreements for products in this market, we do not know if our partners or licensees can successfully compete in this market. This new market is well established and consists of numerous large, well-funded entrenched market participants who have long and established track records and customer relationships.
We use hazardous materials in our business and we must comply with environmental laws and regulations. Any claims relating to improper handling, storage or disposal of these materials or noncompliance of applicable laws and regulations could be time consuming and costly and could adversely affect our business and results of operations.
Our research and development, manufacturing, and commercial processes involve the use of hazardous materials, including chemical, radioactive and biological materials, such as acetonitrile, which is used in some of our purification processes. Our operations also produce hazardous waste. We cannot eliminate entirely the risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state, local and foreign laws and regulations govern the use, manufacture, storage, handling and disposal of, and human exposure to, these materials. We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our total assets. Although we believe that our activities comply in all material respects with environmental laws, there can be no assurance that violations of environmental, health and safety laws will not occur in the future as a result of human error, accident, equipment failure or other causes. Compliance with applicable environmental laws and regulations may be expensive, and the failure to comply with past, present or future laws could result in the imposition of fines, third party property damage, product liability and personal injury claims, investigation and remediation costs, the suspension of production or a cessation of operations, and our liability may exceed our total assets. Liability under environmental laws can be joint and several and without regard to comparative fault. Environmental laws could become more stringent over time imposing greater compliance costs and increasing risks and penalties associated with violations, which could impair our research, development or production efforts and harm our business. In addition, we may be required to indemnify some of our customers or suppliers for losses related to our failure to comply with environmental laws, which could expose us to significant liabilities.
Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.
In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards (“NOLs”), to offset future taxable income. If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations arising from previous ownership changes, our ability to utilize NOLs could be limited by Section 382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. For these reasons, we may not be able to utilize a material portion of the NOLs reflected in our financial statements, even if we attain profitability.
As a public reporting company, we are subject to rules and regulations established from time to time by the SEC and Nasdaq regarding our internal controls over financial reporting. We may not complete needed improvements to our internal controls over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may adversely affect investor confidence in our company and, as a result, the value of our common stock and your investment.
We are subject to the rules and regulations established from time to time by the SEC and Nasdaq. These rules regulations require, among other things, that we establish and periodically evaluate procedures with respect to our internal controls over financial reporting. As part of these evaluations, material weaknesses in our internal controls over financial reporting may be identified. A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis. While we were able to remediate previously identified material weaknesses in our internal controls over financial reporting, there can be no guarantee we will not identify similar or other material weaknesses in the future and if such material weaknesses are identified, there can be no guarantee we would be able to remediate such material weaknesses. Any material weaknesses in our internal controls may adversely affect our ability to record, process, summarize and accurately report timely financial information and, as a result, our consolidated financial statements may contain material misstatements or omissions.
44

Reporting obligations as a public company place a considerable strain on our financial and management systems, processes and controls, as well as on our personnel. In addition, as a public company we are required to document and test our internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act so that our management can certify as to the effectiveness of our internal controls over financial reporting. Likewise, while we currently qualify as a “smaller reporting company” under the SEC rules, for any fiscal years in which we are not considered a smaller reporting company, our independent registered public accounting firm is required to provide an attestation report on the effectiveness of our internal controls over financial reporting in our Annual Reports on Form 10-K. If our management is unable to certify the effectiveness of our internal controls or if our independent registered public accounting firm cannot deliver a report attesting to the effectiveness of our internal controls over financial reporting, or if we identify or fail to remediate material weaknesses in our internal controls, we could be subject to regulatory scrutiny and a loss of public confidence, which could seriously harm our reputation and the market price of our common stock. In addition, if we do not maintain adequate financial and management personnel, processes and controls, we may not be able to manage our business effectively or accurately report our financial performance on a timely basis, which could cause a decline in our common stock price and may seriously harm our business.
We may need additional capital in the future in order to expand our business.
Our future capital requirements may be substantial, particularly as we continue to develop our business. Although we believe that, based on our current level of operations, our existing cash, cash equivalents and equity securities will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months, we may need additional capital if our current plans and assumptions change. Our need for additional capital will depend on many factors, including the financial success of our performance enzyme business, our spending to develop and commercialize new and existing enzyme products and the amount of collaboration funding we may receive to help cover the cost of such expenditures, the effect of any acquisitions of other businesses, technologies or facilities that we may make or develop in the future, our spending on new market opportunities, including the ongoing commercialization of our ECO Synthesis™ manufacturing platform, scaling the ECO Synthesis™ manufacturing platform to GMP capability, and the filing, prosecution, enforcement and defense of patent claims. If our capital resources are insufficient to meet our capital requirements, and we are unable to enter into or maintain collaborations with partners that are able or willing to fund our development efforts or commercialize any enzyme products that we develop or enable, we will have to raise additional funds to continue the development of our technology and products and complete the commercialization of products, if any, resulting from our technologies.
In addition, we may choose to raise additional capital due to market conditions or strategic considerations, such as funding the ongoing commercialization of our ECO Synthesis™ manufacturing platform and a GMP manufacturing facility, even if we believe we have sufficient funds for our current or future operating plans. We may seek to obtain such additional capital through equity offerings, including pursuant to the Cantor Sales Agreement, debt financings, credit facilities and/or strategic collaborations. If future financings involve the issuance of equity securities, our existing stockholders would suffer dilution. In addition, under our Loan Agreement, we are subject to restrictive covenants that limit our ability to conduct our business and could be subject to additional covenants to the extent we seek other debt financing in the future. Strategic collaborations may also place restrictions on our business. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and fail to generate sufficient revenues to achieve planned gross margins and to control operating costs, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research or development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.
Covenants and other provisions in our Loan Agreement with Innovatus restrict our business and operations in many ways, and if we do not effectively manage our covenants, our financial conditions and results of operations could be adversely affected. In addition, our operations may not provide sufficient cash to meet the repayment obligations of our debt incurred under the Loan Agreement.
Pursuant to the Loan Agreement, Innovatus has been granted a security interest in substantially all of our assets. If an event of default occurs under the Loan Agreement, Innovatus may foreclose on its security interest and liquidate some or all of these assets, which would harm our business, financial condition and results of operations.
In the event of a default in connection with our bankruptcy, insolvency, liquidation, or reorganization, Innovatus would have a prior right to substantially all of our assets to the exclusion of our general unsecured creditors. Only after satisfying the claims of Innovatus and any unsecured creditors would any amount be available for our equity holders.
45

The pledge of these assets and other restrictions imposed in the Loan Agreement may limit our flexibility in raising capital for other purposes. Because substantially all of our assets are pledged to secure the Loan Agreement obligations, our ability to incur additional indebtedness or to sell or dispose of assets to raise capital may be impaired, which could have an adverse effect on our financial flexibility.

In addition, if we are unable to comply with certain financial and operating restrictions in the Loan Agreement, we may be limited in our business activities and access to credit or may default under the Loan Agreement. Provisions in the Loan Agreement impose restrictions or require prior approval on our ability, and the ability of certain of our subsidiaries to, among other things:
•sell, lease or transfer certain parts of our business or property, including equity interests of our subsidiaries;
•engage in new lines of business;
•acquire new companies and merge or consolidate;
•incur additional debt or guarantee the indebtedness of others or our subsidiaries;
•create liens or encumbrances;
•pay cash dividends and make distributions or redeem or repurchase our capital stock;
•make certain investments;
•enter into transactions with affiliates; and
•terminate or, in certain cases, amend our material agreements.

The Loan Agreement also contains other customary covenants. We may not be able to comply with these covenants in the future. Our failure to comply with these covenants may result in the declaration of an event of default, which, if not cured or waived, may result in the acceleration of the maturity of indebtedness outstanding under the Loan Agreement and would require us to pay all amounts outstanding. If the maturity of our indebtedness is accelerated, we may not have sufficient funds then available for repayment or we may not have the ability to borrow or obtain sufficient funds to replace the accelerated indebtedness on terms acceptable to us or at all. Our failure to repay our obligations under the Loan Agreement would result in Innovatus foreclosing on all or a portion of our assets, which could force us to curtail or cease our operations.
If we engage in any acquisitions, we will incur a variety of costs and may potentially face numerous risks that could adversely affect our business and operations.
We have made acquisitions in the past, and if appropriate opportunities become available, we expect to acquire additional businesses, assets, technologies, or products to enhance our business in the future. For example, in October 2010, we acquired substantially all of the patents and other intellectual property rights associated with Maxygen Inc.’s directed evolution technology.
In connection with any future acquisitions, we could:
•issue additional equity securities, which would dilute our current stockholders;
•incur substantial debt to fund the acquisitions;
•use our cash to fund the acquisitions; or
•assume significant liabilities including litigation risk.
46

Acquisitions involve numerous risks, including problems integrating the purchased operations, technologies or products, unanticipated costs and other liabilities, diversion of management’s attention from our core businesses, adverse effects on existing business relationships with current and/or prospective collaborators, customers and/or suppliers, risks associated with entering markets in which we have no or limited prior experience and potential loss of key employees. We do not have extensive experience in managing the integration process and we may not be able to successfully integrate any businesses, assets, products, technologies or personnel that we might acquire in the future without a significant expenditure of operating, financial and management resources, if at all. The integration process could divert management’s time from focusing on operating our business, result in a decline in employee morale and cause retention issues to arise from changes in compensation, reporting relationships, future prospects or the direction of the business. Acquisitions may also require us to record goodwill and non-amortizable intangible assets that will be subject to impairment testing on a regular basis and potential periodic impairment charges, incur amortization expenses related to certain intangible assets, and incur large and immediate write offs and restructuring and other related expenses, all of which could harm our operating results and financial condition. In addition, we may acquire companies that have insufficient internal financial controls, which could impair our ability to integrate the acquired company and adversely impact our financial reporting. If we fail in our integration efforts with respect to any of our acquisitions and are unable to efficiently operate as a combined organization, our business and financial condition may be adversely affected.
COVID-19 has adversely affected, and any resurgence of COVID-19 pandemic or another global health epidemic may in the future, directly or indirectly, adversely affect our business, results of operations and financial condition.
COVID-19 has had a significant impact globally, prompting governments and businesses to take unprecedented measures in response. In the United States, COVID-19 has and may continue in the future to, directly or indirectly, adversely affect our business, results of operations and financial condition.
In the future, our business could be materially adversely affected, directly or indirectly, by the widespread outbreak of contagious disease, such as COVID-19 or any resurgence thereof. If national, state and local governments in affected regions implement safety precautions, similar to those implemented in response to COVID-19, including quarantines, border closures, increased border controls, travel restrictions, governmental orders and shutdowns, business closures, cancellations of public gatherings and other measures, such precautions could, and for COVID-19 did, disrupt normal business operations both in and outside of affected areas and could have significant negative impacts on businesses and financial markets worldwide.
The impact of COVID-19 has had, and any resurgence of the COVID-19 pandemic or another pandemic or public health crisis, could in the future have, significant repercussions across regional, national and global economies and financial markets, and could trigger a period of regional, national and global economic slowdown or regional, national or global recessions. The outbreak of COVID-19 in many countries adversely impacted regional, national and global economic activity and has continued to contribute to significant volatility and negative pressure in financial markets. As a result, we may experience difficulty accessing debt and equity capital on attractive terms, or at all, due to the severe disruption and instability in the global financial markets. In addition, our customers may terminate or amend their agreements for the purchase of our technology, products and services due to bankruptcy, lack of liquidity, lack of funding, operational failures or other reasons.
47

Risks Related to Government Regulation
Even if our customers, future customers or collaborators obtain regulatory approval for any products utilizing our enzymes, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.
Any products that receives FDA approval will remain subject to ongoing regulatory requirements for manufacturing, labeling, packaging, distribution, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information, among other things. Any regulatory approvals received for such products may also be subject to limitations on the approved indicated uses for which they may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance studies. For example, the holder of an approved NDA or BLA in the United States is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the NDA or BLA. In the United States, the holder of an approved NDA or BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Similar provisions apply in the European Union (the “EU”). Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Similarly, in the EU any promotion of medicinal products is highly regulated and, depending on the specific jurisdiction involved, may require prior vetting by the competent national regulatory authority. In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA, BLA or foreign marketing application.
If our customers, future customers or our collaborators or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of that product, a regulatory agency may impose restrictions relative to that product, the manufacturing facility or our customers or collaborators, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.
In addition, if our customers or collaborators fail to comply with applicable regulatory requirements, the FDA and other regulatory authorities may:
•issue an untitled letter or a warning letter asserting a violation of the law;
•seek an injunction, impose civil or criminal penalties, and impose monetary fines, restitution or disgorgement of profits or revenues;
•suspend or withdraw regulatory approval;
•issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;
•mandate modification of promotional materials and labeling and issuance of corrective information;
•issue consent decrees or corporate integrity agreements, or debar or exclude from federal healthcare programs;
•suspend or terminate any ongoing clinical trials or implement requirements to conduct post-marketing studies or clinical trials;
•refuse to approve a pending NDA, BLA or comparable foreign marketing application (or any supplements thereto);
•restrict the labeling, marketing, distribution, use or manufacturing of products;
•seize or detain products or otherwise require the withdrawal or recall of products from the market;
•refuse to approve pending applications or supplements to approved applications;
•refuse to permit the import or export of products; or
•refuse government contracts.
Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may also inhibit our customers or collaborators’ ability to commercialize products and our ability to generate revenues.
48

In addition, the FDA’s policies, and policies of foreign regulatory agencies, may change, including due to judicial challenges, and additional regulations may be enacted that could prevent, limit or delay regulatory approval of product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.
If we or our customers fail to comply with certain healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.
The healthcare industry is highly regulated. We, and our customers, are subject to various local, state, federal, national, and international laws and regulations, which include laws and regulations promulgated by the FDA, HHS, state boards of pharmacy, state health departments, and similar regulatory bodies in other countries. Additionally, our business operations and future arrangements with investigators, healthcare professionals, and consultants, among others, may expose us and our customers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, the federal Civil Monetary Penalties Law, and analogous state laws. These laws may constrain the business or financial arrangements and relationships through which we will conduct our operations. Because of the breadth of these laws and narrowness of available statutory and regulatory exceptions, it is possible that some of our business activities could be regulated by or subject to challenge under one or more of such laws. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts of our employees, agents, contractors, or collaborators that turn out to violate any of the laws described above. If we or our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, imprisonment and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results.
Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.
In the United States, there have been, and we expect there will continue to be, a number of legislative initiatives to contain healthcare costs. Some of these initiatives, such as ongoing healthcare reform, including with respect to reforming drug pricing, adverse changes in governmental or private funding of healthcare products and services, legislation or regulations governing patient access to care, and the delivery, coverage, pricing, and reimbursement of pharmaceuticals and healthcare services may cause our customers to change the amount of our offerings that they purchase from us or the price they are willing to pay us for these offerings. If cost-containment efforts or other healthcare reform measures limit our customers’ profitability, they may decrease research and development spending, which could decrease the demand for our products and services and materially adversely affect our growth prospects. Any of these factors could harm our customers’ businesses, which, in turn, could materially adversely affect our business, financial condition, results of operations, cash flows, and prospects.
We cannot predict the likelihood, nature, or extent of other health reform initiatives that may arise from future legislative, administrative, or other action. Any substantial revision of applicable healthcare legislation could have a material adverse effect on the demand for our customers’ products, which in turn could have a negative impact on our results of operations, financial condition, or business. Changes in the healthcare industry’s pricing, selling, inventory, distribution, or supply policies or practices, or in public or government sentiment for the industry as a whole, could also significantly reduce our revenue and results of operations.
Compliance with European Union chemical regulations could be costly and adversely affect our business and results of operations.
Some of our products are subject to the EU regulatory regime known as The Registration, Evaluation and Authorization of Chemicals (“REACH”). REACH mandates that certain chemicals manufactured in, or imported into, the EU be registered and evaluated for their potential effects on human health and the environment. Under REACH, we and our contract manufacturers located in the EU are required to register certain of our products based on the quantity of such product imported into or manufactured in the EU and on the product’s intended end-use. The registration, evaluation and authorization process under REACH can be costly and time consuming. Problems or delays in the registration, evaluation or authorization process under REACH could delay or prevent the manufacture of some of our products in, or the importation of some of our products into, the EU, which could adversely affect our business and results of operations. In addition, if we or our contract manufacturers fail to comply with REACH, we may be subject to penalties or other enforcement actions, which could have a material adverse effect on our business and results of operations.
49

The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to change, including due to judicial challenges.
On June 28, 2024, the U.S. Supreme Court issued an opinion holding that courts reviewing agency action pursuant to the Administrative Procedure Act “must exercise their independent judgment” and “may not defer to an agency interpretation of the law simply because a statute is ambiguous.” The decision will have a significant impact on how lower courts evaluate challenges to agency interpretations of law, including those by the FDA and other agencies with significant oversight of the biopharmaceutical industry. The new framework is likely to increase both the frequency of such challenges and their odds of success by eliminating one way in which the government previously prevailed in such cases. As a result, significant regulatory policies will be subject to increased litigation judicial scrutiny. Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict.
Risks Related to Intellectual Property and Information Technology
Our efforts to prosecute, maintain, protect and/or defend our intellectual property rights may not be successful.
We will continue to file and prosecute patent applications and maintain trade secrets in an ongoing effort to protect our intellectual property rights. It is possible that our current patents, or patents which we may later acquire, may be successfully challenged or invalidated, in whole or in part. It is also possible that we may not obtain issued patents from our pending patent applications. We sometimes permit certain patents or patent applications to lapse or go abandoned under appropriate circumstances. Due to uncertainties inherent in prosecuting patent applications, sometimes patent applications are rejected, and we subsequently abandon them. It is also possible that we may develop proprietary technology, products or services in the future that are not patentable or that the patents of others will limit or altogether preclude our ability to conduct business. In addition, any patent issued to us or to our licensor may provide us with little or no competitive advantage, in which case we may abandon such patent, license it to another entity or terminate the license agreement.
Our means of protecting our proprietary rights may not be adequate and our competitors may independently develop technologies, products or services that are identical or similar to ours or that compete with ours. Patent, trademark, copyright and trade secret laws afford only limited protection for our technology, products and services. The laws of many countries do not protect our proprietary rights to as great of an extent as do the laws of the United States. Despite our efforts to protect our proprietary rights, unauthorized parties have in the past attempted, and may in the future attempt, to operate under the aspects of our intellectual property rights, or proprietary technology, products or services or products, or to obtain and use information that we regard as proprietary. Third parties may also design around our proprietary rights, which may render our protected technology, services and products less valuable, if the design around is favorably received in the marketplace. In addition, if any of our technology, products and services are covered by third-party patents or other intellectual property rights, we could be subject to various legal actions. For example, we are aware of certain third-party intellectual property that does or may overlap with aspects of the Company’s technology. We cannot assure that our technology products and/or services do not infringe, violate or misappropriate any patents or other intellectual property rights owned or controlled by others or that they will not in the future.
Litigation may be necessary to enforce our intellectual property rights, to protect our trade secrets, to determine the validity and scope of the proprietary rights of others, or to defend against claims of infringement, invalidity, misappropriation, or other claims.
Any such litigation could result in substantial costs and diversion of our resources. Moreover, any settlement of or adverse judgment resulting from litigation relating to intellectual property rights could require us to obtain a license to continue to make, use, import, sell or offer for sale the technology, products or services that is the subject of the claim, or otherwise restrict or prohibit our use of the technology, products or services.
50

Our ability to compete may decline if we do not adequately prosecute, maintain, protect and/or defend our proprietary technology, products or services or our intellectual property rights.
Our success depends in part on our ability to obtain patents and maintain adequate protection of our intellectual property rights directed to our technology, products and services in the United States and other countries. We have adopted a strategy of seeking patent protection in the United States and in foreign countries with respect to certain of the technology used in or relating to our products, services, and processes. As such, as of September 30, 2024, we owned or controlled approximately 1,740 active issued patents and pending patent applications in the United States and in various foreign jurisdictions. As of September 30, 2024, our patents and patent applications, if issued, have terms that expire between 2024 and approximately 2045. We also have license rights to a number of issued patents and pending patent applications in the United States and in various foreign jurisdictions. Our owned and licensed patents and patent applications include those directed to our enabling technology and to the methods and products that support our business in the pharmaceutical manufacturing, life sciences, oligonucleotide synthesis, and other markets. We intend to continue to apply for patents relating to our technology, methods, services and products as we deem appropriate.
Issuance of claims in patent applications and enforceability of such claims once issued involve complex legal and factual questions and, therefore, we cannot predict with any certainty whether any of our issued patents will survive invalidity claims asserted by third parties. Issued patents and patents issuing from pending applications may be challenged, invalidated, circumvented, rendered unenforceable or substantially narrowed in scope. In addition, the inventorship and ownership of the patents and patent applications may be challenged by others. Moreover, the United States Leahy-Smith America Invents Act (“AIA”), enacted in September 2011, brought significant changes to the United States patent system, which include a change to a “first to file” system from a “first to invent” system and changes to the procedures for challenging issued patents and disputing patent applications during the examination process, among other things. While interference proceedings are possible for patent claims filed prior to March 16, 2013, many of our filings will be subject to the post- and pre-grant proceedings set forth in the AIA, including citation of prior art and written statements by third parties, third party pre-issuance submissions, ex parte reexamination, inter partes review, post-grant review, and derivation proceedings. We may need to utilize the processes provided by the AIA for supplemental examination or patent reissuance. These proceedings could result in substantial cost to us even if the outcome is favorable. Even if successful, any proceeding may result in loss of certain claims. Any litigation or proceedings could divert our management's time and efforts. Even unsuccessful claims brought by third parties could result in significant legal fees and other expenses, diversion of management time, and disruption in our business. Uncertainties resulting from initiation and continuation of any patent or related litigation could harm our ability to compete.
Additional uncertainty may result from legal precedent handed down by the United States Federal Circuit Court and Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. Accordingly, we cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth of the claims upheld in our, our licensors', and other companies' patents. Given that the degree of future protection for our proprietary rights is uncertain, we cannot ensure that: (i) we or our licensors were the first to invent the inventions covered by each of our pending applications, (ii) we or our licensors were the first to file patent applications for these inventions, or (iii) the proprietary technology, products or services we develop will be patentable. In addition, unauthorized parties may attempt to copy or otherwise obtain and use our technology, products and services. Monitoring unauthorized use of our intellectual property rights is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our technology, products or services, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the United States. Moreover, third parties could practice our inventions in territories where we do not have patent protection. Such third parties may then try to import products made using our inventions into the United States or other countries. If competitors are able to use our proprietary technology, products or services, our ability to compete effectively could be harmed. In addition, others may independently develop and obtain patents for technologies, products or services that are similar to or superior to our technologies, products or services. If that happens, we may need to license these technologies, products or services, and we may not be able to obtain licenses on reasonable terms, if at all, which could cause harm to our business.
51

Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. Changes in patent laws and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them, or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or may obtain in the future. For example, in some cases, we have filed for unitary patent protection under the rules implemented on June 1, 2023, in the European Patent Office. We will continue to assess this route of protection on a case-by-case basis, as applications are filed and patents are granted through the European Patent Office. This may alter our ability to protect our patents in some European countries. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. For example, in some foreign jurisdictions, governments have the right to compel patent owners to grant others licenses to their intellectual property under certain circumstances. In addition, any protection afforded by foreign patents may be more limited than that provided under U.S. patent and intellectual property laws. We may encounter significant problems in enforcing and defending our intellectual property both in the United States and abroad. For example, if the issuance in a given country of a patent covering an invention is not followed by the issuance in other countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the written description or enablement in a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in other countries, our ability to protect our intellectual property rights in those countries may be limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property rights or narrow the scope of our patent protection. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.
Third parties may claim that we are infringing, violating or misappropriating their intellectual property rights, which may subject us to costly and time-consuming litigation and prevent us from developing or commercializing our technology, products or services.
Our commercial success also depends in part on our ability to operate without infringing, violating or misappropriating patents and other intellectual property rights of third parties, and without breaching any licenses or other agreements that we have entered into with regard to our technologies, products or services. We cannot ensure that patents have not been issued, or will not be issued, to third parties that could block our ability to obtain patents or to operate as we would like. There may be patents in some countries that, if valid, may block our ability to make, use, sell, or offer for sale our technology, products or services in those countries, or import our products into those countries, if we are unsuccessful in circumventing or acquiring rights to these patents. There also may be claims in patent applications filed in some countries that, if granted and valid, may also block our ability to commercialize technology, products, services or processes in these countries if we are unable to circumvent or obtain rights to them.
The industries in which we operate and the biotechnology industry, in particular, are characterized by frequent and extensive litigation regarding patents and other intellectual property rights. Many biotechnology companies have employed intellectual property litigation as a way to gain a competitive advantage. We are aware of some patents and patent applications relating to aspects of our technologies, products or services filed by, and issued to, third parties. We cannot assure that if such third-party patents rights are asserted against us that we would ultimately prevail. Any involvement in litigation or other intellectual property proceedings inside and/or outside of the United States to defend against claims that we infringe, misappropriate or violate the intellectual property rights of others may divert our management’s time from focusing on business operations and could cause us to spend significant amounts of money. Any potential intellectual property litigation also could force us to do one or more of the following:
•stop making, using, selling, offering for sale or importing our technologies, products and services that use the subject intellectual property;
•pay monetary damages to the third party asserting claims against us;
•grant or transfer rights to third parties relating to our patents or other intellectual property rights;
•obtain from the third party asserting its intellectual property rights a license to make, sell, offer for sale, import or use the relevant technology, product or service, which license may not be available on reasonable terms, or at all; or
52

•redesign those technologies, products, services or processes that use any allegedly infringing, misappropriated or violated intellectual property rights, or relocate the operations relating to the allegedly infringing, misappropriated or violated intellectual property rights to another jurisdiction, which may result in significant cost or delay to us, could be technically infeasible or could prevent us from making, selling, offering for sale, using or importing some of our technologies, products or services in the United States or other jurisdictions.
We may be involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful.
Competitors may infringe, violate or misappropriate our intellectual property rights or those of our licensors. To prevent infringement, violation, misappropriation or other unauthorized use, we have in the past filed, and may in the future be required to file, enforcement claims, which can be expensive and time-consuming. In addition, in an enforcement proceeding, a court may decide that the intellectual property right that we own or control is not valid, is unenforceable and/or is not infringed, violated or misappropriated. In addition, in legal proceedings against a third party to enforce a patent directed at one of our technologies, products or services, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent enforcement litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a patent validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the United States Patent and Trademark Office (“USPTO”) or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of enforcement litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on the respective technology, products or services. Such a loss of patent protection could have a material adverse impact on our business.
Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our expenses and reduce the resources available for operations and research and development activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with U.S. intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.
We may not be able to enforce our intellectual property rights throughout the world.
The laws of some foreign countries where we do business do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and enforcing intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property rights, particularly those relating to biotechnology technologies. Accordingly, our efforts to protect and enforce our intellectual property rights in such countries may be inadequate. This could make it difficult for us to stop the infringement, violation or misappropriation of our patents or other intellectual property rights. Additionally, proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.
If our biocatalysts, or the genes that code for our biocatalysts, are stolen, misappropriated or reverse engineered, others could use these biocatalysts or genes to produce competing products.
Third parties, including our contract manufacturers, customers and those involved in shipping our biocatalysts, often have custody or control of our biocatalysts. If our biocatalysts, or the genes that code for our biocatalysts, were stolen, misappropriated or reverse engineered, they could be used by other parties who may be able to reproduce these biocatalysts for their own commercial gain. If this were to occur, it may be difficult for us to challenge this type of use, especially in countries with limited intellectual property rights protection or in countries in which we do not have patents covering the misappropriated biocatalysts.
53

Confidentiality and non-use agreements with employees, consultants, advisors and other third parties may not adequately prevent disclosures and non-use of trade secrets and other proprietary information.
In addition to patent protection, we also rely on other intellectual property rights, including protection of copyright, trade secrets, know-how and/or other proprietary information that is not patentable or that we elect not to patent. However, trade secrets can be difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely in part on trade secret law and contractual agreements to protect our confidential and proprietary information and processes. We generally enter into confidentiality and invention assignment agreements with our employees, consultants and third parties working on our behalf upon their commencement of a relationship with us. However, trade secrets and confidential information are difficult to protect and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes and we may not enter into such agreements with all employees, consultants and third parties who have been involved in the development of our intellectual property rights. Nevertheless, without our permission or awareness, our confidential and proprietary information may be disclosed to third parties, used by the respective individuals for purposes other than for the Company’s business, or obtained through illegal means, such that third parties could reverse engineer our biocatalysts, enzyme products and processes, to attempt to develop the same technology or develop substantially equivalent technology.
Costly and time-consuming litigation could be necessary to enforce and determine the scope of our confidential and proprietary rights, and failure to protect our trade secrets could adversely affect our competitive business position. If any of our trade secrets were lawfully obtained, we may be unable to prevent them, or those to whom they communicate it, from using that technology or information to compete with us or disclosing it publicly. Therefore, these events could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to protect our proprietary rights may allow competitors to copy our technology, which could adversely affect our pricing and market share.
In addition to contractual measures, we try to protect the confidential nature of our proprietary information by maintaining physical security of our premises and electronic security of our information technology systems. Such security measures may not, for example, in the case of misappropriation of a trade secret by an employee, consultant or other third party with authorized access or with unauthorized access but an intent to steal, provide adequate protection for our proprietary information. Our security measures may not prevent such employee, consultant or other third party from misappropriating our trade secrets and using them or providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. While we use commonly accepted security measures, trade secret violations are often a matter of state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.
Risks Related to Owning our Common Stock
We are subject to anti-takeover provisions in our certificate of incorporation and bylaws and under Delaware law that could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders.
Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of the Company. Among other things, our amended and restated certificate of incorporation and bylaws provide for a board of directors which is divided into three classes, with staggered three-year terms and provide that all stockholder action must be effected at a duly called meeting of the stockholders and not by a consent in writing, and further provide that only our Board, the chairman of our Board, our chief executive officer or president may call a special meeting of the stockholders. In addition, our amended and restated certificate of incorporation allows our Board, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These provisions may also frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board, who are responsible for appointing the members of our management team. Furthermore, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (“DGCL”) which prohibits, with some exceptions, stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Finally, our charter documents establish advanced notice requirements for nominations for election to our Board and for proposing matters that can be acted upon at stockholder meetings. Although we believe these provisions together provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board, they would apply even if an offer to acquire our company may be considered beneficial by some stockholders.
54

Our bylaws designate a state or federal court located within the State of Delaware as the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us our current or former directors, officers, stockholders, or other employees.
Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of us under Delaware law, (ii) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, or other employee of the Company to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, or other employees arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (as either may be amended from time to time), (iv) any action asserting a claim against us governed by the internal affairs doctrine, or (v) any other action asserting an “internal corporate claim,” as defined under Section 115 of the DGCL. The forgoing provisions do not apply to any claims arising under the Securities Act and, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act.
These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our current or former directors, officers, or other employees, which may discourage lawsuits with respect to such claims. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find the choice of forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations or financial condition.
Our quarterly or annual operating results may fluctuate in the future. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline.
Our financial condition and operating results have varied significantly in the past and may continue to fluctuate from quarter to quarter and year to year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following factors, as well as other factors described elsewhere in this report:
•our ability to achieve or maintain profitability;
•our dependence on a limited number of customers;
•our product supply agreements with customers have finite duration, may not be extended or renewed and generally do not require the customer to purchase any particular quantity or quantities of our products;
•with respect to customers purchasing our products for the manufacture of active pharmaceutical ingredients for which they have exclusivity due to patent protection, the termination or expiration of such patent protection and any resulting generic competition may materially and adversely affect our revenues, financial condition or results of operations;
•our dependence on a limited number of products in our performance enzymes business;
•our reliance on a limited number of contract manufacturers for large scale production of substantially all of our enzyme products;
•our relationships with, and dependence on, collaborators in our principal markets;
•our ability to successfully and timely develop and commercialize new products, including our ECO Synthesis™ manufacturing platform, for the markets we serve;
•the potential of GSK, Merck, Novartis or any other performance enzyme customer terminating their agreements with us;
•the success of our customers’ products in the market and the ability of such customers to obtain regulatory approvals for products and processes;
•our ability to deploy our technology platform in life science tools markets;
•our dependence on our collaborators or customers’ product candidates which could unexpectedly fail at any stage of preclinical or clinical development;
55

•our dependence on our collaborators or customers’ product candidates which may lack the ability to work as intended or cause undesirable side effects;
•our ability to successfully prosecute and protect our intellectual property;
•our ability to compete if we do not adequately protect our proprietary technologies or if we lose some of our intellectual property rights;
•our ability to avoid infringing the intellectual property rights of third parties;
•our involvement in lawsuits to protect or enforce our patents or other intellectual property rights;
•our ability to enforce our intellectual property rights throughout the world;
•our dependence on, and the need to attract and retain, key management and other personnel;
•our ability to prevent the theft or misappropriation of our biocatalysts, the genes that code for our biocatalysts, know-how or technologies;
•our ability to protect our trade secrets and other proprietary information from disclosure by employees and others;
•our ability to obtain substantial additional capital that may be necessary to expand our business;
•our ability to comply with the terms of our Loan Agreement;
•our ability to timely pay debt service obligations;
•our customers’ ability to pay amounts owed to us in a timely manner;
•our ability to avoid charges to earnings as a result of any impairment of goodwill, intangible assets or other long-lived assets;
•changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported results of operations;
•our ability to maintain effective internal control over financial reporting;
•our dependency on information technology systems, infrastructure and data;
•our ability to control and to improve product gross margins;
•our ability to protect against risks associated with the international aspects of our business;
•the cost of compliance with EU chemical regulations;
•potential advantages that our competitors and potential competitors may have in securing funding or developing products;
•our ability to accurately report our financial results in a timely manner;
•results of regulatory tax examinations;
•market and economic conditions may negatively impact our business, financial condition, and share price;
•business interruptions due to natural disasters, disease outbreaks or other events beyond our control;
•public concerns about the ethical, legal and social ramifications of genetically engineered products and processes;
•our ability to integrate our current business with any businesses that we may acquire in the future;
•our ability to properly handle and dispose of hazardous materials in our business;
•potential product liability claims;
•changes to tax law and related regulations could materially affect our tax obligations and effective tax rate; and
56

•our ability to use our NOLs to offset future taxable income.
Due to the various factors mentioned above, and others, the results of any prior quarterly or annual periods should not be relied upon as indications of our future operating performance.
We do not intend to pay cash dividends for the foreseeable future.
We currently intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board and will depend on our financial condition, results of operations, capital requirements, restrictions contained in future agreements and financing instruments, business prospects and such other factors as our Board deems relevant.
General Risk Factors
If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock in a negative manner, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline.
We face risks associated with our international business.
While we have a limited number of employees located outside of the United States, we are and will continue to be dependent upon contract manufacturers located outside of the United States. In addition, we have customers and partners located outside of the United States. Conducting business internationally exposes us to a variety of risks, including:
•changes in or interpretations of U.S. or foreign laws or regulations that may adversely affect our ability to sell our products, repatriate profits to the United States or operate our foreign-located facilities;
•the imposition of tariffs;
•the imposition of limitations on, or increase of, withholding and other taxes on remittances and other payments by foreign subsidiaries or joint ventures;
•the imposition of limitations on genetically-engineered or other products or processes and the production or sale of those products or processes in foreign countries;
•currency exchange rate fluctuations;
•uncertainties relating to foreign laws, regulations and legal proceedings including pharmaceutical, tax, import/export, anti-corruption and exchange control laws;
•the availability of government subsidies or other incentives that benefit competitors in their local markets that are not available to us;
•increased demands on our limited resources created by our operations may constrain the capabilities of our administrative and operational resources and restrict our ability to attract, train, manage and retain qualified management, technicians, scientists and other personnel;
•economic or political instability in foreign countries;
•difficulties associated with staffing and managing foreign operations; and
•the need to comply with a variety of United States and foreign laws applicable to the conduct of international business, including import and export control laws and anti-corruption laws.
57

Market and economic conditions may negatively impact our business, financial condition, and share price.
Concerns about inflation, energy costs, geopolitical issues, the United States mortgage market and a declining real estate market, unstable global credit markets and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished liquidity and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations of slower global economic growth going forward, increased unemployment rates, and increased credit defaults in recent years. Our general business strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions.
During 2023, the closures of Silicon Valley Bank (“SVB”) and Signature Bank (“Signature”) and their placement into receivership with the Federal Deposit Insurance Corporation, and the government-brokered sale of the deposits and majority of assets of First Republic Bank to JPMorgan Chase, created bank-specific and broader financial institution liquidity risk and concerns. Although government intervention ensured that depositors at these banks have access to their funds, future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term working capital needs, and create additional market and economic uncertainty. There can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will not occur, and we cannot predict the impact or follow-on effects of these insolvencies more broadly or on our business in particular. Further, we cannot guarantee that the government will intervene to provide depositors with access to funds if similar events occur in the future. If other banks and financial institutions enter receivership or become insolvent in the future, our ability to access our existing cash, cash equivalents, and investments may be threatened, which could have a material adverse effect on our business and financial condition.
In addition, if the market and economic conditions described above continue to deteriorate or do not improve, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance, and stock price. Additionally, rising rates of inflation have increased the costs associated with conducting our business, including by causing substantial increases in the costs of materials, including raw materials and consumables, equipment, services, and labor. Moreover, given the unpredictable nature of the current economic climate, including future changes in rates of inflation, it may be increasingly difficult for us to predict and control our future expenses, which may harm our ability to conduct our business.
Business interruptions resulting from disasters or other disturbances could delay us in the process of developing our products and could disrupt our sales. Our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or other disturbance.
Our headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced both severe earthquakes and wildfires. Earthquakes, wildfires or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. We are also vulnerable to other types of disasters and other events that could disrupt our operations, such as riot, civil disturbances, war, terrorist acts, public health emergencies, domestic or foreign conflicts, infections in our laboratory or production facilities or those of our customers or contract manufacturers and other events beyond our control. If a natural disaster or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, including due to impacts on our collaborators, suppliers or other third parties on which we rely, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event, and we may incur substantial expenses as a result of the limited nature of such plans. We do not carry insurance for earthquakes and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our cash flows and success as an overall business.
58

We are dependent on information technology systems, infrastructure and data, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.
Information technology helps us operate efficiently, interface with customers, maintain financial accuracy and efficiency and accurately produce our financial statements. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology infrastructure, we could be subject to transaction errors, processing inefficiencies, the loss of customers, business disruptions or the loss of or damage to intellectual property through security breach. If our information technology systems do not effectively collect, store, process and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies, or human error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Our information technology systems and those of our external vendors, strategic partners and other contractors or consultants are vulnerable to attack and damage or interruption from computer viruses and malware (e.g. ransomware), malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Any such impairment could materially and adversely affect our financial condition, results of operations, cash flows and the timeliness with which we report our internal and external operating results.
Our business may require us to use and store personal information of our customers, employees, and business partners. This may include names, addresses, phone numbers, email addresses, contact preferences, tax identification numbers and payment account information. We require usernames and passwords in order to access our information technology systems. We also use encryption and authentication technologies to secure the transmission and storage of data. However, these security measures may be compromised as a result of security breaches by unauthorized persons, employee error, malfeasance, faulty password management or other irregularity, and result in persons obtaining unauthorized access to our data or accounts. Third parties may attempt to fraudulently induce employees or customers into disclosing usernames, passwords or other sensitive information, which may in turn be used to access our information technology systems. For example, our employees have received “phishing” emails and phone calls attempting to induce them to divulge passwords and other sensitive information.
In addition, unauthorized persons may attempt to hack into our products or systems to obtain personal data relating to employees and other individuals, our confidential or proprietary information or confidential information we hold on behalf of third parties. We also rely on external vendors to supply and/or support certain aspects of our information technology systems. The systems of these external vendors may contain defects in design or manufacture or other problems that could unexpectedly compromise information security of our own systems, and we are dependent on these third parties to deploy appropriate security programs to protect their systems. If we or our third-party vendors were to experience a significant cybersecurity breach of our or their information systems or data, the costs associated with the investigation, remediation and potential notification of the breach to counterparties and data subjects could be material. Our remediation efforts may not be successful. Further, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss, corruption or unauthorized disclosure of our trade secrets, personal information or other proprietary or sensitive information or other similar disruptions. Attacks upon information technology systems are also increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the remote work policies we initiated in response to the COVID-19 pandemic, and our continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. We have programs in place to detect, contain and respond to data security incidents, and we make ongoing improvements to our information-sharing products in order to minimize vulnerabilities, in accordance with industry and regulatory standards. However, because the techniques used to obtain unauthorized access to or sabotage systems change frequently and may be difficult to detect, we may not be able to anticipate and prevent these intrusions or mitigate them when and if they occur. Even if identified, we may be unable to adequately and timely investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection and to remove or obfuscate forensic evidence.
59

We and certain of our external vendors are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident, or security breach to date, if such an event were to occur, it could result in the unauthorized access to or unauthorized use, disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws. Any security compromise affecting us, our service providers, vendors, strategic partners, other contractors, consultants or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary or personal information, we could incur liability, including litigation exposure, penalties and fines, which may not be covered by insurance or may be in excess of our insurance coverage. Additionally, we could become the subject of regulatory action or investigation, our competitive position could be harmed and the further development of our products could be delayed. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our business and could materially and adversely affect our business, results of operations and financial condition.
Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations and financial condition.
The global data protection landscape is rapidly evolving, and we are or may become subject to state, federal and foreign laws, regulations, decisions and directives governing the privacy, security, collection, storage, transmission, use, processing, retention and disclosure of personal information. Any failure or perceived failure by us to comply with applicable laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.
In the United States, Health Insurance Portability and Accountability Act (“HIPAA”) imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of certain individually identifiable health information. Certain states have also adopted and continue to adopt new privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act (“CCPA”) went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA also provides for civil penalties for violations, as well as a private right of action for data breaches (which has increased the likelihood of, and risks associated with, data breach litigation). Further, the California Privacy Rights Act (“CPRA”) significantly amended the CCPA, which went into effect in January 2023. It imposes additional data privacy obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data and opt outs for certain uses of sensitive data. It also created a new California privacy protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may also be required. Similar laws regulating personal information generally or health information in particular have passed in more than a dozen states and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. These developments increase our compliance burden and our risk, including risks of regulatory fines, litigation and associated reputational harm. Any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.
Furthermore, the Federal Trade Commission (“FTC”) and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for the collection, use, sharing and security of personal information that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers’ personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.
60

In the European Union (“EU”), the EU General Data Protection Regulation (“EU GDPR”) governs the processing of personal data. The UK has implemented the EU GDPR as the UK GDPR which sits alongside the UK Data Protection Act 2018 (the “UK GDPR”, and together with the EU GDPR, the “GDPR”). The GDPR imposes requirements for controllers, including (among others) specific requirements for obtaining valid consent where consent is the legal basis for processing, requirements around accountability and transparency, the obligation to consider data protection when any new products or services are developed, the obligation to comply with individuals’ data protection rights, and the obligation to notify relevant data supervisory authorities of notifiable personal data breaches without undue delay (and no later than 72 hours) after becoming aware of the personal data breach (and affected data subjects where the personal data breach is likely to result in a high risk to their rights and freedoms). The EU GDPR provides that EU member states may enact their own additional national laws and regulations regarding the processing of genetic, biometric or health data, which could affect our ability to use and share personal data or could cause our costs to increase and potentially harm our business and financial condition. Failure to comply with the requirements of the GDPR can result in (among other things) fines of up to the greater of €20 million (under the EU GDPR) or £17.5 million (under the UK GDPR) or 4% of an organization’s total worldwide annual turnover of the preceding financial year and other administrative penalties. To the extent that we are subject to the GDPR, compliance with the GDPR may require substantial amendments to our procedures and policies and these changes could adversely impact our business by increasing operational and compliance costs or impact business practices. Further, there is a risk that the amended policies and procedures will not be implemented correctly or that individuals within the business will not be fully compliant with the new procedures. There is a risk that we could be impacted by a cybersecurity incident that results in loss or unauthorized disclosure of personal data, potentially resulting in us facing harms similar to those described above.
Among other requirements, the EU GDPR prohibits the international transfer of personal data subject to the GDPR from the European Economic Area (“EEA”) to third countries that the European Commission does not recognize as having an ‘adequate’ level of data protection, unless a data transfer mechanism has been put in place or a derogation under the EU GDPR can be relied on. In July 2020, the Court of Justice of the EU in its Schrems II judgement limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-U.S. Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses (“EU SCCs”), including a requirement for companies to carry out a transfer privacy impact assessment (“TIA”). A TIA, among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under the EU SCCs will need to be implemented to ensure an ‘essentially equivalent’ level of data protection to that afforded in the EEA.
On October 7, 2022, U.S. President Biden introduced an Executive Order to facilitate a new Trans-Atlantic Data Privacy Framework (“DPF”) and in July 2023, the European Commission adopted its Final Implementing Decision granting the United States adequacy (“Adequacy Decision”) for EU-U.S. transfers of personal data for entities self-certified to the DPF. Entities relying on EU SCCs for transfers to the United States are also able to rely on the analysis in the Adequacy Decision as support for their TIA regarding the equivalence of U.S. national security safeguards and redress.
The UK GDPR also imposes similar restrictions on transfers of personal data from the UK to jurisdictions that the UK Government does not consider adequate, including the United States. The UK Government has published its own form of the EU SCCs, known as the International Data Transfer Agreement and an International Data Transfer Addendum to the new EU SCCs. The UK Information Commissioner’s Office has also published its own version of the TIA and guidance on international transfers, although entities may choose to adopt either the EU or UK-style TIA. Further, on September 21, 2023, the UK Secretary of State for Science, Innovation and Technology established a UK-U.S. data bridge (i.e., a UK equivalent of the Adequacy Decision) and adopted UK regulations to implement the UK-U.S. data bridge (“UK Adequacy Regulations”). Personal data may now be transferred from the UK under the UK-U.S. data bridge through the UK extension to the DPF to organizations self-certified under the UK extension to DPF.
As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.
61

Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Various federal, state and foreign legislative or regulatory bodies may enact new or additional laws and regulations concerning privacy, data-retention and data-protection issues, including laws or regulations mandating disclosure to domestic or international law enforcement bodies, which could adversely impact our business or our reputation with customers. For example, some countries have adopted laws mandating that certain personal information regarding customers in their country be maintained solely in their country. Having to maintain local data centers and redesign product, service and business operations to limit processing of personal information to within individual countries could increase our operating costs significantly. Any failure, or perceived failure, by us to comply with federal, state or international privacy, data-retention or data-protection-related laws, regulations, orders or industry self-regulatory principles could result in proceedings or actions against us by governmental entities or others, a loss of customer confidence, damage to our brand and reputation and a loss of customers, any of which could have an adverse effect on our business.
Evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (“ESG”) matters, may expose us to reputational and other risks.
Investors, stockholders, customers, suppliers and other third parties are increasingly focusing on ESG and corporate social responsibility endeavors and reporting. Companies that do not adapt to or comply with the evolving investor or stakeholder expectations and standards, or that are perceived to have not responded appropriately, may suffer from reputational damage, which could result in the business, financial condition and/or stock price of a company being materially and adversely affected. For example, certain customers have inquired about our ESG practices and may impose ESG guidelines, procurement policies, sustainability standards, mandates or reporting requirements for, and may scrutinize relationships more closely with, their suppliers, including us, which may lengthen sales cycles, increase our costs or impair our ability to attract and retain customers. Further, this increased focus on ESG issues may result in new regulations, international accords and/or third-party requirements that could adversely impact our business, or certain shareholders reducing or eliminating their holdings of our stock. An allegation or perception that we have not taken sufficient action in these areas could negatively harm our reputation. Additionally, the subjective nature and wide variety of methods and processes used by various stakeholders, including investors, to assess environmental, social, and governance criteria could result in a negative perception or misrepresentation of the company's sustainability policies and practices.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3.DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4.MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5.OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
During the three months ended September 30, 2024, none of the directors or executive officers of the Company adopted or terminated a Rule 10b5-1 trading arrangement or a “non-Rule 10b5-1 trading arrangement” (each as defined in Item 408 of Regulation S-K).
62

ITEM 6.EXHIBITS
3.1
3.2
3.3
3.4
4.1Reference is made to Exhibits 3.1 through 3.4.
4.2
4.3
10.1+
10.2+
10.3+
10.4+
10.5+
10.6+
31.1
31.2
32.1
101 
The following materials from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline Extensible Business Reporting Language (“iXBRL”) includes: (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2024 and December 31, 2023 (ii) Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023, (iv) Unaudited Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 2023, (v) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 and (v) Notes to Unaudited Condensed Consolidated Financial Statements.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
63

104
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline XBRL and contained in Exhibit 101.
+
Indicates a management contract or compensatory plan or arrangement.
64

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Codexis, Inc.
Date:October 31, 2024By:/s/ Stephen Dilly
Stephen Dilly
Chairman, President and Chief Executive Officer
(principal executive officer)
Date:October 31, 2024By:/s/ Georgia Erbez
Georgia Erbez
Chief Financial Officer
(principal financial and accounting officer)

65
 EX-10.2 2 codexis-ex102firstamendmen.htm EX-10.2 Document

FIRST AMENDMENT TO
CODEXIS, INC.
2023 EMPLOYEE STOCK PURCHASE PLAN

WHEREAS, Codexis, Inc., a Delaware corporation (the “Company”), has heretofore adopted the Codexis, Inc. 2023 Employee Stock Purchase Plan (the “Plan”); and

WHEREAS, the Company wishes to amend the Plan to allow participants under the Plan to increase or decrease the amount of payroll deductions elected by such participants during specified enrollment periods.

NOW, THEREFORE, the Plan shall be amended, effective August 22, 2024, as follows:

1.Subsection (c) of Section 3.2 is deleted and replaced with the following:

With respect to Offering Periods with multiple Purchase Periods, and unless otherwise determined by the Administrator prior to the commencement of an Offering Period, Participants may increase or decrease (to as low as zero) the amount deducted from such Participant’s Compensation during the specified enrollment periods established by the Administrator. Unless otherwise determined by the Administrator prior to the commencement of an Offering Period, a Participant may not increase or decrease the amount deducted from such Participant’s Compensation during an Offering Period except during the specified enrollment periods.

2.Except as modified herein, the remaining terms of the Plan shall remain unchanged and in full force and effect.



 EX-10.3 3 codexis-ex103offerletterxg.htm EX-10.3 Document

Codexis, Inc.
200 Penobscot Drive Redwood City, CA 94063 Tel: +1 (650) 421-8100
Fax: +1 (650) 421-8102
www.codexis.com


September 30, 2024

Georgia Erbez

Dear Georgia,

On behalf of Codexis, Inc. (“Codexis” or the “Company”), I am pleased to extend to you this offer of employment as Chief Financial Officer reporting to Stephen Dilly, Chairman, President and Chief Executive Officer (the “CEO”). Your position is full-time and exempt from overtime pay under the Fair Labor Standards Act. You will work from the Company’s headquarters in Redwood City, California. Your Company employment will commence as of your and the Company’s mutually agreed upon start date, which is expected to be September 30, 2024 (your actual first date of Company employment, the “Start Date”).
Your employment is subject to (i) proof of your legal right to work in the United States, (ii) you successfully completing a professional references and background screening and the United States Citizenship and Immigration Service Employment Eligibility Verification Form I-9, and (iii) the execution of your Proprietary Information, Inventions, and Employment Agreement (Attachment A) (your “Confidentiality Agreement”).
You will not, during your employment by the Company, be employed by or otherwise engaged in any other business activity requiring any of your time, except that, with the prior written approval of the Company’s Board of Directors (the “Board”), you may serve as a member of the board of directors of up to one organization that is not a competitor of the Company, provided that such service does not individually or in the aggregate interfere with the performance of your duties to the Company, violate your Confidentiality Agreement or violate the Company’s standards of conduct then in effect, or raise a conflict under the Company’s conflict of interest policies.
By signing below and accepting this offer, you represent and warrant that you are not bound by any employment contract, restrictive covenant, or other restriction preventing you from carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this offer of employment. You further represent and warrant that you will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.
Compensation
If you accept this offer and you begin employment with Codexis, you will receive an initial salary of USD
$500,000 per year, payable bi-weekly, which will be subject to all applicable withholdings.
You will also be eligible to participate in the Codexis Employee Incentive Compensation Plan (the “Incentive Plan”). Your Incentive Plan target will be fifty percent (50%) of your Codexis base salary earnings, subject to metrics set and approved by the Board (or a committee thereof) and achievement by

1


the Company of such performance targets as shall be determined by the Board (or a committee thereof). Based on the Company’s performance and your individual and group’s goal performance, your actual bonus may be more or less than this target, and under certain circumstances there may be no payout. Any payout will be subject to all applicable withholdings and will be paid no later than March 15th following the conclusion of the applicable performance year. No bonus amount is guaranteed and, in addition to the other conditions for earning such bonus, you must remain an employee in good standing of the Company on the scheduled bonus payment date in order to earn any bonus. For calendar year 2024, you will be eligible to earn a prorated bonus based on the Company’s achievement of the applicable performance targets and metrics, and based on the number of days you were employed by the Company in 2024. Please also note that the Incentive Plan does not constitute a contract of employment or alter the “at will” status of your employment. In addition, Codexis reserves the right to modify or terminate the Incentive Plan at any time and for any reason without your consent.
Equity
Subject to approval by the Board (or a duly authorized committee thereof) and as an inducement for you to join the Company, you will be granted 50,000 restricted stock units (“RSUs”). Each RSU entitles you to be issued one share of Codexis common stock upon vesting. The RSUs will vest in substantially equal installments on each of the first three anniversaries of the date of grant of the RSUs, provided that you provide continuous services to Codexis through the applicable vesting date. The RSUs will be granted in accordance with Codexis’ policy which may be amended from time to time and will be subject to the terms and conditions of the Codexis, Inc. 2024 Inducement Plan (the “Inducement Plan”) and/or the Codexis, Inc. 2019 Incentive Award Plan (the “2019 Plan”), as applicable, and an RSU agreement to be entered into between you and Codexis.
Subject to approval by the Board (or a duly authorized committee thereof) and as an inducement for you to join the Company, you will be granted an option to purchase 300,000 shares of Codexis common stock (the “Option”) with an exercise price equal to the closing trading price of a share of Codexis common stock on the date the Option is granted or the immediately preceding trading day if the grant date is not a trading day. The shares subject to the Option will vest one fourth or 25% on the first anniversary of the Start Date and thereafter will vest 1/48th of the shares originally subject to the Option per month for the following 36 months until the Option is 100% vested on the four-year anniversary of the Start Date. Vesting is contingent upon your continued service to Codexis through the applicable vesting date. Your Option will be granted in accordance with Codexis’ policy which may be amended from time to time and will be subject to the terms and conditions of the Inducement Plan and/or the 2019 Plan, as applicable, and an option agreement to be entered into between you and Codexis.
Change of Control Severance Agreement
In connection with the commencement of your employment with Codexis, you will have the opportunity to enter into a Change of Control Severance Agreement. A copy of the Change of Control Severance Agreement (Attachment B) is included with this offer of employment for your review and signature.
Employee Benefits
As a full-time employee, you will be eligible for the Codexis employee benefit plans, which currently include medical, dental, vision, long-term disability, and life insurance, as well as a 401(k) plan, and paid time off in accordance with Company policy. Codexis reserves the right to modify or terminate any of these plans at any time and for any reason.

2


Other Terms and Conditions of Employment
Your employment with Codexis is at will. “Employment at will” means that you are free to resign from your employment at any time, for any reason or no reason at all, with or without cause and with or without notice. Similarly, Codexis may terminate your employment at any time for any legal reason, with or without cause and with or without notice. It also means that your job duties, title and responsibility and reporting level, work schedule, compensation and benefits, as well as Codexis’ personnel policies and procedures, may be changed with prospective effect, with or without notice, at any time in the sole discretion of Codexis. By accepting this offer of employment, you agree that your employment is at will, and acknowledge that no one, other than the CEO, has the authority to promise you, either orally or in writing, anything to the contrary. Any such agreement must be in writing and signed by both you and the CEO to be effective.
You will be subject to the Company’s Policy on Recoupment of Incentive Compensation (Attachment C), and any other clawback or recoupment policy that the Company adopts in the future. In addition, you acknowledge that you shall also be subject to additional policies of the Company and its affiliates as in effect from time-to-time, including the Company’s Code of Conduct and policies with regard to stock ownership and securities trading by senior executives.
The terms described in this offer of employment, along with the Confidentiality Agreement and the Change of Control Severance Agreement (which are separate agreements that are governed by their own terms and conditions), supersede and replace all prior agreements, understandings, and promises between Codexis and you concerning the terms and conditions of your employment with Codexis.
[Signature Page to Follow]

3


We hope that your association with Codexis will be mutually successful and rewarding, and we look forward to welcoming you aboard. Please indicate your acceptance of this offer by initialing each page and signing this letter below and returning the letter by September 30, 2024.
Sincerely, Codexis, Inc.


By:          Stephen Dilly, MBBS, Ph.D.
Chairman, President & CEO

4


I understand and agree to the foregoing terms and conditions of employment with Codexis.


_______________________________________________________
Georgia Erbez


9/30/2024
_______________________________________________________
Date
5

ATTACHMENT A
CODEXIS, INC. PROPRIETARY INFORMATION, INVENTIONS, AND EMPLOYMENT AGREEMENT

A-1

CODEXIS, INC.
PROPRIETARY INFORMATION, INVENTIONS, AND EMPLOYMENT AGREEMENT
The following confirms an agreement (the “Agreement”) between Codexis, Inc. (“Company”) and me. As a condition of my employment or continued employment, and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, as well as access to Company Proprietary Information and trade secrets, I agree to the following effective as of my first day of employment with the Company or as part of my continued employment as applicable:
1.At-Will Employment. This Agreement is not an employment contract for any particular term. I have a right to resign and Company has the right to terminate my employment at will, at any time, for any or no reason, with or without cause and without notice. In addition, this Agreement does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have obligations to Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only be changed by a subsequent written agreement signed by both parties.
2.Proprietary Information.

(a)Company Information. I agree that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning or obtained in connection with the Company’s business or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company. I agree at all times during the term of my employment and thereafter, to hold in strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any person or other entity, other than employees of the Company, (in writing, verbally, or via email or any other medium) without written advance authorization of the Company, any Proprietary Information of the Company, except as may be necessary in the ordinary course of performing my duties as an employee of Company or as otherwise provided in this Agreement. I will not use any Proprietary Information except in the performance of my authorized duties as an employee of Company. By way of illustration, but not limitation, Proprietary Information includes any tangible or intangible proprietary information, technical data, trade secrets or know-how, including and/or relating to, but not limited to, ideas, concepts, materials (including, but not limited to, cell lines, plasmids, vectors and DNA), data, conclusions, product plans, products, services, customer lists, business lists (including, but not limited to, customers of the Company on whom I called or with whom I became acquainted during my term of my employment), business market analyses, software, development, discoveries, inventions, processes, formulas, techniques, technology, designs, drawings, engineering, hardware configuration information, marketing and pricing strategy, business plans, corporate strategy plans, financial data; or other business information made, generated or developed by me in the course of my employment with Company, or disclosed to me by Company either directly or indirectly in any form, including, without limitation, in writing, orally, electronically, or by drawings, or observation of materials, equipment, or information. Proprietary Information also includes confidential information and materials provided to Company by any third party, which is indicated by such third party to be confidential and/or proprietary, and the identity, appropriate knowledge of personnel, research and/or product requirements, volume and frequency of orders, and price sensitivity of customers of the Company. I further understand that Proprietary Information does not apply to information which: (i) was already rightfully known to me prior to the time that it is disclosed to me hereunder without any confidentiality obligation to Company; (ii) is in or has entered the public domain through no breach of this Agreement or other wrongful act; (iii) pertains to general training, knowledge, skill or experience information within the industry that I possess, that is not specifically related to other Proprietary Information; (iv) pertains to my pay, benefits, and other employment terms and conditions; or (v) has been rightfully received by me from a third party not under obligation of confidentiality to Company.
A-2

(b)Third Party Information. I agree that I will not, during my employment with the Company, use or disclose in the course of my work for Company any proprietary information or trade secrets of any former or concurrent third party employer or other person or entity for whom I perform or have performed work, without the written authorization of the Company after my notice to the Company of the proprietary or trade secret nature of such information. I agree that I will not bring onto the Company premises or introduce into the equipment or databases of the Company any unpublished document or proprietary information belonging to any such third party employer or other person or entity for whom I perform or have performed work, without the written authorization of the Company after my notice to the Company of the proprietary or trade secret nature of such information. I also understand and agree that, in the course of my employment with Company, I am not to breach any other obligation of confidentiality or non-use that I have to any former employer or concurrent.

(c)Third Party Information Received by the Company. I recognize that the Company has received and in the future will likely receive from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. I agree to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out my work for the Company consistent with the Company’s agreement with such third party.

(d)Protected Disclosures and Defend Trade Secrets Act. Nothing in this Agreement prohibits me (a) from disclosing information in good faith to any federal, state, or local governmental agency, legislative body, or official (or staff member to the foregoing) regarding an alleged violation of law or regulation; (b) from discussing or disclosing information about unlawful acts in the workplace or at activities coordinated or sponsored by the Company, whether on or off the Company’s premises, such as harassment, discrimination, retaliation, wage and hour violations, sexual assault, violations of public policy, an unfair labor practice, or any other conduct that I have reason to believe is unlawful; (c) from discussing or disclosing my wages, hours, and working conditions with fellow employees and discussing the wages of others, or inquiring about another colleague’s wages, or aiding or encouraging others to exercise their rights to the extent protected under applicable law; or (d) from otherwise making disclosures that are protected under applicable law, including, without limitation, the National Labor Relations Act, the Defend Trade Secrets Act, and any rule or regulation promulgated by the Securities and Exchange Commission (SEC), the National Labor Relations Board (NLRB), the Equal Employment Opportunity Commission (EEOC), or any other federal, state, or local government agency.

18 U.S.C. § 1833(b) states: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.” Accordingly, I have the right to disclose in confidence trade secrets to Federal, State, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. I also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protectable from public disclosure.

Further, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.

Nothing in this Agreement is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. § 1833(b).
A-3

3.Inventions.

(a)Inventions Retained and Licensed. (i) If I am a new employee, I have attached hereto, as Exhibit A, a list describing all discoveries, ideas, inventions, improvements, software, techniques, methods, works of authorship, developments, and trade secrets (if any) which were made by me prior to my employment with the Company (collectively referred to as “Prior Developments”), which I own or control, which relate directly or indirectly to the Company’s proposed business, products or research and development, and which are not assigned to the Company hereunder; if no such list is attached to or contained in Exhibit A, I represent that there are no such Prior Developments. (ii) If I am a continuing employee, I represent that Exhibit A of my previous agreement with Company includes all Prior Developments; if no such list was attached to or contained in Exhibit A, I represent that there are no such Prior Developments. (iii) All employees: I agree not to or incorporate any Prior Developments into any Company product, material, process or service without the prior written consent of the Company, which written consent identifies the item to be incorporated as a Prior Development. If in the course of my employment with the Company, I incorporate into a Company product, process, machine or service a Prior Development or use a Prior Development in connection with the same, without the aforementioned written consent, the Company is hereby granted and shall have a nonexclusive, fully sublicensable, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify, use, have used, sell, have sold and import such Prior Development as part of or in connection with any Company product, process, machine or service, and I agree to disclose the use of such Prior Developments in writing to the Company promptly after such incorporation.

(b)Assignment of Inventions. I hereby assign to the Company, or its designee, all my right, title, and interest in and to any and all discoveries, ideas, inventions, creations, data, software, techniques, methods, works of authorship, know how, developments, concepts, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws, which I may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time I am in the employ of the Company (collectively referred to as “Inventions”), excepting only any invention (if any) which qualifies fully under the provisions of California Labor Code Section 2870 as provided in Section 3 (e) below. I agree that I will promptly make full written disclosure to the Company of any Invention, and will hold the same in trust for the sole right and benefit of the Company. I further acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of and during the period of my employment with the Company and which are protectable by copyright are “works made for hire”, as that term is defined in the United States Copyright Act.
(c)Maintenance of Records. I agree to keep and maintain adequate and current written records of any and all Inventions hereunder, including any made by me solely or jointly with others during the term of my employment with the Company. The records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times.

(d)Patent and Copyright Registrations. I agree to assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s rights in the Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for, obtain and enforce such rights and in order to assign and convey to the Company, its successors, assigns and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. I further agree that my obligation to
A-4

execute or cause to be executed, when it is in my power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the Company is unable because of my mental or physical incapacity or for any other reason to secure my signature to apply for or to pursue any application for any United States or foreign patents or copyright registrations covering Inventions or original works of authorship assigned to the Company as above, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, to act for and in my behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon with the same legal force and effect as if executed by me.

(e)Exception to Assignments. I understand that the provisions of this Agreement requiring assignment of Inventions to the Company do not apply to any invention which qualifies fully under the provisions of California Labor Code Section 2870 (attached hereto as Exhibit B). I will advise the Company promptly in writing of any invention that I believe meet the criteria in California Labor Code Section 2870 and are not disclosed on Exhibit A.

4.Conflicts of Interest. I agree that, during the term of my employment with the Company, I will comply with the Company’s policies regarding conflicts of interest, including those contained in Company’s Code of Business Conduct and Ethics, as may be updated from time to time.

5.Returning Company Property. I agree that, prior to or at the time of leaving the employ of the Company, I will deliver to the Company, or alternatively, destroy solely at the Company’s discretion, (and will not keep in my possession, recreate or deliver to anyone else) any and all Proprietary Information in my possession, as well as all equipment, devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, biological and other tangible materials (including, but not limited, to cell lines, plasmids, vectors and DNA), other documents or tangible property of the Company (or property of third parties that is lawfully in the possession or control of the Company), or reproductions of any aforementioned items including any and all of the aforementioned items developed by me pursuant to my employment with the Company or otherwise property of the Company, its successors or assigns. In the event of the termination of my employment, I agree to sign and deliver the “Termination Certification” attached hereto as Exhibit C.

6.Notification of New Employer. In the event that I leave the employ of the Company, I hereby grant consent to notification by the Company to my new employer about my rights and obligations under this Agreement.

7.Photography Consent, Waiver, And Release. Upon execution of this Agreement, I agree to sign the Photography Consent, Waiver and Release attached as Exhibit D hereto.

8.Representations. I agree to execute any proper oath or verify any proper document required to carry out the terms of this Agreement. I represent that my performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any oral or written agreement in conflict herewith during the term of my employment.

A-5

9.Arbitration and Equitable Relief.
(a)Arbitration. Except as provided in Section 10(b) below and otherwise in this Section, I agree that any dispute or controversy arising out of or relating to any interpretation, construction, performance or breach of this Agreement, shall be resolved by binding arbitration to be administered by the American Arbitration Association in accordance with its Employment Arbitration Rules and Mediation Procedures then in effect. The decision of the arbitrator shall be final, conclusive and binding on the parties to the arbitration. Judgment may be entered on the arbitrator’s decision in any court having jurisdiction. The Company shall pay the costs and expenses of the arbitration, including all administrative and arbitrator fees, and each of us shall separately pay our counsel fees. However, the arbitrator shall be empowered to make awards of costs or fees as provided by law. Notwithstanding the foregoing, any dispute or controversy seeking to enforce or protect, or concerning the validity of, any of intellectual property right of either party or (b) any dispute or controversy related to, or arising from, allegations of theft, piracy, invasion of privacy, or unauthorized use hereunder, I and the Company will have the right, at my or its sole discretion, as applicable, to adjudicate such dispute or controversy in a court of competent jurisdiction.

(b)Equitable Remedies. To the extent permitted by applicable law, this Agreement does not preclude either the Company or myself from seeking injunctive relief in a court of law.

10.General Provisions.

(a)Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by the laws of the State of California exclusively, (regardless of that jurisdiction or any other jurisdiction’s choice of law principles). I hereby expressly consent to the personal jurisdiction of the state and federal courts located in San Mateo County, California for any lawsuit filed there against me by the Company arising from or relating to this Agreement.
(b)Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter herein and, except as stated in this paragraph, supersedes all prior and contemporaneous discussions between us, including any previous confidentiality agreements that I may have entered into with the Company with the effect that this Agreement shall control with respect to the subject matter hereof and thereof. Any previous agreements relating to the subject matter herein are extinguished other than previously executed assignments of intellectual property and any other obligations regarding intellectual property I that conceived and/or developed on behalf of Codexis during my employment, and my list of Prior Developments on a former employment agreement between us, if any. Further, any previous non- compete provisions between Company and me are void. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by both parties. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.

(c)Severability. If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full force and effect.
(d)Successors and Assigns. This Agreement is binding upon my heirs, executors, administrators, other legal representatives and is for the benefit of the Company, its successors, and assigns.
(e)Survival.    The rights and obligations of the parties to this

A-6

Agreement will survive termination of my employment with Company.
(f)Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.


[SIGNATURE PAGE FOLLOWS]

A-7

I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING THAT ONE COUNTERPART WILL BE RETAINED BY COMPANY AND THE OTHER COUNTERPART WILL BE RETAINED BY ME.




Date:9/30/2024
Georgia Erbez
SignaturePrinted



CODEXIS, INC.

By:      Stephen Dilly, MBBS, Ph.D.
Chairman, President and CEO Date: 9/30/2024____________

A-8



EXHIBIT A
LIST OF PRIOR DEVELOPMENTS (INCLUDING ORIGINAL WORKS OF AUTHORSHIP)


Identifying Number
    Title            Date            Or Brief Description

A-9

EXHIBIT B
CALIFORNIA LABOR CODE SECTION 2870 EMPLOYMENT AGREEMENTS; ASSIGNMENT OF RIGHTS

(a)Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

(1)Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer.
(2)Result from any work performed by the employee for the employer.

(b)To the extent a provision in the employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.

A-10

EXHIBIT C
CODEXIS, INC.
FORM TERMINATION CERTIFICATE
This is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any aforementioned items belonging to Codexis, Inc., its subsidiaries, affiliates, successors or assigns, except where authorized in writing.
I further certify that I have complied with all the terms of the Codexis, Inc. Proprietary Information, Inventions, and Employment Agreement signed by me, including the reporting of any inventions and original works of authorship (as defined therein), conceived or made by me (solely or jointly with others) covered by that agreement.
I further agree that, in compliance with the Proprietary Information, Inventions, and Employment Agreement, I will preserve as confidential all trade secrets, confidential knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship, customer lists, business plans, financial information or other subject matter pertaining to any business of Codexis and any third party confidential information that I have knowledge concerning..
The Federal Defend Trade Secrets Act. 18 U.S.C. § 1833(b) states:
“An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.”
Accordingly, I have the right to disclose in confidence trade secrets to Federal, State, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. I also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protectable from public disclosure. Nothing in this Certification is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. § 1833(b).


Date:     

_________________________________
(Employee’s Signature)


_________________________________
(Type/Print Employee’s Name)

A-11

EXHIBIT D CODEXIS, INC.
PHOTOGRAPHY CONSENT, WAIVER, AND RELEASE

For good and valuable consideration, the receipt and sufficiency of which I hereby acknowledge, I hereby irrevocably consent and give permission to Codexis, Inc. (“Codexis”) or its agent, to photograph me, record my voice, and/or video me (alone or with others), in the context of my association with Codexis and/or at Codexis-related events (creating “Materials”). I understand that any such Materials, and all rights associated with them, will belong solely and exclusively to Codexis and Codexis shall have the irrevocable and absolute right to register copyright(s), duplicate, reproduce, alter, display, distribute, and/or publish them in any manner, for any purpose, and in any form including, but not limited to, print, electronic, radio, video, and/or on the Internet without notifying me.
I voluntarily waive any and all rights I may now or hereafter have with respect to any Materials, including any compensation, ownership, copyright, and any rights of publicity or privacy and any right to inspect or approve Materials and/or copy, print or other materials that may be used in connection with them, whether now or in the future, whether that use is known or unknown to me. I hereby waive any right to inspect or approve of any finished Materials whether printed or electronic, that may be used now or in the future, whether that use is known or unknown to me, and I forever waive any right to royalties or other compensation arising from or related to the use of the Materials. I hereby release and discharge, and agree to hold harmless, Codexis, its officers, agents and employees, and all persons acting under its permission or authority, from any claims, losses, damages or liability arising from or related to such Materials and/or their use under any circumstances.
I represent and warrant to that I am at least 18 years of age and that I have full right, power, and authority to enter into this Photography Consent, Waiver and Release and grant the rights granted hereunder, and that the rights granted hereunder do not, and will not, violate any right of, or conflict with or violate any contract or agreement with or commitment made to, any person or entity, and that no consent or authorization from, or any payment to, any third party is required in connection herewith. This Photography Consent, Waiver, and Release is binding on my heirs, executors, administrators and other legal representatives and is for the benefit of Codexis, its successors and assigns.

I HAVE READ AND FULLY UNDERSTAND THE CONTENTS OF THIS PHOTOGRAPHY CONSENT, WAIVER, AND RELEASE FORM, AND I SIGN IT FREELY AND VOLUNTARILY.

Name:    Georgia Erbez    


___________________________
Signature

Date: 9/30/2024    
A-12

ATTACHMENT B
CHANGE OF CONTROL SEVERANCE AGREEMENT

B-1

CODEXIS, INC.
CHANGE OF CONTROL SEVERANCE AGREEMENT
This Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between Georgia Erbez (the “Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto
below (the “Effective Date”).
R E C I T A L S
A.It is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change of control. The Board of Directors of the Company (the “Board”) recognizes that such consideration as well as the possibility of an involuntary termination or reduction in responsibility can be a distraction to Executive and can cause Executive to consider alternative employment opportunities. The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such an event.
B.The Board believes that it is in the best interests of the Company and its
stockholders to provide Executive with an incentive to continue Executive’s employment and to motivate Executive to maximize the value of the Company upon a Change of Control (as defined below) for the benefit of its stockholders.
C.The Board believes that it is imperative to provide Executive with severance benefits upon certain terminations of Executive’s service to the Company that provide Executive with enhanced financial security and provides incentive and encouragement to Executive to remain with the Company notwithstanding the possibility of such an event.
D.Certain capitalized terms used in the Agreement are defined in Section 9 below. The parties hereto agree as follows:
1.Term of Agreement. This Agreement shall become effective as of the Effective Date and terminate upon the date that all obligations of the parties hereto with respect to this Agreement have been satisfied.
2.At-Will Employment. The Company and Executive acknowledge that
Executive’s employment is and shall continue to be “at-will,” as defined under applicable law. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement.
3.Covered Termination Outside a Change of Control Period. Except as otherwise provided under Section 6, if Executive experiences a Covered Termination other than during a Change of Control Period, and if Executive, within sixty (60) days following the date of the Covered Termination, provides the Company with an executed Release of Claims (as defined below) which is not revoked within the applicable revocation period, if any, then in addition
B-2

to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Severance. Executive shall receive a lump sum cash payment in an
amount equal to twelve (12) months of Executive’s base salary at the rate in effect immediately prior to Executive’s termination of employment (without giving effect to any reduction in base salary that gives rise to a Voluntary Termination for Good Reason), less applicable withholdings. This severance payment shall be made to Executive in substantially equal installments in accordance with the Company’s normal payroll procedures with the first such installment to be made on the first payroll date following the date the Release of Claims becomes effective and irrevocable, provided, that if the Covered Termination occurs after November 1 of any year, the first such installment shall be made on the first payroll date of the subsequent year and, provided further, that, in each case, the first installment shall include any installment payments that would have been made had such installments commenced on the first payroll date after the Covered Termination.
(b)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic
partner from the date of Executive’s Covered Termination through the earlier of (i) the twelve
(12) month anniversary of the date of Executive’s Covered Termination and (ii) the date
Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or
(3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding
sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
4.Covered Termination Within a Change of Control Period. If Executive experiences a Covered Termination during a Change of Control Period, and if Executive, within sixty (60) days following the date of the Covered Termination, provides the Company with an executed Release of Claims (as defined below) which is not revoked within the applicable revocation period, if any, then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Severance. Executive shall receive a lump sum cash payment in an
amount equal to the sum of eighteen (18) months of Executive’s base salary at the rate in effect immediately prior to Executive’s termination of employment (without giving effect to any reduction in base salary subsequent to a Change of Control that gives rise to a Voluntary
B-3

Termination for Good Reason), less applicable withholdings. This severance payment shall be made to Executive within sixty (60) days following the date of the Covered Termination.
(b)Equity Awards. Each outstanding equity award, including, without limitation, stock options, restricted stock, and restricted stock units, held by Executive shall automatically become vested and, if applicable, exercisable and any restrictions thereon shall immediately lapse, in each case, with respect to one hundred percent (100%) of the then unvested shares subject to such equity award. Notwithstanding the foregoing, any outstanding performance stock units or performance stock options held by Executive shall automatically become vested with respect to: (i) in the event of a Change of Control that occurs prior to the applicable Measurement Date, such number of shares of Company common stock corresponding to the target performance level for any applicable performance goals; or (ii) in the event of a Change of Control that occurs on or after the Measurement Date, such number of shares of Company common stock corresponding to the Company’s actual achievement of any applicable performance goals.
(c)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s Covered Termination through the earlier of (i) the eighteen (18) month anniversary of the date of Executive’s Covered Termination and
(ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s
plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code, under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue
healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
5.Death or Disability. If Executive terminates employment with the Company due to death or Disability and such termination constitutes a “separation from service” within the meaning of Section 409A of Code and the Department of Treasury regulations and other guidance promulgated thereunder (a “Separation from Service”), then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Pro-Rata Vesting of Equity Awards. Each outstanding equity award, including, without limitation, stock options, restricted stock and restricted stock units, held by Executive shall automatically become vested and, if applicable, exercisable and any restrictions thereon shall immediately lapse, in each case, with respect to that number of shares of Company common stock that would otherwise vest on the next vesting date for such equity award,
B-4

assuming Executive’s continued service through such date, pro-rated to the date of Executive’s termination due to death or Disability. For purposes of determining the number of shares subject to any outstanding performance stock units or performance stock options that would otherwise vest on the next vesting date pursuant to the foregoing sentence, the applicable performance goals shall be deemed achieved: (i) in the event of a termination due to death or Disability that occurs prior to the applicable Measurement Date, at the target performance level; or (ii) in the event of a termination due to death or Disability that occurs on or after the Measurement Date,
based on the Company’s actual achievement.
(b)Continued Healthcare. If Executive, or any beneficiary of Executive, elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive, or such beneficiary, for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s termination due to death or Disability through the earlier of (i) the twelve
(12) month anniversary of the date of Executive’s termination of employment and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code, under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive, or any beneficiary of Executive, may, if eligible, elect to continue healthcare coverage at his or her expense in accordance with the provisions of COBRA.
6.Termination in Connection With a Change of Control. Notwithstanding anything in this Agreement to the contrary, in the event Executive experiences a Covered Termination and the Involuntary Termination without Cause underlying the Covered Termination, or the event upon which a Voluntary Termination for Good Reason underlying the Covered Termination is based, occurs at the direction of a person or entity that has entered into an agreement with the Company that contemplates a transaction that, if consummated, would constitute a Change of Control, then for all purposes hereunder, including, without limitation, Sections 4 and 7, such Covered Termination shall be deemed to have occurred during a Change of Control Period and, in lieu of the benefits provided under Section 3, Executive shall be entitled to the benefits set forth in Section 4 with such benefits to be paid, or commence being paid, upon the Covered Termination, but otherwise subject to the terms and conditions of Section 4.
7.Termination for Cause; Voluntary Resignation. If Executive’s service with the Company is terminated by the Company for Cause or by Executive for any or no reason other than due to death, Disability or as a Covered Termination, then Executive shall only be entitled to any accrued but unpaid salary, bonus, vacation and expense reimbursement in accordance with applicable law.
B-5

8.Limitation on Payments. In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i) constitute “parachute
payments” within the meaning of Section 280G of the Code and (ii) but for this Section 8, would be subject to the excise tax imposed by Section 4999 of the Code, then Executive’s severance benefits under this Agreement shall be payable either
(a)in full, or
(b)as to such lesser amount which would result in no portion of such severance benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code, results in the receipt by Executive on an after-tax basis, of the greatest amount of severance benefits under this Agreement, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. The specific benefits that shall be reduced, if any, and the order of such reduction shall be determined by the Executive in his or her sole discretion. Unless the Company and Executive otherwise agree in writing, any determination required under this Section 8 shall be made in writing by the Company's independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations required by this Section 8, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 8.
9.Definition of Terms. The following terms referred to in this Agreement shall have the following meanings:
(a)Change of Control. “Change of Control” shall mean (i) a dissolution or liquidation of the Company; (ii) a sale of all or substantially all the assets of the Company; (iii) a merger or consolidation in which the Company is not the surviving corporation and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors has changed; (iv) a reverse merger in which the Company is the surviving corporation but the shares of the common stock of the Company outstanding immediately before the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors has changed; (v) an acquisition by any person, entity or group within the meaning of Section 13(d) or 14(d) of the Securities and
Exchange Act of 1934, as amended (the “Exchange Act”), or any comparable successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors; or, (vi) in the
B-6

event that the individuals who are members of the Incumbent Board cease for any reason to constitute at least fifty percent (50%) of the Board. Notwithstanding the foregoing, a Change of Control shall not include any transaction effected primarily for the purpose of financing the Company with cash (as determined by the Board acting in good faith and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise) or the initial public offering of the Company’s common stock. Further notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event that constitutes “nonqualified deferred
compensation,” the transaction or event constituting the Change of Control must also constitute a “change in control event” (as defined in Treasury Regulation §1.409A-3(i)(5)) in order to give rise to the payment or settlement event, to the extent required by Section 409A.
(b)Change of Control Period. “Change of Control Period” shall mean the period commencing ninety (90) days prior to a Change of Control and ending on the first anniversary of the Change of Control.
(c)Covered Termination. “Covered Termination” shall mean an Involuntary Termination without Cause or a Voluntary Termination for Good Reason that constitutes the Executive’s Separation from Service.
(d)Disability. “Disability” shall mean that Executive has been unable to
perform Executive’s Company duties as the result of Executive’s incapacity due to physical or mental illness, and such inability, at least one hundred eighty (180) days after its commencement, is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to Executive or Executive’s legal representative (such agreement as to acceptability not to be unreasonably withheld). Termination resulting from Disability may only be effected after at least thirty (30) days’ written notice by the Company of its intention to terminate Executive’s employment. In the event that Executive resumes the performance of substantially all of Executive’s duties hereunder before the termination of Executive’s employment becomes effective, the notice of intent to terminate shall automatically be deemed to have been revoked.
(e)Incumbent Board. “Incumbent Board” shall mean the individuals who, as of the Effective Date, are members of the Board. If the election, or nomination for election by
the Company’s stockholders, of any new director is approved by a vote of at least fifty percent (50%) of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board.
(f)Involuntary Termination without Cause. “Involuntary Termination
without Cause” shall mean the termination of Executive’s employment by the Company other than a termination following (i) the willful and continued failure to substantially perform the Executive’s duties with the Company (other than as a result of physical or mental disability) after a written demand for substantial performance is delivered to the Executive by the Company, which demand specifically identifies the manner in which the Company believes that the
Executive has not substantially performed the Executive’s duties and that has not been cured within fifteen (15) days following receipt by the Executive of the written demand; (ii) commission of a felony (other than a traffic-related offense) that in the written determination of the Company is likely to cause or has caused material injury to the Company’s business; (iii)
B-7

dishonesty with respect to a significant matter relating to the Company’s business; or (iv) material breach of any agreement by and between the Executive and the Company, which material breach has not been cured within fifteen (15) days following receipt by the Executive of written notice from the Company identifying such material breach.
(g)Release of Claims. “Release of Claims” shall mean a general release of all claims against the Company and its affiliates in a form reasonably acceptable to the Company.
(h)Voluntary Termination for Good Reason. “Voluntary Termination for Good Reason” shall mean Executive’s voluntarily resignation after the occurrence of any of the following without Executive’s written consent: (i) a material diminution in Executive’s base
compensation; (ii) a material diminution in Executive’s authority, duties or responsibilities; (iii) a material change of at least thirty-five (35) miles in the geographic location at which Executive must perform Executive’s services; or (iv) a material breach of this Agreement by the Company. Notwithstanding the foregoing, a resignation shall not constitute a “Voluntary Termination for Good Reason” unless the condition giving rise to such resignation continues more than thirty
(30) days following Executive’s written notice of the condition within ninety (90) days of the first occurrence of such condition and Executive’s termination occurs within one hundred eighty
(180) days following the first occurrence of such condition.
(i)    Measurement Date. “Measurement Date,” with respect to an award of performance stock units or performance stock options, shall mean the date the Compensation Committee of the Board of Directors determines the achievement of the applicable performance goals for the applicable performance period.
10.Successors.
(a)Company’s Successors. Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or
substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in this Section 10(a) or which becomes bound by the terms of this Agreement by operation of law.
(b)Executive’s Successors. The terms of this Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.
11.Notices. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or one day following mailing via Federal Express or similar overnight courier service. In the case of Executive, mailed notices shall be addressed to Executive at Executive’s home address that the Company has on file for Executive. In the case of the
B-8

Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.
12.Confidentiality; Non-Solicitation.
(a)Confidentiality. While Executive is employed by the Company, and thereafter while Executive receives severance benefits hereunder, Executive shall not directly or indirectly disclose or make available to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, any Confidential Information (as defined
below). Upon termination of Executive’s employment with the Company, all Confidential Information in Executive’s possession that is in written or other tangible form (together with all copies or duplicates thereof, including computer files) shall be returned to the Company and shall not be retained by Executive or furnished to any third party, in any form except as provided herein; provided, however, that Executive shall not be obligated to treat as confidential, or return to the Company copies of any Confidential Information that (i) was publicly known at the time of disclosure to Executive, (ii) becomes publicly known or available thereafter other than by any means in violation of this Agreement or any other duty owed to the Company by any person or entity, or (iii) is lawfully disclosed to Executive by a third party. For purposes of this Agreement, the term “Confidential Information” shall mean information disclosed to Executive or known by Executive as a consequence of or through his or her relationship with the Company, about the customers, employees, business methods, public relations methods, organization, procedures or finances, including, without limitation, information of or relating to customer lists, of the Company and its affiliates. In addition, Executive shall continue to be subject to the Confidential Information, Secrecy, and Invention Agreement entered into between Executive and the Company (the “Confidential Information Agreement”).
(b)Non-Solicitation. In addition to each Executive’s obligations under the Confidential Information Agreement, Executive shall not for a period of one (1) year following Executive’s termination of employment for any reason, either on Executive’s own account or jointly with or as a manager, agent, officer, employee, consultant, partner, joint venturer, owner or stockholder or otherwise on behalf of any other person, firm or corporation, directly or indirectly solicit or attempt to solicit away from the Company any of its officers or employees or offer employment to any person who is an officer or employee of the Company; provided, however, that a general advertisement to which an employee of the Company responds shall in no event be deemed to result in a breach of this Section 12(b). Executive also agrees not to harass or disparage the Company or its employees, clients, directors or agents or divert or attempt to divert any actual or potential business of the company.
(c)Survival of Provisions. The provisions of this Section 12 shall survive the termination or expiration of the applicable Executive’s employment with the Company and shall be fully enforceable thereafter. If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 12 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.
B-9

13.Dispute Resolution. To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach,
performance or interpretation of this Agreement, Executive’s employment, or the termination of Executive’s employment, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in San Mateo County, California, conducted by Judicial Arbitration and Mediation Services, Inc. (“JAMS”) under the applicable JAMS employment rules. By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision, to include
the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS’ arbitration fees in excess of the amount of court fees that would be required if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over intellectual property rights by Court action instead of arbitration.
14.Miscellaneous Provisions.
(a)Section 409A. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive’s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the date of the Executive’s Covered Termination or termination of employment due to Disability or (ii) the date of Executive’s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 14(a) shall be paid in a lump sum to Executive, and any remaining payments due under the Agreement shall be paid as otherwise provided herein.
(b)Waiver. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.
(c)Whole Agreement. This Agreement and the Confidential Information Agreement represent the entire understanding of the parties hereto with respect to the
B-10

subject matter hereof and supersede all prior arrangements and understandings regarding same.
(d)Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California.
(e)Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.
(f)Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument.
[Signature page follows]

B-11



IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year set forth below.


CODEXIS, INC.
By:      Name: Stephen Dilly, MBBS, Ph.D. Title: Chairman, President & CEO
Date: 9/30/2024


EXECUTIVE

        
Georgia Erbez
Date: 9/30/2024




B-12

ATTACHMENT C

POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION

C-1

CODEXIS, INC.
POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION
Introduction
The Board of Directors (the “Board”) of Codexis, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company. This Policy shall be interpreted to comply with the requirements of U.S. Securities and Exchange Commission (“SEC”) rules and Nasdaq Stock Market (“Nasdaq”) listing standards implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) and, to the extent this Policy is in any manner deemed inconsistent with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.
Administration
This Policy shall be administered by the Compensation Committee (the “Compensation Committee”) of the Board. Any determinations made by the Compensation Committee shall be final and binding on all affected individuals. The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in all cases consistent with the Dodd-Frank Act. The Board or Compensation Committee may amend this Policy from time to time in its discretion.
Covered Executives
This Policy applies to any current or former “executive officer,” within the meaning of Rule 10D-1 under the Securities Exchange Act of 1934, as amended, of the Company or a subsidiary of the Company (each such individual, an “Executive”). This Policy shall be binding and enforceable against all Executives and their beneficiaries, executors, administrators, and other legal representatives.
Recoupment Upon Financial Restatement
If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a “Financial Restatement”), the Compensation Committee shall cause the Company to recoup from each Executive, as promptly as reasonably possible, any erroneously awarded Incentive-Based Compensation, as defined below.
No-Fault Recovery
Recoupment under this Policy shall be required regardless of whether the Executive or any other person was at fault or responsible for accounting errors that contributed to the need for the Financial Restatement or engaged in any misconduct.
Compensation Subject to Recovery; Enforcement
This Policy applies to all compensation granted, earned or vested based wholly or in part upon the attainment of any financial reporting measure determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly
C-2

or in part from such measures, whether or not presented within the Company’s financial statements or included in a filing with the SEC, including stock price and total shareholder return (“TSR”), including but not limited to performance-based cash, stock, options or other equity-based awards paid or granted to the Executive (“Incentive-Based Compensation”). Compensation that is granted, vests or is earned based solely upon the occurrence of non-financial events, such as base salary, restricted stock or options with time-based vesting, or a bonus awarded solely at the discretion of the Board or Compensation Committee and not based on the attainment of any financial measure, is not subject to this Policy.
In the event of a Financial Restatement, the amount to be recovered will be the excess of (i) the Incentive- Based Compensation received by the Executive during the Recovery Period (as defined below) based on the erroneous data and calculated without regard to any taxes paid or withheld, over (ii) the Incentive-Based Compensation that would have been received by the Executive had it been calculated based on the restated financial information, as determined by the Compensation Committee. For purposes of this Policy, “Recovery Period” means the three completed fiscal years immediately preceding the date on which the Company is required to prepare the Financial Restatement, as determined in accordance with the last sentence of this paragraph, or any transition period that results from a change in the Company’s fiscal year (as set forth in Section 5608(b)(i)(D) of the Nasdaq Listing Rules). The date on which the Company is required to prepare a Financial Restatement is the earlier to occur of (A) the date the Board or a Board committee (or authorized officers of the Company if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Financial Restatement.
For Incentive-Based Compensation based on stock price or TSR, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the Compensation Committee shall determine the amount to be recovered based on a reasonable estimate of the effect of the Financial Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received and the Company shall document the determination of that estimate and provide it to Nasdaq.
Incentive-Based Compensation is considered to have been received by an Executive in the fiscal year during which the applicable financial reporting measure was attained or purportedly attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.
The Company may use any legal or equitable remedies that are available to the Company to recoup any erroneously awarded Incentive-Based Compensation, including but not limited to by collecting from the Executive cash payments or shares of Company common stock from or by forfeiting any amounts that the Company owes to the Executive.
No Indemnification
The Company shall not indemnify any Executive or pay or reimburse the premium for any insurance policy to cover any losses incurred by such Executive under this Policy.
Exceptions
The compensation recouped under this Policy shall not include Incentive-Based Compensation received by an Executive (i) prior to beginning service as an Executive or (ii) if he or she did not serve as an Executive at any time during the performance period applicable to the Incentive-Based Compensation in question. The Compensation Committee (or a majority of independent directors serving on the Board) may determine not to seek recovery from an Executive in whole or part to the extent it determines in its sole discretion that such recovery would be impracticable because (A) the direct expense paid to a third
C-3

party to assist in enforcing recovery would exceed the recoverable amount (after having made a reasonable attempt to recover the erroneously awarded Incentive-Based Compensation and providing corresponding documentation of such attempt to Nasdaq), (B) recovery would violate the home country law that was adopted prior to November 28, 2022, as determined by an opinion of counsel licensed in the applicable jurisdiction that is acceptable to and provided to Nasdaq, or (C) recovery would likely cause the Company’s 401(k) plan or any other tax-qualified retirement plan to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.
Other Remedies Not Precluded
The exercise by the Compensation Committee of any rights pursuant to this Policy shall be without prejudice to any other rights or remedies that the Company, the Board or the Compensation Committee may have with respect to any Executive subject to this Policy.
Effective Date and Applicability
This Policy has been adopted by the Board on August 24, 2023, and shall apply to any Incentive-Based Compensation that is received by an Executive on or after October 2, 2023.
C-4
 EX-10.4 4 codexis-ex104changeinctrls.htm EX-10.4 Document

CODEXIS, INC.
CHANGE OF CONTROL SEVERANCE AGREEMENT
This Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between Georgia Erbez (the “Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto
below (the “Effective Date”).
R E C I T A L S
A.It is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change of control. The Board of Directors of the Company (the “Board”) recognizes that such consideration as well as the possibility of an involuntary termination or reduction in responsibility can be a distraction to Executive and can cause Executive to consider alternative employment opportunities. The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such an event.
B.The Board believes that it is in the best interests of the Company and its
stockholders to provide Executive with an incentive to continue Executive’s employment and to motivate Executive to maximize the value of the Company upon a Change of Control (as defined below) for the benefit of its stockholders.
C.The Board believes that it is imperative to provide Executive with severance benefits upon certain terminations of Executive’s service to the Company that provide Executive with enhanced financial security and provides incentive and encouragement to Executive to remain with the Company notwithstanding the possibility of such an event.
D.Certain capitalized terms used in the Agreement are defined in Section 9 below. The parties hereto agree as follows:
1.Term of Agreement. This Agreement shall become effective as of the Effective Date and terminate upon the date that all obligations of the parties hereto with respect to this Agreement have been satisfied.
2.At-Will Employment. The Company and Executive acknowledge that
Executive’s employment is and shall continue to be “at-will,” as defined under applicable law. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement.
3.Covered Termination Outside a Change of Control Period. Except as otherwise provided under Section 6, if Executive experiences a Covered Termination other than during a Change of Control Period, and if Executive, within sixty (60) days following the date of the
B-2

Covered Termination, provides the Company with an executed Release of Claims (as defined below) which is not revoked within the applicable revocation period, if any, then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Severance. Executive shall receive a lump sum cash payment in an
amount equal to twelve (12) months of Executive’s base salary at the rate in effect immediately prior to Executive’s termination of employment (without giving effect to any reduction in base salary that gives rise to a Voluntary Termination for Good Reason), less applicable withholdings. This severance payment shall be made to Executive in substantially equal installments in accordance with the Company’s normal payroll procedures with the first such installment to be made on the first payroll date following the date the Release of Claims becomes effective and irrevocable, provided, that if the Covered Termination occurs after November 1 of any year, the first such installment shall be made on the first payroll date of the subsequent year and, provided further, that, in each case, the first installment shall include any installment payments that would have been made had such installments commenced on the first payroll date after the Covered Termination.
(b)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic
partner from the date of Executive’s Covered Termination through the earlier of (i) the twelve
(12) month anniversary of the date of Executive’s Covered Termination and (ii) the date
Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or
(3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding
sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
4.Covered Termination Within a Change of Control Period. If Executive experiences a Covered Termination during a Change of Control Period, and if Executive, within sixty (60) days following the date of the Covered Termination, provides the Company with an executed Release of Claims (as defined below) which is not revoked within the applicable revocation period, if any, then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Severance. Executive shall receive a lump sum cash payment in an
B-3

amount equal to the sum of eighteen (18) months of Executive’s base salary at the rate in effect immediately prior to Executive’s termination of employment (without giving effect to any reduction in base salary subsequent to a Change of Control that gives rise to a Voluntary Termination for Good Reason), less applicable withholdings. This severance payment shall be made to Executive within sixty (60) days following the date of the Covered Termination.
(b)Equity Awards. Each outstanding equity award, including, without limitation, stock options, restricted stock, and restricted stock units, held by Executive shall automatically become vested and, if applicable, exercisable and any restrictions thereon shall immediately lapse, in each case, with respect to one hundred percent (100%) of the then unvested shares subject to such equity award. Notwithstanding the foregoing, any outstanding performance stock units or performance stock options held by Executive shall automatically become vested with respect to: (i) in the event of a Change of Control that occurs prior to the applicable Measurement Date, such number of shares of Company common stock corresponding to the target performance level for any applicable performance goals; or (ii) in the event of a Change of Control that occurs on or after the Measurement Date, such number of shares of Company common stock corresponding to the Company’s actual achievement of any applicable performance goals.
(c)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s Covered Termination through the earlier of (i) the eighteen (18) month anniversary of the date of Executive’s Covered Termination and
(ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s
plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code, under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue
healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
5.Death or Disability. If Executive terminates employment with the Company due to death or Disability and such termination constitutes a “separation from service” within the meaning of Section 409A of Code and the Department of Treasury regulations and other guidance promulgated thereunder (a “Separation from Service”), then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Pro-Rata Vesting of Equity Awards. Each outstanding equity award, including, without limitation, stock options, restricted stock and restricted stock units, held by
B-4

Executive shall automatically become vested and, if applicable, exercisable and any restrictions thereon shall immediately lapse, in each case, with respect to that number of shares of Company common stock that would otherwise vest on the next vesting date for such equity award,
assuming Executive’s continued service through such date, pro-rated to the date of Executive’s termination due to death or Disability. For purposes of determining the number of shares subject to any outstanding performance stock units or performance stock options that would otherwise vest on the next vesting date pursuant to the foregoing sentence, the applicable performance goals shall be deemed achieved: (i) in the event of a termination due to death or Disability that occurs prior to the applicable Measurement Date, at the target performance level; or (ii) in the event of a termination due to death or Disability that occurs on or after the Measurement Date,
based on the Company’s actual achievement.
(b)Continued Healthcare. If Executive, or any beneficiary of Executive, elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive, or such beneficiary, for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s termination due to death or Disability through the earlier of (i) the twelve
(12) month anniversary of the date of Executive’s termination of employment and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code, under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive, or any beneficiary of Executive, may, if eligible, elect to continue healthcare coverage at his or her expense in accordance with the provisions of COBRA.
6.Termination in Connection With a Change of Control. Notwithstanding anything in this Agreement to the contrary, in the event Executive experiences a Covered Termination and the Involuntary Termination without Cause underlying the Covered Termination, or the event upon which a Voluntary Termination for Good Reason underlying the Covered Termination is based, occurs at the direction of a person or entity that has entered into an agreement with the Company that contemplates a transaction that, if consummated, would constitute a Change of Control, then for all purposes hereunder, including, without limitation, Sections 4 and 7, such Covered Termination shall be deemed to have occurred during a Change of Control Period and, in lieu of the benefits provided under Section 3, Executive shall be entitled to the benefits set forth in Section 4 with such benefits to be paid, or commence being paid, upon the Covered Termination, but otherwise subject to the terms and conditions of Section 4.
7.Termination for Cause; Voluntary Resignation. If Executive’s service with the Company is terminated by the Company for Cause or by Executive for any or no reason other
B-5

than due to death, Disability or as a Covered Termination, then Executive shall only be entitled to any accrued but unpaid salary, bonus, vacation and expense reimbursement in accordance with applicable law.
8.Limitation on Payments. In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i) constitute “parachute
payments” within the meaning of Section 280G of the Code and (ii) but for this Section 8, would be subject to the excise tax imposed by Section 4999 of the Code, then Executive’s severance benefits under this Agreement shall be payable either
(a)in full, or
(b)as to such lesser amount which would result in no portion of such severance benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code, results in the receipt by Executive on an after-tax basis, of the greatest amount of severance benefits under this Agreement, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. The specific benefits that shall be reduced, if any, and the order of such reduction shall be determined by the Executive in his or her sole discretion. Unless the Company and Executive otherwise agree in writing, any determination required under this Section 8 shall be made in writing by the Company's independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations required by this Section 8, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 8.
9.Definition of Terms. The following terms referred to in this Agreement shall have the following meanings:
(a)Change of Control. “Change of Control” shall mean (i) a dissolution or liquidation of the Company; (ii) a sale of all or substantially all the assets of the Company; (iii) a merger or consolidation in which the Company is not the surviving corporation and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors has changed; (iv) a reverse merger in which the Company is the surviving corporation but the shares of the common stock of the Company outstanding immediately before the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors has changed; (v) an acquisition by any person, entity or group within the meaning of Section 13(d) or 14(d) of the Securities and
Exchange Act of 1934, as amended (the “Exchange Act”), or any comparable successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) of the
B-6

beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors; or, (vi) in the event that the individuals who are members of the Incumbent Board cease for any reason to constitute at least fifty percent (50%) of the Board. Notwithstanding the foregoing, a Change of Control shall not include any transaction effected primarily for the purpose of financing the Company with cash (as determined by the Board acting in good faith and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise) or the initial public offering of the Company’s common stock. Further notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event that constitutes “nonqualified deferred compensation,” the transaction or event constituting the Change of Control must also constitute a “change in control event” (as defined in Treasury Regulation §1.409A-3(i)(5)) in order to give rise to the payment or settlement event, to the extent required by Section 409A.
(b)Change of Control Period. “Change of Control Period” shall mean the period commencing ninety (90) days prior to a Change of Control and ending on the first anniversary of the Change of Control.
(c)Covered Termination. “Covered Termination” shall mean an Involuntary Termination without Cause or a Voluntary Termination for Good Reason that constitutes the Executive’s Separation from Service.
(d)Disability. “Disability” shall mean that Executive has been unable to
perform Executive’s Company duties as the result of Executive’s incapacity due to physical or mental illness, and such inability, at least one hundred eighty (180) days after its commencement, is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to Executive or Executive’s legal representative (such agreement as to acceptability not to be unreasonably withheld). Termination resulting from Disability may only be effected after at least thirty (30) days’ written notice by the Company of its intention to terminate Executive’s employment. In the event that Executive resumes the performance of substantially all of Executive’s duties hereunder before the termination of Executive’s employment becomes effective, the notice of intent to terminate shall automatically be deemed to have been revoked.
(e)Incumbent Board. “Incumbent Board” shall mean the individuals who, as of the Effective Date, are members of the Board. If the election, or nomination for election by
the Company’s stockholders, of any new director is approved by a vote of at least fifty percent (50%) of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board.
(f)Involuntary Termination without Cause. “Involuntary Termination
without Cause” shall mean the termination of Executive’s employment by the Company other than a termination following (i) the willful and continued failure to substantially perform the Executive’s duties with the Company (other than as a result of physical or mental disability) after a written demand for substantial performance is delivered to the Executive by the Company, which demand specifically identifies the manner in which the Company believes that the
B-7

Executive has not substantially performed the Executive’s duties and that has not been cured within fifteen (15) days following receipt by the Executive of the written demand; (ii) commission of a felony (other than a traffic-related offense) that in the written determination of the Company is likely to cause or has caused material injury to the Company’s business; (iii) dishonesty with respect to a significant matter relating to the Company’s business; or (iv) material breach of any agreement by and between the Executive and the Company, which material breach has not been cured within fifteen (15) days following receipt by the Executive of written notice from the Company identifying such material breach.
(g)Release of Claims. “Release of Claims” shall mean a general release of all claims against the Company and its affiliates in a form reasonably acceptable to the Company.
(h)Voluntary Termination for Good Reason. “Voluntary Termination for Good Reason” shall mean Executive’s voluntarily resignation after the occurrence of any of the following without Executive’s written consent: (i) a material diminution in Executive’s base
compensation; (ii) a material diminution in Executive’s authority, duties or responsibilities; (iii) a material change of at least thirty-five (35) miles in the geographic location at which Executive must perform Executive’s services; or (iv) a material breach of this Agreement by the Company. Notwithstanding the foregoing, a resignation shall not constitute a “Voluntary Termination for Good Reason” unless the condition giving rise to such resignation continues more than thirty
(30) days following Executive’s written notice of the condition within ninety (90) days of the first occurrence of such condition and Executive’s termination occurs within one hundred eighty
(180) days following the first occurrence of such condition.
(i)    Measurement Date. “Measurement Date,” with respect to an award of performance stock units or performance stock options, shall mean the date the Compensation Committee of the Board of Directors determines the achievement of the applicable performance goals for the applicable performance period.
10.Successors.
(a)Company’s Successors. Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or
substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in this Section 10(a) or which becomes bound by the terms of this Agreement by operation of law.
(b)Executive’s Successors. The terms of this Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.
B-8

11.Notices. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or one day following mailing via Federal Express or similar overnight courier service. In the case of Executive, mailed notices shall be addressed to Executive at
Executive’s home address that the Company has on file for Executive. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.
12.Confidentiality; Non-Solicitation.
(a)Confidentiality. While Executive is employed by the Company, and thereafter while Executive receives severance benefits hereunder, Executive shall not directly or indirectly disclose or make available to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, any Confidential Information (as defined
below). Upon termination of Executive’s employment with the Company, all Confidential Information in Executive’s possession that is in written or other tangible form (together with all copies or duplicates thereof, including computer files) shall be returned to the Company and shall not be retained by Executive or furnished to any third party, in any form except as provided herein; provided, however, that Executive shall not be obligated to treat as confidential, or return to the Company copies of any Confidential Information that (i) was publicly known at the time of disclosure to Executive, (ii) becomes publicly known or available thereafter other than by any means in violation of this Agreement or any other duty owed to the Company by any person or entity, or (iii) is lawfully disclosed to Executive by a third party. For purposes of this Agreement, the term “Confidential Information” shall mean information disclosed to Executive or known by Executive as a consequence of or through his or her relationship with the Company, about the customers, employees, business methods, public relations methods, organization, procedures or finances, including, without limitation, information of or relating to customer lists, of the Company and its affiliates. In addition, Executive shall continue to be subject to the Confidential Information, Secrecy, and Invention Agreement entered into between Executive and the Company (the “Confidential Information Agreement”).
(b)Non-Solicitation. In addition to each Executive’s obligations under the Confidential Information Agreement, Executive shall not for a period of one (1) year following Executive’s termination of employment for any reason, either on Executive’s own account or jointly with or as a manager, agent, officer, employee, consultant, partner, joint venturer, owner or stockholder or otherwise on behalf of any other person, firm or corporation, directly or indirectly solicit or attempt to solicit away from the Company any of its officers or employees or offer employment to any person who is an officer or employee of the Company; provided, however, that a general advertisement to which an employee of the Company responds shall in no event be deemed to result in a breach of this Section 12(b). Executive also agrees not to harass or disparage the Company or its employees, clients, directors or agents or divert or attempt to divert any actual or potential business of the company.
(c)Survival of Provisions. The provisions of this Section 12 shall survive the termination or expiration of the applicable Executive’s employment with the Company and shall be fully enforceable thereafter. If it is determined by a court of
B-9

competent jurisdiction in any state that any restriction in this Section 12 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.
13.Dispute Resolution. To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach,
performance or interpretation of this Agreement, Executive’s employment, or the termination of Executive’s employment, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in San Mateo County, California, conducted by Judicial Arbitration and Mediation Services, Inc. (“JAMS”) under the applicable JAMS employment rules. By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision, to include
the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS’ arbitration fees in excess of the amount of court fees that would be required if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over intellectual property rights by Court action instead of arbitration.
14.Miscellaneous Provisions.
(a)Section 409A. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive’s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period
measured from the date of the Executive’s Covered Termination or termination of
employment due to Disability or (ii) the date of Executive’s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 14(a) shall be paid in a lump sum to Executive, and any remaining payments due under the Agreement shall be paid as otherwise provided herein.
(b)Waiver. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver
B-10

by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.
(c)Whole Agreement. This Agreement and the Confidential Information Agreement represent the entire understanding of the parties hereto with respect to the subject matter hereof and supersede all prior arrangements and understandings regarding same.
(d)Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California.
(e)Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.
(f)Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument.
[Signature page follows]

B-11



IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year set forth below.


CODEXIS, INC.
By:      Name: Stephen Dilly, MBBS, Ph.D. Title: Chairman, President & CEO
Date: 9/30/2024


EXECUTIVE

        
Georgia Erbez
Date: 9/30/2024

B-12
 EX-10.5 5 codexis-ex105offerletterxa.htm EX-10.5 Document





Codexis, Inc.
200 Penobscot Drive Redwood City, CA 94063 Tel: +1 (650) 421-8100
Fax: +1 (650) 421-8102
www.codexis.com


September 19, 2024
Dr. Alison Moore, Ph.D. Dear Alison,
On behalf of Codexis, Inc. (“Codexis” or the “Company”), I am pleased to extend to you this offer of employment as Executive Vice President, Chief Technical Officer reporting to Stephen Dilly, Chairman, President and Chief Executive Officer (the “CEO”). Your position is full-time and exempt from overtime pay under the Fair Labor Standards Act. You will work from the Company’s headquarters in Redwood City, California. Your Company employment will commence as of your and the Company’s mutually agreed upon start date, which is expected to be September 30, 2024 (your actual first date of Company employment, the “Start Date”).
Your employment is subject to (i) proof of your legal right to work in the United States, (ii) you completing the United States Citizenship and Immigration Service Employment Eligibility Verification Form I-9, and (iii) the execution of your Proprietary Information, Inventions, and Employment Agreement (Attachment A) (your “Confidentiality Agreement”).
By executing this offer of employment and in accordance with the Amended and Restated Bylaws of the Company, you hereby tender your resignation as a member of the board of directors of the Company (the “Board”) and all committees thereof, effective as the Start Date. You agree and acknowledge that your resignation is not as a result of any disagreement between yourself and the Company on any matter relating to the Company’s operations, policies or practices. For the avoidance of doubt, upon your resignation as a member of the Board, you shall cease to participate in the Company’s director compensation program; provided, however, that your 2024 restricted stock award shall continue to vest based on your continued service to the Company in accordance with the terms of the Company’s 2019 Incentive Award Plan (the “2019 Plan”).
You will not, during your employment by the Company, be employed by or otherwise engaged in any other business activity requiring any of your time, except that, with the prior written approval of the Board or the CEO, CEO, you may serve as a member of (a) the board of directors of up to one organization that is not a competitor of the Company and (b) the scientific advisory board of up to one organization that is not a competitor of the Company, provided in each case that such service does not individually or in the aggregate interfere with the performance of your duties to the Company, violate your Confidentiality Agreement or violate the Company’s standards of conduct then in effect, or raise a conflict under the Company’s conflict of interest policies. In the event of any conflict between this paragraph and your Confidentiality Agreement, this paragraph shall control.
1

By signing below and accepting this offer, you represent and warrant that you are not bound by any employment contract, restrictive covenant, or other restriction preventing you from carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this offer of employment. You further represent and warrant that you will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.
Compensation
If you accept this offer and you begin employment with Codexis, you will receive an initial salary of USD $500,000 per year, payable bi-weekly, which will be subject to all applicable withholdings.
You will also be eligible to participate in the Codexis Employee Incentive Compensation Plan (the “Incentive Plan”). Your Incentive Plan target will be fifty-percent (50%) of your Codexis base salary earnings, subject to metrics set and approved by the Board (or a committee thereof) and achievement by the Company of such performance targets as shall be determined by the Board (or a committee thereof). Based on the Company’s performance and your individual and group’s goal performance, your actual bonus may be more or less than this target, and under certain circumstances there may be no payout. Any payout will be subject to all applicable withholdings and will be paid no later than March 15th following the conclusion of the applicable performance year. No bonus amount is guaranteed and, in addition to the other conditions for earning such bonus, you must remain an employee in good standing of the Company on the scheduled bonus payment date in order to earn any bonus. For calendar year 2024, you will be eligible to earn a prorated bonus based on the Company’s achievement of the applicable performance targets and metrics, and based on the number of days you were employed by the Company in 2024. Please also note that the Incentive Plan does not constitute a contract of employment or alter the “at will” status of your employment. In addition, Codexis reserves the right to modify or terminate the Incentive Plan at any time and for any reason without your consent.
Equity
Subject to approval by the Board (or a duly authorized committee thereof) and as an inducement for you to join the Company, you will be granted 50,000 restricted stock units (“RSUs”). Each RSU entitles you to be issued one share of Codexis common stock upon vesting. The RSUs will vest in substantially equal installments on each of the first three anniversaries of the date of grant of the RSUs, provided that you provide continuous services to Codexis through the applicable vesting date. The RSUs will be granted in accordance with Codexis’ policy which may be amended from time to time and will be subject to the terms and conditions of the 2019 Plan and an RSU agreement to be entered into between you and Codexis.
Subject to approval by the Board (or a duly authorized committee thereof) and as an inducement for you to join the Company, you will be granted an option to purchase 300,000 shares of Codexis common stock (the “Option”) with an exercise price equal to the closing trading price of a share of Codexis common stock on the date the Option is granted or the immediately preceding trading day if the grant date is not a trading day. The shares subject to the Option will vest one fourth or 25% on the first anniversary of the Start Date and thereafter will vest 1/48th of the shares originally subject to the Option per month for the following 36 months until the Option is 100% vested on the four-year anniversary of the Start Date. Vesting is contingent upon your continued service to Codexis through the applicable vesting date. Your Option will be granted in
2

accordance with Codexis’ policy which may be amended from time to time and will be subject to the terms and conditions of the 2019 Plan and an option agreement to be entered into between you and Codexis.
Change of Control Severance Agreement
In connection with the commencement of your employment with Codexis, you will have the opportunity to enter into a Change of Control Severance Agreement. A copy of the Change of Control Severance Agreement (Attachment B) is included with this offer of employment for your review and signature.
Employee Benefits
As a full-time employee, you will be eligible for the Codexis employee benefit plans, which currently include medical, dental, vision, long-term disability, and life insurance, as well as a 401(k) plan, and paid time off in accordance with Company policy. Codexis reserves the right to modify or terminate any of these plans at any time and for any reason.
Other Terms and Conditions of Employment
Your employment with Codexis is at will. “Employment at will” means that you are free to resign from your employment at any time, for any reason or no reason at all, with or without cause and with or without notice. Similarly, Codexis may terminate your employment at any time for any legal reason, with or without cause and with or without notice. It also means that your job duties, title and responsibility and reporting level, work schedule, compensation and benefits, as well as Codexis’ personnel policies and procedures, may be changed with prospective effect, with or without notice, at any time in the sole discretion of Codexis. By accepting this offer of employment, you agree that your employment is at will, and acknowledge that no one, other than the CEO, has the authority to promise you, either orally or in writing, anything to the contrary. Any such agreement must be in writing and signed by both you and the CEO to be effective.
As an Executive Vice President, you will be subject to the Company’s Policy on Recoupment of Incentive Compensation (Attachment C), and any other clawback or recoupment policy that the Company adopts in the future. In addition, you acknowledge that you shall also be subject to additional policies of the Company and its affiliates as in effect from time-to-time, including the Company’s Code of Conduct and policies with regard to stock ownership and securities trading by senior executives.
The terms described in this offer of employment, along with the Confidentiality Agreement and the Change of Control Severance Agreement (which are separate agreements that are governed by their own terms and conditions), supersede and replace all prior agreements, understandings, and promises between Codexis and you concerning the terms and conditions of your employment with Codexis.
3

We hope that your association with Codexis will be mutually successful and rewarding, and we look forward to welcoming you aboard. Please indicate your acceptance of this offer by initialing each page and signing this letter below and returning the letter by September 30, 2024.



Sincerely, Codexis, Inc.
By:          Stephen Dilly, Ph.D.
Chairman, President & CEO

4





I understand and agree to the foregoing terms and conditions of employment with Codexis.


__________________________________
Dr. Alison Moore, Ph.D.

9/30/2024 | 2:07 AM PDT
__________________________________
Date
5




ATTACHMENT A
CODEXIS, INC. PROPRIETARY INFORMATION, INVENTIONS, AND EMPLOYMENT AGREEMENT

A-1



CODEXIS, INC.
PROPRIETARY INFORMATION, INVENTIONS, AND EMPLOYMENT AGREEMENT
The following confirms an agreement (the “Agreement”) between Codexis, Inc. (“Company”) and me. As a condition of my employment or continued employment, and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, as well as access to Company Proprietary Information and trade secrets, I agree to the following effective as of my first day of employment with the Company or as part of my continued employment as applicable:
1.At-Will Employment. This Agreement is not an employment contract for any particular term. I have a right to resign and Company has the right to terminate my employment at will, at any time, for any or no reason, with or without cause and without notice. In addition, this Agreement does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have obligations to Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only be changed by a subsequent written agreement signed by both parties.
2.Proprietary Information.
(a)Company Information. I agree that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning or obtained in connection with the Company’s business or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company. I agree at all times during the term of my employment and thereafter, to hold in strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any person or other entity, other than employees of the Company, (in writing, verbally, or via email or any other medium) without written advance authorization of the Company, any Proprietary Information of the Company, except as may be necessary in the ordinary course of performing my duties as an employee of Company or as otherwise provided in this Agreement. I will not use any Proprietary Information except in the performance of my authorized duties as an employee of Company. By way of illustration, but not limitation, Proprietary Information includes any tangible or intangible proprietary information, technical data, trade secrets or know-how, including and/or relating to, but not limited to, ideas, concepts, materials (including, but not limited to, cell lines, plasmids, vectors and DNA), data, conclusions, product plans, products, services, customer lists, business lists (including, but not limited to, customers of the Company on whom I called or with whom I became acquainted during my term of my employment), business market analyses, software, development, discoveries, inventions, processes, formulas, techniques, technology, designs, drawings, engineering, hardware configuration information, marketing and pricing strategy, business plans, corporate strategy plans, financial data; or other business information made, generated or developed by me in the course of my employment with Company, or disclosed to me by Company either directly or indirectly in any form, including, without limitation, in writing, orally, electronically, or by drawings, or observation of materials, equipment, or information. Proprietary Information also includes confidential information and materials provided to Company by any third party, which is indicated by such third party to be confidential and/or proprietary, and the identity, appropriate knowledge of personnel, research and/or product requirements, volume and frequency of orders, and price sensitivity of customers of the
A-2

Company. I further understand that Proprietary Information does not apply to information which: (i) was already rightfully known to me prior to the time that it is disclosed to me hereunder without any confidentiality obligation to Company;
(ii) is in or has entered the public domain through no breach of this Agreement or other wrongful act; (iii) pertains to general training, knowledge, skill or experience information within the industry that I possess, that is not specifically related to other Proprietary Information; (iv) pertains to my pay, benefits, and other employment terms and conditions; or (v) has been rightfully received by me from a third party not under obligation of confidentiality to Company.
(b)Third Party Information. I agree that I will not, during my employment with the Company, use or disclose in the course of my work for Company any proprietary information or trade secrets of any former or concurrent third party employer or other person or entity for whom I perform or have performed work, without the written authorization of the Company after my notice to the Company of the proprietary or trade secret nature of such information. I agree that I will not bring onto the Company premises or introduce into the equipment or databases of the Company any unpublished document or proprietary information belonging to any such third party employer or other person or entity for whom I perform or have performed work, without the written authorization of the Company after my notice to the Company of the proprietary or trade secret nature of such information. I also understand and agree that, in the course of my employment with Company, I am not to breach any other obligation of confidentiality or non-use that I have to any former employer or concurrent.
(c)Third Party Information Received by the Company. I recognize that the Company has received and in the future will likely receive from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. I agree to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out my work for the Company consistent with the Company’s agreement with such third party.
(d)Protected Disclosures and Defend Trade Secrets Act. Nothing in this Agreement prohibits me (a) from disclosing information in good faith to any federal, state, or local governmental agency, legislative body, or official (or staff member to the foregoing) regarding an alleged violation of law or regulation; (b) from discussing or disclosing information about unlawful acts in the workplace or at activities coordinated or sponsored by the Company, whether on or off the Company’s premises, such as harassment, discrimination, retaliation, wage and hour violations, sexual assault, violations of public policy, an unfair labor practice, or any other conduct that I have reason to believe is unlawful; (c) from discussing or disclosing my wages, hours, and working conditions with fellow employees and discussing the wages of others, or inquiring about another colleague’s wages, or aiding or encouraging others to exercise their rights to the extent protected under applicable law; or (d) from otherwise making disclosures that are protected under applicable law, including, without limitation, the National Labor Relations Act, the Defend Trade Secrets Act, and any rule or regulation promulgated by the Securities and Exchange Commission (SEC), the National Labor Relations Board (NLRB), the Equal Employment Opportunity Commission (EEOC), or any other federal, state, or local government agency.
18 U.S.C. § 1833(b) states: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law;
A-3

or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.” Accordingly, I have the right to disclose in confidence trade secrets to Federal, State, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. I also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protectable from public disclosure.
Further, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.
Nothing in this Agreement is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. § 1833(b).
3.Inventions.
(a)Inventions Retained and Licensed. (i) If I am a new employee, I have attached hereto, as Exhibit A, a list describing all discoveries, ideas, inventions, improvements, software, techniques, methods, works of authorship, developments, and trade secrets (if any) which were made by me prior to my employment with the Company (collectively referred to as “Prior Developments”), which I own or control, which relate directly or indirectly to the Company’s proposed business, products or research and development, and which are not assigned to the Company hereunder; if no such list is attached to or contained in Exhibit A, I represent that there are no such Prior Developments. (ii) If I am a continuing employee, I represent that Exhibit A of my previous agreement with Company includes all Prior Developments; if no such list was attached to or contained in Exhibit A, I represent that there are no such Prior Developments. (iii) All employees: I agree not to or incorporate any Prior Developments into any Company product, material, process or service without the prior written consent of the Company, which written consent identifies the item to be incorporated as a Prior Development. If in the course of my employment with the Company, I incorporate into a Company product, process, machine or service a Prior Development or use a Prior Development in connection with the same, without the aforementioned written consent, the Company is hereby granted and shall have a nonexclusive, fully sublicensable, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify, use, have used, sell, have sold and import such Prior Development as part of or in connection with any Company product, process, machine or service, and I agree to disclose the use of such Prior Developments in writing to the Company promptly after such incorporation.
(b)Assignment of Inventions. I hereby assign to the Company, or its designee, all my right, title, and interest in and to any and all discoveries, ideas, inventions, creations, data, software, techniques, methods, works of authorship, know how, developments, concepts, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws, which I may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time I am in the employ of the Company (collectively referred to as “Inventions”), excepting only any invention (if any) which qualifies fully under the provisions of California Labor Code Section 2870 as provided in Section 3(e) below. I agree that I will promptly make full written disclosure to the Company of any Invention, and will hold the same in trust for the sole right and benefit of the Company. I further acknowledge that all original works of authorship which are made by me (solely or jointly
A-4

with others) within the scope of and during the period of my employment with the Company and which are protectable by copyright are “works made for hire”, as that term is defined in the United States Copyright Act.
(c)Maintenance of Records. I agree to keep and maintain adequate and current written records of any and all Inventions hereunder, including any made by me solely or jointly with others during the term of my employment with the Company. The records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times.
(d)Patent and Copyright Registrations. I agree to assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s rights in the Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for, obtain and enforce such rights and in order to assign and convey to the Company, its successors, assigns and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. I further agree that my obligation to execute or cause to be executed, when it is in my power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the Company is unable because of my mental or physical incapacity or for any other reason to secure my signature to apply for or to pursue any application for any United States or foreign patents or copyright registrations covering Inventions or original works of authorship assigned to the Company as above, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, to act for and in my behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon with the same legal force and effect as if executed by me.
(e)Exception to Assignments. I understand that the provisions of this Agreement requiring assignment of Inventions to the Company do not apply to any invention which qualifies fully under the provisions of California Labor Code Section 2870 (attached hereto as Exhibit B). I will advise the Company promptly in writing of any invention that I believe meet the criteria in California Labor Code Section 2870 and are not disclosed on Exhibit A.

4.Conflicts of Interest. I agree that, during the term of my employment with the Company, I will comply with the Company’s policies regarding conflicts of interest, including those contained in Company’s Code of Business Conduct and Ethics, as may be updated from time to time.
5.Returning Company Property. I agree that, prior to or at the time of leaving the employ of the Company, I will deliver to the Company, or alternatively, destroy solely at the Company’s discretion, (and will not keep in my possession, recreate or deliver to anyone else) any and all Proprietary Information in my possession, as well as all equipment, devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, biological and other tangible materials (including, but not limited, to cell lines, plasmids, vectors and DNA), other documents or tangible property of the Company (or property of third parties that is lawfully in the possession or control of the Company), or reproductions of
A-5

any aforementioned items including any and all of the aforementioned items developed by me pursuant to my employment with the Company or otherwise property of the Company, its successors or assigns. In the event of the termination of my employment, I agree to sign and deliver the “Termination Certification” attached hereto as Exhibit C.
6.Notification of New Employer. In the event that I leave the employ of the Company, I hereby grant consent to notification by the Company to my new employer about my rights and obligations under this Agreement.
7.Photography Consent, Waiver, And Release. Upon execution of this Agreement, I agree to sign the Photography Consent, Waiver and Release attached as Exhibit D hereto.
8.Representations. I agree to execute any proper oath or verify any proper document required to carry out the terms of this Agreement. I represent that my performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any oral or written agreement in conflict herewith during the term of my employment.

9.Arbitration and Equitable Relief.
(a)Arbitration. Except as provided in Section 10(b) below and otherwise in this Section, I agree that any dispute or controversy arising out of or relating to any interpretation, construction, performance or breach of this Agreement, shall be resolved by binding arbitration to be administered by the American Arbitration Association in accordance with its Employment Arbitration Rules and Mediation Procedures then in effect. The decision of the arbitrator shall be final, conclusive and binding on the parties to the arbitration. Judgment may be entered on the arbitrator’s decision in any court having jurisdiction. The Company shall pay the costs and expenses of the arbitration, including all administrative and arbitrator fees, and each of us shall separately pay our counsel fees. However, the arbitrator shall be empowered to make awards of costs or fees as provided by law. Notwithstanding the foregoing, any dispute or controversy seeking to enforce or protect, or concerning the validity of, any of intellectual property right of either party or (b) any dispute or controversy related to, or arising from, allegations of theft, piracy, invasion of privacy, or unauthorized use hereunder, I and the Company will have the right, at my or its sole discretion, as applicable, to adjudicate such dispute or controversy in a court of competent jurisdiction.
(b)Equitable Remedies. To the extent permitted by applicable law, this
Agreement does not preclude either the Company or myself from seeking
injunctive relief in a court of law.
10.General Provisions.
(a)Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by the laws of the State of California exclusively, (regardless of that jurisdiction or any other jurisdiction’s choice of law principles). I hereby expressly consent to the personal jurisdiction of the state and federal courts located in San Mateo County, California for any lawsuit filed there against me by the Company arising from or relating to this Agreement.
(b)Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter herein and, except as
A-6

stated in this paragraph, supersedes all prior and contemporaneous discussions between us, including any previous confidentiality agreements that I may have entered into with the Company with the effect that this Agreement shall control with respect to the subject matter hereof and thereof. Any previous agreements relating to the subject matter herein are extinguished other than previously executed assignments of intellectual property and any other obligations regarding intellectual property I that conceived and/or developed on behalf of Codexis during my employment, and my list of Prior Developments on a former employment agreement between us, if any. Further, any previous non-compete provisions between Company and me are void. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by both parties. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.
(c)Severability. If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full force and effect.
(d)Successors and Assigns. This Agreement is binding upon my heirs, executors, administrators, other legal representatives and is for the benefit of the Company, its successors, and assigns.
(e)Survival. The rights and obligations of the parties to this Agreement will survive termination of my employment with Company.
(f)COUNTERPARTS. THIS AGREEMENT MAY BE EXECUTED IN ANY NUMBER OF COUNTERPARTS, EACH OF WHICH SHALL BE DEEMED TO BE AN ORIGINAL AND ALL OF WHICH TOGETHER SHALL BE DEEMED TO BE ONE AND THE SAME INSTRUMENT.
[SIGNATURE PAGE FOLLOWS]

A-7




I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING THAT ONE COUNTERPART WILL BE RETAINED BY COMPANY AND THE OTHER COUNTERPART WILL BE RETAINED BY ME.


Date:9/30/2024 | 2:07 AM PDT
Alison Moore
SignaturePrinted



CODEXIS, INC.

By:     
Title: CEO
Date: 9/29/2024 | 8:29 PM PDT






A-8






EXHIBIT A

LIST OF PRIOR DEVELOPMENTS (INCLUDING ORIGINAL WORKS OF AUTHORSHIP)



Title    Date

Identifying Number or
Brief Description

A-9






EXHIBIT B
CALIFORNIA LABOR CODE SECTION 2870 EMPLOYMENT AGREEMENTS; ASSIGNMENT OF RIGHTS

(a)Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:
(1)Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer.
(2)Result from any work performed by the employee for the employer.

(b)To the extent a provision in the employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.
A-10



EXHIBIT C
CODEXIS, INC.
FORM TERMINATION CERTIFICATE
This is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any aforementioned items belonging to Codexis, Inc., its subsidiaries, affiliates, successors or assigns, except where authorized in writing.
I further certify that I have complied with all the terms of the Codexis, Inc. Proprietary Information, Inventions, and Employment Agreement signed by me, including the reporting of any inventions and original works of authorship (as defined therein), conceived or made by me (solely or jointly with others) covered by that agreement.
I further agree that, in compliance with the Proprietary Information, Inventions, and Employment Agreement, I will preserve as confidential all trade secrets, confidential knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship, customer lists, business plans, financial information or other subject matter pertaining to any business of Codexis and any third party confidential information that I have knowledge concerning..
The Federal Defend Trade Secrets Act 18 U.S.C. § 1833(b) states:
“An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.”
Accordingly, I have the right to disclose in confidence trade secrets to Federal, State, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. I also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protectable from public disclosure. Nothing in this Certification is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. § 1833(b).
Date:     
__________________________________
(Employee’s Signature)


__________________________________
(Type/Print Employee’s Name)


A-11



EXHIBIT D CODEXIS, INC.
PHOTOGRAPHY CONSENT, WAIVER, AND RELEASE
For good and valuable consideration, the receipt and sufficiency of which I hereby acknowledge, I hereby irrevocably consent and give permission to Codexis, Inc. (“Codexis”) or its agent, to photograph me, record my voice, and/or video me (alone or with others), in the context of my association with Codexis and/or at Codexis-related events (creating “Materials”). I understand that any such Materials, and all rights associated with them, will belong solely and exclusively to Codexis and Codexis shall have the irrevocable and absolute right to register copyright(s), duplicate, reproduce, alter, display, distribute, and/or publish them in any manner, for any purpose, and in any form including, but not limited to, print, electronic, radio, video, and/or on the Internet without notifying me.
I voluntarily waive any and all rights I may now or hereafter have with respect to any Materials, including any compensation, ownership, copyright, and any rights of publicity or privacy and any right to inspect or approve Materials and/or copy, print or other materials that may be used in connection with them, whether now or in the future, whether that use is known or unknown to me. I hereby waive any right to inspect or approve of any finished Materials whether printed or electronic, that may be used now or in the future, whether that use is known or unknown to me, and I forever waive any right to royalties or other compensation arising from or related to the use of the Materials. I hereby release and discharge, and agree to hold harmless, Codexis, its officers, agents and employees, and all persons acting under its permission or authority, from any claims, losses, damages or liability arising from or related to such Materials and/or their use under any circumstances.
I represent and warrant to that I am at least 18 years of age and that I have full right, power, and authority to enter into this Photography Consent, Waiver and Release and grant the rights granted hereunder, and that the rights granted hereunder do not, and will not, violate any right of, or conflict with or violate any contract or agreement with or commitment made to, any person or entity, and that no consent or authorization from, or any payment to, any third party is required in connection herewith. This Photography Consent, Waiver, and Release is binding on my heirs, executors, administrators and other legal representatives and is for the benefit of Codexis, its successors and assigns.
I HAVE READ AND FULLY UNDERSTAND THE CONTENTS OF THIS PHOTOGRAPHY CONSENT, WAIVER, AND RELEASE FORM, AND I SIGN IT FREELY AND VOLUNTARILY.
Alison Moore
Name:    

Signature

Date: 9/30/2024 | 2:07 AM PDT


A-12





ATTACHMENT B
CHANGE OF CONTROL SEVERANCE AGREEMENT

B-1



CODEXIS, INC.
CHANGE OF CONTROL SEVERANCE AGREEMENT
This Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between Alison Moore (the “Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).
R E C I T A L S
AIt is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change of control. The Board of Directors of the Company (the “Board”) recognizes that such consideration as well as the possibility of an involuntary termination or reduction in responsibility can be a distraction to Executive and can cause Executive to consider alternative employment opportunities. The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such an event.
BThe Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive’s employment and to motivate Executive to maximize the value of the Company upon a Change of Control (as defined below) for the benefit of its stockholders.
CThe Board believes that it is imperative to provide Executive with severance benefits upon certain terminations of Executive’s service to the Company that provide Executive with enhanced financial security and provides incentive and encouragement to Executive to remain with the Company notwithstanding the possibility of such an event.
DCertain capitalized terms used in the Agreement are defined in Section 9 below. The parties hereto agree as follows:
1.Term of Agreement. This Agreement shall become effective as of the Effective Date and terminate upon the date that all obligations of the parties hereto with respect to this Agreement have been satisfied.
2.At-Will Employment. The Company and Executive acknowledge that Executive’s employment is and shall continue to be “at-will,” as defined under applicable law. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement.
3.Covered Termination Outside a Change of Control Period. Except as otherwise provided under Section 6, if Executive experiences a Covered Termination other than during a Change of Control Period, and if Executive, within sixty (60) days following the date of the Covered Termination, provides the Company with an executed Release of Claims (as defined below) which is not revoked within the applicable revocation period, if any, then in addition to
B-2

any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Severance. Executive shall receive a lump sum cash payment in an amount equal to twelve (12) months of Executive’s base salary at the rate in effect immediately prior to Executive’s termination of employment (without giving effect to any reduction in base salary that gives rise to a Voluntary Termination for Good Reason), less applicable withholdings. This severance payment shall be made to Executive in substantially equal installments in accordance with the Company’s normal payroll procedures with the first such installment to be made on the first payroll date following the date the Release of Claims becomes effective and irrevocable, provided, that if the Covered Termination occurs after November 1 of any year, the first such installment shall be made on the first payroll date of the subsequent year and, provided further, that, in each case, the first installment shall include any installment payments that would have been made had such installments commenced on the first payroll date after the Covered Termination.
(b)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s Covered Termination through the earlier of (i) the twelve (12) month anniversary of the date of Executive’s Covered Termination and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
4.Covered Termination Within a Change of Control Period. If Executive experiences a Covered Termination during a Change of Control Period, and if Executive, within sixty (60) days following the date of the Covered Termination, provides the Company with an executed Release of Claims (as defined below) which is not revoked within the applicable revocation period, if any, then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Severance. Executive shall receive a lump sum cash payment in an amount equal to the sum of eighteen (18) months of Executive’s base salary at the rate in effect immediately prior to Executive’s termination of employment (without giving effect to any reduction in base salary subsequent to a Change of Control that gives rise to a Voluntary Termination for Good Reason), less applicable withholdings. This severance payment shall be made to Executive within sixty (60) days following the date of the Covered Termination.
B-3

(b)Equity Awards. Each outstanding equity award, including, without limitation, stock options, restricted stock, and restricted stock units, held by Executive shall automatically become vested and, if applicable, exercisable and any restrictions thereon shall immediately lapse, in each case, with respect to one hundred percent (100%) of the then unvested shares subject to such equity award. Notwithstanding the foregoing, any outstanding performance stock units or performance stock options held by Executive shall automatically become vested with respect to: (i) in the event of a Change of Control that occurs prior to the applicable Measurement Date, such number of shares of Company common stock corresponding to the target performance level for any applicable performance goals; or (ii) in the event of a Change of Control that occurs on or after the Measurement Date, such number of shares of Company common stock corresponding to the Company’s actual achievement of any applicable performance goals.
(c)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s Covered Termination through the earlier of (i) the eighteen (18) month anniversary of the date of Executive’s Covered Termination and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code, under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
5.Death or Disability. If Executive terminates employment with the Company due to death or Disability and such termination constitutes a “separation from service” within the meaning of Section 409A of Code and the Department of Treasury regulations and other guidance promulgated thereunder (a “Separation from Service”), then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Pro-Rata Vesting of Equity Awards. Each outstanding equity award, including, without limitation, stock options, restricted stock and restricted stock units, held by Executive shall automatically become vested and, if applicable, exercisable and any restrictions thereon shall immediately lapse, in each case, with respect to that number of shares of Company common stock that would otherwise vest on the next vesting date for such equity award, assuming Executive’s continued service through such date, pro-rated to the date of Executive’s termination due to death or Disability. For purposes of determining the number of shares subject to any outstanding performance stock units or performance stock options that would otherwise vest on the next vesting date pursuant to the foregoing sentence, the applicable performance goals shall be deemed achieved: (i) in the event of a termination due to death or Disability that occurs prior to the applicable Measurement Date, at the target performance level; or (ii) in the event of a termination due to death or Disability that occurs on or after the Measurement Date, based on the Company’s actual achievement.
B-4

(b)Continued Healthcare. If Executive, or any beneficiary of Executive, elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive, or such beneficiary, for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s termination due to death or Disability through the earlier of (i) the twelve (12) month anniversary of the date of Executive’s termination of employment and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code, under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive, or any beneficiary of Executive, may, if eligible, elect to continue healthcare coverage at his or her expense in accordance with the provisions of COBRA.
6.Termination in Connection With a Change of Control. Notwithstanding anything in this Agreement to the contrary, in the event Executive experiences a Covered Termination and the Involuntary Termination without Cause underlying the Covered Termination, or the event upon which a Voluntary Termination for Good Reason underlying the Covered Termination is based, occurs at the direction of a person or entity that has entered into an agreement with the Company that contemplates a transaction that, if consummated, would constitute a Change of Control, then for all purposes hereunder, including, without limitation, Sections 4 and 7, such Covered Termination shall be deemed to have occurred during a Change of Control Period and, in lieu of the benefits provided under Section 3, Executive shall be entitled to the benefits set forth in Section 4 with such benefits to be paid, or commence being paid, upon the Covered Termination, but otherwise subject to the terms and conditions of Section 4.
7.Termination for Cause; Voluntary Resignation. If Executive’s service with the Company is terminated by the Company for Cause or by Executive for any or no reason other than due to death, Disability or as a Covered Termination, then Executive shall only be entitled to any accrued but unpaid salary, bonus, vacation and expense reimbursement in accordance with applicable law.
8.Limitation on Payments. In the event that the severance and other benefits provided
for in this Agreement or otherwise payable to Executive (i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for this Section 8, would be subject to the excise tax imposed by Section 4999 of the Code, then Executive’s severance benefits under this Agreement shall be payable either
(a)in full, or
(b)as to such lesser amount which would result in no portion of such severance benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code, results in the receipt by Executive on an after-tax
B-5

basis, of the greatest amount of severance benefits under this Agreement, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. The specific benefits that shall be reduced, if any, and the order of such reduction shall be determined by the Executive in his or her sole discretion. Unless the Company and Executive otherwise agree in writing, any determination required under this Section 8 shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations required by this Section 8, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 8.
9.Definition of Terms. The following terms referred to in this Agreement shall have the following meanings:
(a)Change of Control. “Change of Control” shall mean (i) a dissolution or liquidation of the Company; (ii) a sale of all or substantially all the assets of the Company; (iii) a merger or consolidation in which the Company is not the surviving corporation and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors has changed; (iv) a reverse merger in which the Company is the surviving corporation but the shares of the common stock of the Company outstanding immediately before the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors has changed; (v) an acquisition by any person, entity or group within the meaning of Section 13(d) or 14(d) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or any comparable successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors; or, (vi) in the event that the individuals who are members of the Incumbent Board cease for any reason to constitute at least fifty percent (50%) of the Board. Notwithstanding the foregoing, a Change of Control shall not include any transaction effected primarily for the purpose of financing the Company with cash (as determined by the Board acting in good faith and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise) or the initial public offering of the Company’s common stock. Further notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event that constitutes “nonqualified deferred compensation,” the transaction or event constituting the Change of Control must also constitute a “change in control event” (as defined in Treasury Regulation §1.409A-3(i)(5)) in order to give rise to the payment or settlement event, to the extent required by Section 409A.
(b)Change of Control Period. “Change of Control Period” shall mean the period commencing ninety (90) days prior to a Change of Control and ending on the first anniversary of the Change of Control.
B-6

(c)Covered Termination. “Covered Termination” shall mean an Involuntary Termination without Cause or a Voluntary Termination for Good Reason that constitutes the Executive’s Separation from Service.
(d)Disability. “Disability” shall mean that Executive has been unable to perform Executive’s Company duties as the result of Executive’s incapacity due to physical or mental illness, and such inability, at least one hundred eighty (180) days after its commencement, is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to Executive or Executive’s legal representative (such agreement as to acceptability not to be unreasonably withheld). Termination resulting from Disability may only be effected after at least thirty (30) days’ written notice by the Company of its intention to terminate Executive’s employment. In the event that Executive resumes the performance of substantially all of Executive’s duties hereunder before the termination of Executive’s employment becomes effective, the notice of intent to terminate shall automatically be deemed to have been revoked.
(e)Incumbent Board. “Incumbent Board” shall mean the individuals who, as of the Effective Date, are members of the Board. If the election, or nomination for election by the Company’s stockholders, of any new director is approved by a vote of at least fifty percent (50%) of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board.
(f)Involuntary Termination without Cause. “Involuntary Termination without Cause” shall mean the termination of Executive’s employment by the Company other than a termination following (i) the willful and continued failure to substantially perform the Executive’s duties with the Company (other than as a result of physical or mental disability) after a written demand for substantial performance is delivered to the Executive by the Company, which demand specifically identifies the manner in which the Company believes that the Executive has not substantially performed the Executive’s duties and that has not been cured within fifteen (15) days following receipt by the Executive of the written demand; (ii) commission of a felony (other than a traffic-related offense) that in the written determination of the Company is likely to cause or has caused material injury to the Company’s business; (iii) dishonesty with respect to a significant matter relating to the Company’s business; or (iv) material breach of any agreement by and between the Executive and the Company, which material breach has not been cured within fifteen (15) days following receipt by the Executive of written notice from the Company identifying such material breach.
(g)Release of Claims. “Release of Claims” shall mean a general release of all claims against the Company and its affiliates in a form reasonably acceptable to the Company.
(h)Voluntary Termination for Good Reason. “Voluntary Termination for Good Reason” shall mean Executive’s voluntarily resignation after the occurrence of any of the following without Executive’s written consent: (i) a material diminution in Executive’s base compensation; (ii) a material diminution in Executive’s authority, duties or responsibilities; (iii) a material change of at least thirty-five (35) miles in the geographic location at which Executive must perform Executive’s services; or (iv) a material breach of this Agreement by the Company. Notwithstanding the foregoing, a resignation shall not constitute a “Voluntary Termination for Good Reason” unless the condition giving rise to such resignation continues more than thirty (30) days following Executive’s written notice of the condition within ninety (90) days of the first occurrence of such condition and Executive’s termination occurs within one hundred eighty (180) days following the first occurrence of such condition.
B-7

(i)Measurement Date. “Measurement Date,” with respect to an award of performance stock units or performance stock options, shall mean the date the Compensation Committee of the Board of Directors determines the achievement of the applicable performance goals for the applicable performance period.
10.Successors.
(a)Company’s Successors. Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in this Section 10(a) or which becomes bound by the terms of this Agreement by operation of law.
(b)Executive’s Successors. The terms of this Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.
11.Notices. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or one day following mailing via Federal Express or similar overnight courier service. In the case of Executive, mailed notices shall be addressed to Executive at Executive’s home address that the Company has on file for Executive. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.
12.Confidentiality; Non-Solicitation.
(a)Confidentiality. While Executive is employed by the Company, and thereafter while Executive receives severance benefits hereunder, Executive shall not directly or indirectly disclose or make available to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, any Confidential Information (as defined below). Upon termination of Executive’s employment with the Company, all Confidential Information in Executive’s possession that is in written or other tangible form (together with all copies or duplicates thereof, including computer files) shall be returned to the Company and shall not be retained by Executive or furnished to any third party, in any form except as provided herein; provided, however, that Executive shall not be obligated to treat as confidential, or return to the Company copies of any Confidential Information that (i) was publicly known at the time of disclosure to Executive, (ii) becomes publicly known or available thereafter other than by any means in violation of this Agreement or any other duty owed to the Company by any person or entity, or (iii) is lawfully disclosed to Executive by a third party. For purposes of this Agreement, the term “Confidential Information” shall mean information disclosed to Executive or known by Executive as a consequence of or through his or her relationship with the Company, about the customers, employees, business methods, public relations methods, organization, procedures or finances, including, without limitation, information of or relating to customer lists, of the Company and its affiliates. In addition, Executive shall continue to be subject to the Confidential
B-8

Information, Secrecy, and Invention Agreement entered into between Executive and the Company (the “Confidential Information Agreement”).
(b)Non-Solicitation. In addition to each Executive’s obligations under the Confidential Information Agreement, Executive shall not for a period of one (1) year following Executive’s termination of employment for any reason, either on Executive’s own account or jointly with or as a manager, agent, officer, employee, consultant, partner, joint venturer, owner or stockholder or otherwise on behalf of any other person, firm or corporation, directly or indirectly solicit or attempt to solicit away from the Company any of its officers or employees or offer employment to any person who is an officer or employee of the Company; provided, however, that a general advertisement to which an employee of the Company responds shall in no event be deemed to result in a breach of this Section 12(b). Executive also agrees not to harass or disparage the Company or its employees, clients, directors or agents or divert or attempt to divert any actual or potential business of the company.
(c)Survival of Provisions. The provisions of this Section 12 shall survive the termination or expiration of the applicable Executive’s employment with the Company and shall be fully enforceable thereafter. If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 12 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.
13.Dispute Resolution. To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance or interpretation of this Agreement, Executive’s employment, or the termination of Executive’s employment, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in San Mateo County, California, conducted by Judicial Arbitration and Mediation Services, Inc. (“JAMS”) under the applicable JAMS employment rules. By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS’ arbitration fees in excess of the amount of court fees that would be required if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over intellectual property rights by Court action instead of arbitration.
14.Miscellaneous Provisions.
(a)Section 409A. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section
B-9

409A(a)(2)(B)(i) of the Code, such portion of Executive’s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the date of the Executive’s Covered Termination or termination of employment due to Disability or (ii) the date of Executive’s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 14(a) shall be paid in a lump sum to Executive, and any remaining payments due under the Agreement shall be paid as otherwise provided herein.
(b)Waiver. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.
(c)Whole Agreement. This Agreement and the Confidential Information Agreement represent the entire understanding of the parties hereto with respect to the subject matter hereof and supersede all prior arrangements and understandings regarding same.
(d)Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California.
(e)Severability. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.
(f)Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument.
[Signature page follows]

B-10



IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year set forth below.


CODEXIS, INC.
By:      Name: Stephen Dilly
Title: Chairman, President & CEO Date:

EXECUTIVE

        
Georgia Erbez
Date: 9/30/2024 | 2:07 AM PDT

B-11



ATTACHMENT C
POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION

C-1



CODEXIS, INC.
POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION
Introduction
The Board of Directors (the “Board”) of Codexis, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company. This Policy shall be interpreted to comply with the requirements of U.S. Securities and Exchange Commission (“SEC”) rules and Nasdaq Stock Market (“Nasdaq”) listing standards implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) and, to the extent this Policy is in any manner deemed inconsistent with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.
Administration
This Policy shall be administered by the Compensation Committee (the “Compensation Committee”) of the Board. Any determinations made by the Compensation Committee shall be final and binding on all affected individuals. The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in all cases consistent with the Dodd-Frank Act. The Board or Compensation Committee may amend this Policy from time to time in its discretion.
Covered Executives
This Policy applies to any current or former “executive officer,” within the meaning of Rule 10D- 1 under the Securities Exchange Act of 1934, as amended, of the Company or a subsidiary of the Company (each such individual, an “Executive”). This Policy shall be binding and enforceable against all Executives and their beneficiaries, executors, administrators, and other legal representatives.
Recoupment Upon Financial Restatement
If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a “Financial Restatement”), the Compensation Committee shall cause the Company to recoup from each Executive, as promptly as reasonably possible, any erroneously awarded Incentive-Based Compensation, as defined below.





C-2

No-Fault Recovery
Recoupment under this Policy shall be required regardless of whether the Executive or any other person was at fault or responsible for accounting errors that contributed to the need for the Financial Restatement or engaged in any misconduct.
Compensation Subject to Recovery; Enforcement
This Policy applies to all compensation granted, earned or vested based wholly or in part upon the attainment of any financial reporting measure determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measures, whether or not presented within the Company’s financial statements or included in a filing with the SEC, including stock price and total shareholder return (“TSR”), including but not limited to performance-based cash, stock, options or other equity-based awards paid or granted to the Executive (“Incentive-Based Compensation”). Compensation that is granted, vests or is earned based solely upon the occurrence of non-financial events, such as base salary, restricted stock or options with time-based vesting, or a bonus awarded solely at the discretion of the Board or Compensation Committee and not based on the attainment of any financial measure, is not subject to this Policy.
In the event of a Financial Restatement, the amount to be recovered will be the excess of (i) the Incentive-Based Compensation received by the Executive during the Recovery Period (as defined below) based on the erroneous data and calculated without regard to any taxes paid or withheld, over (ii) the Incentive-Based Compensation that would have been received by the Executive had it been calculated based on the restated financial information, as determined by the Compensation Committee. For purposes of this Policy, “Recovery Period” means the three completed fiscal years immediately preceding the date on which the Company is required to prepare the Financial Restatement, as determined in accordance with the last sentence of this paragraph, or any transition period that results from a change in the Company’s fiscal year (as set forth in Section 5608(b)(i)(D) of the Nasdaq Listing Rules). The date on which the Company is required to prepare a Financial Restatement is the earlier to occur of (A) the date the Board or a Board committee (or authorized officers of the Company if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Financial Restatement.
For Incentive-Based Compensation based on stock price or TSR, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the Compensation Committee shall determine the amount to be recovered based on a reasonable estimate of the effect of the Financial Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received and the Company shall document the determination of that estimate and provide it to Nasdaq.
Incentive-Based Compensation is considered to have been received by an Executive in the fiscal year during which the applicable financial reporting measure was attained or purportedly attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.
C-3

The Company may use any legal or equitable remedies that are available to the Company to recoup any erroneously awarded Incentive-Based Compensation, including but not limited to by collecting from the Executive cash payments or shares of Company common stock from or by forfeiting any amounts that the Company owes to the Executive.
No Indemnification
The Company shall not indemnify any Executive or pay or reimburse the premium for any insurance policy to cover any losses incurred by such Executive under this Policy.
Exceptions
The compensation recouped under this Policy shall not include Incentive-Based Compensation received by an Executive (i) prior to beginning service as an Executive or (ii) if he or she did not serve as an Executive at any time during the performance period applicable to the Incentive-Based Compensation in question. The Compensation Committee (or a majority of independent directors serving on the Board) may determine not to seek recovery from an Executive in whole or part to the extent it determines in its sole discretion that such recovery would be impracticable because
(A) the direct expense paid to a third party to assist in enforcing recovery would exceed the recoverable amount (after having made a reasonable attempt to recover the erroneously awarded Incentive-Based Compensation and providing corresponding documentation of such attempt to Nasdaq), (B) recovery would violate the home country law that was adopted prior to November 28, 2022, as determined by an opinion of counsel licensed in the applicable jurisdiction that is acceptable to and provided to Nasdaq, or (C) recovery would likely cause the Company’s 401(k) plan or any other tax-qualified retirement plan to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.
Other Remedies Not Precluded
The exercise by the Compensation Committee of any rights pursuant to this Policy shall be without prejudice to any other rights or remedies that the Company, the Board or the Compensation Committee may have with respect to any Executive subject to this Policy.
Effective Date and Applicability
This Policy has been adopted by the Board on August 24, 2023, and shall apply to any Incentive- Based Compensation that is received by an Executive on or after October 2, 2023.
C-4
 EX-10.6 6 codexis-ex106changeinctrls.htm EX-10.6 Document


CODEXIS, INC.
CHANGE OF CONTROL SEVERANCE AGREEMENT
This Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between Alison Moore (the “Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).
R E C I T A L S
AIt is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change of control. The Board of Directors of the Company (the “Board”) recognizes that such consideration as well as the possibility of an involuntary termination or reduction in responsibility can be a distraction to Executive and can cause Executive to consider alternative employment opportunities. The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such an event.
BThe Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive’s employment and to motivate Executive to maximize the value of the Company upon a Change of Control (as defined below) for the benefit of its stockholders.
CThe Board believes that it is imperative to provide Executive with severance benefits upon certain terminations of Executive’s service to the Company that provide Executive with enhanced financial security and provides incentive and encouragement to Executive to remain with the Company notwithstanding the possibility of such an event.
DCertain capitalized terms used in the Agreement are defined in Section 9 below. The parties hereto agree as follows:
1.Term of Agreement. This Agreement shall become effective as of the Effective Date and terminate upon the date that all obligations of the parties hereto with respect to this Agreement have been satisfied.
2.At-Will Employment. The Company and Executive acknowledge that Executive’s employment is and shall continue to be “at-will,” as defined under applicable law. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement.
3.Covered Termination Outside a Change of Control Period. Except as otherwise provided under Section 6, if Executive experiences a Covered Termination other than during a Change of Control Period, and if Executive, within sixty (60) days following the date of the Covered Termination, provides the Company with an executed Release of Claims (as defined below) which is not revoked within the applicable revocation period, if any, then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:


(a)Severance. Executive shall receive a lump sum cash payment in an amount equal to twelve (12) months of Executive’s base salary at the rate in effect immediately prior to Executive’s termination of employment (without giving effect to any reduction in base salary that gives rise to a Voluntary Termination for Good Reason), less applicable withholdings. This severance payment shall be made to Executive in substantially equal installments in accordance with the Company’s normal payroll procedures with the first such installment to be made on the first payroll date following the date the Release of Claims becomes effective and irrevocable, provided, that if the Covered Termination occurs after November 1 of any year, the first such installment shall be made on the first payroll date of the subsequent year and, provided further, that, in each case, the first installment shall include any installment payments that would have been made had such installments commenced on the first payroll date after the Covered Termination.
(b)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s Covered Termination through the earlier of (i) the twelve (12) month anniversary of the date of Executive’s Covered Termination and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
4.Covered Termination Within a Change of Control Period. If Executive experiences a Covered Termination during a Change of Control Period, and if Executive, within sixty (60) days following the date of the Covered Termination, provides the Company with an executed Release of Claims (as defined below) which is not revoked within the applicable revocation period, if any, then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Severance. Executive shall receive a lump sum cash payment in an amount equal to the sum of eighteen (18) months of Executive’s base salary at the rate in effect immediately prior to Executive’s termination of employment (without giving effect to any reduction in base salary subsequent to a Change of Control that gives rise to a Voluntary Termination for Good Reason), less applicable withholdings. This severance payment shall be made to Executive within sixty (60) days following the date of the Covered Termination.
(b)Equity Awards. Each outstanding equity award, including, without limitation, stock options, restricted stock, and restricted stock units, held by Executive shall


automatically become vested and, if applicable, exercisable and any restrictions thereon shall immediately lapse, in each case, with respect to one hundred percent (100%) of the then unvested shares subject to such equity award. Notwithstanding the foregoing, any outstanding performance stock units or performance stock options held by Executive shall automatically become vested with respect to: (i) in the event of a Change of Control that occurs prior to the applicable Measurement Date, such number of shares of Company common stock corresponding to the target performance level for any applicable performance goals; or (ii) in the event of a Change of Control that occurs on or after the Measurement Date, such number of shares of Company common stock corresponding to the Company’s actual achievement of any applicable performance goals.
(c)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s Covered Termination through the earlier of (i) the eighteen (18) month anniversary of the date of Executive’s Covered Termination and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code, under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
5.Death or Disability. If Executive terminates employment with the Company due to death or Disability and such termination constitutes a “separation from service” within the meaning of Section 409A of Code and the Department of Treasury regulations and other guidance promulgated thereunder (a “Separation from Service”), then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:
(a)Pro-Rata Vesting of Equity Awards. Each outstanding equity award, including, without limitation, stock options, restricted stock and restricted stock units, held by Executive shall automatically become vested and, if applicable, exercisable and any restrictions thereon shall immediately lapse, in each case, with respect to that number of shares of Company common stock that would otherwise vest on the next vesting date for such equity award, assuming Executive’s continued service through such date, pro-rated to the date of Executive’s termination due to death or Disability. For purposes of determining the number of shares subject to any outstanding performance stock units or performance stock options that would otherwise vest on the next vesting date pursuant to the foregoing sentence, the applicable performance goals shall be deemed achieved: (i) in the event of a termination due to death or Disability that occurs prior to the applicable Measurement Date, at the target performance level; or (ii) in the event of a termination due to death or Disability that occurs on or after the Measurement Date, based on the Company’s actual achievement.


(b)Continued Healthcare. If Executive, or any beneficiary of Executive, elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive, or such beneficiary, for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the date of Executive’s termination due to death or Disability through the earlier of (i) the twelve (12) month anniversary of the date of Executive’s termination of employment and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Code, under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive, or any beneficiary of Executive, may, if eligible, elect to continue healthcare coverage at his or her expense in accordance with the provisions of COBRA.
6.Termination in Connection With a Change of Control. Notwithstanding anything in this Agreement to the contrary, in the event Executive experiences a Covered Termination and the Involuntary Termination without Cause underlying the Covered Termination, or the event upon which a Voluntary Termination for Good Reason underlying the Covered Termination is based, occurs at the direction of a person or entity that has entered into an agreement with the Company that contemplates a transaction that, if consummated, would constitute a Change of Control, then for all purposes hereunder, including, without limitation, Sections 4 and 7, such Covered Termination shall be deemed to have occurred during a Change of Control Period and, in lieu of the benefits provided under Section 3, Executive shall be entitled to the benefits set forth in Section 4 with such benefits to be paid, or commence being paid, upon the Covered Termination, but otherwise subject to the terms and conditions of Section 4.
7.Termination for Cause; Voluntary Resignation. If Executive’s service with the Company is terminated by the Company for Cause or by Executive for any or no reason other than due to death, Disability or as a Covered Termination, then Executive shall only be entitled to any accrued but unpaid salary, bonus, vacation and expense reimbursement in accordance with applicable law.
8.Limitation on Payments. In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for this Section 8, would be subject to the excise tax imposed by Section 4999 of the Code, then Executive’s severance benefits under this Agreement shall be payable either
(a)in full, or
(b)as to such lesser amount which would result in no portion of such severance benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code, results in the receipt by Executive on an after-tax


basis, of the greatest amount of severance benefits under this Agreement, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. The specific benefits that shall be reduced, if any, and the order of such reduction shall be determined by the Executive in his or her sole discretion. Unless the Company and Executive otherwise agree in writing, any determination required under this Section 8 shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations required by this Section 8, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 8.
9.Definition of Terms. The following terms referred to in this Agreement shall have the following meanings:
(a)Change of Control. “Change of Control” shall mean (i) a dissolution or liquidation of the Company; (ii) a sale of all or substantially all the assets of the Company; (iii) a merger or consolidation in which the Company is not the surviving corporation and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors has changed; (iv) a reverse merger in which the Company is the surviving corporation but the shares of the common stock of the Company outstanding immediately before the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors has changed; (v) an acquisition by any person, entity or group within the meaning of Section 13(d) or 14(d) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or any comparable successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors; or, (vi) in the event that the individuals who are members of the Incumbent Board cease for any reason to constitute at least fifty percent (50%) of the Board. Notwithstanding the foregoing, a Change of Control shall not include any transaction effected primarily for the purpose of financing the Company with cash (as determined by the Board acting in good faith and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise) or the initial public offering of the Company’s common stock. Further notwithstanding the foregoing, if a Change of Control would give rise to a payment or settlement event that constitutes “nonqualified deferred compensation,” the transaction or event constituting the Change of Control must also constitute a “change in control event” (as defined in Treasury Regulation §1.409A-3(i)(5)) in order to give rise to the payment or settlement event, to the extent required by Section 409A.
(b)Change of Control Period. “Change of Control Period” shall mean the period commencing ninety (90) days prior to a Change of Control and ending on the first anniversary of the Change of Control.


(c)Covered Termination. “Covered Termination” shall mean an Involuntary Termination without Cause or a Voluntary Termination for Good Reason that constitutes the Executive’s Separation from Service.
(d)Disability. “Disability” shall mean that Executive has been unable to perform Executive’s Company duties as the result of Executive’s incapacity due to physical or mental illness, and such inability, at least one hundred eighty (180) days after its commencement, is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to Executive or Executive’s legal representative (such agreement as to acceptability not to be unreasonably withheld). Termination resulting from Disability may only be effected after at least thirty (30) days’ written notice by the Company of its intention to terminate Executive’s employment. In the event that Executive resumes the performance of substantially all of Executive’s duties hereunder before the termination of Executive’s employment becomes effective, the notice of intent to terminate shall automatically be deemed to have been revoked.
(e)Incumbent Board. “Incumbent Board” shall mean the individuals who, as of the Effective Date, are members of the Board. If the election, or nomination for election by the Company’s stockholders, of any new director is approved by a vote of at least fifty percent (50%) of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board.
(f)Involuntary Termination without Cause. “Involuntary Termination without Cause” shall mean the termination of Executive’s employment by the Company other than a termination following (i) the willful and continued failure to substantially perform the Executive’s duties with the Company (other than as a result of physical or mental disability) after a written demand for substantial performance is delivered to the Executive by the Company, which demand specifically identifies the manner in which the Company believes that the Executive has not substantially performed the Executive’s duties and that has not been cured within fifteen (15) days following receipt by the Executive of the written demand; (ii) commission of a felony (other than a traffic-related offense) that in the written determination of the Company is likely to cause or has caused material injury to the Company’s business; (iii) dishonesty with respect to a significant matter relating to the Company’s business; or (iv) material breach of any agreement by and between the Executive and the Company, which material breach has not been cured within fifteen
(15) days following receipt by the Executive of written notice from the Company identifying such material breach.
(g)Release of Claims. “Release of Claims” shall mean a general release of all claims against the Company and its affiliates in a form reasonably acceptable to the Company.
(h)Voluntary Termination for Good Reason. “Voluntary Termination for Good Reason” shall mean Executive’s voluntarily resignation after the occurrence of any of the following without Executive’s written consent: (i) a material diminution in Executive’s base compensation; (ii) a material diminution in Executive’s authority, duties or responsibilities; (iii) a material change of at least thirty-five (35) miles in the geographic location at which Executive must perform Executive’s services; or (iv) a material breach of this Agreement by the Company. Notwithstanding the foregoing, a resignation shall not constitute a “Voluntary Termination for Good Reason” unless the condition giving rise to such resignation continues more than thirty (30) days following Executive’s written notice of the condition within ninety (90) days of the


first occurrence of such condition and Executive’s termination occurs within one hundred eighty (180) days following the first occurrence of such condition.
(i)Measurement Date. “Measurement Date,” with respect to an award of performance stock units or performance stock options, shall mean the date the Compensation Committee of the Board of Directors determines the achievement of the applicable performance goals for the applicable performance period.
10.Successors.
(a)Company’s Successors. Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in this Section 10(a) or which becomes bound by the terms of this Agreement by operation of law.
(b)Executive’s Successors. The terms of this Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.
11.Notices. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or one day following mailing via Federal Express or similar overnight courier service. In the case of Executive, mailed notices shall be addressed to Executive at Executive’s home address that the Company has on file for Executive. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.
12.Confidentiality; Non-Solicitation.
(a)Confidentiality. While Executive is employed by the Company, and thereafter while Executive receives severance benefits hereunder, Executive shall not directly or indirectly disclose or make available to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, any Confidential Information (as defined below). Upon termination of Executive’s employment with the Company, all Confidential Information in Executive’s possession that is in written or other tangible form (together with all copies or duplicates thereof, including computer files) shall be returned to the Company and shall not be retained by Executive or furnished to any third party, in any form except as provided herein; provided, however, that Executive shall not be obligated to treat as confidential, or return to the Company copies of any Confidential Information that (i) was publicly known at the time of disclosure to Executive, (ii) becomes publicly known or available thereafter other than by any means in violation of this Agreement or any other duty owed to the Company by any person or entity, or (iii) is lawfully disclosed to Executive by a third party. For purposes of this Agreement, the term “Confidential Information” shall mean information disclosed to Executive or known by Executive as a consequence of or through his or her relationship with the Company, about the customers, employees, business methods, public relations methods, organization, procedures or


finances, including, without limitation, information of or relating to customer lists, of the Company and its affiliates. In addition, Executive shall continue to be subject to the Confidential Information, Secrecy, and Invention Agreement entered into between Executive and the Company (the “Confidential Information Agreement”).
(b)Non-Solicitation. In addition to each Executive’s obligations under the Confidential Information Agreement, Executive shall not for a period of one (1) year following Executive’s termination of employment for any reason, either on Executive’s own account or jointly with or as a manager, agent, officer, employee, consultant, partner, joint venturer, owner or stockholder or otherwise on behalf of any other person, firm or corporation, directly or indirectly solicit or attempt to solicit away from the Company any of its officers or employees or offer employment to any person who is an officer or employee of the Company; provided, however, that a general advertisement to which an employee of the Company responds shall in no event be deemed to result in a breach of this Section 12(b). Executive also agrees not to harass or disparage the Company or its employees, clients, directors or agents or divert or attempt to divert any actual or potential business of the company.
(c)Survival of Provisions. The provisions of this Section 12 shall survive the termination or expiration of the applicable Executive’s employment with the Company and shall be fully enforceable thereafter. If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 12 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.
13.Dispute Resolution. To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance or interpretation of this Agreement, Executive’s employment, or the termination of Executive’s employment, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in San Mateo County, California, conducted by Judicial Arbitration and Mediation Services, Inc. (“JAMS”) under the applicable JAMS employment rules. By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS’ arbitration fees in excess of the amount of court fees that would be required if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over intellectual property rights by Court action instead of arbitration.
14.Miscellaneous Provisions.
(a)Section 409A. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive’s Separation from


Service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive’s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the date of the Executive’s Covered Termination or termination of employment due to Disability or (ii) the date of Executive’s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 14(a) shall be paid in a lump sum to Executive, and any remaining payments due under the Agreement shall be paid as otherwise provided herein.
(b)Waiver. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.
(c)Whole Agreement. This Agreement and the Confidential Information Agreement represent the entire understanding of the parties hereto with respect to the subject matter hereof and supersede all prior arrangements and understandings regarding same.
(d)Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California.
(e)Severability.    The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.
(f)Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument.
[Signature page follows]




IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year set forth below.


CODEXIS, INC.
By:      Name: Stephen Dilly
Title: Chairman, President & CEO Date: September 30, 2024




EXECUTIVE
Alison Moore
Date:    September 30, 2024

 EX-31.1 7 cdxs_20240930xex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Stephen Dilly, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Codexis, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2024
/s/ Stephen Dilly
Stephen Dilly
Chairman, President and Chief Executive Officer
(principal executive officer)


 EX-31.2 8 cdxs_20240930xex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Georgia Erbez, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Codexis, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2024
/s/ Georgia Erbez
Georgia Erbez
Chief Financial Officer
(principal financial and accounting officer)


 EX-32.1 9 cdxs_20240930xex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Codexis, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2024, as filed with the Securities and Exchange Commission (the “Report”), Stephen Dilly, Chairman, President and Chief Executive Officer of the Company, and Georgia Erbez, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
•The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
•The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: October 31, 2024
/s/ Stephen Dilly
Stephen Dilly
Chairman, President and Chief Executive Officer
(principal executive officer)
/s/ Georgia Erbez
Georgia Erbez
Chief Financial Officer
(principal financial and accounting officer)


 EX-101.SCH 10 cdxs-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Investments in Non-Marketable Securities link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Balance Sheets Details link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Segment, Geographical and Other Revenue Information link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Investments in Non-Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Balance Sheets Details (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Segment, Geographical and Other Revenue Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Revenue Recognition - Contracts with Customer (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Revenue Recognition - Revenue Recognized During Period (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Revenue Recognition - Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Revenue Recognition - Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Net Loss per Share - Shares Not Included in Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Investments in Non-Marketable Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Balance Sheets Details - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Balance Sheets Details - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Balance Sheets Details - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Balance Sheets Details - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Stock-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Capital Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Commitments and Contingencies - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Commitments and Contingencies - Other Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Commitments and Contingencies - Cash Paid for Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Commitments and Contingencies - Other Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Debt - Schedule of Long-Term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Debt - Schedule of Maturities of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Segment, Geographical and Other Revenue Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Segment, Geographical and Other Revenue Information - Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 cdxs-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 cdxs-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 cdxs-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT U.S. agency securities US Government Corporations and Agencies Securities [Member] Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Geographic Areas, Long-Lived Assets [Abstract] Geographic Areas, Long-Lived Assets [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Work-in-process Inventory, Work in Process, Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Customer E Customer E [Member] Customer E Lease Cost Lease, Cost [Table Text Block] Cover page. Cover [Abstract] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Operating Lease Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Assets Held For Sale Assets Held For Sale [Policy Text Block] Assets Held For Sale Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Office equipment and furniture Office Equipment and Furniture [Member] Office Equipment and Furniture [Member] Other Commitments [Line Items] Other Commitments [Line Items] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Short-term Investments Short-Term Investments [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Costs and operating expenses: Operating Costs and Expenses [Abstract] 2025 and Thereafter Other Commitment, To Be Paid, Year One And Thereafter Other Commitment, To Be Paid, Year One And Thereafter Total revenues Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Investment in non-marketable equity securities Investments and Other Noncurrent Assets Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Proceeds from exercises of stock options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount San Carlos San Carlos [Member] San Carlos Common stock, shares, outstanding (in shares) Common Stock, Shares, Outstanding Operating lease, cost Operating Lease, Cost Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Long-term lease obligations - Operating leases Operating Lease, Liability, Noncurrent Segment Information Segment Reporting, Policy [Policy Text Block] Geographic Distribution [Axis] Geographic Distribution [Axis] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Deferred revenue Contract with Customer, Liability, Current United States UNITED STATES Schedule of Inventory Components Inventory, Net [Abstract] Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds Money Market Funds [Member] RSAs and RSUs RSUs and RSAs RSAs and RSUs [Member] RSAs and RSUs [Member] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expenses [Member] Changes in the period: Change in Contract with Customer, Liability [Abstract] Receivable Type [Axis] Receivable Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net proceeds received Sale of Stock, Consideration Received on Transaction Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] U.S. treasury securities US Treasury Securities [Member] Secured Debt Secured Debt [Member] Prepaid expense, current Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Other assets, current Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value Debt Securities, Available-for-Sale Cantor Cantor [Member] Cantor Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Revenue Revenue, Product and Service Benchmark [Member] Issuance of common stock upon release of stock awards (in shares) Stock Issued During Period, Shares, Other Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Total costs and operating expenses Costs and Expenses Contract assets Contract with Customer, Asset, before Allowance for Credit Loss, Current Receivable [Domain] Receivable [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Investment, Variable Interest Rate, Type [Extensible Enumeration] Investment, Variable Interest Rate, Type [Extensible Enumeration] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Payment of debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Loss contingency accrual Loss Contingency, Accrual, Current Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] EMEA EMEA [Member] Debt instrument, exit fee, percent Debt Instrument, Exit Fee, Percent Debt Instrument, Exit Fee, Percent Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Class of warrant or right, number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Other accrued liabilities Total other accrued liabilities Accrued Liabilities, Current Total shares excluded as anti-dilutive (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Impairment of long-lived assets to be disposed of Impairment of Long-Lived Assets to be Disposed of Tranche One Share-Based Payment Arrangement, Tranche One [Member] Performance Obligation, Expected Timing of Satisfaction Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Innovatus Loan - First Tranche Innovatus Loan - First Tranche [Member] Innovatus Loan - First Tranche Facility maintenance agreement Facility Maintenance Agreement [Member] Facility Maintenance Agreement Cash, cash equivalents and restricted cash at the beginning of the period Cash, cash equivalents and restricted cash at the end of the period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-based payment arrangement, nonvested award, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Goodwill Goodwill Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Other comprehensive gain: Other Comprehensive Income (Loss), Net of Tax [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Performance obligations satisfied from new activities in the period - contract revenue Contract with Customer, Liability, New Activities, Performance Obligation Satisfied, Revenue Recognition Contract with Customer, Liability, New Activities, Performance Obligation Satisfied, Revenue Recognition PSC Piper Sandler & Co [Member] Piper Sandler & Co Product and Service [Domain] Product and Service [Domain] Stock Options Stock options Share-Based Payment Arrangement, Option [Member] Depreciation Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Early repayment fee, percentage Early Repayment Fee, Percentage Early Repayment Fee, Percentage Warrant Warrant [Member] Security Exchange Name Security Exchange Name Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Corporate debt Corporate Debt Securities [Member] Net proceeds from stock options exercised Net Proceeds From Stock Options Exercised Net Proceeds From Stock Options Exercised Schedule of Long-Lived Assets by Geographical Area Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Weighted average exercise price of stock options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Equity securities earned from research and development activities Other Noncash Income Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Long-lived assets Long-Lived Assets Convertible Debt Convertible Debt [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Total Other Commitment Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Current portion of lease obligations - Operating leases Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares, issued (in shares) Common Stock, Shares, Issued Credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk, percentage Concentration Risk, Percentage Total financial assets Financing Receivable, before Allowance for Credit Loss Computer equipment and software Computer Equipment [Member] seqWell seqWell [Member] seqWell Customer J Customer J [Member] Customer J Schedule of Supply and Service Commitments Supply Commitment [Table Text Block] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Cash Cash Property and equipment Property, Plant and Equipment, Gross Issuance of common stock upon exercise of stock options (in shares) Stock options exercised (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Less: allowances Financing Receivable, Allowance for Credit Loss, Current Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and development Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Investments in Non-Marketable Securities Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Debt instrument, number of tranches Debt Instrument, Number Of Tranches Debt Instrument, Number Of Tranches Unrealized gain on available-for-sale short-term investments, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Weighted average common stock shares used in computing net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Sale of stock, period Sale Of Stock, Period Sale Of Stock, Period Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Proceeds from sale of short-term investments Proceeds from Sale of Short-Term Investments Selling, general and administrative Selling, General and Administrative Expense Cost of product revenue Cost of Sales [Member] Product revenue Product [Member] Sale of Stock [Domain] Sale of Stock [Domain] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Asset impairment and other charges Asset Impairment Charges Total long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Other comprehensive gain Other Comprehensive Income (Loss), Net of Tax Balance Sheets Details Balance Sheets Details [Text Block] Balance sheets details. Document Type Document Type Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Commercial paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Add: payment in-kind interest Debt Instrument, Payment In-kind Interest Debt Instrument, Payment In-kind Interest Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Contract with Customer Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Maximum Maximum [Member] Contract liabilities: deferred revenue Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Revenues: Revenues [Abstract] Debt instrument, unamortized discount Less: unamortized debt issuance fee Debt Instrument, Unamortized Discount Leasehold improvements Leasehold Improvements [Member] Carrying Value of Non-marketable Equity Securities Equity Securities without Readily Determinable Fair Value [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Short-term investments Short-Term Investments Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Share-based compensation arrangement by share-based payment award, shares issued in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Goodwill impairment Goodwill, Impairment Loss Operating lease, write-off due to lease modification Operating Lease, Write-off Due To Lease Modification Operating Lease, Write-off Due To Lease Modification Variable lease cost Variable Lease, Cost Shares Not Included in Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Performance based options (“PBOs”) Performance Based Options (PBOs) [Member] Performance Based Options (PBOs) [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Class of Stock [Line Items] Class of Stock [Line Items] Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Unbilled receivables Unbilled Receivables, Current Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Reduction in the carrying amount of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Cash, cash equivalents, and short-term investments Total Cash, Cash Equivalents, and Short-Term Investments Award vesting rights Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Income taxes paid Income Taxes Paid Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Innovatus Loan Warrants Innovatus Loan Warrants [Member] Innovatus Loan Warrants Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation Share-based payment arrangement, noncash expense Share-Based Payment Arrangement, Noncash Expense Indemnification Agreement Indemnification Agreement [Member] Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment 2024 Inducement Plan 2024 Inducement Plan [Member] 2024 Inducement Plan Provision for income taxes Income Tax Expense (Benefit) Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Issuance of common stock warrants in connection with debt issuance Adjustments to Additional Paid in Capital, Warrant Issued Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Innovatus Loan - Second Tranche Innovatus Loan - Second Tranche [Member] Innovatus Loan - Second Tranche Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Security Owned Not Readily Marketable [Axis] Security Owned Not Readily Marketable [Axis] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Debt instrument, interest, paid in kind Debt Instrument, Interest, Paid In Kind Debt Instrument, Interest, Paid In Kind Number of reportable segments Number of Reportable Segments Total liabilities and stockholders' equity Liabilities and Equity Other non-cash items Other Operating Activities, Cash Flow Statement Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation Employee-related Liabilities, Current Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Operating Lease, Impairment Loss Operating Lease, Impairment Loss Restructuring charges Restructuring Charges Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest income Investment Income, Interest Schedule of Stock-based Compensation Expense by Security Types Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedule of Maturities of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Sale of stock, consideration received on transaction, gross Sale of Stock, Consideration Received On Transaction, Gross Sale of Stock, Consideration Received On Transaction, Gross Taxes paid related to net share settlement of equity awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Name of Property [Domain] Name of Property [Domain] Cantor Sales Agreement Cantor Sales Agreement [Member] Cantor Sales Agreement Expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Restricted cash, current Restricted Cash Inventories Total Inventories Inventory, Net Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Vesting [Domain] Vesting [Domain] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Accrued compensation and other accrued liabilities Increase (Decrease) in Employee Related Liabilities and Other Accrued Liabilities Increase (Decrease) in Employee Related Liabilities and Other Accrued Liabilities Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Unamortized debt issuance expense Less: unamortized debt issuance costs Unamortized Debt Issuance Expense Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Concentration Risk [Table] Concentration Risk [Table] Right-of-use assets - Operating leases, net Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Class of warrant or right, fair value Class Of Warrant Or Right, Fair Value Class Of Warrant Or Right, Fair Value Total principal payments Long-Term Debt, Gross Exercise Price Award Exercise Price Unrealized or realized gains or losses Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount Arzeda Arzeda [Member] Arzeda Other Other Accrued Liabilities Net Loss per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Stockholders' equity: Equity, Attributable to Parent [Abstract] Name of Property [Axis] Name of Property [Axis] Marketable Securities [Table] Marketable Securities [Table] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt instrument, term Debt Instrument, Term All Individuals All Individuals [Member] Fixed contribution rate Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount PEO PEO [Member] Name Trading Arrangement, Individual Name Interest and other expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Sale of stock, securities registered aggregate amount Sale Of Stock, Securities Registered Aggregate Amount Sale Of Stock, Securities Registered Aggregate Amount Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Compensation not yet recognized, share-based awards other than options Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year Schedule of Customers that Contributed 10% or More of Total Accounts Receivable Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other Commitments [Domain] Other Commitments [Domain] Sale of stock, value of shares for issuance Sale Of Stock, Value Of Shares For Issuance Sale Of Stock, Value Of Shares For Issuance Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Consecutive offering period Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Americas Americas [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less: uncapitalized payment in-kind interest Debt Instrument, Uncapitalized Payment In-kind Interest Debt Instrument, Uncapitalized Payment In-kind Interest PEO Total Compensation Amount PEO Total Compensation Amount Purchase price of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Customer I Customer I [Member] Customer I Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Costs incurred in connection with offering Payments of Stock Issuance Costs Long-Term Unbilled Receivables Long-Term Unbilled Receivables [Member] Long-Term Unbilled Receivables Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accrued professional and outside service fees Accrued Professional Fees Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of common stock in connection with an equity sales agreement, net of issuance costs (shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Entity Emerging Growth Company Segment Reporting [Abstract] Segment Reporting [Abstract] Taxes paid related to net share settlement of equity awards (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key 2029 Long-Term Debt, Maturity, Year Five Other investments in non-marketable equity securities Other Security Investments [Member] Schedule of Inventory Components Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Capital Stock Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Segment, Geographical and Other Revenue Information Segment Reporting Disclosure [Text Block] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Balance Sheets Details [Abstract] Balance Sheets Details [Abstract] -- None. No documentation exists for this element. -- Interest expense, debt Interest Expense, Debt Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Geographic Distribution [Domain] Geographic Distribution [Domain] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Customer K Customer K [Member] Customer K Purchases of short-term investments Payments to Acquire Short-Term Investments Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Supplemental non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Research and development revenue Research and Development Revenue [Member] Research and Development Revenue [Member] MAI Molecular Assemblies, Inc. [Member] Molecular Assemblies, Inc. 2027 Long-Term Debt, Maturity, Year Three Other-than-temporary impairment losses Debt Securities, Available-for-Sale, Unrealized Loss Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt Long-Term Debt, Excluding Current Maturities Performance-contingent restricted stock units (“PSUs”) Performance-contingent Restricted Stock Units (PSU) [Member] Performance-contingent Restricted Stock Units (PSU) Other Commitments [Axis] Other Commitments [Axis] Total non-marketable equity securities Equity Securities without Readily Determinable Fair Value, Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Earnings Per Share [Abstract] Sale of stock, commission fee, percent Sale Of Stock, Commission Fee, Percent Sale Of Stock, Commission Fee, Percent Equity [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Short-Term Unbilled Receivables Short-Term Unbilled Receivables [Member] Short-Term Unbilled Receivables 2024 (Remaining 3 Months) Other Commitment, to be Paid, Remainder of Fiscal Year Inventories Increase (Decrease) in Inventories 2026 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Lease obligations Lease obligations Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Amendment Flag Amendment Flag Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Total Cash, Cash Equivalents And Short Term Investments, Amortized Cost Cash, Cash Equivalents And Short Term Investments, Amortized Cost Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Debt Debt Disclosure [Text Block] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Customer H Customer H [Member] Customer H Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Face value of debt Debt Instrument, Face Amount Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Issuance of common stock in connection with an equity sales agreement, net of issuance costs Stock Issued During Period, Value, New Issues Unbilled receivables Unbilled Contracts Receivable Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stock-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.0001 par value per share; 200,000 shares authorized; 81,376 shares and 69,905 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Customer B Customer B [Member] Customer B [Member] Unbilled receivables, not billable Unbilled Receivables, Not Billable Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Amounts included in contract liabilities at the beginning of the period: Change in Contract with Customer, Asset and Liability [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Security Owned Not Readily Marketable, Name [Domain] Security Owned Not Readily Marketable, Name [Domain] Customer G Customer G [Member] Customer G Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Raw materials Inventory, Raw Materials, Gross Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding Preferred Stock, Value, Issued Finished goods Inventory, Finished Goods, Gross Shares issuable under the Equity Incentive Plan and ESPP Share-Based Payment Arrangement [Member] ESPP Employee Stock [Member] Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from issuance of common stock in connection with equity sales agreements Proceeds from Issuance of Common Stock Proceeds from issuance of stock under employee stock purchase plan Proceeds from Stock Plans Operating cash flows from operating leases Operating Lease, Payments Cash and Cash Equivalents Cash and Cash Equivalents [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Financial assets: Financing Receivable, before Allowance for Credit Loss [Abstract] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other Liabilities Disclosure [Abstract] Capital expenditures incurred but not yet paid Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Customer A Customer A [Member] Customer A [Member] Financial assets Increase (Decrease) in Finance Receivables Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Compensation not yet recognized, stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Cost of product revenue Cost of Goods and Services Sold Add: amortized exit fee Debt Instrument, Amortized Exit Fee Debt Instrument, Amortized Exit Fee Summary of Financial Instruments Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Cash reconciliation: Cash and Cash Equivalents [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Debt instrument, interest payable, term Debt Instrument, Interest Payable, Term Debt Instrument, Interest Payable, Term Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Commitments and Contingencies (Note 10) Commitments and Contingencies Termination Date Trading Arrangement Termination Date Amortization of discount on short-term investments Amortization Of Discount On Short-term Investments Amortization Of Discount On Short-term Investments Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Description of Business Nature of Operations [Text Block] Class of warrant or right, exercise price of warrants or rights (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Long-Term Debt, Maturity, Year One Stock-based Compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Proceeds from long-term debt Proceeds from Issuance of Long-Term Debt Debt Instrument [Axis] Debt Instrument [Axis] Proceeds from maturity of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Other Commitments [Table] Other Commitments [Table] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Customer F Customer F [Member] Customer F Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Revenue Recognition Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Name Forgone Recovery, Individual Name 2024 (remaining 3 months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Short-term Investments Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Innovatus Loan Innovatus Loan [Member] Innovatus Loan Impairment of investment in non-marketable equity securities Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Performance obligations satisfied Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accounts Receivable Accounts Receivable [Member] Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Total financial assets, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current Document Transition Report Document Transition Report Customer C Customer C [Member] Customer C Document Quarterly Report Document Quarterly Report Accrued purchases Purchase Obligation Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Investment in non-marketable securities Payments to Acquire Other Investments Customer [Domain] Customer [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Restricted cash, current and non-current Restricted Cash and Cash Equivalents Non-cash interest expense Amortization of Debt Issuance Costs Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Impairment of leasehold Impairment of Leasehold Weighted average common stock shares used in computing net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Marketable Securities [Line Items] Marketable Securities [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] RSUs Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] APAC APAC [Member] Regions of Australia, New Zealand, Southeast Asia and China Executive Category: Executive Category [Axis] Customer D Customer D [Member] Customer D Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Entity Filer Category Entity Filer Category Impairment charges related to contract assets Contract with Customer, Asset, Credit Loss Expense (Reversal) Performance obligation Revenue, Remaining Performance Obligation, Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name Costs incurred in connection with equity sales agreements Costs Incurred In Connection With Equity Sales Agreements Costs Incurred In Connection With Equity Sales Agreements Prime Rate [Member] EX-101.PRE 14 cdxs-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 16 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2024
Oct. 28, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-34705  
Entity Registrant Name Codexis, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 71-0872999  
Entity Address, Address Line One 200 Penobscot Drive  
Entity Address, City or Town Redwood City  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94063  
City Area Code 650  
Local Phone Number 421-8100  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol CDXS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   81,377,855
Entity Central Index Key 0001200375  
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 37,452 $ 65,116
Restricted cash, current 514 519
Short-term investments 52,803 0
Financial assets:    
Accounts receivable 9,721 10,036
Contract assets 3,424 815
Unbilled receivables 3,460 9,142
Total financial assets 16,605 19,993
Less: allowances (65) (65)
Total financial assets, net 16,540 19,928
Inventories 2,103 2,685
Prepaid expenses and other current assets 3,490 5,218
Total current assets 112,902 93,466
Restricted cash 1,062 1,062
Investment in non-marketable equity securities 5,790 9,700
Right-of-use assets - Operating leases, net 10,772 13,137
Property and equipment, net 13,266 15,487
Goodwill 2,463 2,463
Other non-current assets 1,928 1,246
Total assets 148,183 136,561
Current liabilities:    
Accounts payable 4,212 5,947
Accrued compensation 10,320 11,246
Other accrued liabilities 6,505 4,735
Current portion of lease obligations - Operating leases 4,081 3,781
Deferred revenue 10,011 10,121
Total current liabilities 35,129 35,830
Deferred revenue, net of current portion 610 640
Long-term lease obligations - Operating leases 9,134 12,243
Long-term debt 28,631 0
Other long-term liabilities 1,279 1,233
Total liabilities 74,783 49,946
Commitments and Contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.0001 par value per share; 200,000 shares authorized; 81,376 shares and 69,905 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 8 7
Additional paid-in capital 625,696 584,138
Accumulated other comprehensive income 126 0
Accumulated deficit (552,430) (497,530)
Total stockholders' equity 73,400 86,615
Total liabilities and stockholders' equity $ 148,183 $ 136,561
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares, issued (in shares) 81,376,000 69,905,000
Common stock, shares, outstanding (in shares) 81,376,000 69,905,000
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues:        
Total revenues $ 12,833 $ 9,277 $ 37,885 $ 43,582
Costs and operating expenses:        
Cost of product revenue 4,317 2,249 12,634 9,947
Research and development 11,505 13,662 34,164 47,651
Selling, general and administrative 13,568 12,302 42,100 41,066
Restructuring charges 0 3,140 0 3,284
Asset impairment and other charges 0 9,984 165 9,984
Total costs and operating expenses 29,390 41,337 89,063 111,932
Loss from operations (16,557) (32,060) (51,178) (68,350)
Interest income 849 1,056 2,730 3,266
Interest and other expense, net (4,922) (3,895) (6,421) (3,930)
Loss before income taxes (20,630) (34,899) (54,869) (69,014)
Provision for income taxes 10 9 31 34
Net loss $ (20,640) $ (34,908) $ (54,900) $ (69,048)
Net loss per share, basic (in dollars per share) $ (0.29) $ (0.50) $ (0.78) $ (1.02)
Net loss per share, diluted (in dollars per share) $ (0.29) $ (0.50) $ (0.78) $ (1.02)
Weighted average common stock shares used in computing net loss per share, basic (in shares) 72,032 69,466 70,759 67,670
Weighted average common stock shares used in computing net loss per share, diluted (in shares) 72,032 69,466 70,759 67,670
Product revenue        
Revenues:        
Total revenues $ 11,158 $ 5,395 $ 26,968 $ 24,807
Research and development revenue        
Revenues:        
Total revenues $ 1,675 $ 3,882 $ 10,917 $ 18,775
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
Net loss $ (20,640) $ (34,908) $ (54,900) $ (69,048)
Other comprehensive gain:        
Unrealized gain on available-for-sale short-term investments, net of tax 149 0 126 0
Comprehensive loss $ (20,491) $ (34,908) $ (54,774) $ (69,048)
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   65,811,000      
Beginning balance at Dec. 31, 2022 $ 144,797 $ 6 $ 566,081 $ 0 $ (421,290)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares) 214,284 214,000      
Issuance of common stock upon exercise of stock options $ 422   422    
Issuance of common stock upon release of stock awards (in shares)   787,000      
Issuance of common stock in connection with an equity sales agreement, net of issuance costs (shares)   3,080,000      
Issuance of common stock in connection with an equity sales agreement, net of issuance costs 7,931   7,931    
Stock-based compensation 7,808   7,808    
Taxes paid related to net share settlement of equity awards (in shares)   (65,000)      
Taxes paid related to net share settlement of equity awards (404)   (404)    
Net loss (69,048)       (69,048)
Ending balance (in shares) at Sep. 30, 2023   69,827,000      
Ending balance at Sep. 30, 2023 91,506 $ 6 581,838 0 (490,338)
Beginning balance (in shares) at Jun. 30, 2023   69,804,000      
Beginning balance at Jun. 30, 2023 124,131 $ 6 579,555 0 (455,430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon release of stock awards (in shares)   23,000      
Stock-based compensation 2,283   2,283    
Net loss (34,908)       (34,908)
Ending balance (in shares) at Sep. 30, 2023   69,827,000      
Ending balance at Sep. 30, 2023 91,506 $ 6 581,838 0 (490,338)
Beginning balance (in shares) at Dec. 31, 2023   69,905,000      
Beginning balance at Dec. 31, 2023 $ 86,615 $ 7 584,138 0 (497,530)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares) 72,856 73,000      
Issuance of common stock upon exercise of stock options $ 143   143    
Issuance of common stock upon release of stock awards (in shares)   834,000      
Issuance of common stock warrants in connection with debt issuance 859   859    
Issuance of common stock under employee stock purchase plan (in shares)   124,000      
Issuance of common stock under employee stock purchase plan 260   260    
Issuance of common stock in connection with an equity sales agreement, net of issuance costs (shares)   10,440,000      
Issuance of common stock in connection with an equity sales agreement, net of issuance costs 29,736 $ 1 29,735    
Stock-based compensation 10,561   10,561    
Net loss (54,900)       (54,900)
Other comprehensive gain 126     126  
Ending balance (in shares) at Sep. 30, 2024   81,376,000      
Ending balance at Sep. 30, 2024 73,400 $ 8 625,696 126 (552,430)
Beginning balance (in shares) at Jun. 30, 2024   70,914,000      
Beginning balance at Jun. 30, 2024 61,447 $ 7 593,253 (23) (531,790)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon release of stock awards (in shares)   22,000      
Issuance of common stock in connection with an equity sales agreement, net of issuance costs (shares)   10,440,000      
Issuance of common stock in connection with an equity sales agreement, net of issuance costs 29,736 $ 1 29,735    
Stock-based compensation 2,708   2,708    
Net loss (20,640)       (20,640)
Other comprehensive gain 149     149  
Ending balance (in shares) at Sep. 30, 2024   81,376,000      
Ending balance at Sep. 30, 2024 $ 73,400 $ 8 $ 625,696 $ 126 $ (552,430)
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]      
Costs incurred in connection with offering $ 1,584 $ 1,584 $ 721
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Operating activities:      
Net loss $ (20,640) $ (54,900) $ (69,048)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization   3,737 4,302
Reduction in the carrying amount of right-of-use assets   2,364 3,647
Stock-based compensation 2,708 10,561 7,808
Asset impairment and other charges 0 165 9,984
Impairment of investment in non-marketable equity securities 3,900 3,910 3,875
Equity securities earned from research and development activities   0 (187)
Non-cash interest expense   611 0
Amortization of discount on short-term investments   (1,009) 0
Other non-cash items   11 (3)
Changes in operating assets and liabilities:      
Financial assets   2,818 21,580
Inventories   582 (276)
Prepaid expenses and other assets   1,417 (252)
Accounts payable   (1,339) (105)
Accrued compensation and other accrued liabilities   1,334 (7,269)
Other long-term liabilities   (3,064) (4,384)
Deferred revenue   (140) (11,273)
Net cash used in operating activities   (32,942) (41,601)
Investing activities:      
Purchase of property and equipment   (2,531) (4,798)
Proceeds from sale of property and equipment   84 27
Purchases of short-term investments   (72,643) 0
Proceeds from maturity of short-term investments   19,000 0
Proceeds from sale of short-term investments   1,973 0
Investment in non-marketable securities   0 (1,191)
Net cash used in investing activities   (54,117) (5,962)
Financing activities:      
Proceeds from exercises of stock options   281 422
Proceeds from issuance of stock under employee stock purchase plan   525 0
Proceeds from issuance of common stock in connection with equity sales agreements   31,320 8,652
Costs incurred in connection with equity sales agreements   (1,615) (503)
Proceeds from long-term debt   29,521 0
Payment of debt issuance costs   (642) 0
Taxes paid related to net share settlement of equity awards   0 (404)
Net cash provided by financing activities   59,390 8,167
Net decrease in cash, cash equivalents and restricted cash   (27,669) (39,396)
Cash, cash equivalents and restricted cash at the beginning of the period   66,697 116,026
Cash, cash equivalents and restricted cash at the end of the period 39,028 39,028 76,630
Supplemental disclosure of cash flow information:      
Interest paid   1,633 28
Income taxes paid   17 193
Supplemental non-cash investing and financing activities:      
Capital expenditures incurred but not yet paid   249 159
Cash reconciliation:      
Cash and cash equivalents 37,452 37,452 74,577
Restricted cash, current and non-current 1,576 1,576 2,053
Total cash, cash equivalents and restricted cash 39,028 39,028 $ 76,630
Short-term investments 52,803 52,803  
Cash, cash equivalents, and short-term investments $ 90,255 $ 90,255  
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Description of Business
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business Description of Business
In these notes to the unaudited condensed consolidated financial statements, the “Company,” “Codexis,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.
We discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins leveraging our proprietary CodeEvolver® directed evolution technology platform.
We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our Chief Executive Officer (“CEO”), our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment. Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocates resources based on the consolidated results of operations. We believe that these changes better align internal resources to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of December 31, 2023. Comparative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024 and 2023, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2023.
The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2024 and results of operations for the interim periods presented. The interim results are not necessarily indicative of the results for any future interim period or for the entire year.
The unaudited condensed consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.
Short-term Investments
We classify all marketable debt securities that have effective maturities of three months or less from the date of purchase as cash equivalents and those with effective maturities of greater than three months as short-term investment securities in the condensed consolidated balance sheets. We determine the appropriate classification of our short-term investments at the time of purchase and reevaluate such designation at each balance sheet date. We have classified and accounted for our short-term investments as available-for-sale. After consideration of our risk versus reward objectives, as well as our liquidity requirements, we may sell these debt securities prior to their effective maturities.
We carry these short-term investments at fair value, and report the unrealized gains and losses, net of taxes, as a component of stockholders’ equity, except for the changes in allowance for expected credit losses, which are included in “Interest and other expense, net” in the unaudited condensed consolidated statements of operations. We determine any realized gains or losses on the sale of short-term investments on a specific identification method, and we record such gains and losses as a component of interest income.
Short-term investments are reviewed periodically for allowances for credit losses and impairment. When evaluating the investments, the Company reviews factors such as the extent to which the fair value of the security is less than the amortized cost basis, adverse conditions specifically related to the security, the financial condition of the issuer, the Company’s intent to sell, and whether it would be more likely than not that the Company would be required to sell the investments before the recovery of the amortized cost basis.
Impairment of Long-Lived Assets
We evaluate the carrying values of long-lived assets, which include property and equipment and right-of-use assets, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with the future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Assets Held For Sale
The Company classifies assets as held for sale when the following conditions are met: (i) management has committed to a plan to sell, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to identify a buyer, (iv) it is probable that a sale will occur within one year, (v) the assets are actively marketed for sale at a reasonable price in relation to their current fair value, and (vi) there is a low likelihood of significant changes to the plan or that the plan will be withdrawn. If all of the criteria are met as of the balance sheet date, the assets are presented separately in the consolidated balance sheet as held for sale at the lower of the carrying amount or fair value less costs to sell. The assets are then no longer depreciated or amortized while classified as held for sale. There were no assets classified as held for sale as of September 30, 2024 and December 31, 2023.
Accounting Pronouncements
Recently adopted accounting pronouncements
There were no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2024, that are of significance or potential significance to us.
Recently issued accounting pronouncements not yet adopted
In March 2024, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2024-02, Codification Improvements - Amendments to Remove References to the Concepts Statements. This ASU amends the FASB Accounting Standard Codification (the “ASC”) to remove references to various concepts statements and impacts a variety of topics in the ASC. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
In December 2023, FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in the ASU require public companies, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in the ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The standard should be applied retrospectively to all prior periods presented in the financial statements. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
In October 2023, FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. The amendments in the ASU are intended to amend certain disclosure and presentation requirements for a variety of topics within the ASC. These amendments align the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, as announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenue
The following table provides information about disaggregated revenue from contracts with customers by geographic regions. The geographic regions that are tracked are the Americas (United States, Canada, and Latin America), EMEA (Europe, Middle East, and Africa), and APAC (Australia, New Zealand, Southeast Asia, and China).
Disaggregated information is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Primary geographical markets:
Americas$1,534 $4,278 $9,823 $10,798 
EMEA2,229 3,191 6,768 14,630 
APAC9,070 1,808 21,294 18,154 
Total revenues$12,833 $9,277 $37,885 $43,582 
Contract Balances
The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):
September 30, 2024December 31, 2023
Contract assets$3,424 $815 
Unbilled receivables$4,793 $9,904 
Contract liabilities: deferred revenue$10,621 $10,761 
We had no asset impairment charges related to financial assets in the three and nine months ended September 30, 2024 and 2023.
The increase in contract assets was primarily due to increases in product revenue from contracts subject to over time revenue recognition. The decrease in unbilled receivables was primarily due to the timing of billings. The decrease in deferred revenue was primarily due to the timing of recognition of revenue.
As of September 30, 2024, we have $3.5 million of short-term unbilled receivables presented as unbilled receivables within current assets and $1.3 million of long-term unbilled receivables that is included within the other non-current assets line item in the condensed consolidated balance sheets. As of December 31, 2023, we had $9.1 million of short-term unbilled receivables presented as unbilled receivables within current assets and $0.8 million of long-term unbilled receivables that is included within the other non-current assets line item in the condensed consolidated balance sheets.
We recognized the following revenues (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
Revenue recognized in the period for:2024202320242023
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied$— $1,303 $475 $9,111 
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods146 1,018 (446)4,238 
Performance obligations satisfied from new activities in the period - contract revenue12,687 6,956 37,856 30,233 
Total revenues$12,833 $9,277 $37,885 $43,582 
Performance Obligations
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2024.
The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2024 (in thousands):
Remainder of 2024
20252026
2027 and Thereafter
Total
Product revenue$9,981 $140 $140 $360 $10,621 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Net Loss per Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding, less restricted stock awards (“RSAs”) subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock shares outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common stock shares had been issued for other dilutive securities. For all periods presented, diluted and basic net loss per share are identical since potential common stock shares are excluded from the calculation, as their effect was anti-dilutive.
Anti-Dilutive Securities
In periods of net loss, the weighted average number of shares outstanding, prior to the application of the treasury stock method, excludes potentially dilutive securities from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect.
The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Shares issuable under the Equity Incentive Plan and ESPP12,9318,87312,9318,873
Warrants(1)
424—424—
Total potentially dilutive securities13,3558,87313,3558,873
(1) Pertains to the warrants issued in connection with the Innovatus Loan. For additional information, see Note 11, “Debt.”
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Investments in Non-Marketable Securities
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Investments in Non-Marketable Securities Investments in Non-Marketable Securities
Non-Marketable Equity Securities
Our non-marketable equity securities are investments in privately held companies without readily determinable market value and primarily relate to our investments in Molecular Assemblies, Inc. (“MAI”) and seqWell, Inc. (“seqWell”). These investments are accounted for under the measurement alternative and are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes for identical or similar securities of the same issuer. Non-marketable equity securities are measured at fair value on a non-recurring basis and classified within Level 2 in the fair value hierarchy when we estimate the fair value of these investments using the observable transaction price paid by third party investors for the same or similar security of the same issuers. The fair value of non-marketable equity securities are classified within Level 3 when we estimate fair value using unobservable inputs such as when we remeasure due to impairment and we use discount rates, market data of comparable companies, and rights and obligations of the securities the Company holds, among others. We adjust the carrying value of non-marketable equity securities which have been remeasured during the period and recognize resulting gains or losses as a component of interest and other expense, net in the unaudited condensed consolidated statements of operations.
For the three and nine months ended September 30, 2024, we recognized an impairment charge of $3.9 million which is presented within interest and other expense, net in the condensed consolidated statements of operations. This adjustment is related to the write-down of our investment in MAI to its related fair value as determined based on valuation methods using the latest observed transaction price of MAI’s preferred stock securities to be issued during the fourth quarter of 2024 and adjusted for the rights and obligations of the preferred stock securities the Company holds. There was no remeasurement event for our investments in seqWell and other non-marketable equity securities that occurred during the three and nine months ended September 30, 2024.
For the three and nine months ended September 30, 2023, we recognized an impairment charge of $3.9 million and included this as an adjustment to the carrying value of our investments in seqWell and Arzeda Corp. (“Arzeda”). This adjustment, which is presented within interest and other expense, net in the condensed consolidated statements of operations, is related to the write-down of the carrying value of our investments in seqWell by $3.0 million and in Arzeda by $0.9 million to their estimated fair values as determined based on valuation methods using the recent transaction price of similar preferred stock securities issued by the investees and adjusted for the rights and obligations of the preferred stock securities the Company holds. We recognized no realized gains or losses during the three and nine months ended September 30, 2024 and 2023.
The following table presents the carrying value of our non-marketable equity securities (in thousands):
 September 30, 2024December 31, 2023
MAI
$2,783 $6,693 
seqWell2,625 2,625 
Other investments in non-marketable equity securities382 382 
Total non-marketable equity securities$5,790 $9,700 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following tables show the Company’s cash, cash equivalents, and short-term investments by significant investment category as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Amortized CostUnrealized GainsUnrealized LossesFair ValueCash and Cash Equivalents
Short-term Investments
Cash$7,359 $— $— $7,359 $7,359 $— 
Level 1:
Money market funds
30,093 — — 30,093 30,093 — 
Level 2(1):
Commercial paper8,416 7 — 8,423 — 8,423 
Corporate debt8,723 14 (2)8,735 — 8,735 
U.S. agency securities1,983 9 — 1,992 — 1,992 
U.S. treasury securities33,555 98 — 33,653 — 33,653 
Subtotal52,677 128 (2)52,803 — 52,803 
Total$90,129 $128 $(2)$90,255 $37,452 $52,803 
(1) The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments uses inputs that are either directly or indirectly observable for the asset through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
December 31, 2023
Amortized CostUnrealized GainsUnrealized LossesFair ValueCash and Cash Equivalents
Short-term Investments
Cash$8,742 $— $— $8,742 $8,742 $— 
Level 1:
Money market funds
56,374 — — 56,374 56,374 — 
Total$65,116 $— $— $65,116 $65,116 $— 
We limit the credit risk associated with our cash equivalents and short-term investments by placing them with banks and institutions we believe are highly credit-worthy and investing in highly-rated investments. As of September 30, 2024, and December 31, 2023, the contractual maturity of all investments held was less than one year.
During the three and nine months ended September 30, 2024 and 2023, we did not recognize any significant credit losses nor other-than-temporary impairment losses on our short-term investments.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Balance Sheets Details
 9 Months Ended
Sep. 30, 2024
Balance Sheets Details [Abstract]  
Balance Sheets Details Balance Sheets Details
Inventories
Inventories consisted of the following (in thousands):
September 30, 2024December 31, 2023
Raw materials$— $108 
Work-in-process36 7 
Finished goods2,067 2,570 
Total Inventories$2,103 $2,685 
Prepaid expenses and other current assets
As of September 30, 2024, prepaid expenses and other current assets consisted of prepaid expenses of $3.2 million and other current assets of $0.3 million. As of December 31, 2023, prepaid expenses and other current assets consisted of prepaid expenses of $4.6 million and other current assets of $0.6 million.
Property and Equipment, net
Property and equipment, net consisted of the following (in thousands):
September 30, 2024December 31, 2023
Laboratory equipment$36,468 $37,216 
Leasehold improvements12,086 11,912 
Computer equipment and software2,675 2,565 
Office equipment and furniture1,131 1,469 
Construction in progress1,629 1,636 
Property and equipment53,989 54,798 
Less: accumulated depreciation and amortization(40,723)(39,311)
Property and equipment, net$13,266 $15,487 
Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the unaudited condensed consolidated statements of operations was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Research and development$965 $1,121 $3,017 $3,606 
Selling, general and administrative219 236 658 696 
Total depreciation expense$1,184 $1,357 $3,675 $4,302 
Other Accrued Liabilities
Other accrued liabilities consisted of the following (in thousands):
September 30, 2024December 31, 2023
Accrued purchases $3,291 $1,402 
Accrued professional and outside service fees2,810 2,330 
Other404 1,003 
Total other accrued liabilities$6,505 $4,735 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-based Compensation
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Stock-based Compensation
Equity Incentive Plans
In August 2024, our board of directors (the “Board”) approved the 2024 Employment Inducement Award Plan (the “2024 Inducement Plan”) which provides for the grant of non-qualified stock options, RSAs, restricted stock units (“RSUs”), and performance awards to eligible employees with respect to an aggregate of up to 1,000,000 shares of our common stock.
Employee Stock Purchase Plan
In April 2023, the Board approved an employee stock purchase plan (as may be amended from time to time, the “ESPP”) which became effective upon approval at the Annual Meeting in June 2023. The ESPP allows eligible employees of the Company to purchase shares of our common stock through payroll deductions. Offering periods are generally over a 24-month period and begin in May and November of each year. The per share purchase price will be the lower of 85% of the closing trading price per share of our common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date. Participant purchases are limited to a maximum of $25,000 of fair value of our stock per calendar year. The Company is authorized to grant up to 2,000,000 shares of common stock under the ESPP. The first offering period of the ESPP commenced in December 2023.
For the three and nine months ended September 30, 2024, nil and 123,889 shares of our common stock were purchased under the ESPP, respectively. As of September 30, 2024, 1,876,111 shares of common stock were available for future issuance under the ESPP. We recognized $0.1 million and $0.2 million of stock-based compensation expenses related to the ESPP for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the total unrecognized stock-based compensation expense, net of expected forfeitures, related to the ESPP was $0.6 million and is expected to be recognized over the remaining offering period.
Stock Options
Stock options granted to employees generally have a maximum term of ten years and vest over four years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. In January 2024, the Board approved the grants of stock options with a vesting term over three years from the date of grant, of which 33% vest at the end of one year, and 67% vest monthly over the remaining two years.
Restricted Stock Units (“RSUs”)
We also grant employees RSUs, which generally vest over either a period with 33% of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. We may grant RSUs with different vesting terms from time to time.
Stock-Based Compensation Expense
Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Cost of product revenue$93 $60 $309 $272 
Research and development 690 450 2,151 1,978 
Selling, general and administrative1,925 1,773 8,101 5,558 
Total$2,708 $2,283 $10,561 $7,808 
The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Stock options$1,506 $1,017 $5,137 $3,035 
RSUs and RSAs1,109 942 3,578 3,441 
Performance-contingent restricted stock units (“PSUs”)— 292 247 1,408 
Performance based options (“PBOs”)— 32 1,357 (76)
ESPP93 — 242 — 
Total$2,708 $2,283 $10,561 $7,808 
On June 29, 2024, we entered into an Advisory Services Agreement with a former executive of the Company. Pursuant to the advisory agreement, the exercise period for the former executive’s vested stock options and performance-based options was also extended. The modification resulted in a stock-based compensation expense of $2.0 million recognized in selling, general and administrative expenses during the nine months ended September 30, 2024.
As of September 30, 2024, unrecognized stock-based compensation expense, net of expected forfeitures, was $12.0 million related to unvested stock options, and $5.0 million related to unvested RSUs and RSAs. Stock-based compensation expense for these awards will be recognized through 2028.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Capital Stock
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Capital Stock Capital Stock
Exercise of Options
For the nine months ended September 30, 2024 and September 30, 2023, we issued 72,856 and 214,284 shares, respectively, upon option exercises at a weighted-average exercise price of $1.97 per share, with net cash proceeds of $0.1 million and $0.4 million, respectively.
Sales Agreements
In May 2021, we filed a Registration Statement on Form S-3 with the SEC (the “2021 Registration Statement”), that automatically became effective upon its filing, under which we were permitted to sell common stock, preferred stock, debt securities, warrants, purchase contracts, and units from time to time in one or more offerings. On February 27, 2023, we filed a post-effective amendment to the 2021 Registration Statement. Pursuant to that post-effective amendment, we registered an aggregate $200.0 million of securities. In May 2021, we entered into an Equity Distribution Agreement (“EDA”) with Piper Sandler & Co (“PSC”), under which PSC, as our exclusive agent, at our discretion and at such times that we determined from time to time, may have sold over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock. Under the terms of the EDA, PSC was permitted to sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”).
We were not required to sell any shares at any time during the term of the EDA. On April 24, 2024, we terminated the EDA.
No shares of our common stock were issued and sold pursuant to the EDA during the three and nine months ended September 30, 2024. During the three and nine months ended September 30, 2023, nil and 3,079,421 shares of our common stock, respectively, were issued and sold pursuant to the EDA and we received gross proceeds of nil and $8.7 million, or nil and $7.9 million in net proceeds after PSC's commissions and direct offering expenses of nil and $0.7 million, respectively.
On May 2, 2024, we entered into a Controlled Equity Offering℠ Sales Agreement (the “Cantor Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), under which Cantor, at our discretion and at such times that we may determine from time to time, may sell up to a maximum of $75.0 million of shares of our common stock. Under the terms of the Cantor Sales Agreement, Cantor may sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act. On May 2, 2024, we filed a registration statement on Form S-3 registering the offer and sale of these shares under the Securities Act which became effective on May 14, 2024. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the Cantor Sales Agreement.
During the three and nine months ended September 30, 2024, 10,440,000 shares of our common stock were issued and sold pursuant to the Cantor Sales Agreement and we received gross proceeds of $31.3 million, or $29.7 million in net proceeds after Cantor’s commissions and direct offering expenses of $1.6 million. As of September 30, 2024, $43.7 million remained available for sale under the Cantor Sales Agreement.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Lease and other information
The Company has entered into operating leases primarily for office and laboratory space. Lease cost amounts included in the measurement of lease obligations and other information related to non-cancellable operating leases were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Operating lease costs(1)
$1,032 $1,618 $3,097 $5,278 
(1) The Company had no variable lease costs.
Other information:Operating Leases
Weighted-average remaining lease term (in years)3.1 years
Weighted-average discount rate6.6 %
Nine Months Ended September 30,
Cash paid (in thousands):
20242023
Operating cash flows from operating leases$3,542 $5,668 
As of September 30, 2024, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands):
Years Ending December 31,Operating Leases
2024 (remaining 3 months)$1,184 
20254,868 
20265,014 
20272,533 
2028760 
Thereafter318 
Total minimum lease payments14,677 
Less: imputed interest1,462 
Lease obligations$13,215 
Reconciliation of operating lease liabilities as shown within the unaudited condensed consolidated balance sheets (in thousands):
Current portion of lease obligations - Operating leases$4,081 
Long-term lease obligations - Operating leases9,134 
Total operating lease liabilities$13,215 
In July 2023, we announced our plan to consolidate operations from our previous San Carlos facility to our headquarters in Redwood City. On September 1, 2023, the Company entered into an Assignment and Assumption of Lease (the “Assignment Agreement”) with Vaxcyte, Inc. (“Vaxcyte”) to assign to Vaxcyte all of the Company’s right, title and interest in, under and to the San Carlos facility and the Lease Agreement, dated as of January 29, 2021. On September 6, 2023, the Company, Vaxcyte and ARE-San Francisco No. 63, LLC (“ARE”) entered into a Consent to Assignment and First Amendment pursuant to which ARE consented to the Assignment Agreement and the assignment by the Company and the assumption by Vaxcyte of the Company’s interest as tenant in the lease. The effective date of the assignment was October 1, 2023.
As a result of the Assignment Agreement, the Company remeasured the lease obligation for the San Carlos facility to its present value of $3.1 million and wrote off the remaining lease liability of $19.6 million and the corresponding right of use asset balance. Simultaneously, the Company determined that indicators of impairment existed because the lease assignment impacts the utilization of the related right of use assets and leasehold improvements in the San Carlos facility, and therefore performed a recoverability test by estimating future undiscounted net cash flows expected to be generated from the use of these assets. As there were no substantial future cash inflows associated with these assets, the carrying values of these assets were deemed unrecoverable. As a result, during the third quarter of 2023, the Company recognized a non-cash impairment charge of $7.7 million, of which $4.7 million was related to leasehold improvements and $3.0 million for the right of use assets, presented within the asset impairment and other charges line item in the condensed consolidated statements of operations, for the three and nine months ended September 30, 2023.
As part of the plan, the Company entered into agreements to sell certain laboratory equipment previously located in the San Carlos facility through an asset auction and as part of the lease assignment of the San Carlos facility to Vaxcyte. These certain items of laboratory equipment met the assets held for sale criteria and were sold during the fourth quarter of 2023. Using a fair value estimate based of Level 3 inputs in the fair value hierarchy, the Company determined that the carrying value of these assets exceeds fair value less costs to sell, which resulted in a write-down of $1.5 million, presented within the asset impairment and other charges line item in the consolidated statements of operations for the three and nine months ended September 30, 2023.
Other Commitments
We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes. Commitments under service agreements are typically subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work.
The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):
Payments Due by Period
Total2024 (Remaining 3 Months)2025 and Thereafter
Facility maintenance agreement$281 $281 $— 
Legal Proceedings
We may be involved in legal actions in the ordinary course of business, including inquiries and proceedings concerning business practices and intellectual property infringement, employee relations and other claims. We will recognize a loss contingency in the condensed consolidated financial statements when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. We will disclose any loss contingencies that do not meet both conditions if there is a reasonable possibility that a material loss may have been incurred. Gain contingencies are not recorded until they are realized. We are not currently a party to any material pending litigation or other material legal proceedings that management believes could have a material adverse effect on our financial statements.
Indemnifications
We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Debt
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Debt Debt
Innovatus Loan Agreement
On February 13, 2024 (the “Closing Date”), we entered into a five-year term loan and security agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP (“Innovatus”), an affiliate of Innovatus Capital Partners, LLC, for an aggregate principal amount of up to $40.0 million and with a maturity date of February 13, 2029 (the “Innovatus Loan”). The Innovatus Loan consists of two tranches, of which the first tranche of $30.0 million was funded on February 13, 2024. We will be eligible to draw down the second tranche of $10.0 million upon achievement of certain milestones including pre-specified revenue thresholds.
The floating per annum interest rate of the Innovatus Loan is equal to the sum of (a) the greater of (i) prime rate published in the Money Rates section of the Wall Street Journal and (ii) 7.50%, plus (b) 3.25%; provided that, at the election of the Company, up to 2.0% of such rate shall be payable in-kind until the third anniversary of the closing date. The Company is required to make monthly interest-only payments through February 1, 2027, after which the Company is required to make monthly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. 2.0% of the interest is payable in-kind for the first three years of the term by increasing the principal balance. Prepayments of the loan, in whole or in part, will be subject to an early prepayment fee which ranges between 3.0% and 1.0% and declines each year until the third anniversary date of the Closing Date, after which no prepayment fee is required. The Company is also required to pay an exit fee upon any payment or prepayment equal to 3.0% of the aggregate principal amount of the tranches funded under the Innovatus Loan.
The Innovatus Loan contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and net product revenue, with the latter beginning with the period ended September 30, 2024. The Innovatus Loan is secured by perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company's intellectual property.
In connection with the issuance of the Innovatus Loan, we recorded a debt discount of $1.3 million and capitalized debt issuance costs of $0.6 million. The discount and issuance costs will be amortized over the life of the Innovatus Loan. Interest expense for the Innovatus Loan for the three and nine months ended September 30, 2024 was $1.0 million and $2.5 million respectively, and is inclusive of non-cash amortization of the debt discount, debt issuance costs, payable in-kind interest, and accretion of final payment. The carrying amount of the Innovatus Loan approximates fair value given its recent issuance and the interest rate is based on the current prime rate. The effective interest rate for the Innovatus Loan was 13.5% as of September 30, 2024.
Additionally, in connection with entering into the Innovatus Loan, we entered into a Warrant Agreement with Innovatus on February 13, 2024 and issued to Innovatus a warrant to purchase an aggregate of 424,028 shares of the Company’s common stock at an exercise price of $2.83 per share. The warrants may be exercised on a cashless basis, and are immediately exercisable through the 10th anniversary of the issuance date. At the time of issuance, the Company determined the estimated fair value of the warrants of $0.9 million using the Black-Scholes model. As the warrants represent a freestanding equity instrument, the Company recorded the fair value of the warrants in additional paid-in capital during the first quarter of 2024.
The Company accounts for the amortization of the debt discount and issuance costs utilizing the effective interest method. Long-term debt consisted of the following at September 30, 2024 (in thousands):
September 30, 2024
Face value of debt$30,000 
Add: payment in-kind interest332 
Add: amortized exit fee87 
Less: unamortized debt discount(1,208)
Less: unamortized debt issuance costs(580)
Total long-term debt$28,631 
The future principal payments under the Innovatus Loan are as follows (in thousands):
Years Ending December 31,
2024$— 
2025— 
2026— 
202713,264 
202815,917 
20292,653 
Total principal payments31,834 
Add: amortized exit fee87 
Less: uncapitalized payment in-kind interest(1,502)
Less: unamortized debt issuance fee(1,208)
Less: unamortized debt issuance costs(580)
Total long-term debt$28,631 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Segment, Geographical and Other Revenue Information
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Segment, Geographical and Other Revenue Information Segment, Geographical and Other Revenue Information
Segment Information
We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our CEO, our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment.
Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocated resources based on the consolidated results of operations. We believe that these changes better align internal resources and external go to market activities in order to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of December 31, 2023. Comparative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.
As a result of the restructuring of our business, the Company determined that a triggering event had occurred that required an interim goodwill impairment test during the third quarter of 2023. The fair value estimate used in the interim goodwill impairment test was primarily based on Level 3 inputs in the fair value hierarchy. Based on the results of the impairment evaluation, the Company determined that the goodwill within the Novel Biotherapeutics reporting unit was impaired, which resulted in a non-cash impairment charge of $0.8 million to write off all of the associated goodwill. The impairment charge is recorded within asset impairment and other charges in the condensed consolidated statements of operation for the three and nine months ended September 30, 2023.
Significant Customers
Customers that each accounted for 10% or more of our total revenues were as follows:
Percentage of Total Revenues for the
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Customer A
18 %*17 %10 %
Customer B
17 %*10 %*
Customer C
11 %***
Customer D
11 %***
Customer E
***15 %
Customer F
*20 %**
Customer G
**16 %*
Customer H
***10 %
* Percentage was less than 10%
Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:
Percentage of Accounts Receivables as of
September 30, 2024December 31, 2023
Customer A
*12 %
Customer B
21 %12 %
Customer D
15 %13 %
Customer I
15 %*
Customer J
12 %*
Customer K
*21 %
* Percentage was less than 10%
Identifiable long-lived assets by location was as follows (in thousands):
September 30, 2024December 31, 2023
United States$24,277 $28,624 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure        
Net loss $ (20,640) $ (34,908) $ (54,900) $ (69,048)
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024 and 2023, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2023.
The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2024 and results of operations for the interim periods presented. The interim results are not necessarily indicative of the results for any future interim period or for the entire year.
The unaudited condensed consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.
Short-term Investments
Short-term Investments
We classify all marketable debt securities that have effective maturities of three months or less from the date of purchase as cash equivalents and those with effective maturities of greater than three months as short-term investment securities in the condensed consolidated balance sheets. We determine the appropriate classification of our short-term investments at the time of purchase and reevaluate such designation at each balance sheet date. We have classified and accounted for our short-term investments as available-for-sale. After consideration of our risk versus reward objectives, as well as our liquidity requirements, we may sell these debt securities prior to their effective maturities.
We carry these short-term investments at fair value, and report the unrealized gains and losses, net of taxes, as a component of stockholders’ equity, except for the changes in allowance for expected credit losses, which are included in “Interest and other expense, net” in the unaudited condensed consolidated statements of operations. We determine any realized gains or losses on the sale of short-term investments on a specific identification method, and we record such gains and losses as a component of interest income.
Short-term investments are reviewed periodically for allowances for credit losses and impairment. When evaluating the investments, the Company reviews factors such as the extent to which the fair value of the security is less than the amortized cost basis, adverse conditions specifically related to the security, the financial condition of the issuer, the Company’s intent to sell, and whether it would be more likely than not that the Company would be required to sell the investments before the recovery of the amortized cost basis.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
We evaluate the carrying values of long-lived assets, which include property and equipment and right-of-use assets, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with the future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Assets Held For Sale
Assets Held For Sale
The Company classifies assets as held for sale when the following conditions are met: (i) management has committed to a plan to sell, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to identify a buyer, (iv) it is probable that a sale will occur within one year, (v) the assets are actively marketed for sale at a reasonable price in relation to their current fair value, and (vi) there is a low likelihood of significant changes to the plan or that the plan will be withdrawn. If all of the criteria are met as of the balance sheet date, the assets are presented separately in the consolidated balance sheet as held for sale at the lower of the carrying amount or fair value less costs to sell. The assets are then no longer depreciated or amortized while classified as held for sale.
Accounting Pronouncements
Accounting Pronouncements
Recently adopted accounting pronouncements
There were no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2024, that are of significance or potential significance to us.
Recently issued accounting pronouncements not yet adopted
In March 2024, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2024-02, Codification Improvements - Amendments to Remove References to the Concepts Statements. This ASU amends the FASB Accounting Standard Codification (the “ASC”) to remove references to various concepts statements and impacts a variety of topics in the ASC. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
In December 2023, FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in the ASU require public companies, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in the ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The standard should be applied retrospectively to all prior periods presented in the financial statements. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
In October 2023, FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. The amendments in the ASU are intended to amend certain disclosure and presentation requirements for a variety of topics within the ASC. These amendments align the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, as announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.
Segment Information
Segment Information
We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our CEO, our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment.
Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocated resources based on the consolidated results of operations. We believe that these changes better align internal resources and external go to market activities in order to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of December 31, 2023. Comparative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table provides information about disaggregated revenue from contracts with customers by geographic regions. The geographic regions that are tracked are the Americas (United States, Canada, and Latin America), EMEA (Europe, Middle East, and Africa), and APAC (Australia, New Zealand, Southeast Asia, and China).
Disaggregated information is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Primary geographical markets:
Americas$1,534 $4,278 $9,823 $10,798 
EMEA2,229 3,191 6,768 14,630 
APAC9,070 1,808 21,294 18,154 
Total revenues$12,833 $9,277 $37,885 $43,582 
Contract with Customer
The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):
September 30, 2024December 31, 2023
Contract assets$3,424 $815 
Unbilled receivables$4,793 $9,904 
Contract liabilities: deferred revenue$10,621 $10,761 
We recognized the following revenues (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
Revenue recognized in the period for:2024202320242023
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied$— $1,303 $475 $9,111 
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods146 1,018 (446)4,238 
Performance obligations satisfied from new activities in the period - contract revenue12,687 6,956 37,856 30,233 
Total revenues$12,833 $9,277 $37,885 $43,582 
Performance Obligation, Expected Timing of Satisfaction
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2024.
The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2024 (in thousands):
Remainder of 2024
20252026
2027 and Thereafter
Total
Product revenue$9,981 $140 $140 $360 $10,621 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Net Loss per Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Shares Not Included in Computation of Diluted Net Loss Per Share
The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Shares issuable under the Equity Incentive Plan and ESPP12,9318,87312,9318,873
Warrants(1)
424—424—
Total potentially dilutive securities13,3558,87313,3558,873
(1) Pertains to the warrants issued in connection with the Innovatus Loan. For additional information, see Note 11, “Debt.”
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Investments in Non-Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Carrying Value of Non-marketable Equity Securities The following table presents the carrying value of our non-marketable equity securities (in thousands):
 September 30, 2024December 31, 2023
MAI
$2,783 $6,693 
seqWell2,625 2,625 
Other investments in non-marketable equity securities382 382 
Total non-marketable equity securities$5,790 $9,700 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Summary of Financial Instruments Measured at Fair Value on a Recurring Basis
The following tables show the Company’s cash, cash equivalents, and short-term investments by significant investment category as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Amortized CostUnrealized GainsUnrealized LossesFair ValueCash and Cash Equivalents
Short-term Investments
Cash$7,359 $— $— $7,359 $7,359 $— 
Level 1:
Money market funds
30,093 — — 30,093 30,093 — 
Level 2(1):
Commercial paper8,416 7 — 8,423 — 8,423 
Corporate debt8,723 14 (2)8,735 — 8,735 
U.S. agency securities1,983 9 — 1,992 — 1,992 
U.S. treasury securities33,555 98 — 33,653 — 33,653 
Subtotal52,677 128 (2)52,803 — 52,803 
Total$90,129 $128 $(2)$90,255 $37,452 $52,803 
(1) The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments uses inputs that are either directly or indirectly observable for the asset through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
December 31, 2023
Amortized CostUnrealized GainsUnrealized LossesFair ValueCash and Cash Equivalents
Short-term Investments
Cash$8,742 $— $— $8,742 $8,742 $— 
Level 1:
Money market funds
56,374 — — 56,374 56,374 — 
Total$65,116 $— $— $65,116 $65,116 $— 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Balance Sheets Details (Tables)
 9 Months Ended
Sep. 30, 2024
Balance Sheets Details [Abstract]  
Schedule of Inventory Components
Inventories consisted of the following (in thousands):
September 30, 2024December 31, 2023
Raw materials$— $108 
Work-in-process36 7 
Finished goods2,067 2,570 
Total Inventories$2,103 $2,685 
Schedule of Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
September 30, 2024December 31, 2023
Laboratory equipment$36,468 $37,216 
Leasehold improvements12,086 11,912 
Computer equipment and software2,675 2,565 
Office equipment and furniture1,131 1,469 
Construction in progress1,629 1,636 
Property and equipment53,989 54,798 
Less: accumulated depreciation and amortization(40,723)(39,311)
Property and equipment, net$13,266 $15,487 
Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the unaudited condensed consolidated statements of operations was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Research and development$965 $1,121 $3,017 $3,606 
Selling, general and administrative219 236 658 696 
Total depreciation expense$1,184 $1,357 $3,675 $4,302 
Schedule of Other Accrued Liabilities
Other accrued liabilities consisted of the following (in thousands):
September 30, 2024December 31, 2023
Accrued purchases $3,291 $1,402 
Accrued professional and outside service fees2,810 2,330 
Other404 1,003 
Total other accrued liabilities$6,505 $4,735 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense
Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Cost of product revenue$93 $60 $309 $272 
Research and development 690 450 2,151 1,978 
Selling, general and administrative1,925 1,773 8,101 5,558 
Total$2,708 $2,283 $10,561 $7,808 
Schedule of Stock-based Compensation Expense by Security Types
The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Stock options$1,506 $1,017 $5,137 $3,035 
RSUs and RSAs1,109 942 3,578 3,441 
Performance-contingent restricted stock units (“PSUs”)— 292 247 1,408 
Performance based options (“PBOs”)— 32 1,357 (76)
ESPP93 — 242 — 
Total$2,708 $2,283 $10,561 $7,808 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Lease Cost Lease cost amounts included in the measurement of lease obligations and other information related to non-cancellable operating leases were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Operating lease costs(1)
$1,032 $1,618 $3,097 $5,278 
(1) The Company had no variable lease costs.
Other information:Operating Leases
Weighted-average remaining lease term (in years)3.1 years
Weighted-average discount rate6.6 %
Nine Months Ended September 30,
Cash paid (in thousands):
20242023
Operating cash flows from operating leases$3,542 $5,668 
Operating Lease Maturity
As of September 30, 2024, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands):
Years Ending December 31,Operating Leases
2024 (remaining 3 months)$1,184 
20254,868 
20265,014 
20272,533 
2028760 
Thereafter318 
Total minimum lease payments14,677 
Less: imputed interest1,462 
Lease obligations$13,215 
Reconciliation of operating lease liabilities as shown within the unaudited condensed consolidated balance sheets (in thousands):
Current portion of lease obligations - Operating leases$4,081 
Long-term lease obligations - Operating leases9,134 
Total operating lease liabilities$13,215 
Schedule of Supply and Service Commitments
The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):
Payments Due by Period
Total2024 (Remaining 3 Months)2025 and Thereafter
Facility maintenance agreement$281 $281 $— 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Debt (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt Instruments
The Company accounts for the amortization of the debt discount and issuance costs utilizing the effective interest method. Long-term debt consisted of the following at September 30, 2024 (in thousands):
September 30, 2024
Face value of debt$30,000 
Add: payment in-kind interest332 
Add: amortized exit fee87 
Less: unamortized debt discount(1,208)
Less: unamortized debt issuance costs(580)
Total long-term debt$28,631 
Schedule of Maturities of Long-Term Debt
The future principal payments under the Innovatus Loan are as follows (in thousands):
Years Ending December 31,
2024$— 
2025— 
2026— 
202713,264 
202815,917 
20292,653 
Total principal payments31,834 
Add: amortized exit fee87 
Less: uncapitalized payment in-kind interest(1,502)
Less: unamortized debt issuance fee(1,208)
Less: unamortized debt issuance costs(580)
Total long-term debt$28,631 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Segment, Geographical and Other Revenue Information (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Customers that Contributed 10% or More of Total Accounts Receivable
Significant Customers
Customers that each accounted for 10% or more of our total revenues were as follows:
Percentage of Total Revenues for the
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Customer A
18 %*17 %10 %
Customer B
17 %*10 %*
Customer C
11 %***
Customer D
11 %***
Customer E
***15 %
Customer F
*20 %**
Customer G
**16 %*
Customer H
***10 %
* Percentage was less than 10%
Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:
Percentage of Accounts Receivables as of
September 30, 2024December 31, 2023
Customer A
*12 %
Customer B
21 %12 %
Customer D
15 %13 %
Customer I
15 %*
Customer J
12 %*
Customer K
*21 %
* Percentage was less than 10%
Schedule of Long-Lived Assets by Geographical Area
Identifiable long-lived assets by location was as follows (in thousands):
September 30, 2024December 31, 2023
United States$24,277 $28,624 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Description of Business (Details) - segment
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Number of reportable segments 1 2
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Total revenues $ 12,833 $ 9,277 $ 37,885 $ 43,582
Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 1,534 4,278 9,823 10,798
EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 2,229 3,191 6,768 14,630
APAC        
Disaggregation of Revenue [Line Items]        
Total revenues $ 9,070 $ 1,808 $ 21,294 $ 18,154
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition - Contracts with Customer (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]    
Contract assets $ 3,424 $ 815
Unbilled receivables 4,793 9,904
Contract liabilities: deferred revenue $ 10,621 $ 10,761
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]        
Impairment charges related to contract assets $ 0 $ 0    
Short-Term Unbilled Receivables        
Disaggregation of Revenue [Line Items]        
Unbilled receivables, not billable     $ 3,500,000 $ 9,100,000
Long-Term Unbilled Receivables        
Disaggregation of Revenue [Line Items]        
Unbilled receivables, not billable     $ 1,300,000 $ 800,000
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition - Revenue Recognized During Period (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Amounts included in contract liabilities at the beginning of the period:        
Performance obligations satisfied $ 0 $ 1,303 $ 475 $ 9,111
Changes in the period:        
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 146 1,018 (446) 4,238
Performance obligations satisfied from new activities in the period - contract revenue 12,687 6,956 37,856 30,233
Total revenues $ 12,833 $ 9,277 $ 37,885 $ 43,582
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition - Performance Obligation (Details) - Product revenue
$ in Thousands
Sep. 30, 2024
USD ($)
Disaggregation of Revenue [Line Items]  
Performance obligation $ 10,621
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01  
Disaggregation of Revenue [Line Items]  
Performance obligation $ 9,981
Expected timing of satisfaction, period 3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01  
Disaggregation of Revenue [Line Items]  
Performance obligation $ 140
Expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01  
Disaggregation of Revenue [Line Items]  
Performance obligation $ 140
Expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01  
Disaggregation of Revenue [Line Items]  
Performance obligation $ 360
Expected timing of satisfaction, period
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Net Loss per Share - Shares Not Included in Computation of Diluted Net Loss Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total shares excluded as anti-dilutive (shares) 13,355 8,873 13,355 8,873
Shares issuable under the Equity Incentive Plan and ESPP        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total shares excluded as anti-dilutive (shares) 12,931 8,873 12,931 8,873
Warrant        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total shares excluded as anti-dilutive (shares) 424 0 424 0
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Investments in Non-Marketable Securities - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Marketable Securities [Line Items]        
Impairment of investment in non-marketable equity securities $ 3,900,000 $ 3,900,000 $ 3,910,000 $ 3,875,000
Unrealized or realized gains or losses $ 0 0 $ 0 0
seqWell        
Marketable Securities [Line Items]        
Impairment of investment in non-marketable equity securities   3,000,000.0   3,000,000.0
Arzeda        
Marketable Securities [Line Items]        
Impairment of investment in non-marketable equity securities   $ 900,000   $ 900,000
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Marketable Securities [Line Items]    
Total non-marketable equity securities $ 5,790 $ 9,700
MAI    
Marketable Securities [Line Items]    
Total non-marketable equity securities 2,783 6,693
seqWell    
Marketable Securities [Line Items]    
Total non-marketable equity securities 2,625 2,625
Other investments in non-marketable equity securities    
Marketable Securities [Line Items]    
Total non-marketable equity securities $ 382 $ 382
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash $ 7,359 $ 8,742
Unrealized Gains 128 0
Unrealized Losses (2) 0
Total 90,129 65,116
Total 90,255 65,116
Fair Value, Inputs, Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 30,093 56,374
Unrealized Gains 0 0
Unrealized Losses 0 0
Fair Value 30,093 56,374
Fair Value, Inputs, Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 52,677  
Unrealized Gains 128  
Unrealized Losses (2)  
Fair Value 52,803  
Fair Value, Inputs, Level 2 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 8,416  
Unrealized Gains 7  
Unrealized Losses 0  
Fair Value 8,423  
Fair Value, Inputs, Level 2 | Corporate debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 8,723  
Unrealized Gains 14  
Unrealized Losses (2)  
Fair Value 8,735  
Fair Value, Inputs, Level 2 | U.S. agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 1,983  
Unrealized Gains 9  
Unrealized Losses 0  
Fair Value 1,992  
Fair Value, Inputs, Level 2 | U.S. treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 33,555  
Unrealized Gains 98  
Unrealized Losses 0  
Fair Value 33,653  
Cash and Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash 7,359 8,742
Total 37,452 65,116
Cash and Cash Equivalents | Fair Value, Inputs, Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 30,093 56,374
Cash and Cash Equivalents | Fair Value, Inputs, Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0  
Cash and Cash Equivalents | Fair Value, Inputs, Level 2 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0  
Cash and Cash Equivalents | Fair Value, Inputs, Level 2 | Corporate debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0  
Cash and Cash Equivalents | Fair Value, Inputs, Level 2 | U.S. agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0  
Cash and Cash Equivalents | Fair Value, Inputs, Level 2 | U.S. treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0  
Short-term Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash 0 0
Total 52,803 0
Short-term Investments | Fair Value, Inputs, Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 $ 0
Short-term Investments | Fair Value, Inputs, Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 52,803  
Short-term Investments | Fair Value, Inputs, Level 2 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 8,423  
Short-term Investments | Fair Value, Inputs, Level 2 | Corporate debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 8,735  
Short-term Investments | Fair Value, Inputs, Level 2 | U.S. agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 1,992  
Short-term Investments | Fair Value, Inputs, Level 2 | U.S. treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value $ 33,653  
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Narrative (Details) - Convertible Debt - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Credit losses $ 0 $ 0 $ 0 $ 0
Other-than-temporary impairment losses $ 0 $ 0 $ 0 $ 0
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Balance Sheets Details - Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Schedule of Inventory Components    
Raw materials $ 0 $ 108
Work-in-process 36 7
Finished goods 2,067 2,570
Total Inventories $ 2,103 $ 2,685
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Balance Sheets Details - Narrative (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Other Liabilities Disclosure [Abstract]    
Prepaid expense, current $ 3.2 $ 4.6
Other assets, current $ 0.3 $ 0.6
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.3
Balance Sheets Details - Property and Equipment, net (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Property, Plant and Equipment [Line Items]          
Property and equipment $ 53,989   $ 53,989   $ 54,798
Less: accumulated depreciation and amortization (40,723)   (40,723)   (39,311)
Property and equipment, net 13,266   13,266   15,487
Depreciation 1,184 $ 1,357 3,675 $ 4,302  
Research and development          
Property, Plant and Equipment [Line Items]          
Depreciation 965 1,121 3,017 3,606  
Selling, general and administrative          
Property, Plant and Equipment [Line Items]          
Depreciation 219 $ 236 658 $ 696  
Laboratory equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment 36,468   36,468   37,216
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property and equipment 12,086   12,086   11,912
Computer equipment and software          
Property, Plant and Equipment [Line Items]          
Property and equipment 2,675   2,675   2,565
Office equipment and furniture          
Property, Plant and Equipment [Line Items]          
Property and equipment 1,131   1,131   1,469
Construction in progress          
Property, Plant and Equipment [Line Items]          
Property and equipment $ 1,629   $ 1,629   $ 1,636
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.3
Balance Sheets Details - Other Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Balance Sheets Details [Abstract]    
Accrued purchases $ 3,291 $ 1,402
Accrued professional and outside service fees 2,810 2,330
Other 404 1,003
Total other accrued liabilities $ 6,505 $ 4,735
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-based Compensation - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2024
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Aug. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based payment arrangement, noncash expense     $ 2,708,000 $ 2,283,000 $ 10,561,000 $ 7,808,000  
Selling, general and administrative              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based payment arrangement, noncash expense     $ 1,925,000 1,773,000 8,101,000 5,558,000  
Stock-based compensation expense         $ 2,000,000    
2024 Inducement Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares authorized (in shares)             1,000,000
ESPP              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Consecutive offering period   24 months          
Purchase price of common stock   85.00%          
Fixed contribution rate   $ 25,000          
Number of shares authorized (in shares)   2,000,000          
Share-based compensation arrangement by share-based payment award, shares issued in period (in shares)     0   123,889    
Common stock, capital shares reserved for future issuance (in shares)     1,876,111   1,876,111    
Share-based payment arrangement, noncash expense     $ 93,000 0 $ 242,000 0  
Share-based payment arrangement, nonvested award, cost not yet recognized, amount     600,000   600,000    
Stock Options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based payment arrangement, noncash expense     1,506,000 1,017,000 $ 5,137,000 3,035,000  
Expiration period         10 years    
Award vesting period 3 years       4 years    
Compensation not yet recognized, stock options     12,000,000.0   $ 12,000,000.0    
Stock Options | Tranche One              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Award vesting period 1 year       1 year    
Award vesting rights 33.00%       25.00%    
Stock Options | Tranche Two              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Award vesting period 2 years       3 years    
Award vesting rights 67.00%       75.00%    
RSUs              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Award vesting rights         33.00%    
RSAs and RSUs              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based payment arrangement, noncash expense     1,109,000 $ 942,000 $ 3,578,000 $ 3,441,000  
Compensation not yet recognized, share-based awards other than options     $ 5,000,000.0   $ 5,000,000.0    
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation $ 2,708 $ 2,283 $ 10,561 $ 7,808
Stock options        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation 1,506 1,017 5,137 3,035
RSUs and RSAs        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation 1,109 942 3,578 3,441
Performance-contingent restricted stock units (“PSUs”)        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation 0 292 247 1,408
Performance based options (“PBOs”)        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation 0 32 1,357 (76)
ESPP        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation 93 0 242 0
Cost of product revenue        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation 93 60 309 272
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation 690 450 2,151 1,978
Selling, general and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation $ 1,925 $ 1,773 $ 8,101 $ 5,558
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.3
Capital Stock (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
May 02, 2024
USD ($)
May 31, 2021
USD ($)
Sep. 30, 2024
USD ($)
shares
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
$ / shares
shares
Feb. 27, 2023
USD ($)
Class of Stock [Line Items]              
Stock options exercised (shares) | shares         72,856 214,284  
Weighted average exercise price of stock options exercised (in dollars per share) | $ / shares         $ 1.97 $ 1.97  
Net proceeds from stock options exercised         $ 100 $ 400  
Sale of stock, securities registered aggregate amount             $ 200,000
Costs incurred in connection with offering     $ 1,584   $ 1,584 $ 721  
Cantor Sales Agreement              
Class of Stock [Line Items]              
Net proceeds received $ 75,000            
Sale of stock, commission fee, percent 0.030            
PSC              
Class of Stock [Line Items]              
Sale of stock, period   3 years          
Issuance of common stock in connection with an equity sales agreement, net of issuance costs (shares) | shares     0 0 0 3,079,421  
Sale of stock, consideration received on transaction, gross       $ 0   $ 8,700  
Net proceeds received       0   7,900  
Costs incurred in connection with offering       $ 0   $ 700  
PSC | Maximum              
Class of Stock [Line Items]              
Sale of stock, value of shares for issuance   $ 50,000          
Cantor              
Class of Stock [Line Items]              
Sale of stock, value of shares for issuance     $ 43,700   $ 43,700    
Issuance of common stock in connection with an equity sales agreement, net of issuance costs (shares) | shares     10,440,000   10,440,000    
Sale of stock, consideration received on transaction, gross     $ 31,300   $ 31,300    
Net proceeds received     29,700   29,700    
Costs incurred in connection with offering     $ 1,600   $ 1,600    
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Lease Cost (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]        
Operating lease, cost $ 1,032 $ 1,618 $ 3,097 $ 5,278
Variable lease cost $ 0 $ 0 $ 0 $ 0
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Other Lease Information (Details)
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Weighted-average remaining lease term (in years) 3 years 1 month 6 days
Weighted-average discount rate 6.60%
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Cash Paid for Lease Obligations (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]    
Operating cash flows from operating leases $ 3,542 $ 5,668
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Maturity Analysis of Operating Lease (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Operating Leases    
2024 (remaining 3 months) $ 1,184  
2025 4,868  
2026 5,014  
2027 2,533  
2028 760  
Thereafter 318  
Total minimum lease payments 14,677  
Less: imputed interest 1,462  
Lease obligations 13,215  
Current portion of lease obligations - Operating leases 4,081 $ 3,781
Long-term lease obligations - Operating leases $ 9,134 $ 12,243
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Oct. 01, 2023
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Other Commitments [Line Items]            
Lease obligations   $ 13,215,000     $ 13,215,000  
Asset impairment and other charges   0   $ 9,984,000 165,000 $ 9,984,000
Indemnification Agreement            
Other Commitments [Line Items]            
Loss contingency accrual   $ 0     $ 0  
San Carlos            
Other Commitments [Line Items]            
Lease obligations $ 3,100,000          
Operating lease, write-off due to lease modification $ 19,600,000          
Asset impairment and other charges       7,700,000    
Impairment of leasehold       4,700,000    
Operating Lease, Impairment Loss       $ 3,000,000.0    
Impairment of long-lived assets to be disposed of     $ 1,500,000      
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Other Commitments (Details) - Facility maintenance agreement
$ in Thousands
Sep. 30, 2024
USD ($)
Other Commitments [Line Items]  
Total $ 281
2024 (Remaining 3 Months) 281
2025 and Thereafter $ 0
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.3
Debt - Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Feb. 13, 2024
USD ($)
tranche
$ / shares
shares
Sep. 30, 2024
USD ($)
Sep. 30, 2024
USD ($)
Debt Instrument [Line Items]      
Face value of debt   $ 30,000 $ 30,000
Investment, Variable Interest Rate, Type [Extensible Enumeration] Prime Rate [Member]    
Debt instrument, unamortized discount   1,208 1,208
Unamortized debt issuance expense   580 580
Class of warrant or right, fair value     900
Secured Debt | Innovatus Loan Warrants      
Debt Instrument [Line Items]      
Class of warrant or right, number of securities called by warrants or rights (in shares) | shares 424,028    
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares $ 2.83    
Innovatus Loan | Secured Debt      
Debt Instrument [Line Items]      
Debt instrument, term 5 years    
Face value of debt $ 40,000    
Debt instrument, number of tranches | tranche 2    
Stated interest rate 7.50%    
Basis spread on variable rate 3.25%    
Debt instrument, interest, paid in kind 0.020    
Debt instrument, interest payable, term 3 years    
Debt instrument, exit fee, percent 0.030    
Debt instrument, unamortized discount $ 1,300    
Unamortized debt issuance expense $ 600    
Interest expense, debt   $ 1,000 $ 2,500
Debt instrument, interest rate, effective percentage   13.50% 13.50%
Innovatus Loan | Secured Debt | Maximum      
Debt Instrument [Line Items]      
Early repayment fee, percentage 0.030    
Innovatus Loan | Secured Debt | Minimum      
Debt Instrument [Line Items]      
Early repayment fee, percentage 0.010    
Innovatus Loan - First Tranche | Secured Debt      
Debt Instrument [Line Items]      
Face value of debt $ 30,000    
Innovatus Loan - Second Tranche | Secured Debt      
Debt Instrument [Line Items]      
Face value of debt $ 10,000    
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.24.3
Debt - Schedule of Long-Term Debt Instruments (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Debt Disclosure [Abstract]  
Face value of debt $ 30,000
Add: payment in-kind interest 332
Add: amortized exit fee 87
Less: unamortized debt issuance fee (1,208)
Less: unamortized debt issuance costs (580)
Total long-term debt $ 28,631
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.24.3
Debt - Schedule of Maturities of Long-Term Debt (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Debt Disclosure [Abstract]  
2024 $ 0
2025 0
2026 0
2027 13,264
2028 15,917
2029 2,653
Total principal payments 31,834
Add: amortized exit fee 87
Less: uncapitalized payment in-kind interest (1,502)
Less: unamortized debt issuance fee (1,208)
Less: unamortized debt issuance costs (580)
Total long-term debt $ 28,631
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.24.3
Segment, Geographical and Other Revenue Information - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
segment
Dec. 31, 2022
segment
Segment Reporting [Abstract]        
Number of reportable segments | segment     1 2
Goodwill impairment | $ $ 0.8 $ 0.8    
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.24.3
Segment, Geographical and Other Revenue Information - Concentration Risk (Details) - Customer Concentration Risk
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Revenue | Customer A          
Concentration Risk [Line Items]          
Concentration risk, percentage 18.00%   17.00% 10.00%  
Revenue | Customer B          
Concentration Risk [Line Items]          
Concentration risk, percentage 17.00%   10.00%    
Revenue | Customer C          
Concentration Risk [Line Items]          
Concentration risk, percentage 11.00%        
Revenue | Customer D          
Concentration Risk [Line Items]          
Concentration risk, percentage 11.00%        
Revenue | Customer E          
Concentration Risk [Line Items]          
Concentration risk, percentage       15.00%  
Revenue | Customer F          
Concentration Risk [Line Items]          
Concentration risk, percentage   20.00%      
Revenue | Customer G          
Concentration Risk [Line Items]          
Concentration risk, percentage     16.00%    
Revenue | Customer H          
Concentration Risk [Line Items]          
Concentration risk, percentage       10.00%  
Accounts Receivable | Customer A          
Concentration Risk [Line Items]          
Concentration risk, percentage         12.00%
Accounts Receivable | Customer B          
Concentration Risk [Line Items]          
Concentration risk, percentage     21.00%   12.00%
Accounts Receivable | Customer D          
Concentration Risk [Line Items]          
Concentration risk, percentage     15.00%   13.00%
Accounts Receivable | Customer I          
Concentration Risk [Line Items]          
Concentration risk, percentage     15.00%    
Accounts Receivable | Customer J          
Concentration Risk [Line Items]          
Concentration risk, percentage     12.00%    
Accounts Receivable | Customer K          
Concentration Risk [Line Items]          
Concentration risk, percentage         21.00%
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.24.3
Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
United States    
Geographic Areas, Long-Lived Assets [Abstract]    
Long-lived assets $ 24,277 $ 28,624
EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 231 294 1 false 73 0 false 6 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.codexis.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 9952157 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 9952158 - Disclosure - Description of Business Sheet http://www.codexis.com/role/DescriptionofBusiness Description of Business Notes 9 false false R10.htm 9952159 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 10 false false R11.htm 9952160 - Disclosure - Revenue Recognition Sheet http://www.codexis.com/role/RevenueRecognition Revenue Recognition Notes 11 false false R12.htm 9952161 - Disclosure - Net Loss per Share Sheet http://www.codexis.com/role/NetLossperShare Net Loss per Share Notes 12 false false R13.htm 9952162 - Disclosure - Investments in Non-Marketable Securities Sheet http://www.codexis.com/role/InvestmentsinNonMarketableSecurities Investments in Non-Marketable Securities Notes 13 false false R14.htm 9952163 - Disclosure - Fair Value Measurements Sheet http://www.codexis.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 9952164 - Disclosure - Balance Sheets Details Sheet http://www.codexis.com/role/BalanceSheetsDetails Balance Sheets Details Notes 15 false false R16.htm 9952165 - Disclosure - Stock-based Compensation Sheet http://www.codexis.com/role/StockbasedCompensation Stock-based Compensation Notes 16 false false R17.htm 9952166 - Disclosure - Capital Stock Sheet http://www.codexis.com/role/CapitalStock Capital Stock Notes 17 false false R18.htm 9952167 - Disclosure - Commitments and Contingencies Sheet http://www.codexis.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 9952168 - Disclosure - Debt Sheet http://www.codexis.com/role/Debt Debt Notes 19 false false R20.htm 9952169 - Disclosure - Segment, Geographical and Other Revenue Information Sheet http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformation Segment, Geographical and Other Revenue Information Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 23 false false R24.htm 9954472 - Disclosure - Revenue Recognition (Tables) Sheet http://www.codexis.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.codexis.com/role/RevenueRecognition 24 false false R25.htm 9954473 - Disclosure - Net Loss per Share (Tables) Sheet http://www.codexis.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://www.codexis.com/role/NetLossperShare 25 false false R26.htm 9954474 - Disclosure - Investments in Non-Marketable Securities (Tables) Sheet http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesTables Investments in Non-Marketable Securities (Tables) Tables http://www.codexis.com/role/InvestmentsinNonMarketableSecurities 26 false false R27.htm 9954475 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.codexis.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.codexis.com/role/FairValueMeasurements 27 false false R28.htm 9954476 - Disclosure - Balance Sheets Details (Tables) Sheet http://www.codexis.com/role/BalanceSheetsDetailsTables Balance Sheets Details (Tables) Tables http://www.codexis.com/role/BalanceSheetsDetails 28 false false R29.htm 9954477 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.codexis.com/role/StockbasedCompensationTables Stock-based Compensation (Tables) Tables http://www.codexis.com/role/StockbasedCompensation 29 false false R30.htm 9954478 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.codexis.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.codexis.com/role/CommitmentsandContingencies 30 false false R31.htm 9954479 - Disclosure - Debt (Tables) Sheet http://www.codexis.com/role/DebtTables Debt (Tables) Tables http://www.codexis.com/role/Debt 31 false false R32.htm 9954480 - Disclosure - Segment, Geographical and Other Revenue Information (Tables) Sheet http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationTables Segment, Geographical and Other Revenue Information (Tables) Tables http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformation 32 false false R33.htm 9954481 - Disclosure - Description of Business (Details) Sheet http://www.codexis.com/role/DescriptionofBusinessDetails Description of Business (Details) Details http://www.codexis.com/role/DescriptionofBusiness 33 false false R34.htm 9954482 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 34 false false R35.htm 9954483 - Disclosure - Revenue Recognition - Contracts with Customer (Details) Sheet http://www.codexis.com/role/RevenueRecognitionContractswithCustomerDetails Revenue Recognition - Contracts with Customer (Details) Details 35 false false R36.htm 9954484 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://www.codexis.com/role/RevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 36 false false R37.htm 9954485 - Disclosure - Revenue Recognition - Revenue Recognized During Period (Details) Sheet http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails Revenue Recognition - Revenue Recognized During Period (Details) Details 37 false false R38.htm 9954486 - Disclosure - Revenue Recognition - Performance Obligation (Details) Sheet http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails Revenue Recognition - Performance Obligation (Details) Details 38 false false R39.htm 9954487 - Disclosure - Net Loss per Share - Shares Not Included in Computation of Diluted Net Loss Per Share (Details) Sheet http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails Net Loss per Share - Shares Not Included in Computation of Diluted Net Loss Per Share (Details) Details 39 false false R40.htm 9954488 - Disclosure - Investments in Non-Marketable Securities - Narrative (Details) Sheet http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails Investments in Non-Marketable Securities - Narrative (Details) Details 40 false false R41.htm 9954489 - Disclosure - Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details) Sheet http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details) Details 41 false false R42.htm 9954490 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) Details 42 false false R43.htm 9954491 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 43 false false R44.htm 9954492 - Disclosure - Balance Sheets Details - Inventories (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails Balance Sheets Details - Inventories (Details) Details 44 false false R45.htm 9954493 - Disclosure - Balance Sheets Details - Narrative (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsNarrativeDetails Balance Sheets Details - Narrative (Details) Details 45 false false R46.htm 9954494 - Disclosure - Balance Sheets Details - Property and Equipment, net (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails Balance Sheets Details - Property and Equipment, net (Details) Details 46 false false R47.htm 9954495 - Disclosure - Balance Sheets Details - Other Accrued Liabilities (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails Balance Sheets Details - Other Accrued Liabilities (Details) Details 47 false false R48.htm 9954496 - Disclosure - Stock-based Compensation - Narrative (Details) Sheet http://www.codexis.com/role/StockbasedCompensationNarrativeDetails Stock-based Compensation - Narrative (Details) Details 48 false false R49.htm 9954497 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails Stock-based Compensation - Stock-based Compensation Expense (Details) Details 49 false false R50.htm 9954498 - Disclosure - Capital Stock (Details) Sheet http://www.codexis.com/role/CapitalStockDetails Capital Stock (Details) Details http://www.codexis.com/role/CapitalStock 50 false false R51.htm 9954499 - Disclosure - Commitments and Contingencies - Lease Cost (Details) Sheet http://www.codexis.com/role/CommitmentsandContingenciesLeaseCostDetails Commitments and Contingencies - Lease Cost (Details) Details 51 false false R52.htm 9954500 - Disclosure - Commitments and Contingencies - Other Lease Information (Details) Sheet http://www.codexis.com/role/CommitmentsandContingenciesOtherLeaseInformationDetails Commitments and Contingencies - Other Lease Information (Details) Details 52 false false R53.htm 9954501 - Disclosure - Commitments and Contingencies - Cash Paid for Lease Obligations (Details) Sheet http://www.codexis.com/role/CommitmentsandContingenciesCashPaidforLeaseObligationsDetails Commitments and Contingencies - Cash Paid for Lease Obligations (Details) Details 53 false false R54.htm 9954502 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease (Details) Sheet http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails Commitments and Contingencies - Maturity Analysis of Operating Lease (Details) Details 54 false false R55.htm 9954503 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 55 false false R56.htm 9954504 - Disclosure - Commitments and Contingencies - Other Commitments (Details) Sheet http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails Commitments and Contingencies - Other Commitments (Details) Details 56 false false R57.htm 9954505 - Disclosure - Debt - Narrative (Details) Sheet http://www.codexis.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 57 false false R58.htm 9954506 - Disclosure - Debt - Schedule of Long-Term Debt Instruments (Details) Sheet http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails Debt - Schedule of Long-Term Debt Instruments (Details) Details 58 false false R59.htm 9954507 - Disclosure - Debt - Schedule of Maturities of Long-Term Debt (Details) Sheet http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails Debt - Schedule of Maturities of Long-Term Debt (Details) Details 59 false false R60.htm 9954508 - Disclosure - Segment, Geographical and Other Revenue Information - Narrative (Details) Sheet http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationNarrativeDetails Segment, Geographical and Other Revenue Information - Narrative (Details) Details http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationTables 60 false false R61.htm 9954509 - Disclosure - Segment, Geographical and Other Revenue Information - Concentration Risk (Details) Sheet http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails Segment, Geographical and Other Revenue Information - Concentration Risk (Details) Details 61 false false R62.htm 9954510 - Disclosure - Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details) Sheet http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details) Details 62 false false All Reports Book All Reports cdxs-20240930.htm cdxs-20240930.xsd cdxs-20240930_cal.xml cdxs-20240930_def.xml cdxs-20240930_lab.xml cdxs-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cdxs-20240930.htm": { "nsprefix": "cdxs", "nsuri": "http://www.codexis.com/20240930", "dts": { "inline": { "local": [ "cdxs-20240930.htm" ] }, "schema": { "local": [ "cdxs-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "cdxs-20240930_cal.xml" ] }, "definitionLink": { "local": [ "cdxs-20240930_def.xml" ] }, "labelLink": { "local": [ "cdxs-20240930_lab.xml" ] }, "presentationLink": { "local": [ "cdxs-20240930_pre.xml" ] } }, "keyStandard": 266, "keyCustom": 28, "axisStandard": 27, "axisCustom": 0, "memberStandard": 40, "memberCustom": 33, "hidden": { "total": 11, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 6 }, "contextCount": 231, "entityCount": 1, "segmentCount": 73, "elementCount": 588, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 761, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.codexis.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R3": { "role": "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R5": { "role": "http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R6": { "role": "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-50", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "longName": "9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "9952157 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R9": { "role": "http://www.codexis.com/role/DescriptionofBusiness", "longName": "9952158 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "9952159 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.codexis.com/role/RevenueRecognition", "longName": "9952160 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.codexis.com/role/NetLossperShare", "longName": "9952161 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.codexis.com/role/InvestmentsinNonMarketableSecurities", "longName": "9952162 - Disclosure - Investments in Non-Marketable Securities", "shortName": "Investments in Non-Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.codexis.com/role/FairValueMeasurements", "longName": "9952163 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.codexis.com/role/BalanceSheetsDetails", "longName": "9952164 - Disclosure - Balance Sheets Details", "shortName": "Balance Sheets Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "cdxs:BalanceSheetsDetailsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cdxs:BalanceSheetsDetailsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.codexis.com/role/StockbasedCompensation", "longName": "9952165 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.codexis.com/role/CapitalStock", "longName": "9952166 - Disclosure - Capital Stock", "shortName": "Capital Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.codexis.com/role/CommitmentsandContingencies", "longName": "9952167 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.codexis.com/role/Debt", "longName": "9952168 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformation", "longName": "9952169 - Disclosure - Segment, Geographical and Other Revenue Information", "shortName": "Segment, Geographical and Other Revenue Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-13", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.codexis.com/role/RevenueRecognitionTables", "longName": "9954472 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.codexis.com/role/NetLossperShareTables", "longName": "9954473 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesTables", "longName": "9954474 - Disclosure - Investments in Non-Marketable Securities (Tables)", "shortName": "Investments in Non-Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.codexis.com/role/FairValueMeasurementsTables", "longName": "9954475 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.codexis.com/role/BalanceSheetsDetailsTables", "longName": "9954476 - Disclosure - Balance Sheets Details (Tables)", "shortName": "Balance Sheets Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.codexis.com/role/StockbasedCompensationTables", "longName": "9954477 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.codexis.com/role/CommitmentsandContingenciesTables", "longName": "9954478 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.codexis.com/role/DebtTables", "longName": "9954479 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationTables", "longName": "9954480 - Disclosure - Segment, Geographical and Other Revenue Information (Tables)", "shortName": "Segment, Geographical and Other Revenue Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.codexis.com/role/DescriptionofBusinessDetails", "longName": "9954481 - Disclosure - Description of Business (Details)", "shortName": "Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-59", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "longName": "9954482 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-60", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R35": { "role": "http://www.codexis.com/role/RevenueRecognitionContractswithCustomerDetails", "longName": "9954483 - Disclosure - Revenue Recognition - Contracts with Customer (Details)", "shortName": "Revenue Recognition - Contracts with Customer (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerAssetGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:UnbilledContractsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R36": { "role": "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails", "longName": "9954484 - Disclosure - Revenue Recognition - Narrative (Details)", "shortName": "Revenue Recognition - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:ContractWithCustomerAssetCreditLossExpense", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:ContractWithCustomerAssetCreditLossExpense", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails", "longName": "9954485 - Disclosure - Revenue Recognition - Revenue Recognized During Period (Details)", "shortName": "Revenue Recognition - Revenue Recognized During Period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails", "longName": "9954486 - Disclosure - Revenue Recognition - Performance Obligation (Details)", "shortName": "Revenue Recognition - Performance Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-80", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-80", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails", "longName": "9954487 - Disclosure - Net Loss per Share - Shares Not Included in Computation of Diluted Net Loss Per Share (Details)", "shortName": "Net Loss per Share - Shares Not Included in Computation of Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails", "longName": "9954488 - Disclosure - Investments in Non-Marketable Securities - Narrative (Details)", "shortName": "Investments in Non-Marketable Securities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "cdxs:NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "cdxs:NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R41": { "role": "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails", "longName": "9954489 - Disclosure - Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details)", "shortName": "Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails", "longName": "9954490 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails", "longName": "9954491 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-127", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-127", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails", "longName": "9954492 - Disclosure - Balance Sheets Details - Inventories (Details)", "shortName": "Balance Sheets Details - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.codexis.com/role/BalanceSheetsDetailsNarrativeDetails", "longName": "9954493 - Disclosure - Balance Sheets Details - Narrative (Details)", "shortName": "Balance Sheets Details - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails", "longName": "9954494 - Disclosure - Balance Sheets Details - Property and Equipment, net (Details)", "shortName": "Balance Sheets Details - Property and Equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R47": { "role": "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails", "longName": "9954495 - Disclosure - Balance Sheets Details - Other Accrued Liabilities (Details)", "shortName": "Balance Sheets Details - Other Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PurchaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PurchaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "longName": "9954496 - Disclosure - Stock-based Compensation - Narrative (Details)", "shortName": "Stock-based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-144", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R49": { "role": "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails", "longName": "9954497 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)", "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R50": { "role": "http://www.codexis.com/role/CapitalStockDetails", "longName": "9954498 - Disclosure - Capital Stock (Details)", "shortName": "Capital Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R51": { "role": "http://www.codexis.com/role/CommitmentsandContingenciesLeaseCostDetails", "longName": "9954499 - Disclosure - Commitments and Contingencies - Lease Cost (Details)", "shortName": "Commitments and Contingencies - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.codexis.com/role/CommitmentsandContingenciesOtherLeaseInformationDetails", "longName": "9954500 - Disclosure - Commitments and Contingencies - Other Lease Information (Details)", "shortName": "Commitments and Contingencies - Other Lease Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.codexis.com/role/CommitmentsandContingenciesCashPaidforLeaseObligationsDetails", "longName": "9954501 - Disclosure - Commitments and Contingencies - Cash Paid for Lease Obligations (Details)", "shortName": "Commitments and Contingencies - Cash Paid for Lease Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails", "longName": "9954502 - Disclosure - Commitments and Contingencies - Maturity Analysis of Operating Lease (Details)", "shortName": "Commitments and Contingencies - Maturity Analysis of Operating Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails", "longName": "9954503 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-194", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R56": { "role": "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails", "longName": "9954504 - Disclosure - Commitments and Contingencies - Other Commitments (Details)", "shortName": "Commitments and Contingencies - Other Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-198", "name": "us-gaap:OtherCommitment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SupplyCommitmentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-198", "name": "us-gaap:OtherCommitment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SupplyCommitmentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.codexis.com/role/DebtNarrativeDetails", "longName": "9954505 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cdxs:ClassOfWarrantOrRightFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R58": { "role": "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails", "longName": "9954506 - Disclosure - Debt - Schedule of Long-Term Debt Instruments (Details)", "shortName": "Debt - Schedule of Long-Term Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "cdxs:DebtInstrumentPaymentInKindInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R59": { "role": "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails", "longName": "9954507 - Disclosure - Debt - Schedule of Maturities of Long-Term Debt (Details)", "shortName": "Debt - Schedule of Maturities of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationNarrativeDetails", "longName": "9954508 - Disclosure - Segment, Geographical and Other Revenue Information - Narrative (Details)", "shortName": "Segment, Geographical and Other Revenue Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-59", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "unique": true } }, "R61": { "role": "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails", "longName": "9954509 - Disclosure - Segment, Geographical and Other Revenue Information - Concentration Risk (Details)", "shortName": "Segment, Geographical and Other Revenue Information - Concentration Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-211", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-211", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails", "longName": "9954510 - Disclosure - Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details)", "shortName": "Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-230", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-230", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cdxs-20240930.htm", "first": true, "unique": true } } }, "tag": { "cdxs_A2024InducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "A2024InducementPlanMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Inducement Plan", "label": "2024 Inducement Plan [Member]", "documentation": "2024 Inducement Plan" } } }, "auth_ref": [] }, "cdxs_APACMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "APACMember", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "APAC", "label": "APAC [Member]", "documentation": "Regions of Australia, New Zealand, Southeast Asia and China" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial assets, net", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": [ "r979" ] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable Type [Axis]", "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r67", "r73" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r56", "r822" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_NotesReceivableGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r176", "r273", "r760" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r740" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails", "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other accrued liabilities", "totalLabel": "Total other accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r58" ] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional and outside service fees", "label": "Accrued Professional Fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": [ "r115" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r37", "r168", "r617" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r14", "r15", "r77", "r179", "r614", "r643", "r644" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r8", "r15", "r488", "r491", "r534", "r639", "r640", "r956", "r957", "r958", "r968", "r969", "r970", "r971" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r888" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r68", "r822", "r1105" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r656", "r968", "r969", "r970", "r971", "r1040", "r1106" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r901" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r901" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r901" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r901" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r49", "r50", "r434" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock warrants in connection with debt issuance", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r9", "r39", "r109" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r934" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r860", "r870", "r880", "r912" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r863", "r873", "r883", "r915" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r935" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r901" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r908" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r864", "r874", "r884", "r908", "r916", "r920", "r928" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r926" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r463", "r468" ] }, "us-gaap_AllowanceForNotesAndLoansReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForNotesAndLoansReceivableCurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: allowances", "label": "Financing Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on financing receivable, classified as current." } } }, "auth_ref": [ "r180", "r274", "r310" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AmericasMember", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Americas", "label": "Americas [Member]" } } }, "auth_ref": [ "r1108", "r1109", "r1110", "r1111" ] }, "cdxs_AmortizationOfDiscountOnShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "AmortizationOfDiscountOnShortTermInvestments", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of discount on short-term investments", "label": "Amortization Of Discount On Short-term Investments", "documentation": "Amortization Of Discount On Short-term Investments" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r84", "r381", "r961", "r1052" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total shares excluded as anti-dilutive (shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r232" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r26" ] }, "cdxs_ArzedaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "ArzedaMember", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arzeda", "label": "Arzeda [Member]", "documentation": "Arzeda" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 }, "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairment and other charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r5", "r35" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r113", "r126", "r171", "r208", "r236", "r243", "r260", "r263", "r307", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r483", "r485", "r512", "r609", "r687", "r771", "r772", "r822", "r851", "r1002", "r1003", "r1057" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r164", "r184", "r208", "r307", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r483", "r485", "r512", "r822", "r1002", "r1003", "r1057" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "cdxs_AssetsHeldForSalePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "AssetsHeldForSalePolicyTextBlock", "presentation": [ "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Held For Sale", "label": "Assets Held For Sale [Policy Text Block]", "documentation": "Assets Held For Sale" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r279" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r280" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r276", "r318", "r608" ] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other-than-temporary impairment losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r981" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r277", "r318", "r499", "r601", "r808", "r813", "r980", "r1044", "r1045", "r1046" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r923" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r924" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r919" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r919" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r919" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r919" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r919" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r919" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r922" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r921" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r920" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r920" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r336", "r1072", "r1073" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r51", "r52", "r336", "r1072", "r1073" ] }, "cdxs_BalanceSheetsDetailsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "BalanceSheetsDetailsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheets Details [Abstract]", "label": "Balance Sheets Details [Abstract]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": [] }, "cdxs_BalanceSheetsDetailsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "BalanceSheetsDetailsTextBlock", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Balance Sheets Details", "label": "Balance Sheets Details [Text Block]", "documentation": "Balance sheets details." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "cdxs_CantorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CantorMember", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cantor", "label": "Cantor [Member]", "documentation": "Cantor" } } }, "auth_ref": [] }, "cdxs_CantorSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CantorSalesAgreementMember", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cantor Sales Agreement", "label": "Cantor Sales Agreement [Member]", "documentation": "Cantor Sales Agreement" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures incurred but not yet paid", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r130", "r611", "r657", "r682", "r822", "r851", "r950" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash reconciliation:", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r166", "r758" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash, cash equivalents, and short-term investments", "terseLabel": "Total", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r955" ] }, "cdxs_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CashCashEquivalentsAndShortTermInvestmentsAmortizedCost", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Cash, Cash Equivalents And Short Term Investments, Amortized Cost", "documentation": "Cash, Cash Equivalents And Short Term Investments, Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r90", "r204" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r90" ] }, "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts included in contract liabilities at the beginning of the period:", "label": "Change in Contract with Customer, Asset and Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInContractWithCustomerLiabilityAbstract", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in the period:", "label": "Change in Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r899" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r896" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r894" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r173", "r174", "r175", "r238", "r391", "r392", "r393", "r395", "r398", "r403", "r405", "r651", "r652", "r653", "r654", "r789", "r938", "r964" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r406" ] }, "cdxs_ClassOfWarrantOrRightFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "ClassOfWarrantOrRightFairValue", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, fair value", "label": "Class Of Warrant Or Right, Fair Value", "documentation": "Class Of Warrant Or Right, Fair Value" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r406" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r900" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r900" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r103", "r349", "r845", "r846", "r847", "r848" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies (Note 10)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r63", "r117", "r610", "r673" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r101", "r340", "r341", "r741", "r990", "r996" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r66" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r841", "r842", "r843", "r845", "r846", "r847", "r848", "r968", "r969", "r971", "r1040", "r1104", "r1106" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r66" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r66", "r674" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r66", "r674", "r693", "r1106", "r1107" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.0001 par value per share; 200,000 shares authorized; 81,376 shares and 69,905 shares issued and outstanding as of September\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r66", "r613", "r822" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r905" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r904" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r906" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r903" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r16", "r190", "r192", "r197", "r603", "r623", "r624" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and software", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r28", "r29", "r53", "r54", "r271", "r740" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r28", "r29", "r53", "r54", "r271", "r646", "r740" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r28", "r29", "r53", "r54", "r271", "r740", "r941" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r740" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r28", "r29", "r53", "r54", "r271" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r27", "r28", "r29", "r30", "r53", "r111", "r740" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r28", "r29", "r53", "r54", "r271", "r740" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1008" ] }, "us-gaap_ContractWithCustomerAssetCreditLossExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetCreditLossExpense", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charges related to contract assets", "label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r313", "r419", "r791" ] }, "us-gaap_ContractWithCustomerAssetGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetGrossCurrent", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_NotesReceivableGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.codexis.com/role/RevenueRecognitionContractswithCustomerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract assets", "label": "Contract with Customer, Asset, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r1006", "r1007" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionContractswithCustomerDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract liabilities: deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r408", "r409", "r421" ] }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "crdr": "credit", "calculation": { "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied." } } }, "auth_ref": [ "r792" ] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "calculation": { "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails": { "parentTag": "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": [ "r790" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r408", "r409", "r421" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue, net of current portion", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r408", "r409", "r421" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "calculation": { "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails": { "parentTag": "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Performance obligations satisfied", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r422" ] }, "cdxs_ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition", "crdr": "credit", "calculation": { "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails": { "parentTag": "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/RevenueRecognitionRevenueRecognizedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations satisfied from new activities in the period - contract revenue", "label": "Contract with Customer, Liability, New Activities, Performance Obligation Satisfied, Revenue Recognition", "documentation": "Contract with Customer, Liability, New Activities, Performance Obligation Satisfied, Revenue Recognition" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r104", "r360", "r361", "r371", "r372", "r373", "r377", "r378", "r379", "r380", "r381", "r784", "r785", "r786", "r787", "r788" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r800", "r802", "r808", "r823", "r839", "r1101" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product revenue", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r80", "r81", "r569" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r86" ] }, "cdxs_CostsIncurredInConnectionWithEquitySalesAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CostsIncurredInConnectionWithEquitySalesAgreements", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Costs incurred in connection with equity sales agreements", "label": "Costs Incurred In Connection With Equity Sales Agreements", "documentation": "Costs Incurred In Connection With Equity Sales Agreements" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "cdxs_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerAMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer A", "label": "Customer A [Member]", "documentation": "Customer A [Member]" } } }, "auth_ref": [] }, "cdxs_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerBMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer B", "label": "Customer B [Member]", "documentation": "Customer B [Member]" } } }, "auth_ref": [] }, "cdxs_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerCMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer C", "label": "Customer C [Member]", "documentation": "Customer C" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r95", "r271" ] }, "cdxs_CustomerDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerDMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer D", "label": "Customer D [Member]", "documentation": "Customer D" } } }, "auth_ref": [] }, "cdxs_CustomerEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerEMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer E", "label": "Customer E [Member]", "documentation": "Customer E" } } }, "auth_ref": [] }, "cdxs_CustomerFMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerFMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer F", "label": "Customer F [Member]", "documentation": "Customer F" } } }, "auth_ref": [] }, "cdxs_CustomerGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerGMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer G", "label": "Customer G [Member]", "documentation": "Customer G" } } }, "auth_ref": [] }, "cdxs_CustomerHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerHMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer H", "label": "Customer H [Member]", "documentation": "Customer H" } } }, "auth_ref": [] }, "cdxs_CustomerIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerIMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer I", "label": "Customer I [Member]", "documentation": "Customer I" } } }, "auth_ref": [] }, "cdxs_CustomerJMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerJMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer J", "label": "Customer J [Member]", "documentation": "Customer J" } } }, "auth_ref": [] }, "cdxs_CustomerKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "CustomerKMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer K", "label": "Customer K [Member]", "documentation": "Customer K" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.codexis.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r102", "r206", "r331", "r332", "r333", "r334", "r335", "r348", "r349", "r359", "r365", "r366", "r367", "r368", "r369", "r370", "r375", "r382", "r383", "r385", "r520" ] }, "cdxs_DebtInstrumentAmortizedExitFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "DebtInstrumentAmortizedExitFee", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 }, "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails", "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Add: amortized exit fee", "label": "Debt Instrument, Amortized Exit Fee", "documentation": "Debt Instrument, Amortized Exit Fee" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r12", "r57", "r58", "r114", "r116", "r209", "r360", "r361", "r362", "r363", "r364", "r366", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r784", "r785", "r786", "r787", "r788", "r820", "r965", "r991", "r992", "r993", "r1051", "r1053" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total principal payments", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r12", "r116", "r386" ] }, "cdxs_DebtInstrumentExitFeePercent": { "xbrltype": "pureItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "DebtInstrumentExitFeePercent", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, exit fee, percent", "label": "Debt Instrument, Exit Fee, Percent", "documentation": "Debt Instrument, Exit Fee, Percent" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails", "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face value of debt", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r360", "r520", "r521", "r785", "r786", "r820" ] }, "cdxs_DebtInstrumentInterestPaidInKind": { "xbrltype": "pureItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "DebtInstrumentInterestPaidInKind", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest, paid in kind", "label": "Debt Instrument, Interest, Paid In Kind", "documentation": "Debt Instrument, Interest, Paid In Kind" } } }, "auth_ref": [] }, "cdxs_DebtInstrumentInterestPayableTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "DebtInstrumentInterestPayableTerm", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest payable, term", "label": "Debt Instrument, Interest Payable, Term", "documentation": "Debt Instrument, Interest Payable, Term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, effective percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r60", "r388", "r520", "r521", "r820" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r60", "r361" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r209", "r360", "r361", "r362", "r363", "r364", "r366", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r384", "r784", "r785", "r786", "r787", "r788", "r820", "r965", "r1051", "r1053" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r12", "r209", "r360", "r361", "r362", "r363", "r364", "r366", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r784", "r785", "r786", "r787", "r788", "r820", "r965", "r991", "r992", "r993", "r1051", "r1053" ] }, "cdxs_DebtInstrumentNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "DebtInstrumentNumberOfTranches", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, number of tranches", "label": "Debt Instrument, Number Of Tranches", "documentation": "Debt Instrument, Number Of Tranches" } } }, "auth_ref": [] }, "cdxs_DebtInstrumentPaymentInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "DebtInstrumentPaymentInKindInterest", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Add: payment in-kind interest", "label": "Debt Instrument, Payment In-kind Interest", "documentation": "Debt Instrument, Payment In-kind Interest" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r12", "r42", "r45", "r55", "r107", "r108", "r209", "r360", "r361", "r362", "r363", "r364", "r366", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r384", "r784", "r785", "r786", "r787", "r788", "r820", "r965", "r1051", "r1053" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 }, "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails", "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails", "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, unamortized discount", "negatedTerseLabel": "Less: unamortized debt issuance fee", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1005", "r1050", "r1051", "r1053" ] }, "cdxs_DebtInstrumentUncapitalizedPaymentInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "DebtInstrumentUncapitalizedPaymentInKindInterest", "crdr": "debit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: uncapitalized payment in-kind interest", "label": "Debt Instrument, Uncapitalized Payment In-kind Interest", "documentation": "Debt Instrument, Uncapitalized Payment In-kind Interest" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit losses", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff", "documentation": "Amount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r322" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r36" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r236", "r247", "r263", "r771", "r772" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails", "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r420", "r793", "r794", "r795", "r796", "r797", "r798", "r799" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails", "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r420", "r793", "r794", "r795", "r796", "r797", "r798", "r799" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1009" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.codexis.com/role/StockbasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r432", "r436", "r464", "r465", "r467", "r804" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r855" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r887" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r898" ] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEAMember", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EMEA", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1108", "r1109", "r1110", "r1111" ] }, "cdxs_EarlyRepaymentFeePercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "EarlyRepaymentFeePercentage", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Early repayment fee, percentage", "label": "Early Repayment Fee, Percentage", "documentation": "Early Repayment Fee, Percentage" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r198", "r215", "r216", "r217", "r218", "r219", "r220", "r225", "r227", "r229", "r230", "r231", "r235", "r479", "r482", "r496", "r497", "r604", "r625", "r763" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r198", "r215", "r216", "r217", "r218", "r219", "r220", "r227", "r229", "r230", "r231", "r235", "r479", "r482", "r496", "r497", "r604", "r625", "r763" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.codexis.com/role/NetLossperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r224", "r232", "r233", "r234" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r58" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r466" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation not yet recognized, share-based awards other than options", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1037" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation not yet recognized, stock options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1037" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "verboseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r853" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r853" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r853" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r937" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r853" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r853" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r853" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r853" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r892" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r933" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r933" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r933" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r162", "r193", "r194", "r195", "r210", "r211", "r212", "r214", "r219", "r221", "r223", "r237", "r308", "r309", "r329", "r407", "r473", "r474", "r476", "r477", "r478", "r480", "r481", "r482", "r487", "r488", "r489", "r490", "r491", "r492", "r495", "r513", "r515", "r516", "r517", "r518", "r519", "r522", "r523", "r534", "r621", "r639", "r640", "r641", "r656", "r713" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-marketable equity securities", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r305" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of investment in non-marketable equity securities", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r306" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value of Non-marketable Equity Securities", "label": "Equity Securities without Readily Determinable Fair Value [Table Text Block]", "documentation": "Tabular disclosure of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r983", "r984", "r985" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r902" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r860", "r870", "r880", "r912" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r857", "r867", "r877", "r909" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r908" ] }, "cdxs_FacilityMaintenanceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "FacilityMaintenanceAgreementMember", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility maintenance agreement", "label": "Facility Maintenance Agreement [Member]", "documentation": "Facility Maintenance Agreement" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails", "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r499", "r500", "r507", "r808" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails", "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r499", "r500", "r507", "r808" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Financial Instruments Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1042", "r1043" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r373", "r425", "r426", "r427", "r428", "r429", "r430", "r498", "r500", "r501", "r502", "r503", "r506", "r507", "r509", "r538", "r539", "r540", "r785", "r786", "r800", "r801", "r802", "r808", "r813" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r373", "r425", "r430", "r500", "r507", "r538", "r800", "r801", "r802", "r808" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r373", "r425", "r430", "r500", "r501", "r507", "r539", "r785", "r786", "r800", "r801", "r802", "r808" ] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://www.codexis.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Measurements", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r373", "r425", "r426", "r427", "r428", "r429", "r430", "r498", "r500", "r501", "r502", "r503", "r506", "r507", "r509", "r538", "r539", "r540", "r785", "r786", "r800", "r801", "r802", "r808", "r813" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r311", "r312", "r314", "r315", "r316", "r319", "r320", "r321", "r384", "r403", "r493", "r510", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r622", "r781", "r808", "r811", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r823", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r982", "r983", "r984", "r985", "r1041", "r1044", "r1045", "r1046", "r1047", "r1048" ] }, "us-gaap_FinancingReceivableBeforeAllowanceForCreditLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableBeforeAllowanceForCreditLossAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets:", "label": "Financing Receivable, before Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r864", "r874", "r884", "r916" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r864", "r874", "r884", "r916" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r864", "r874", "r884", "r916" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r864", "r874", "r884", "r916" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r864", "r874", "r884", "r916" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r897" ] }, "us-gaap_GeographicAreasLongLivedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicAreasLongLivedAssetsAbstract", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Areas, Long-Lived Assets [Abstract]", "label": "Geographic Areas, Long-Lived Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GeographicDistributionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicDistributionAxis", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Distribution [Axis]", "label": "Geographic Distribution [Axis]", "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r156", "r157", "r158", "r159", "r160", "r161", "r605", "r606", "r778" ] }, "us-gaap_GeographicDistributionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicDistributionDomain", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Distribution [Domain]", "label": "Geographic Distribution [Domain]", "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r156", "r157", "r158", "r159", "r160", "r161", "r605", "r606" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r169", "r325", "r600", "r772", "r782", "r809", "r822", "r988", "r989" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r5", "r326", "r327", "r328", "r782", "r809" ] }, "us-gaap_ImpairmentOfLeasehold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLeasehold", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of leasehold", "label": "Impairment of Leasehold", "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced." } } }, "auth_ref": [ "r5", "r35" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets to be disposed of", "label": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r5", "r98", "r810" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r100" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r79", "r121", "r125", "r606", "r619", "r765", "r771", "r973", "r975", "r976", "r977", "r978" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails", "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r330", "r336", "r337", "r504", "r505", "r508", "r636", "r638", "r698", "r754", "r812", "r1074" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails", "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r336", "r337", "r504", "r505", "r508", "r636", "r638", "r698", "r754", "r812", "r1074" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r129", "r139", "r222", "r223", "r236", "r248", "r263", "r471", "r472", "r475", "r627", "r807" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r22", "r92", "r962", "r1038", "r1039" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r567", "r960" ] }, "cdxs_IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued compensation and other accrued liabilities", "label": "Increase (Decrease) in Employee Related Liabilities and Other Accrued Liabilities", "documentation": "Increase (Decrease) in Employee Related Liabilities and Other Accrued Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInFinanceReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInFinanceReceivables", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Financial assets", "label": "Increase (Decrease) in Finance Receivables", "documentation": "The increase (decrease) during the reporting period in outstanding loans including accrued interest." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndemnificationGuaranteeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndemnificationGuaranteeMember", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification Agreement", "label": "Indemnification Agreement [Member]", "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor." } } }, "auth_ref": [ "r1001" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r864", "r874", "r884", "r908", "r916", "r920", "r928" ] }, "cdxs_InnovatusLoanFirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "InnovatusLoanFirstTrancheMember", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Innovatus Loan - First Tranche", "label": "Innovatus Loan - First Tranche [Member]", "documentation": "Innovatus Loan - First Tranche" } } }, "auth_ref": [] }, "cdxs_InnovatusLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "InnovatusLoanMember", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Innovatus Loan", "label": "Innovatus Loan [Member]", "documentation": "Innovatus Loan" } } }, "auth_ref": [] }, "cdxs_InnovatusLoanSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "InnovatusLoanSecondTrancheMember", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Innovatus Loan - Second Tranche", "label": "Innovatus Loan - Second Tranche [Member]", "documentation": "Innovatus Loan - Second Tranche" } } }, "auth_ref": [] }, "cdxs_InnovatusLoanWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "InnovatusLoanWarrantsMember", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Innovatus Loan Warrants", "label": "Innovatus Loan Warrants [Member]", "documentation": "Innovatus Loan Warrants" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r926" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r856", "r932" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r856", "r932" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r856", "r932" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, debt", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r84", "r379", "r389", "r787", "r788" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r200", "r202", "r203" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r951" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails", "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Total Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r181", "r759", "r822" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNetAbstract", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Inventory Components", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r953" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r952" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r236", "r246", "r263", "r771", "r959" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r626", "r647", "r648", "r649", "r650", "r721", "r722" ] }, "us-gaap_InvestmentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentVariableInterestRateTypeExtensibleEnumeration", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Variable Interest Rate, Type [Extensible Enumeration]", "label": "Investment, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate of investment." } } }, "auth_ref": [ "r719", "r724", "r726", "r732" ] }, "us-gaap_InvestmentsAndOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAndOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Investment in non-marketable equity securities", "label": "Investments and Other Noncurrent Assets", "documentation": "Amount of investments, and noncurrent assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Non-Marketable Securities", "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]", "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment." } } }, "auth_ref": [ "r511" ] }, "cdxs_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory Equipment [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1055" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r99", "r533" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating Lease Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1056" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r532" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r532" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r532" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r532" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r532" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining 3 months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1056" ] }, "cdxs_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r532" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r57", "r58", "r59", "r61", "r62", "r63", "r64", "r208", "r307", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r484", "r485", "r486", "r512", "r672", "r764", "r851", "r1002", "r1057", "r1058" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r72", "r118", "r616", "r822", "r966", "r986", "r1049" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r59", "r165", "r208", "r307", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r484", "r485", "r486", "r512", "r822", "r1002", "r1057", "r1058" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails", "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r12", "r116", "r372", "r387", "r785", "r786", "r820", "r1069" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r209", "r377" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r209", "r377" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r209", "r377" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r209", "r377" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r209", "r377" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r967" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r172" ] }, "cdxs_LongTermUnbilledReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "LongTermUnbilledReceivablesMember", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Unbilled Receivables", "label": "Long-Term Unbilled Receivables [Member]", "documentation": "Long-Term Unbilled Receivables" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r12", "r991", "r992", "r993" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r12", "r38", "r991", "r992", "r993" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r342", "r343", "r344", "r347", "r469", "r645", "r783", "r997", "r998" ] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual", "label": "Loss Contingency, Accrual, Current", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r342" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r342", "r343", "r344", "r347", "r469", "r645", "r783", "r997", "r998" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r271", "r795", "r833", "r837", "r1009", "r1071", "r1075", "r1076", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1103" ] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails", "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Line Items]", "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails", "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Table]", "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails", "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r343", "r344", "r345", "r346", "r431", "r469", "r503", "r566", "r635", "r637", "r645", "r664", "r665", "r718", "r723", "r727", "r728", "r731", "r752", "r753", "r777", "r789", "r803", "r813", "r814", "r818", "r819", "r834", "r1004", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r900" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r900" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r343", "r344", "r345", "r346", "r431", "r469", "r503", "r566", "r635", "r637", "r645", "r664", "r665", "r718", "r723", "r727", "r728", "r731", "r752", "r753", "r777", "r789", "r803", "r813", "r814", "r818", "r834", "r1004", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r919" ] }, "cdxs_MolecularAssembliesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "MolecularAssembliesIncMember", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MAI", "label": "Molecular Assemblies, Inc. [Member]", "documentation": "Molecular Assemblies, Inc." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1010" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r927" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r271", "r795", "r833", "r837", "r1009", "r1071", "r1075", "r1076", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1103" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r901" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://www.codexis.com/role/DescriptionofBusiness" ], "lang": { "en-us": { "role": { "verboseLabel": "Description of Business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r132", "r140" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r201" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r201" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r90", "r91", "r93" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 }, "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r82", "r93", "r122", "r163", "r188", "r191", "r195", "r208", "r213", "r215", "r216", "r217", "r218", "r219", "r222", "r223", "r228", "r307", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r479", "r482", "r497", "r512", "r620", "r695", "r711", "r712", "r849", "r1002" ] }, "cdxs_NetProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "NetProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from stock options exercised", "label": "Net Proceeds From Stock Options Exercised", "documentation": "Net Proceeds From Stock Options Exercised" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r900" ] }, "cdxs_NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized or realized gains or losses", "label": "Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount", "documentation": "Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount" } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r864", "r874", "r884", "r908", "r916" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r891" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r890" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r908" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r927" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r927" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental non-cash investing and financing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r270" ] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableGross", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "label": "Financing Receivable, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r127", "r128", "r154", "r155", "r177", "r272", "r314", "r317", "r779", "r780", "r949", "r987" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.codexis.com/role/DescriptionofBusinessDetails", "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r766", "r776", "r974" ] }, "cdxs_OfficeEquipmentAndFurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "OfficeEquipmentAndFurnitureMember", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment and furniture", "label": "Office Equipment and Furniture [Member]", "documentation": "Office Equipment and Furniture [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpensesAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Costs and operating expenses:", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r125", "r765", "r973", "r975", "r976", "r977", "r978" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r527", "r821" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Impairment Loss", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1054" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails", "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lease obligations", "terseLabel": "Lease obligations", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r525" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails", "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of lease obligations - Operating leases", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r525" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesMaturityAnalysisofOperatingLeaseDetails", "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term lease obligations - Operating leases", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r525" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesCashPaidforLeaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r526", "r529" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets - Operating leases, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r524" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in the carrying amount of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r961" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesOtherLeaseInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r531", "r821" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesOtherLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r530", "r821" ] }, "cdxs_OperatingLeaseWriteOffDueToLeaseModification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "OperatingLeaseWriteOffDueToLeaseModification", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, write-off due to lease modification", "label": "Operating Lease, Write-off Due To Lease Modification", "documentation": "Operating Lease, Write-off Due To Lease Modification" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": [ "r115" ] }, "us-gaap_OtherAggregatedInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAggregatedInvestmentsMember", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments in non-marketable equity securities", "label": "Other Security Investments [Member]", "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests." } } }, "auth_ref": [ "r660", "r661", "r729" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets, current", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r183", "r822" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r170" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitment", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "cdxs_OtherCommitmentToBePaidYearOneAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "OtherCommitmentToBePaidYearOneAndThereafter", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails": { "parentTag": "us-gaap_OtherCommitment", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 and Thereafter", "label": "Other Commitment, To Be Paid, Year One And Thereafter", "documentation": "Other Commitment, To Be Paid, Year One And Thereafter" } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Axis]", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Domain]", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails": { "parentTag": "us-gaap_OtherCommitment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (Remaining 3 Months)", "label": "Other Commitment, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Line Items]", "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.codexis.com/role/CommitmentsandContingenciesOtherCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on available-for-sale short-term investments, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r185", "r186", "r187", "r621" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive gain", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r9", "r11", "r189", "r192", "r196", "r219", "r513", "r514", "r519", "r602", "r621", "r956", "r957" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive gain:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r62" ] }, "us-gaap_OtherNoncashIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncome", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Equity securities earned from research and development activities", "label": "Other Noncash Income", "documentation": "Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r93" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r85" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-cash items", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r900" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r862", "r872", "r882", "r914" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r865", "r875", "r885", "r917" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r865", "r875", "r885", "r917" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r889" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r20" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails", "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Costs incurred in connection with offering", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r199" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment in non-marketable securities", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r88" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r89" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r88" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r899" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r899" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r891" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r908" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r901" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r890" ] }, "cdxs_PerformanceBasedOptionsPBOsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "PerformanceBasedOptionsPBOsMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Performance based options (\u201cPBOs\u201d)", "label": "Performance Based Options (PBOs) [Member]", "documentation": "Performance Based Options (PBOs) [Member]" } } }, "auth_ref": [] }, "cdxs_PerformanceContingentRestrictedStockUnitsPSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "PerformanceContingentRestrictedStockUnitsPSUMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Performance-contingent restricted stock units (\u201cPSUs\u201d)", "label": "Performance-contingent Restricted Stock Units (PSU) [Member]", "documentation": "Performance-contingent Restricted Stock Units (PSU)" } } }, "auth_ref": [] }, "cdxs_PiperSandlerCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "PiperSandlerCoMember", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PSC", "label": "Piper Sandler & Co [Member]", "documentation": "Piper Sandler & Co" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r892" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r936" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r891" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r65", "r391" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r65", "r674" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r65", "r391" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r65", "r674", "r693", "r1106", "r1107" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r65", "r612", "r822" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r955" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expense, current", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r182", "r323", "r324", "r761" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock in connection with equity sales agreements", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r18", "r651" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturity of short-term investments", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r17", "r88" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r87" ] }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfShortTermInvestments", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of short-term investments", "label": "Proceeds from Sale of Short-Term Investments", "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from exercises of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r10" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of stock under employee stock purchase plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r793" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r267", "r569", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r755", "r793", "r832", "r834", "r835", "r838", "r840", "r999", "r1000", "r1009", "r1071", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1103" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r267", "r569", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r755", "r793", "r832", "r834", "r835", "r838", "r840", "r999", "r1000", "r1009", "r1071", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1103" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r533" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r99", "r167", "r618" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r533" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails", "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r533", "r607", "r618", "r822" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r99", "r533" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "calculation": { "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued purchases", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r889" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r889" ] }, "cdxs_RSAsandRSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "RSAsandRSUsMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSAs and RSUs", "verboseLabel": "RSUs and RSAs", "label": "RSAs and RSUs [Member]", "documentation": "RSAs and RSUs [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails", "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r343", "r344", "r345", "r346", "r424", "r431", "r459", "r460", "r461", "r469", "r503", "r541", "r550", "r566", "r635", "r637", "r645", "r664", "r665", "r718", "r723", "r727", "r728", "r731", "r752", "r753", "r777", "r789", "r803", "r813", "r814", "r818", "r819", "r834", "r843", "r994", "r1004", "r1045", "r1060", "r1061", "r1062", "r1063", "r1064" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails", "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r343", "r344", "r345", "r346", "r424", "r431", "r459", "r460", "r461", "r469", "r503", "r541", "r550", "r566", "r635", "r637", "r645", "r664", "r665", "r718", "r723", "r727", "r728", "r731", "r752", "r753", "r777", "r789", "r803", "r813", "r814", "r818", "r819", "r834", "r843", "r994", "r1004", "r1045", "r1060", "r1061", "r1062", "r1063", "r1064" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r742", "r746", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r742", "r746", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable [Domain]", "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r67", "r73" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r857", "r867", "r877", "r909" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r470", "r754", "r771", "r1065" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "verboseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "cdxs_ResearchandDevelopmentRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "ResearchandDevelopmentRevenueMember", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development revenue", "label": "Research and Development Revenue [Member]", "documentation": "Research and Development Revenue [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r858", "r868", "r878", "r910" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r859", "r869", "r879", "r911" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r866", "r876", "r886", "r918" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash, current", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r950", "r963", "r1067", "r1070" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash, current and non-current", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r112", "r166", "r204", "r611" ] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r131", "r204" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r5", "r338", "r339", "r995" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r69", "r109", "r615", "r642", "r644", "r655", "r675", "r822" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r162", "r210", "r211", "r212", "r214", "r219", "r221", "r223", "r308", "r309", "r329", "r473", "r474", "r476", "r477", "r478", "r480", "r481", "r482", "r487", "r489", "r490", "r492", "r495", "r522", "r523", "r639", "r641", "r656", "r1106" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r123", "r124", "r236", "r244", "r245", "r259", "r263", "r267", "r269", "r271", "r418", "r420", "r569" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.codexis.com/role/RevenueRecognition" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r141", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r423" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligation", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r137" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected timing of satisfaction, period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r138" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r138" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Obligation, Expected Timing of Satisfaction", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]", "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [ "r939" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r927" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r927" ] }, "cdxs_SaleOfStockCommissionFeePercent": { "xbrltype": "pureItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "SaleOfStockCommissionFeePercent", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, commission fee, percent", "label": "Sale Of Stock, Commission Fee, Percent", "documentation": "Sale Of Stock, Commission Fee, Percent" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds received", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "cdxs_SaleOfStockConsiderationReceivedOnTransactionGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "SaleOfStockConsiderationReceivedOnTransactionGross", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, consideration received on transaction, gross", "label": "Sale of Stock, Consideration Received On Transaction, Gross", "documentation": "Sale of Stock, Consideration Received On Transaction, Gross" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "cdxs_SaleOfStockPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "SaleOfStockPeriod", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, period", "label": "Sale Of Stock, Period", "documentation": "Sale Of Stock, Period" } } }, "auth_ref": [] }, "cdxs_SaleOfStockSecuritiesRegisteredAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "SaleOfStockSecuritiesRegisteredAggregateAmount", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, securities registered aggregate amount", "label": "Sale Of Stock, Securities Registered Aggregate Amount", "documentation": "Sale Of Stock, Securities Registered Aggregate Amount" } } }, "auth_ref": [] }, "cdxs_SaleOfStockValueOfSharesForIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "SaleOfStockValueOfSharesForIssuance", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, value of shares for issuance", "label": "Sale Of Stock, Value Of Shares For Issuance", "documentation": "Sale Of Stock, Value Of Shares For Issuance" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueProductLineMember", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue, Product and Service Benchmark [Member]", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r940" ] }, "cdxs_SanCarlosMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "SanCarlosMember", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "San Carlos", "label": "San Carlos [Member]", "documentation": "San Carlos" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.codexis.com/role/NetLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Not Included in Computation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.codexis.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r12", "r42", "r45", "r55", "r107", "r108", "r785", "r787", "r967", "r1051" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Stock-based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Long-Lived Assets by Geographical Area", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area." } } }, "auth_ref": [ "r96" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Inventory Components", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r13", "r74", "r75", "r76" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.codexis.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-Term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r533" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r34", "r78" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r433", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-based Compensation Expense by Security Types", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r40", "r41", "r42", "r43", "r44", "r45", "r105", "r107", "r108", "r109", "r173", "r174", "r175", "r238", "r391", "r392", "r393", "r395", "r398", "r403", "r405", "r651", "r652", "r653", "r654", "r789", "r938", "r964" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Customers that Contributed 10% or More of Total Accounts Receivable", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r27", "r28", "r29", "r30", "r53", "r111" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r852" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r854" ] }, "us-gaap_SecurityOwnedNotReadilyMarketableAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityOwnedNotReadilyMarketableAxis", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails", "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails", "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security Owned Not Readily Marketable [Axis]", "label": "Security Owned Not Readily Marketable [Axis]", "documentation": "Information by name of not readily marketable security." } } }, "auth_ref": [ "r1066" ] }, "us-gaap_SecurityOwnedNotReadilyMarketableNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityOwnedNotReadilyMarketableNameDomain", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails", "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails", "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security Owned Not Readily Marketable, Name [Domain]", "label": "Security Owned Not Readily Marketable, Name [Domain]", "documentation": "Name of the security category or actual security title." } } }, "auth_ref": [ "r1066" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r269", "r270", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r659", "r662", "r663", "r720", "r725", "r730", "r733", "r739", "r742", "r743", "r744", "r745", "r747", "r748", "r749", "r750", "r751", "r756", "r794", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r836", "r843", "r1009", "r1071", "r1075", "r1076", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1103" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Segment, Geographical and Other Revenue Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r126", "r236", "r239", "r240", "r241", "r242", "r243", "r249", "r250", "r251", "r261", "r262", "r263", "r264", "r265", "r267", "r268", "r271", "r766", "r769", "r770", "r771", "r773", "r775", "r776" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r266", "r269", "r767", "r768", "r774" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r83" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.codexis.com/role/BalanceSheetsDetailsPropertyandEquipmentnetDetails", "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "cdxs_SeqWellMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "SeqWellMember", "presentation": [ "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesCarryingValueandFairValueofSecuritiesDetails", "http://www.codexis.com/role/InvestmentsinNonMarketableSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "seqWell", "label": "seqWell [Member]", "documentation": "seqWell" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "terseLabel": "Share-based payment arrangement, noncash expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r804" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r433", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r806" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement by share-based payment award, shares issued in period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r47" ] }, "cdxs_ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardConsecutiveOfferingPeriod", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consecutive offering period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period", "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails", "http://www.codexis.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of stock options exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r445" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche Two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting rights", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1011" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r805" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "cdxs_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumEmployeeSubscriptionAmount", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed contribution rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r119", "r120", "r954" ] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r734", "r735", "r736", "r757" ] }, "cdxs_ShortTermUnbilledReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.codexis.com/20240930", "localname": "ShortTermUnbilledReceivablesMember", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Unbilled Receivables", "label": "Short-Term Unbilled Receivables [Member]", "documentation": "Short-Term Unbilled Receivables" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r94", "r205" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r66", "r70", "r71", "r162", "r193", "r194", "r195", "r210", "r211", "r212", "r214", "r219", "r221", "r223", "r237", "r308", "r309", "r329", "r407", "r473", "r474", "r476", "r477", "r478", "r480", "r481", "r482", "r487", "r488", "r489", "r490", "r491", "r492", "r495", "r513", "r515", "r516", "r517", "r518", "r519", "r522", "r523", "r534", "r621", "r639", "r640", "r641", "r656", "r713" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r269", "r270", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r659", "r662", "r663", "r720", "r725", "r730", "r733", "r739", "r742", "r743", "r744", "r745", "r747", "r748", "r749", "r750", "r751", "r756", "r794", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r836", "r843", "r1009", "r1071", "r1075", "r1076", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1103" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r210", "r211", "r212", "r237", "r523", "r569", "r647", "r658", "r666", "r667", "r668", "r669", "r670", "r671", "r674", "r677", "r678", "r679", "r680", "r681", "r683", "r684", "r685", "r686", "r688", "r689", "r690", "r691", "r692", "r694", "r696", "r697", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r713", "r844" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r210", "r211", "r212", "r237", "r272", "r523", "r569", "r647", "r658", "r666", "r667", "r668", "r669", "r670", "r671", "r674", "r677", "r678", "r679", "r680", "r681", "r683", "r684", "r685", "r686", "r688", "r689", "r690", "r691", "r692", "r694", "r696", "r697", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r713", "r844" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r861", "r871", "r881", "r913" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": [ "http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issuable under the Equity Incentive Plan and ESPP", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r972" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r9", "r65", "r66", "r109" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails", "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with an equity sales agreement, net of issuance costs (shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r65", "r66", "r109", "r651", "r713", "r737" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon release of stock awards (in shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails", "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)", "terseLabel": "Stock options exercised (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r65", "r66", "r109", "r445" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r9", "r65", "r66", "r109" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with an equity sales agreement, net of issuance costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r65", "r66", "r109", "r656", "r713", "r737", "r850" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock upon exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r66", "r70", "r71", "r109" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.codexis.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r66", "r70", "r71", "r97", "r676", "r693", "r714", "r715", "r822", "r851", "r966", "r986", "r1049", "r1106" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.codexis.com/role/CapitalStock" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r106", "r207", "r390", "r392", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r404", "r407", "r494", "r716", "r717", "r738" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.codexis.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentTableTextBlock", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supply and Service Commitments", "label": "Supply Commitment [Table Text Block]", "documentation": "Tabular disclosure of arrangements in which the entity has committed resources to supply goods or services to a customer. May include identification of the goods or services to be furnished, identity of the purchasing party, pricing, effects on pricing for failing to deliver the [minimum] quantities required to be furnished, cancellation rights, and termination provisions." } } }, "auth_ref": [ "r63" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r907" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r899" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r906" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r926" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r928" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.codexis.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r384", "r403", "r493", "r510", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r622", "r808", "r811", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r823", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r982", "r983", "r984", "r985", "r1041", "r1044", "r1045", "r1046", "r1047", "r1048" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r929" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r930" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r930" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r928" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r928" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r931" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r929" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.codexis.com/role/SegmentGeographicalandOtherRevenueInformationLongLivedAssetsbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. agency securities", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r1068" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.codexis.com/role/FairValueMeasurementsSummaryofFinancialInstrumentsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r762", "r800", "r802", "r808", "r1068" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 }, "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.codexis.com/role/DebtNarrativeDetails", "http://www.codexis.com/role/DebtScheduleofLongTermDebtInstrumentsDetails", "http://www.codexis.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized debt issuance expense", "negatedTerseLabel": "Less: unamortized debt issuance costs", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "us-gaap_UnbilledContractsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledContractsReceivable", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionContractswithCustomerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled receivables", "label": "Unbilled Contracts Receivable", "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet." } } }, "auth_ref": [ "r568" ] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "calculation": { "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_NotesReceivableGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled receivables", "label": "Unbilled Receivables, Current", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_UnbilledReceivablesNotBillableAtBalanceSheetDate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledReceivablesNotBillableAtBalanceSheetDate", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/RevenueRecognitionNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled receivables, not billable", "label": "Unbilled Receivables, Not Billable", "documentation": "Amount of unbilled receivables under long-term contracts that have not been billed and were not billable." } } }, "auth_ref": [ "r178" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r925" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.codexis.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r31", "r32", "r33", "r133", "r134", "r135", "r136" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.codexis.com/role/CommitmentsandContingenciesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r528", "r821" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.codexis.com/role/StockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r895" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.codexis.com/role/NetLossperShareSharesNotIncludedinComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r841", "r842", "r845", "r846", "r847", "r848" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common stock shares used in computing net loss per share, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r226", "r231" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.codexis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common stock shares used in computing net loss per share, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r225", "r231" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r893" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Subparagraph": "(Instruction 5)", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)(Instruction 5)", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)(Instruction 5)", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)(Instruction 5)", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(4)(Instruction 5)", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(5)(Instruction 5)", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(1)(i)(Instruction 5)", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(1)(ii)(Instruction 5)", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)(Instruction 5)", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)(Instruction 5)", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)(Instruction 5)", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Subparagraph": "(Instruction 5)", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(3)", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(4)", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(5)", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "c", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r938": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "a", "Publisher": "SEC" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 86 0001200375-24-000027-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001200375-24-000027-xbrl.zip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

'0/ MW,6@/GNV1 ]>">.&JUU&:Q/JQ+RB#JO5Y&![;KZB[3F/>9*)D)>52P)3S5K9 M_ $6&B>HA0B-^_XH[@R AR-O9Z[5J;AVI+CV]%1&2J M9(4SFO,UVX%QL=KU(U#[24J\L&EG.UVU6@6A]%26QV4.$_&"""%@+;--35^+I(@(+YI?Q?1)]1I=]M0C MRA4R%="Y[%LK0F$<$\Q.KN>HB+R25*9U49Z1EHN?B _)2!',,'0 M4VX2;2;1H8FQ;!\\TI1"!0),T'.?G>_/ ,\]+SD=WDWQT_Q"/HE)OT42 X2M MS/MV[!%_NJP4T-<+-,]-4^:B:)I4QM:NZ [K;^*.NM0THJ(R\>FI;S1"?\XC M/^')E=M@;!_&RXK?1K-00TWP)ACH[.J8K;04;L&+<U(PX(K M&IDC\0WL).17J [YMKS8+)62 _"GH/"T2AB?RW&*OH9.D&J$$^6=8G?C-A+? MV%)2?&^T)6I<(FR7T^-K$J6S',('F!7M]J-V@&U &2UW?>)H?#V6/RF)K,?,M$[S[[X"Z>#];$V[YMGP^O M!8A2VL#+NI8EG9V<0MD\.HIP2$R:/J?G]M*O3:7NK\#;>+8:DG M \4>EUS2!,,TXIJR(:E"='[,'\\UN=,=-&#I+TR+!+OF6+X1FE'O;MP*, [" M0P03X[GEV*&@$Z1Q1&ZC@7(,#C>BNO.# 'CV!_VR#PT]FP!W46A7^A$6;T[1^ZRQ3QX*DX; M![3X- B-8<:-E:4,OGV\^NKH+9I@O7UHWT1.4>%\TRQ? MWP SE 20S FC5*[Q;8I7429LC;9F[*ZGLXSN"O<)CH=TP,[=WN&S"9==S "S M;[-G9LYR1T8U906:?C@)'F0E07.9X7/Q0N2^7L@L^""BLP'18<(.4%#$473, MVN@0#HRCQENT9-V8X@ZS YLKT,R-7S%NY)*",A]WF5OD!T<3\C+(! MV3XX2_938O<3@GMKZ[8M(01DYU7C &U*OU&HH>/@FZXD@&W)W(_=X\3V9K_SAK%PF%HN9P0_&8>Y\ []AR3I%W&8QV^P+ M"Y:UBV$9WP07\O"Y49_B+?+8O&7.]Z*@H%W,HT+%H3:R2K!G<]UU6ARA%U*4 ME[80#!;FT'QOTT!>7Y/51S^'#[?LSY:CLTD+,MBLL*)R*IEM6+>3*SA M'#=-N>A]?*G?Y'UFB_L4>:&X_X7OZ3H5[F<*]Q\_D,+]:9O?<9NW02A).'\Q M[_X<"NS-$:(0411Z@2Y+";<\-%BYV.!0N.BX8^(. [,V0\&3>^_/#'#2_*ZW M]IQ1OLJ:D\+,0;8!8E>":Q6/,EP6QI:ZR_@YHSFJI+4FTR>UQ*]ZL8?=UT*! M:MZ+]<35MXAZ#RF&3M__7N:1[U@/^(>E&B6<1HZ,*DM#-2)9:N_ 0>*Q8>=! M4/J0XQCE^H$_=>G ^SBD1\W8\PE!V,UT.+L\)_*GSQ89@3J'%;8&F G?5L!,P6?,Y@1V M27_%E+ ID""C%@"A3ZA6(:&%CXSI&((D3=M:.Y>$+\#IOLU/\D+R*1WP59$, MYV1VQT#3JK8^"-?A)3%7F;F1#CEE)7]K]B5FIOH.AJP0E#YEK-@6(_W#H ]7 M]'-UZZK33DA]\7PTYFDS+=_NI\REA.8,:I$_F#U2QT<7/.G:,Q.-'H:3\,SC MM8U1K[""?0NZ 0;JV@BFOE)3E;2^PUJ/2J@(('<9O?(0K$NC(T%(*KF9'*87 M=?:]:S@EZ_?G5R=2&VE5G"4EMA]8Y$$JKC"MK,F.P'H+R8)([+E]K7Z0V MMR7Z/%<2G#7W>DL P4NW9[@UI=&$..,-1\\\?>2Y352X^B,]0DF-=G0(T!S( M&X3VLMQUC/K.%U(.>>0@U3"S-Y?AT8Y06C?B]*+'01^Y(E9JYGM@+H1V;Q+W MEWI@:-ZE!L]BMK Q/5'&::,;N:U](2#:EB$' FI?I:L<0/"K7#J"0#!#L)=@ M[9;Q/AV9H8V9D8IL7[0MZ&;;47<=5EXU04>"82 YC:(51I4EZAAC9( L/X?5 MN0PE%!"CV]/(5O69LC:>Y2=SZ=97(#-\K5LCYO:<7,: A,? M #&(GT1129/18Y(YEQ!"RUY>,#JHZIC4G%,'M38==0.="%#F3"@KFY%T9\>@ M/*;.&[UFXL-*"J=SU+RNE:4;NE[%MIELSU2C#]X&A2G?/P2T+;>GF?8%+[^J M92;;,%($5N:^H\W$[*@>;2A6?-_,QI_./PU#O&[5S3!4H>(AMOQ)'R*M)C[J5[@I[37N7+BY1^%[9L?.\2"*M0^K M@VC[7:(I3T0^' <=!UB/^U9'&2H,%+P%ID/):1\2.BMKA]6_.ZBE^ZB,(=P3 M#(%WK1VP_G: FM&MV1'VWDP.M?&![ZC=_@ [N.-%NA5BG1F3QH#U:.?E'))V M&]4"?@U:_:0S@\8DAE=0Z9W-_6RB9@JY3"2#=ZKZQ7$P=/6&G6T[)$:&07E) M[&UGE\U=V&O[;-S1Z-'WTIC!PAB,[LSA1S>WASX48_Q"7JBBS#Q[CB:A>!'J M!!!=!>-%R#^,5N&^V81QZH[32Y3M@]M(:?Q 1L2ZEWF:!FL ]M>%5@C?OY'P M*ZC/Q%$W K+[>!S>8/DSA'%*P!R6B"R<2#NC"YLN3W@3!]=.+S*:RC7UY\". MXRJKO<\?-M/91[#^+RX)Q/=W7!,],:*8>S1TCAS,$BK7E\W85VZ#+HZ9-92$ M8REOZB#HE+^4]O2JLW1$LUP2KTC5ZTWFS&)*PV4>&K+12!YH)#,F)=4VN*,& MW&#U^21 M/2%0XX"Z:DW'=8F\=+FZJI!!3$[8E/9CPC;-=:442G79OE?QD0,]&_YN;_5X\=?F.C#O3#:I4K ;"2?BN3D=K T4K2"X M(>Q"G3)2>1]J_8=SPK-[H(J9M.4X3Y\M>:UR39;;@3$H6/:&CPUM@QH+(EFN MI16&4]]QE'>U9NF'(_<=\T?_@P_X%B<8K# WPXS?CYNTM7^Y["@JY-3::'_# MMY[=X^+)^#U-6J0" H=+$>))&P_67:.$%CC ZQ2IE1)HQ:L2"2GN.'0'EX:, MWWQB9D9M,\5?B>7I8BC1:)-DWZ9-7HC )I:NA*"9">"0 <-7XY+#?R_+&'IP M8YQVAF5/WQSB&,HG<E5N0H;I8R0;65ZG>'A([D4:3DDO>P^PXK2PRJW\VE MUOK $81 )QXES.FF:]-HN/YBH0) M8]AX36?+*SOT4WY?S#86(.]41B)+!6VSEVY))N_F*"]<2[X$ODR/;G]@IV^I167S*)]B<^!AH#Z>-5T__=C[TS%"#^ &IX%!N"J7M MF567F>-,]:$4M",.CHI9&YR'MW\Y!M:.^_[G?6^U2V$KOE1\%_L-F-O3)BW$ M(%"P5JM9WAD2_Q)^3>54OT;F2^KH MM/GCA$ L9S)RN7.;LO(1GO0F:4W9XLX)L& M6E5H#Y=O=YF2V7TLZGVOYL>I>=XL?A;,[CN)5]5B=-TX(O+2]T1/?8MA=^/5X\6RB5%'\ M"P\C#Z(6G2&YYPT1MP!-0K!FL&RS$@@10S.EG;"'$+GX5N38@&[V([=,R3!9^04=7E8C50S;N$A!>!?V$ MU.JF=27)4/8@<+(*]0"1N#$XG:(31M;DCX.SB,;R+S0 #,U>7I95/-QM^257O/-/JSD' M?6L9Y_/]9%@L!)T%<7PG2GO &TO\2_ M1.O!&TX[*(X 7Q9)JGA"754$[38L&W1"LWR8MFA"V\AP].-5@TE MELCR&L12('WQM&ZJVH[JT9>]3$8HMP=@848+IDN!,U9J[4W*FBDW4SK(C2L$ MZ7AI?/SD$UV?=EY\RSG3:(K26OLNGB$**__JV^??&:J<#<9.Q%[-.#1 Z9"W MQP2@V?@U?*H3R> ;]M[7BZ>?_8>. T'&HX\,;_:JX:XQK#]VCT-[D=C&SCD* MLESI-Y6@+GCCDAQ-C,.;Y< Y0MI7,0KO+IG,91E@0@CRZ1L),%=UHPHR_&^$ M4!+BV50KDQ_B!([TV4?5HC*G[YD&$*E?0M8Y2R@V@D C&]J[%ZB'GH=-%0S= MZF:N;RY"9L^D7Z&!=!PQ\.YY=3(Z]C+NQ4 IMA5V"+\CHD;C$&%R)UG5=;AH M^DK9R48F6F![+;6[[2'8P-J ^V9#K5,RS4[1D9^%9++8<*FT8I[*3QN\P> MR>F\=;4:XN(BGIN!THK"^0SD[<'U9,MI9OV,0B'179.$7+[V6-#GZ-,Z)K,F MT[^<7=K3Q1R=J0H'^VYHB<%:HO5].I;-@8I^D3[F4<>]L>7V*-H.(5I6()B$ M =R=0)1BM,[B?S^BM[VZ_J\UB285VC2,C+2UW-IT\_\R/%8.BX+)A0V#DYJKP./T,& M6_M192Z2HL"KU"KTC,O;O^NVU>, [5;$%RU0BUE..A6'NG'?GLT; MWO:AV5D.\):7C?18\8", CX^X4J_T:T6[4ZY\]:/%,Z[T2G'0!PT/JVP)ZZE M7%PE#6/*?L\($&O3[N%)<)3STC^O!KW^;RPH50 M)O 9\S%0MZ8C5!=$?M![ M:"1^@\O^RX"EM]GS3JVIN"JO3KS$,AXT'^O-0+77U&EG//;H;\,G;?*H]FTD M RAD+J'E=#Z+V8 I4BUFGJH2]"G[1F(NZ2%XO/B&/S[IX39PB@'>\)7JG 2'C!);WT!,*;-$ M])Y>-3T/Z,8I9:Q +/F+Z(^)' 4*-5SXFA]>]2">=\NL>0' M!C9:=3<>&^MHOOA#7YQFXBW.A(I!+H/0:DC;23U0[AS ;>TF.DW$VYP(I;:$ MSOI^ KQ-/5TB"T>1$35_*PM6:I%&]^Y*6Z?J<"U5KX35E@A0JZD^@'U$#7,(!^";G"*8NOBG MI?M^CYI=TE117#\@@?051JXGO/QIKM[F7$7GO"J/.06SK<3H&'4EG*;V+4^M-4&Q543"(JX2,;^&<"$PYY7:(U"Z9K#&Y6 AZMJQ55I5Y@8:BYK0(T Q8^2@;2$Y@Z" M^:42!0)NNH'^[+JA#\_Z":'WY6>?/1"$WFE+ON\M";0#\93[(Y2*_4W[FFI" M:%B4/*GP ]>$6608 UBUN7/B9(??2Y2C5.E!/9>L'7*JMG>:I'S1'$?WP703U/U-J=J M+ =\LX31W9053Y/W;O;9OT1C?9JE=^:+)LQG';AUONRY ,+]EI2"*1:OP]YW M&3K&0-6).$F6OJN=Y0B)Z/_7_3$"ZIPDZ_;,M49=V.0B5:>=^]5B"QNLXTP&)[VQUN=BTFF MTI];Y5[4ACKNZ.0F3/19R<3%YZI#>YJB=YKQH!:L"U:1"&5;LR17:FSA9L8] MM/BJ5JEK+YIF1;V)A+*()]<%.K"HW="'VYN&'J B ES^TVEFW];,QDFL+U@" M(:$_RR6T$9CM)#H*9;L2EF1"PRZ#UPD42&GAZGF9]IF*;6?-*,"B>@0J?2H< MX D]3?X[VM;64V)B=PO78BVR)EX-=JQ M4T@L?4">[#1O;Q,#2'WK#)V/L3*#ZS$]7_\*$CF4*3G':?K>FL\!<1H:YV7TPXEI2Y$&CS>K[M!&_*"R;,=M9GM5Q94J??V&W4V MA2))27TSGIW3Y+V["'H'VJO+N'F$49#(ZQH6V+DL?RW;53-T1CI@K;"GH/G= MQ6F:98IALTP=<_J=T%1OO89"A>3HI:N@:"O:,2Y1(:U/GI4C54'HNZ[@S ZH M9>+IKV0YOZ#?G[J>CG0]?7[J>OHP]]GH/%)>P[__\!TW]Z[77>B5?2_N%R'* M7#;;!Z?C]]6@/'Y@#Z1350GYMJP-3+7Q\^9*B$89?E>HV*KF#Y@;NFKF22OC M:5XUJRX&I;!*0HE%=":F$-%!K]7YU4@/\0@GLD774'\/!QI7O),>EO3I<-.; M0E"697+_#P[Y*SUX^6*F7S%L[C&E7$S>#8M MN5*ZB')BEQQ-$IPUOJ1[K*2C@H]RU56[*V=S.K. A<( F%[)IOU>XHZEYL5;U26WSJU>D+K5/Q+ZR.9 3Z2X3\V^CJ!G- MC^0)2 AK\U0H618)"5YM4V!) M4'E]M1%5O=X, :I,2<-<29=7-I;(3MPTASH3//!)/T*'__$BG3FLN%SO<\ - M\_GJ!:'\Z=7/1 ' ;DB:7TM\<: 5=%U? .Z?)KF!(%4,6H3CAJIOS@Z:Q%J9 M5@]7?:8KY5JT8%XSPY*LCMD'=*^P6"+ABH<4M@>OU$3TX4*'S=$3.2YI#_#8 M-Z134["T IZ!$A%$H2XNHIX99K>%*>0V_-A-.U[^CC'[_BW]N[LX:U*,F\= MF(BN82#20KU_KW[3"@ M5L_^\P'JO]O<:B3+J.^0Z(R0P8Y.?7W[*SYG467(\&0U$IUI2I:_H81>1Y9C M3%Z.Y>+HT?[[@\XHG9?+UQ=M,]2K,WF:-?[OB_N0:JIJ/FKBW.W(4;?X[.?' MKQZ+5DB\%G<[L[.0DE#6%C1+!^LI)H@1WI/DD@^[*_NV$HGRM?113_5GZ(B# M0\RV51[G3-=IW MT%VK_^[#SDO=R%0'EMM5,'XQ%W.7K]6DR[L5DX)32+5T7 MO--CJ(H2]9IE34F-B$6;M'6S+]\$.$4QWJSZGH+RK+.SW'-D&=U9-0[4/EBM MJK(5U_6?I B[H(IW/*=.B^$>+@9?USYS=6W#*UB!6U7W4$35AGS/,1P=7J(= MAJ?0=.' -RDY(:L%/2'MR62_GX,?&;HE^6<2N>%L]5TUIVEY]].2Y-'(A'J9 M'N^ %9G[19MQHDKF2(=SJ8&"#'L!H]#V?R#OO.TIY]]7<1@4W*3J?KPR-'5 MMSXMBO=CQ,NKLMHX+EJ6P$1&7$[=D/$+43KYX:I4KC#5:=U@\T]T#J>T-+SAE]L.<$([3F MDWR>*'IU?5M*%FM9[G@U.169>D<8EU3O R-M77S)3JXI$7$G')TQSL7&ZXE\ESL/V0_.,S)OKD<8'3I/W M/HYZ93GSQ"Y9WC3/C*&RZ[-S3N954FE+SM.R6O=<(MYK5+!GJ'7V!AJVR?\3 MK:C<6Z0_',GEGT!D7W[VQP<"(KNW-:;OWTT7S3TLQAU=6,_SK@8J,XLJ(0$< M+O8LV5PL+D+CCNVN@S[;-,V^C?O]@OPUU[142J&R@@QN_'KT_"A7P!\AH@YR M J*UN=@TYS2XI&376T#AD"=^Y$7*^ZJAYZ6\4;7A&1"5Q0T;0<640=_;Y';3 M$G >"/7=P(&]#%1 _F6(05'/@CWR2#Z(*K3\BDB(G.-A"V'P>ETQ\Z3@T073 M0TQG'17CXC!D=\K$E!7%)4/!C[E78YJ)+G>;YCK>,/MD?*%X)%U'@W_1R,%\ M7;:K8I&B@*'F$B-"OY:+B) &MT_(RZ["NM1>RS:0]8.H<#34I'@L@I2I;@>W M/USLE=]M7,OAN )Z"@0,LN\XX3S$(G@5UV)\M\7_DL3\?O&7 MLGZ]> 2GYQ?5? M>5?TQ_G7V80_O=IEPJ43&P#\M0 MT;1>5KO$3_!-6&$I?!5PS"Y>Q*W0 H/WO&EWC:J<:LXW91[B4=6\1KHX97Y1 MLJ;+=#)]_VQ:25DH*]-Z\4W5=OWBQR"=67B=^'C_\_+[IKV(,_2<%%"+%,_& MOY\1,HUV/RX;;URN,N(8L@-5/[ [8GN?*LRZ[F F'R^>;?I+8O/U&10X15>, M@XUKEF9GQ8D0>1F WWK!G-#CB)$J65J(W:RJ11=7Z; M:SP7@')LF!922"F9W)L%S\\:I3;J$B(I/A.Q@\?GY.-4IHZ!TDW>OT2/E#1^ M'R^^8;QKX>Y_,91Q3/H@@Y)O0'YV7;U!FJH(GNH7+@<0ME*Q1@EQV\4SC*2% MI245KY^WPC'N"LD77O3Y+&3K%-YU;F'B"Y\'0LO;H/3Y]8M)\DBDNDB7\DW5 M];S8NLN"\;N$?KV*I@:P53[TKJ(SPAM+SJW^$BNQ#JL(->5()? M,^@PD<2"!I-H\>,4QKE.4&1L$QYON7#,0*,BRSNE^C. MH3>C8\#SFF^#$8KU8EU<-J\XP<>I=5HOX:NHZ^0C#M3!(C)'0@/$0 M,C-);Q9/*?C6#'19)R=>:4[4LU,JFVE>9YF06'G,D^+Z'D-#C13S@ YFO&)#$ M&>0;YMZ?N#CB3&A+;UJGFXIN[Q])#XH$99J.I"W-A[BEZF9(6.9JI[")S;_60)OWH84+# M>!D=3&G^\L69!,!#\5!Q>3)_K^)+?$.^70RGF^CO[Q?/XA;4#:23'$UKEJ:X*_3GXKT^S0;$Y(.62M\9=B! MM&A\YPW=YVZNP\$FGAEW0FDCN.T&N'V@@3==L[@:-A2B2QI7,%G['1NV]!YI M"L2/$]V$\4[P3X((/@YT7+O14"^KJVJ3[<(XA&5+);FVC=%;G)426$T)U^(* MB#'4(L:5[07[N45T!.(RZ[D\E*I T?I6HH",MF.R!]("9L)R^T72284R0%I( M"'V$#2 C=4:_P3P4>C(<4Z85>+7E9$F,.%K8'[9 4"0M*'$AFY^/4BBIMV0) M7'8*'*:I_<%OF4+BRG(;PS *FZR2YCDVTQ2Q1#M@N57GFP^$G1,M$9EXM)9I M8<9JK?6X:Z#^VCM^3XPS4;#1VU_31V3AA%6V;-*1*]0W'!!ULWJ!] I4B,A, M?:9215]C W"-+M&]/Z33N=RT!0(Y#API$)#PM>DZ8GLNW,EMKFKFRZ]Y@IS3 MPUE%.!G1/B(4G3D'D&F8.37X?% $/<5PE&9Q38^P@%*>1US:DIQG@5SM+#6\%*^[:Z>:UI>?_>E4T_J7^Z;* MUC?Y_'8RYD(*LRQ]//@>.3TI=)=(I)*:L%YQOV&TNW&:EI=D7FFSP<^(EW9G MJIP+CGJ$MG \#>G0Z.)6KH3E.[V#LI:0#^.-,DY]-GGF3F,K(N?CCD6[DE:D MNR#6WBAI\DS/;!?*#=[9P7S/@TOWS*Z>R[#9H05+>VB"FFFEO5Y1F\CGIW_E'Q\="KCB<2^*/Q? MY*,%@N?%1Z51T,@Z-2%;2S]O?JUHVEX9JBM/\ 0B!02=,VZOV;KY\\XKW# '7#9S44PT%"R! M$&W?BAUESA_&Z,GZ+Y/)U3BGL;"'S%>)@FH1+?Y4,#2TJX^];]@ M:&D@!G(KKZIVT'Z.+1W,\8J/PN.+QPO:!>'UI[+2R['%/QJY?QD5%47^[/:8W1*]"FNZRZ2X0O_!LW M)D+2J/TJ2&D2CSL/G!PWHVF)/.MH49& M.7?'QN@"/J.'-E$0WL+RCT0')'=[:&=QEG2D8$;86\1[@=@-%P8(?(3)'7D\ MX[Q'6MV2F4HV3@P'A;)5IU%AC-8IH8Y]4:Y6+5JP:&<1EP+WK..:1(W@_@XJ MF25R'NM 74(XZ,HW"RJD]L:+JE>0SG%&I(C4CW\-!)7IW6EVMT&_U7773;N2 M!F0J<.=5P./&E1-FE"RCP8P/VNY3^PIM-WKC;4MR6@E'//!YU%ZU$IU^E M*1$6"3H#'R_^VEP'5"W$H];C>!M*AG)(UB)YPZMQZ-V-G6S:]IE1D/WM3)C8 M*CI&XXVXE@10S]Y&SFO>IO:/5E@NX!L+6I^>@W(58D58\9&VUYQE$F\='@!E M3WA6>7FY# Z:OOLX%3OX3C"JPT:9G^ )D*$QF?P@$<1 5 \A*Z+PBT*>Z'9 MT,+77\CK&UH@"89.1()OOXJ^H=3&FY+*CNQQI(=&4D&JVJN%0&[T:!+$#>\@ M6='86]1/V>G(2 .7C$=\GRTJJ54\NB^">UMWOLV][D,S?UGE>6ZACUNJM6 6J9D@M=LS/CP/R13VXP^ZO]& M^;]F@QKR>;B,6Y0C;K<]DGE"B8$"BI'O!T-$:5(YXN!/Z#9720A:6>,XZ^B"[?MO#H/P[)L>#CF%+HD M7/R,+KZWD;D.#"=():A1:A\^ZLB6VXNUGO,TAXOX+!9$B!;A;"5' M:QM657*@$R]O#.S222RI77D<9%8')/QEY#1+I(%NET)?]0$YF/'WB[$6>)$T MPXLX&49U/6P<6*F2##(YU\CGZ" RH@B1%TB1\L*P%(*R H,NJW1/<4V <^&"'%UQ MH%'LS)&@&YP'Y.@8WL"XX#PZPA1P#!+_127K72<7,T.L?2U *+;H,R;,2<-= MJPJ8CLNW([S,M(P15VK<"X DHB$->#M4!.+X:NV9<)9Q#*T1YOD/__OBJ[.G M?XXF)5J:;;4L;+DD9/+E_KRM5@9V=!CFPHCC:8B1,7.PZ\PR,!66+#/6I!3A M*4PB&>30^QG4@"E12>6."'&PT>#K8_'[;_;>"YJ",!N<)D/-!57*Y> QERWA MUVD6V-9MFKCU-)4@Y5><7G!_;&M9J4N08)1'TG-$O,Q=PYR;;&UT-.(HX0SM M7-WJ-0T%P]P%/\8X/ADOM]#/J#_#RSEET0(!\;=QH8V?'U5#I.C;NG,_]2/)%#WC-A3\X; MNF!#RWT\LV["7J MGA0\W>"Z^AI!\C7+0U%-M=/4@Z;1%7_:MT.G^<9MA;-$W,YH_6138P]9>>UK M@F+%WVE\!^QDT">+;Z@W3E 8+%?&TZ4C*S S%!\A(-^--NX*TSG?T4:9*KVN6PO>*LZO?G4]7OCFS(\(#$GS^0!,:Z1FZ6-I5*R/NZ MA$^.P8W> MYQ%B MA33I(?A$^4&)U17KBC(^.\65D%"!8O(\=BOWLWM-U XXJ0I+K2NIF- M)'?.(D.KOW)1%*=A.3TB3*F2EA:8/Z7OCI01BFD-H<@J"!()Z:F8_&/T^7'. MF5,?Q;A\W(;=T&NK83R7PZC5 H@6K=;4 M[D5Q@GSYC IEPE>E8^DY?M$%^> M.D78>Z--@W..SH%ZGP4$T]6I:]#'$E)Z*[+:6Y&ENCPJ*KI(+M#,(X%C*01+ MUH\7H=4<&;?B"M@)6[6I-/SC:C>6?(R,RXV%<#<)Y M 3X3IX^;BO0A)U+@8V1D%H+2FI*H MX1#KNSRP.8#V72"%PPJA_7N*0K.>D=L75CX<1,(=42_/N,CMK8M5 R>\!ZE, MBPTJ>1TLK(,&-:/'*I)O[PRT)](_P4; 9BZ-R*-AC@-:KZ*?O(L;IXMQ^JZB M3%^X:C97J-FZ_)T9&E@*Y[J@*%HLUM)G.B:L&$W7*BRKS@9W%6=IR3D!/I81 M'@#@@=DO;.H+Q39@<4@)I\B*.P7[$LE=H%OWTO>I[=[)Q,_9<-&'4(S5S!I& M7>?80IZAT"WR.JCE,P0>'CVU0>'L0SK._9"(=;S!#9H8-J-C9VPWAC%KC'6F M7+(R=#5I*F:;3SX%),&8V=YG;!T0P=(@R6T ,_OZ-W3IS:/J7.49#1]<>7 QIL44,4%XQJ_K$>]G9#.J822)0CSPF4(D7]R%&WDC&;.Q4U;2X6;XC2W&3':X7BEOQR$%@[I,RT>2*UF$][P?SDQ MR:P@BJ;7O*AVUV4\\=-08U1$1;*5:-Z::)Y*(HIG>HV7,B=^=3Y__C(MSFLC M*TA;_G_*>B"W^FE!+ I/N,I%WY*$9^?6E,UZ2SN*W\8]B/)\:#I:>Q_=G.?K MQ0OH$;U_W7,J%9J52(/+ IV?GLN"R M(\"S]8'?"CT"TBTC9:647GO$:_FRM,2:-(ZB_:"Z;-#W(*B .;V&PE_012,? MN9+/:'IU5G_D,<\F]^6/:7)=IH'-ED"5E@"Q:$1?OU(3GAND7I@?,(F-@D'('$96@?(1V\_Z2X*.+ M5?-KL&/(N@+/0_PEA?Z-?$7J>.EC0MJ@SB\*;^1VKC>2VBGC\:GYQG;SQ9Y7(!1G_5QONJP[Q8J<>:] M(]FF62S&WS/#E\5^Y*M']&&'8.QU"+MT_-/H/?WC M%_-/)M! 8J8!9)TX3NSI2J.TIR-X:=HI*5=+L&<*"ND/=J"#[$F&];-'Y4=: MQCXXU?$09?;&9);W"/33B10*8&BZ3W"OL"#<=S2#5>B MI0ZYD,YH_F4+EO+[[]ZN6/9JXY6-.(8S9APWX?[?V?_\:./.VJ+;>? MZQ/$:U)HT/.G\$]VGYE[;1-#>_0#R ?&3TH^^L=/GOYI\8@^(,\J%Y)GE2W; M7'!)R YJN3L/AGS3OR(_.IY(O?2)6RRU^@V*5,GS>.12$MU'B1MM\OV$7KZ* M^XU):)#T9TXQ^5?%X\/B".=E5_&7\_R?NW()<@U%._OD"C(,A(.TZKT;8QH@-=&9;:Y:R='R=4I]0@;WY$#EV1O\XM) MO3/O\?)E39<_H$7),$.8Z1QS:P$G/1=T*&M"=C!SRR.TQ#0+RHNT[$'_\>-X M8@PTJS VG":&LX"N(SF&YN[!5S,6RAS'R!-^\*MQQE/;O:_G4%S&49F1]TG$ MA_1T&\*JV7:REG6_6?P.WR7^=AL UA)WG\*5&,X;[)2 KBZT--;EV110_+D4 MUV9B&42DIUB<5\TV4 .5BV8859HUP,Z*KUF_"9/=9J/5: ]]4J]DB&K?I" B M"]HV^VDG\<%JB"?JNH7;SX--[E>:L4?39.5'')30EX:=.H07B)*!GXL;Y)// M/_WBXR>+>&1L8)/C&F7U4YW2C^C5__/?GW[^R1=/__CXL[E/BE'$)S_]#U9! MSSJLS!?K&TK 73?M9@54H\BB4V,"Q%-UC5,[ 3-7V5@1,ZO+Z(V4&"Q)-%L* ME_*+[V&5,2Q\T&.0))F0R(Y^H/O )<;8)C- W7QV':# DSEZ8- MFNKE);HN7UC,K^\<.^.(*:* M^^%O:7V2'/NFF[8<'BAML?7PV_K_M7=E38TCR_JO*'@9.JXW+=Y@IB/<8'H\ M0P.#X<:Y3Q.R5<8Z(UL^DMS ^?4W,ZM**LDR8!K:6-;#]!A;2RV97V;EFA3L M(J,4%>2!/Y#;PSA F8C,)WM#JEC@KOE:>@JJI)NK1VG*EZII]6=D.*V(E6F,_L9K2_>A5B]MJ)/0=/T8Y.3H^ILC[ M$16RN9O3V8P\)_QH3BJ;WCJ6P9Q2CR#+5%SS076T+^<>H3O_)9[PC"'CN^&, M=%1N"5M&29 P5=T!%/6%]K$"OK+V*X9&8ZFA.?6H_6/ID9VW(S:9DI4#R/#D)$S.,(K=6Z5YH954T,W0<))817LV+5\E=-9VG/ HQRHGKG30- MX[(*W!(H$IZ$ MZPV2:;47>10C+T^]?)// M &*%]$4NKIU5G*C.HFZ"-JM>?AJ_0\(_:<81:% M-I![CN1[*N)70!6UYS$R9'JV$/;"F.1(>O(+>7<\+N1*"2L)4JP(&ZK.)9V3 MH'U-JNA7XFVV!'S!;&M:7UZ#*8FD@LUC4I[P+O7B%;F@%^<7R90 F=E(RA:, MYA$/V8(V5R:%P[ MQPTWB@6'IVX)HXG4M58$P!-4(*46/! VY]^P4*$C;XV5!GQ;$N,3JPNQ#4-J M!JJHR'@ %$E%C#.0// *CU5B1VDAJ%>V?.9V.N48U2,E#8MH;*6]Z M<*)CL=,0MN?)BQW836&8]7+9&4<#4+XF/<)2;B,)H,]]JOS @/ M.$K:)1(P#NYNZ3KI%*\5$0]23_8?B+F5,K>FOA\J\2O,%:*2E@Q8Y?9/'F:) M+U,./O"F(0,T(C.$P0,D!'3!5(>4HT@1R1.^;<1V0RJW ]L[F,/!-/'FW239 M:(R:<_!9V_ARXD%A67%!R=(.W1JK5>A'18[))5EA_4\B$)9#)]R3:B#O)V)3 MC#WGA8F1,GYZ8F\-$Y7C*L42/#SZGDK#BUW 0 "54]2S_NI[90TF<3&=O,-8 M)!.L\JP%5J2EF MRE%)4;]R[61Q:4AAY4(%_SYI<596;GR)?T@O_4,;4;S$['N1^8X MFK*2"N"E,'@E4"DQ '*7A?*;+#V3\5>P.!1;S26=^8[(XHRC"&4E6BK)2YJN M3?$]*//#B!=KH[8(!(Q8PT1E5IYUZG.9(U\DZSOS-F1% GV5B*"1Y%/UH@GH$3T1B(9Q>+ MF$]$_VHF,!R_4HYCLH.:DK:S&M6-2RJ, XKU#;/FE&K9:44!GI**L)9)9OGU M+?,,K")&/ G'R11US$14A!BKGZ TCZ\54IJFE,R!E_UX(MQ1T>+50C]"S9>G M=:HYPJ)ID,X?/6/'GA4N$>RUN/9&* M E>S-JAVZ,R-7A(Q#]<*[RU1YTF445H,7S<7G)$.1+33="2*K9'#K[%I8X;%GWB9V<=T9=]4,*&2M86!B1]P)YX)+L&P M5Y&AZX__P;@IFK5"EDFI_&2RF4R:(-.X9N*/>:T$-. ,OPHCJ-Q%L0F9S41? M&+8[4LN]PB-J> Z69E_J3B"*\CHVK\PE#,.JVS96.UPQ/8IIP/ [/K\,E65T M(.%3$XYH 7]4 NP[$ZX+JB3"4D%KF)"*I()%YJ6FDJ(4C@QI:9E..7^R&2P. MDVIP):V:>#E^$70G"M\\D]R)(=6!!O\B#(FAQCS:^''L"35*#516 M/+]NL-(C+N)]/S@)IUEUE ICO:DHD9<$&=;84R& 8>\$B<#43D4:$>:4:&U<"KN'P5Z?1(K*A5 M8 UM=A<7E"*^6B21MK+Z W(7LNE<[=4@LDE<67?-QE43LU"Z*N&B=#&?,3A4.8I'GGQ!5%U'2792("5%5FZ"JI$O7$GYDJB2 M%4587!X9."?+.TF'3%:/5Q"&&<.%^& 9S)-Y 1"RNB:_W1 M&.6:Z_QVX#H.,[JM\:@U<;K6N&V-6IT.((W#6H9E6ZWVWW#0/GA6&L(5O+]: M;,Q 1:]*+5L6(3N2'X[AI++P[,_AID[^+XV:GOO]NB=UVK6N\?2C MZC0R/CJ8/Z[^;P?F06+_<)#4CHS%@Z:GK3<>FZPLP0QVRF/OKF2L*'=D9AG< M]+]A&%/CV$B(+'+>:&I 0UN:U^W%=?_K8'C3O^Z?:L/>>7^H79YI_;]N!S?_ MIPW[)[?7@YL!?-F[.-5NAWW\\>KZ\J3?/QVFEH&VND[$O#.*XX4_SXNG>2DH MF"4H;!\4ML 1<#"ZO%238=ZYOE5Q?%X/9(\1[] -]W2[XO^1[YOEDHOK^\ M^;U_K0TNSBZOO_5N!I<7N\#Q&QKFKY? DWICU*SJE :,YHU>0"6QR:2T8_;N M4]Z&%LTCT31@Z(V>1]-0XXD82;22V:!H):NBS=%W+"PJO-Z7Z)G$XHA/GV*R M@CA#Z$189']U'X[@]@M,4,;N\/ J6(5K-H'Y5G4@>.PI\ML!&SM'N,RXRCJL M;8][.,\\^^Y X[X^@-F'Z&CB/C 'UL4+V0%A[Z3:,=NPDB]_#RAPKW]5Y^"S M\+[^6D^]\G/V;UR?5\[^)IC-HY>.J/LCD]_D35;CX'/$ C)WOF#ZMJ;R323X MQD[XANK/=^"18AW$5UA8MND?A<@;+_GB\934+)E)K\,EL MJ&>UK#?3L\S6GNE9K4+I6?U__3[X,KAY_8%J5ZB^4VN9G8VH?MWW1LUHO]$Y MI56# ]R;#*I1,SOF6W%BF^!2RR%>2I7?!O6N2!FB +.F;\",#9R-6**WXME8 MBN1,?3)YMZGSP3EL[//0MB,*-,>K8$QVKM!B#Y3*>KSU 6IP. -1OG3EW=E#'\+4ZZ!,-L]VLXX"[S89N-G3\J)N= MNL,>3+TVC6:8S\N/&>AVO684*>=0#5'>*XN.&8.YC),1GMP3'Y[@AI@/,:YI M$]=3&W*EATO)#%7.LM M<3WCA*<-,;O'2N+(>/VB7 NF?:?+B@F:1@F:^P.:NMXU=:.I&V8;S[EUQVHT&YVF@IT9F#REH.JD].V0 M43'UB8 ,=-TBR?]OAH/X[SG%Z$B?V>+O[-$Q"(AHE4B MXAXA(E<'#0O@L N(Z+0[>K?5?NXH_>61YSEF#\W9H^T9&P54L+_#G7SOB4X) M.,5O[?*WEOA4''RRMF[CV\:LKV,N<3%?Q5&Y)>3L(LI3 'YOXI$H:?Q#TGAI MDMD_&:P;IM4VFZVZ8S;U=ML"N6H)&7RFE$Y:$8C^;(9F"C*WJ&>/EXE::[VH M?8TAFNJ4)I7A@59I0]@FLA G%(KKJUL64+&OL/(15 MM 8 C@G8.J6BP(N,X>,7M'$L16GY:ZSD$E%/KBNE2;9LD:(;L>4CN:?_P"M- M4_,"^!G@TTH!RL]G@Z=H03M\9EPEC;[;H=8TVY:%A]JV;G05@?I"T6BM$XT] M7M)]52ZJ-K+X&&ITRG-HT<2>WMCH(/KA3YC_\UZ3*:7S-I!/[[8[.APE.AVC MT>THR)>VUQD-0J0]7@_#VO<5 $K VMKHU]K[I;CR *=>=G#>][4B0^Q^+\%J M1 D_S@A?+SEK>0J*4!"'U8YV> ;ZH7;AUS33-*O[OH1&1[>,[KZOPJ>5*(#^ M"1+-OJ^+M!KN^SI42D6M5-0^E^:#0ID/-O'QE>:#TGRP*0:-^4D?QJC LV*_;= DZD4:"[8F ,CK"EDND#SBE/G"C2G(NV/ MN4M&I62@I#R4_@B86#_5TY^,H\$(1 MPL*C/UWLVXN=P3UMR& +J*E'TB:XF*>5O/503BOLO[NJ%^=-3.C%!9K13JOX M>1-*JF,4:%([JQ?G36:7]>*\^>RJ7IPWEU(O+I)>W"SUXE(O_DEHTE1/V?;> M&.OSIMWSW!"+%/I^P HTK5U5Y//FDC)P[[S*F#?#G549VJ+IDWE]TV"N?-:*>-PGD3 MVGD-/V]2.ZOAYP+"#FOX>?/950T_;RZEAE\8#=_4MUZMLM2=7\VGSD/X-Y;M M:73-Q@,6Q%UID" *6UT%P,#NPO:T?MRI\I)WJM2NV7^6+I:WNL7GBV:%IEW5 MK4/[$ZG/>M,1?[VLU%4%[6@VK\I;8D61L**L^EDQ8HS=P[G;!<^E5A1 M8L5F6&'LJU[Q41$!>U>O!0/C-8H#LOLKP6+T&GBH<(#I:+>U8>VDIF''M_:Q M;C8;)7 4!CCT1J&*%O*NA-MP.[SKM&Z ^Y_GWV%)M9D?P&-L+M4G@S]Z@ MV6-LGA,-'QN\.FE%M&:/1*]S:LP+L!&Q>>AB2]\ORQ"^"4/Q*AS;.2#*T@90 M.10-UMU_?;D^%RW4/\%CQM[28>&1=NA^ J"REXX+C^?O/?%A-/,0.R;Y\]#W M7&[8_6)[Y'X83AF+ )VB=>,EO#IE8_4G/6Z"Y'[B7\4OU=:\+Z[215;8RP4+ M1*\[N7@W@.J,7G:!"_(-MF\*I[(&_"7[0^R)_H\:W&]%VACQ>NCQU.M3-@DF1=-G\S?3B4ZW'A M1\#%D?_\4!)YG RJ5LK(@LC(VO#D]SWL,B,@'R%Y0" .L9CJ=L M9FNG_GC)BX5NOD EG7^I?,3VQLO/7Y(.W?G_XRP3%!)]<6A M^M/^64GU6:H_91-W[I9$7U2B/^]]*8D^2_3G]HAY);T7D=ZOKOLEO6?I_2I@ M(=!WJ=OP<=^0Q>6"'?S+3L RB^..%'Y)D/ H8ZH7?V?&]ZT13Z9%0;ASY M4>3/CAK)+?8H]+UEM/Z6E!LC7,YF=O!X#/_HH8/8_57L"@SVRO7O[,<1E5^8]@_EEUCF[1'R2GW\= M!?6L R*[8^D%0^+#K4VV)7!84(5E\NQ%R([DAV/'#1>>_7CD$M]4Z2:Y^&(O M<6!9_L;MX#\G8ZXU^+@%EHHWBY]K\%-]]?M.K65VON M6#NF5DUO=-]D4(V:V3&?O*.8TN\6U _>VEC;W V1]S)>T_-DSL?AL$TRC0K%7X.Y0\U]0\W6 MX&' 8Y2@@T2.ZH,&C#,&5@-MSX[\X%%;8#\C^-(. O3]X\4_2OBESK2ISF2M MUYEP2J[SVX'K.,SHML:CUL3I6N.V-6IU.O9DXK"68=E6J_VWKC!% MLOD4/&IJAYJS!/$ZMI?HNXRF;@@/)E$+KQF!8@P;QMN4NO":$9O:W@03_?!! M%-[(+Z G!VPYA[OH@?8RFOH!3,^)@>3G:MK=5JV-2N5FBG:SUK1:;Z(>6U8- M=)@W>919,SIOH[,#6S>;3P\J7VO1"Z.V_,C;6Q_9T+,"=P3:LL,%5X:QS45* M)RKZ;G^@_6R$+O(LJ)P=N>RZC(:M>,3667BV9,/;NAUIC;FNN=Y<5Q_YSB/\;QK-O,__#U!+ P04 M " !8@E]9&XP\VN4/ "=L@ $0 &-D>',M,C R-# Y,S N>'-D[5U; M<]LV%G[/K\#J9;,S92S?8T^>"&8\(D.N,$2^*A9RI'2(X(^AKP;_0)HSL? MRT' QX[S69.=!9,II\.11#OMG;VD67*7'Q_NMC_NM'==9Y]\W'?VO+U#![MX MVSDX\ [P;AL/MMW#GX;'_9VC_L$^.7 .RT^%B1I[GI+S)7CR L5ZM_Q%EC;/MIM)XV!%2UA M3IF0F+DSYI[DCIQ.B-C.)U+WM^ ^"&H[[6UG9SM#:J;<<=J[SJZBQ%)RV@\E MN538G9,!#GUYT@K9GR'VZ8 23P6&3P#ZA0:IVQ+S(9$W>$S$!+O$[)C/[Q " MN.AX$G")6(9R@$5?:RRXU&0M%$%[%;A8ZHB%ED(UU<9EVF\17PKXY<"O#R_" M:VW92PV%,\1X4DERFB:2'E^IHD%9<.2ID4L"OYR$SH%+SO:.@GIE'>;17TV' MA.Z5.N3&>Q$H)DK]6[Q6C5GGJ:Q&3%E)#.3,Q8(#4]7(FO32:4#8+H@KH$H7N< MQ.\]&21#>6:>B&>5[:.CHRU]5PW%FAASEP<^*6^\->'!A'!)B4C/,9K!B)/! M20MF&B<9./^8^D=1:H M%/D.#Y5ZX=$\=-2@B7'&1-M]B?XXE$!T=[>]L[P-$/>5;,L,H9H[2W%','D7\T?N9 MA/]LH,QS_!WFRLX1D51IOGY<%]D;0=YY+TZ=OY6)P%8V7A2+6A3^0J$.M'NT2"$?2]54!?$(A MX@;\?&AZ,G"_C0+?(UQ<_!E2.5T[^F4BC/#OKP)_6N*_421S$P"5T5G;5+^2 M/&-H'+Q%:&SR@9)A'(O1I1\\O\$$D>5LA/]PI8E!"4):4D/'@W,B7$XGP"T8 MG(:",B*$)8SYM$:@/L):F0K7#T3("?R8\P%,$DX-0N$4"ZK"_BYE!&9>+QR/ M,9^J,9(.&1VH\8?)CJMKOI0-[U1(NY38@O4J$49,CY8QU>( S;1 I"2B6*0> M?.="T5PJ2L0V* #NR1-A(;DG;C",F%K"FD-H NN@O0Q6S 2EN#3(]S=$PHI MK0M[(S776SI^FUEKRL.T5)$\4":28.M4( MVU >5);4*@-7F+(+B(TP["_#H!DYFA-*LVH0$&=X0B7VM2=L%Y]I$J/3#Y:= M'I-'SF^2IX/QF$;3H'_"62AD,";\M=B6,C4BFREFY",[$Q*]^B$1L\%5,[W!'!X2>7IU M/\TP,N*7*6SDXS=CO$%,,UV\\A?QSD,.M77":>"]%D4KYD9D,V60?&27KBII M*!*'(GD;P#53Y0R="#*7W/9]&LU0KP6ZE*D1X$PY)1_@E! TE[*!U8C ']MO M JQBNX%V[= N[<7H_XB;0':9ZX<>\2B#(E8HXP3VG/JA)%Y,=1=35>O/:Q5I M#(E,@2YGU\B)_A5(:8$2-6![(J4(9-6Q*G,6=_.-IP;&CLU&T8HIVDJLC;&0 M*0):[T8U/9.SP>-,>6BJ$B"]8X29-]N,"@;S1NL/@TIBC2&2*516")%$DWC/ M#(IBJ2TT.-J1VMYL8!#E[D[.#MU<4J8F9(K]+A.2ZU>TB+BAA^4<58;OP8V0 M:NOS--4BZFUU,(774::>6K3'ZJ2/!,W40BF]DO8>PG(ASAC":*9>?.9H$VZQ M8U>'/5&6+X6_V?).W70XC,9,!KSR+6#(SHI>IQA;LPT>31LQ] U]L M_XH]SXJ5$;I,N;40NDV_6_;V7?3BN*G*9^#%"Q,8H1B1KX?1P-@(JN4#3[#@ MCR7IG&PFZR>DI&U@CNW7^[<=U^4A\:XH[E-_A81]!<9&F#,%V4*8HRWH6!1* MR6HDR/D'FU8O2@.I2(F-XR E>!,'BQA=8PDE^6F' M87^J'PJ-WSS+AMIW:PL&6T'&B,A4H4P1D4A&B>C4^W79, Z135BL@I;U48>U MB-J$1AU"8\4%=!6.1J SY4P3T,U>2INRL]3]]:9].8R-V&:JFG897[I5$S&& M!XI6[)JYI$:<,F5)_4A3T[L:. $^\^>%/@D&5P$;/A#X@EU?IK:NJ\-CS=(( M6Z8 &<.62( 9$&0X("2ZF=YTWV :YPQJ[%D$XS6@FG@:4S#)?!0$ORXIZ)B=7H]LHQQL8Y7 M;T6/7\T50*#!)D!,H,' >J6ZDM<1@DC1G\[).IS@-PP72\FFX-E>RT//3C3# M:'U0I!#J3U,<$.CT3P^G3UN+'_J,?B]\#!0^!1I_[%@'&WR&\(][91_F[DCY M^%PYUP_T@8W8S]=DW">\A7!?Z(%C%@I11WX<#O FI_E[T M\40_N?6@/U3HA5&O;R$1*CE4AO#K"P_"R4DK:DXE&;=0]%W#^0>DC[U@C"GK MJIO :?X-U(R1G7' )?U+B[D=0,3!R]YN66^DKD-JDCI[G+9V@'TQ,[<:DRIV M1_?ZT6$+=8/TJ;3T1G1E'# 5W'QJX8HN=R>MA7 MQ@TY(>4!M0JKVOHE[SQ2)[:[: IIUG[R!%=4>PI&ZYHT0-YD:>^?K=R :@& MJK<<#F4BQF9$U//D+\3W+@,.4:;?=3DUVVF1D*?>/?$)?1)O].EW!0;RC?$Q=K"I.10V4 +PCK8E[Q%(OVFBF1>F]Z0 MYXX:WY_T%)?[ &Y/_5<,*)B7_?Q-X2SR=B)K.]OTR)]?B>\;.L5BHUIT\0[_ MBWC8,"XMM*F%V@M/!.J*XNP!.TA6@E"E_=BC_E3->*J74@;M9H_R=!@+L:_R M9Y4O%\;Q.D74-?F^5DLV6!5RF$7'J@\2R/_*HZ&ZB3[G.KJ>,==?5%7C M)VPYJ. C\]<4%8X^;R'JC=:R"9&M S-/&Z2LZA=8=8U?Z#@<)V6;VA M849_2Y&US4Q32?;L^(C*7*#JX.J/^JK5ZZ,:\<1=[[&\*Z["J19]-:6X[D:W M&CEQ=WIK&'PL".MA((57ZJAATH>#1P:;[8<>A?O!#N4D&*9RL[XKHNB "4V^B3]_/E MWCT94J'6>,3KQ.]:)::9IB*;U=<);US6F-MA2E*R+6N08\R5THMR];=^V]=E MP+M"A.!!&X.*:7\ W" )I!Z)3U+H*B7LW3ZHI$=@-Q8KBC>%5F'U _1N?6A6 M",7^DA 5L7#8P\X'>705XJ""91.U"K59S1,A"%E\=&!6<'T(3@D\$]09J)'G M?P3SRR#DA8:NPJJ^?8"=8>X'IIV*Y6:U2(46(?BJ)A!8PIV'Y"'05ZX#3W\I MKK027XU)73OM)79U^%TKSTD"K\,BEGF6#64]T%Y\8B#I:-#';AGI,.]!W2<8 M^ETQV%5XU+7/=AD+GK ,Q55@*G#E-JU#]KR@V"7E0L($Z8X,E4@C6>UL4YEM MH,*JLG&Y=+6S[BL<#-8O ;0V;)FD#C8M/BQQ$X)FMX/8^<59GXGL;1(>&*:' MA%L4,^%WS>6*U)N"1K#75-FP%.7W7Y!=J$QK>D\F M46UUGD'C8?%"K)2F1F!=O%!IL98H)_JN]ISY6(C;03R,W?)[.AS-7WU:O#MJ M(*MM:7P1BKC@'PT#2?^QA+& MJYIUJ+RLSWK.!@M;L,1Z/X: MT&T8U?0 0'(NJV,H5"\WJ\5J*='JU$[YTUHJ;S@*FFE6AUQR]JDK.]W/:^GX M"SOE+^KH^$L[W2_KJ/L7.]V_U%'W7^QT_Z6.NG?M=._64?=?[73_M8ZZ_V:G M^V_?17?],)Y02_DQ_OSN_U!+ P04 " !8@E]9G.JZ2P(B #X4 $ %0 M &-D>',M,C R-# Y,S!?8V%L+GAM;-U]67-;1Y+N>_\*C>[KS5;MBZ/=$[(6 MAV)D2Z'E]MPG1"U9(L8@P % 29Q?/UF'.PF26.J 1^IPTQ9)X7Q5^9WG_._LZ1.3[_\^O3SI]?@GO[[/__VMW_\&\!_ M_O;A[9.7LW1\B-/EDQ=S#$O,3[Z-EP=/E@?XY%^S^5_CK^')^TE8EMG\$."? MW5][,3LZF8^_'"R?"";4^:^=_W3^BY7,"283:'0:5%860@H/?OV[=O?O\?YY.^S^9=G@C'Y[/RWGY[]^O=;O_]-=K_-O??/NI]> M_.IBO.H7Z6/YL__\X^W'=("' <;3Q3),4WW 8OS+HOOFVUD*RV[7'\3UY,[? MJ'^"\U^#^BW@ B3_^_=%?OK/OSUY/W\8+^ M??BL_OS9B]DTXW2!F?YC,9N,+/V1(7SZ?Y[2Q,%Q\P(;T$<8)_XO+%\7Q.;]0H:\:+=09DUAE41 0GM""! MRER25LX;=GUSZ[H7M/".$R4L8D>,LR<_J[O^#"?+Q?EW.CET,M@8W*DDMM^% M[@&7'_S[?+98C%)!QE6V(*/SH% RB$5I2"QY4>C5USPT7O J'-?7=H5GS^?I MR6R><4Z*\>F3;UB5V)F./ 45YND6 :^_GV>_\6QQ?'C8?280T0[/_WZ9SP[W MP9;EK+$T3L5.B]N5%\\GD]FW^BJ^GLWO6//Y@DM.(6=-:C_:"$J% *%D!2%[ MI8.+24G3^O58&]TZ'!*7'(*?@$0]B:X9M=Z.0QQ/QLLQ+LYQ&)U*+A;!>&U M&>_(?3#$"*)Q<-CXU)L0ZN=2@B?TR*-!=+ M,\*\.\(Y;TMRVHPZY!" M_YBD:". /MSLD58JEV@#,; 4"B%%A.BX!6U87"I@^GS M_IQ-T]G..FUSL%R"*9H<..<$+5$8T-90,*,DR\ZV5GIWHAFH*[V1]&]INC9[ MWX[5L^F73S@_?(EQ>05+LE8B-PJ2S8P,LBS@T9 'IZPUS.?0WD]:C62@SO-. M'&BPY_OQFJ^ PX"!Z,E &$_K=>37.XX4WDG&G7)%R;17QWDSACR"[[P30_J0 M2M]^\Q587BO+%2)P3W162M=LFV? BTC9*","NOVXSIO1Y!&\Y]V,25-)])F0 MM!A,L9Y#2D1/E9B&B%&"RU$B>D.[V-IE_F%\Y=ULR6Y[W2Y:6BQP><5!CUZE M6 A"R;2BE&E%(H#PY/W'S!.:UOGG:P!V7\77$0S)$]Y>TC>YN\,N-^/MQX/9?%F=L3?3KP2G MWOA8D"6]"L>0?-]V4M]YQYO)O@*8 MTJ^<_(D4?45>I$L.. :*OKSF$#U'*$6Y4$+)VUDO?4.MXMO M2+,\GW8*YM5_'X^_ADGEV_/EBS"?GY#G]/_"Y!A'P6H;T49(79H*#87>F7PE MS1"5+LY(V]H]60O8D)S6=JQH+Y-F='D_QZ,PSJ^^']6K5 2RR]=<7WKQ(C(1 M(Q1>W36N/,7I#B%R\M1TBK'PUM'-&K"&Y-RVHTIK>30_='[XZHGG12>3/62E M1 W!- 29)87LHB2?F3)1#^.VVVK2F!^.-/W(IH_PF,!]7,[27P>S">WUHFK# MY/J3O!G.HT)X1.PJ@3R((GISP68/T MY >H;!B$$ A,4=+IS%5NGC-N;_@^X#*,IYA?A?F4WK4%^2;'A\?=_5L MVBWV- )F27NRU_0B,E5]8($0M',@T'-5?Z2;U\G4O6S-G!Z%U3*967 ^QWQ%R2'J8LG1 MAX3*@-*&+)L5DB+!))Q'9G/SJH@5,(:4K&S,C%TWO9GT5]8^2F=BIB50@. H MR"N90R2G'E(T0A6OG0FMQ?]P)>KF:_L\I8AH@OGR8R\2A\'EY"W74)BK5Z+J M7CMZYU!$STQB6FMLO,*[T0S)B]Z9#S>9WD@(O5YE[)+*W5(O3@L23\S4"[:^ M>/J"":*IITQ!Q*!%)L>_]=64M8 -R=-N3I7VHFE^D'-CN1<%#(%YX;@G)N=J MN!6Y@BHB*"EYT:HP%EM?_;D?T9#<\>8\:2B,QC?;1H2(E!F14\>JTD*)X&,D M (XP22V93"K#HU&B1(SLI!:'ZS?M6S96[X,860YZ8 M!J^%)O.J. 0F';"090I)>)M;EW"LCVY(9JT!47H22].KCXN+@\ NA7$)Z6+] M+A<1.;":!56%EA[(M -ALN2.*2UEZUAQ#5A#2BHU($IK0?14Y?.A[N:[\GF! M':81U]I:422PHJN35Y<"80BN!2EJ)"SJV/J%8"&=Y%MMWDO_-F]U38PR,/5AD& MIGHVBE761:4 =W=R0M_3GEGTQ/R[I M:V>G9N5,/=%/VS?(?.@Y?77*W&A]C5IF7JCYRQ.C$86-II#/5^U\O<(3.CMO MH%YZM:JXR$QOEO42QNYAR5><'N-K>FE6Y?Y>?4^3X]IZM[X ]$^N9V3:>^L- MCR!*[NJ_L%[YC4RMB5/[>CEGZEUC#5O^C\Y;.Z@,6( M)64M9@:.)7*1G%1&,^K]7EQ$.9?ZHWM6'LI%@/. MH"%A,5I9[51K%>->%)6E:GTI<#62(>F[G>2_TO?:;>-;9O&0/J8FBEZ2#I[, MNJ3BV3)'1OB,1B9P:'WU^PO$$A20*Q6CLXG<__871.\!-*2D;E-*M!-#V_SN M<5H>STF9GW/4!!&29!)*,J1\8Q! _U=0VVLZ'3FI\EXRN3=P#"EGVYH'NVUZ MNVOQ.*$???D=IV3/)[2^Y_EP/!T3/-J4KWA.S:@$4SD$*$96:\PX1!D29,,+ M,T$)T;S?\WK(AI2M;4J1'@33U$UZ5^HA95?(8(-E4 MEVP0?":WS5F'W$>E56A?=W47FB$E;9N2HY$ VET%)$?G,@X(W&M1KS/J5+NI M)L_ "UEJM1?/)0J)HK7UN 9@][.K\T\Z#U3'TV-Z%R^S-K]AFXS?3)!&^*&#"UHJ_[,CCWMX]; .NNMM%E@!4EI!?EHR8% MP;F.0(HH@A(R0;3&U"RDRRRZZ'CKH_%[X+1-1YB81>"A^MF<@=)%D()% :DP M95/-L)?F)8EWIR,>^X"K#0=NS<'<>L?;VK4[RJ2??PWC2:WV>3V;?PP3_(CI M>'[:\";_U_&I;;[8!^^<8,DQ2$(*4L1:@>\:_R6966 2??-&K:VP#\D;ZXMJ MCR+GQ[6*87'P>C+[UK^7 M>/IO>LCUFH"K;?U$S$K7/@7%YD"*W)-/RI@#8P633$@=9/N>U>OC&Y)E[8E? M*S**_8AO/W4=SP]G\^7X?[H-/8].M"U!D@T EVMWN4!^@UZ1DQ"I8+YH6G=9=:SA(9A;^HZ[P2 MC1@"B[$UP=;!M6%BH_^"KPVN"%=A]F7HNI%<.W*FZZHRG?EE.WUTE>]#C(B?CND MH!A<\+JV!W?@Z[5IZ8WT&&.RS6_+W(=G2/=E]L2>9N)I1IC3%F&7D6LMD)@= M+S]@R./)R4MJ-=; MU)]6K]^:WC[2W 1K#)*!MHSVHB3P1A.OZ7_1BY(XOV'L;J=)&^)9AU'^)]$V MCR7&9NKI)1[-,8V[K:3_GF GJ&F^ZB".N!%"1HL@3"%DJM1V7)QV)@@;;=)) M^-87;];!M58>E/U]7)#UF,<_&TKT\:_6\F06Y-E\WMZ/UGZ>WL)M*M /PAS_"UT-X0.JT4\==V] MM5PG\KQ2HJ4I5!Q<$I;46G04 #(N8NMZF=5(UJ+%3Y:";B"3'JW,JM91Y_F# MDY%CWEEI-#A6._T',HK>%00>E*'_AQ)%:^)L"'$M1NVKR>"C6:!V4FS7UX V MXD8?Y5M]EJ]_X\IOOL?Y>)9OK_.LI=FK[^D@3+_@A[#$5Z5@6HYD9.BL"U$B4$)AQ@+,P0 M5;-30[FS^<@5 ,/E^ KGI _QMW1?5^$[32==QY><4-JZ DD$\JQJI.:BL6", M\EDB.=VJM5%:']V0;C?^^/3<5?Q]T_/BCLL5?)Q%2=+RX+DG?+((B%Q:",H% MQW*((K0NWU\?W9 *0']\>NXJ_L?0GEY+*PIR2";5X5T>(297+V,QDX5 13') M0+3GYOOP/IQT1P^?9L\3<66.73;XZID$6L=,K$VBI*GE23Q!X"81'VP)-CHK ML/E(S8= ;>C2/$H*=EF25\B4'4A4R0 MKDT(?";#U#K86 O8T#K_/ J1=I98R]E?"3%W_0W^",NS*XC=R=7)^1"9%V$R M6;PK'>CE#= $#'FN*42)J8X.2>#J0#U9N$Q"ZJQM:U6](^0AN1?[XM\>A=P+ M,VMM[[MRY["TD4I:#VR:Z5.-JH8*[0!+G@&)2BDB?4SN+K#^? M[&ZZHY4LI3K&D>M("ICFU>^;IO7V4UEOUDLCFL9Z;OR=C;]4E7 2XRU M^"6RPK0 P[6G>$Q'H/VH@W2Y%J5@\+E//V UJB&=!O3$I?M4=0-1-5?39]?3 M/\T^A>_U//)@-JD9N=I%9O5).&H*P:)-8*TU];Z5) ^XCI./3B2;?,_+MX-P'S]-=(1Q9L3@(T3PP4.@JX9-9$$DXQ MEU&ZE/WHL2N@?H"X>3]J;%M!-==B[TK5I.? 3DN8HY 902;=Z4]4%0 M0YK]_%BDV4E0P[B(.!#2D= MLC_>W9KHU5R&;2=$7MV!F^N6M6U(\@6B\/6N=N#@R.T 1"XY)^V1<^L,]D.8 M?IHKC3N1JJGD^FR!?#87_ .FV9?IN'[8]>_\#^:7W:S,TRMT+W$9QI/%=63K M=4'>\DD-&B&W6&.S20#WE%Z\Z"XAOIE^&A]BF8=#)#QE-C_LDAUQ,O[2+?TC M?5V4,>9;BQAY+$EP*R'5IAU*"@2'Y)0P+(9YPXMJ7I;>ZX)VGY9Y#[C;VZ=Y M%JE68M*_PFG3N< B@K<154&5LMCK]CVP'X\]SV H3+X]HK,WJ3>S(].)*F)&F9 MA:(XN2P994U/%)#,RF1XX"JV'@:ZAV4-RK_X,=^!1^!7JQ3JZ:J^K5K5G_CM M,C3?9*]/"VRU=)H7!R5B[7RL'Z:BOY8Q38_F9VWT0V3-],ZY[[[X=DOYK"\^+NS:?A0NYQ6 MI_>WL!@O=O#K^P74P/W?XXXUBA)N#M.IQU=7!NJ<=M6JY^>+98>ECC-,3OD( MQM;V !2<0D13R)&QJ+GQ1MK6>8!-,>['HZ&K!.'G*T(\6;!!B[47]<0;3(R7IQY[PH4C?O=-($^*"*?GJEYZU.J7N7 M>[N^NW?.Q+J^B%$6"CF+#+"$3"&(T^"C8J"EM;SXXKCMFY5W81N2N_VHO&LB MO-ZHM>Y;49L-7;X53&,@2=!;D6.]^1<3!)L,).5H+8D'PUK/TV@"?$B>\ ^A M#+<7>Y^N[&]A4OWOCP>(RW-_ZDIKO1U\TC4_N8%SNU=GOSH,WF4-A] .3?2K8OHGA"B!#RKMN+?55L]%WV_*&C<;.H/QK-O^K M=FN=)5S4^U4AQ5(T,$GJ4@5IP64"A$K%I*RUJ?FXI]5(AN0$M9?_]IO>G@ 4 MC8\7!V2_9K.\&)FBK5)*0/#=-&.L'7F-@*(3BJ(L#\V;OJ]&,B2'HST!MM_T M?7L'Y_5@X4HIV!27C3V%!Y[2D]>PR=H:>1!WEM=5:O$B L7&&4*HC8U]LA"+ M=A3F,,E-%!Y=ZPJV^_ TN!BY^K,[5[GV#\F)>0V&6[)[7AMPM@YKLAD+SY8E ME_:UV@[1D'R.9CQ9<0FRE5#:A=:74=0ZDR[N+E$E36F$*Q8XLQ3H.=GU;-7 MK6;.2&F+:3YBL!'V056N]<:^1Y'TODWF':-^&IO,!Y[2D\G<9&VMCF9N/>W% MZ?3O$<9L$),A1RE*4-%%",@1?/3,E!*3[N-U7PVF@0ZL'TR,+Q03D*C"Y#5> M?#IQ_W+J^0B=%#D4":G4_O71T)*3QQHP:,5T4KQYYF$#>$,RHVVXLT*+]2*K M=B4IQ_-T$!97SME'I!6=1T4*,[,,BA0D!&,S:6TT1:9NXDIK;^L6BB%%]?U0 M8\>=;SN4],XE7J=HR -*1'0#V?Z MDE6??D^M Q^?-AVBZ+E> AI/O^ T$>ZS)FLGSTDMGBS&BUFY:&+]]K07[-9^ M4(.G-O"+6J^]D9_TEFP1XO7G7=S$.B_,?GF,(^>4R-I*,-ZF.G4K@Y/2 ^-) M)!&5E:KU+=5UL>VJ]M9ZS@<\#&/:\'F=@;X@%OQ_#/,1)]M1=W:&&^+=4C>W'!(N*M0]T[!^I)\^C8; MY<2B3\6"9$'5]T1#8.1I1,DS>1<^%]FZG\&&$(?D"@Z*<-N(\'%X1L2A+1'( M,X^UB6!UEB4GA"G62LQ4"E>>%?M8.NX"Y)#ZU@Z/:QN+\5'8]GIV/!^%E#!+ M#)!*Z,I^%3A+L5,*PKBL5+&B]8V633$.J9_MX+BVL1#;%#[="_'3[#=\'\;Y M>5GB_ *D4$)$DRW88.ML41V!HO\ 5@H?+2.='->;<+[YLX?4 JA7!NU#-NV2 M<*L1CB(ODD>K('GF0/G@(1;48)70,@!_DH MQ9$\X("0C0DVLZRU:.U2WH]H2'%S"W;<2B6VDT??;\&5I*9!SF.T'GSAL=:# M1W H*$823L5Z-\ZRUAT_'P0UI.!VCTS94BK#3C6/;LR;VU>RF9X[B'3SS?7O M/>%1:'&!L<1,LE+X$T>!&/X5S^*/GA'=C30B2/9$F[,^@K/^_G MD/:NI_1K)==:6R.;>.-9(YL29\$;R#(1G8((X'60@-Y2#.JX3,WKC&] :'*3 MY,KNO3XFGP/_&$_'A\>']Y^\8=8I9]*+BB)Z4*D4"+I63AA'2M$PQ)L=7EHO M?@.T0[)UN[!HY>V2_N77)NMV ^QY+J>B>3?%Y]/\B7Z.H:9V1HF"'VDI(%'= M574A*#[1:"&9:'R4W&2^7O^@#1XZ))/6@B2];GJ?IJPKPTX'F(\G.+LV7.=* M4YD=C-A&G]_ ?&V_GE;!W-7Y1/1N9V-J4A9S :7I[?=6%4"KLG-&1.]:EX'> M/31J\[5$N#EF?\^%UD'4_8@&51[4C!P-I=#&_[C.UHM6(J^^CY>O$4>(T<3,+=B8:*VH'#AK M(X2BK,N,!R?R6B['_<\9U#V7767=>E_[$/29&_QF^A_D!+^9DJ.#B^4H>4]/ MCAJ8K[-Y4=4V0RX 03)>>5OBS9L#:TE[Y<,&==VD!Y'OOL/-5/]U8*]#PK,T M7@[,>.$81%YGT.NB("(9HJ!*X0:9%[YUN'H7ED'=".G'%=ARX_<75%P.B[_N MD#>+*AYZ0/.P8J,5]1%7%(S*!*X 39WO()B!"#SXQRTPPMOFY1\.XX@%W MA 8#FM3#)Z36[.CAN T_@X$<4F1-C0:=Q$"GWX$I^G M*1R-EZ==X%:;/9>++YST'3?U/,#1%H102/,II;6/*(UD6S@6#S]YN%'$-H3H M?_/W$E0((S5Z$\'X.K0NL4!.$*/XUWN?BHE)RY\ZJ&@D^IWVM2?GDL;>LZLR:II[V-JFUF*-K*HB>*G,\\.W.%K6>. MD5L-PD0BK2T4$24K@*'@,J;@$5M?E;D/SV#CD':\V$$ ^Z%$1I^TH?B8 )#! M"F2U@A,>O'))9$&14FS=N6%]2NP6$%P&)!_PZ&)T]/OY>)K&1W4^P&6Q"::L M?)U.SZ2@72C>0J1H$XPNV7MF+?W38^BP/M(AG2,WX]6M>U+]"[%=Q=#&6+_- M1L'Z.IRJSA_,LMZ43A"TI#\*20NP*CG3^H!H&YQ#.H\>$-DV%.#C4.U6E3 : MB8C%@1"AD.E)%EPAE\3Z@(ZJXB@N$"01E6():@@2O+DI0LSOZ_'7W&4>,1H M3&W844>Q,W+!O8KD[Y="3H0KV35O1+T5T"%%2$,@WI8B?$2VU?)0*5.VPM1V MIC+66>.Q3B0ET"(:Y7E!:1X]NAA:G>^ V+:I"-<\1#S[?OT2PP+_^;?_!5!+ M P04 " !8@E]9>:E2" -% #_ ( %0 &-D>',M,C R-# Y,S!?9&5F M+GAM;.V]V78;29(F?-]/D9/_[7BE[TN=[IY#;3F:5HHZDK)KY@K'%W,*4R!" M X!*J9_^-P\ 7+"06#P $M2I;B5%4HC/S;YP-S.WY5__Q_?+P2_?8#3N-\-_ M^Y7]C?[Z"PQCD_K#BW_[]<_/;XC]]7_\^[_\R[_^-T+^]XN/[WYYU<2K2QA. M?GDY C^!],M?_$__U[^"'X,O^#RAN/VK__VZY?)Y.O??_OM MK[_^^MOW,!K\K1E=_,8I%;_-?_O7V:]_7_K]OT3[V\PY]UO[T^M?'?=7_2)^ M+/OM?__Q[E/\ I>>](?CB1_&FP?@X]/D^A_>1J-^F_X0?W7<__NX_??OFN@G MK8(>7,(O:W^C_(W,?XV4;Q'&B6!_^SY.O_[[O_SRRU1R?A1'S0 ^0OYE]N6? M']\N(^T/)[^E_N5OL]_YS0\&B+C]A,F/K_!OOX[[EU\',/_>EQ'DM>CG2RZ@ M5('S_Y5/^VUO3%\0R"A>!2#X71@6BE?$N.K3]\=\_5DD0?97@TE%Q,N?715O M<^G[-06\]-$5T+8?1"[A,L"H)M0[GWL+YQSD(L+RD;C+PO?^&/][^5N+[F4S M3+AB2/C%N!GT4]E@/TWPS[+CCIM\CHQK-X+QGT-_E?KXXX<7$=/W,2E;+W6" MMFAW>LZM12%[^L-^^?D[_.OL864%72\/OD\ /V.Z7[G5\9)'S655?4Z::F*< M:@I!__I+,THP0HL*?]1N%G^/@P:Y_V^_3D97M _$%Q@NRA>[ M,F$\FO0^C)IT%2?GHT\P^M:/<(8O88\:QPP81B &3R381((0@B1AN',,32J9 M-N$"/N 6#_!O-QQ8]^R*++CG0+^'%3NHL:DHSE612E;R/7BLJ>[V(S8'^TEF4O1BZ9,8D8*8'(:!GZRE*0:"-G MD45RE-+8DNJY?NJMYBE/<^PACPT[[X87H%WV#0 M?"W'U4?\2Y=#JAI6J31 *&0!Q$281()CHN+-OFX+Z1_]R9>75^-)FL2GP3+)%.!"0]S\1*8,):'ZWRW?!@&YB'I\I^NEU-E,X4T\&&,0N* M#"]>-N-VLWS]_6N)HMP(1/C@F: )_1DE<$=#F\=%00G/ACG%*=->5F;.@Z"> M_)925^P=\*+@.L^_-TVZ?8)^:@:IYZ(,>/A[HCD+R%AMB=5)$!9M\BQ)!%?[ M2%F/YO!,J*RZIA.Y=V):3*V?LSO6SVSQ/4^]-48EDL'BRR".&&^$[-3(TH$^EEDC*FPHDQ&Z:%>C(H77WU_5/:R.2K&)>.).F2E=&B \[),:4EVS,ML/'>JMGFQ&LFI<:""O)=9 MH&H8FK>7VC,T!AZ,)RX(9&5P#L^R($EF-C&T>BAN3!V8E[(4T]OA!$;XG5Y6C&8F& $)GDA3 K'&%DO$>BN#YYIM=*>T MAJ\BY Z,O//)%QB];X;-75[.35#C0^;%4Z&:XZ[FI29>^4B"M9E: ME9U4*Y*F]GOK[T7TY(E04> =V'PWN](\2-H?7B'(F]RL%Y";$4Q_[[/_#N/7 MW_$ Q.?WAW[THY4/KJXDMJ"0!^WZ9DPW0FJ>HB#645%2,%*)CV024@Q,2>ND ML=6WD\Z6\^2)^%A4W8'->@UY]E:]0$<[]R<]*VQ()C.2 Y=$*F-):*\2E$]* M6REIRITP< G*B;!G/Q%W8+F^A\DMPXKG8)F1@0#G%AWH&(GSGA+&64+[.M.8 M:KNJ=P \>2WO+LYEW9I]=?O:CX:XR8P_P.@3^L;PPH_[L9>\HYYR0U3T""I* M/KT/!"U3"$9[)VN_TRN!/'E=[R_>99W;VCI_U1]<32#U!%5H#Y70*%[:OY?T I&H-T]@W-D0MX?U6$YE!I12YXDV@N,N1QD)DB)\%Z)SN!BM:]=_; GQ5 E4 M124K*#2[3O_7WQ;DA8OY9U?U69\F3?SGEV: ",:O_]]5?_*CVSJM^YYW@'JM MC9?;7=T6DT*DX!W15)3@&3/$,A\)GDUHI&03P3VYNBV!QZV26A$10*,'I12Q M 2(1(@/3+DD&M8^R1U.WM8T^'ZC;VD:,QZ[;6EK"]'5ZV5Q^;8;E96N+&V)@ M.:>R!::,.Z+G@@01'*%>2 #CT/_JC!BK #V2RJZM%+V.,WL+O(.$K@5,L^SX M34!M4^:UC0>T"M!AR[TZ4-RB.U1-Z@>CA.#:,I?CI,*:&K!C,6$;87>2]WMYV0Q;TVM6T<)T\+;D%B;<[$J64"3.&4_0 M XN)>IT%KY_NNP#B\-Y)!>4L)6'L(]D.RDC.4FJ%Z #XH6U M=\AEX2/X4K;);[-+NGE1HX_>4\N)U\ZA1>0L?L43T2PIR9+-VE3/T-L4W$G0 MI!--=)#9\Q$FN%9(\Q#O#)667&JA+ F&42*3#^AEH0 LE<9F$TI,IWH.[RHD MIT"&"C+N(*T'63@"/X97,/WOV^%RM.9C,QB\:49_^5'J9323@HZXMQ5/2J(/ M3H(.C% 7#0M!*ZMJ%Y%M"?%1!$#WB4]TJ9(.K(_EB"QDZFFRE !C@DCG%0E. MXDMC//Y/V&1B]?*0XX?!.U7;8CAB+YEW8',L+[5GF&?..T%B4 8124: M?X=1[(\A]63,R= "5DITGJ35:"VC\0R>1RTT"]:S+GBR%U$]2QKMJI4.LHK/TO^] MFI9PC#\W:T)%__"CD1].INOH<; LM_W'>$F#YEJ0($MW*91*2BD8? FJQ^BV M!'G:K.I69QTD,-_[&KR^_#IH?L!T6_UP55I=C>'#P _'**22FU/< X;8I?:, M>.'0/4U9Y)R\%_2@YM9ZJ*=-N$/HKX/QJXLH8Z-!2IQ@U9H;5( M\2"GF2K'E7%@:T>-=@+Z+"E747<=)';?^YZ\A[_:'XU[ $EST)0H:A!J*/G' MVK35D2()ZI/-]7->-D'V+"FUCW8Z2!&_C_@W($V$E(--;9D*>ALZ$)MS)B%K MQX*ST5:_']\(V+-DT!ZZZ2)/?!/SL"5]&9J2RK41#,=M<>1'0'&-^Q.8M0"; M+N\CQ.9BJL9VI;UH762)9R)4@E((J7"!PA!-C14R^23K7\5VO*;3YNVC8L3Z MO/9][W7*>E!.!/"L M7$HXPZH?PSO@/&UJ=JZY%73;^^;@UOOT$=J4B<_-IMA=="!+!9J2 LT+ $-" MS(A=X$G!-*6>UD]QVAGN:9/O4'I%'Y(GN\MZA>;W#O6O2\\JX!#I>2X=GCGDD T%$L&@)VQP M=_2HR-,C;:U-X\'OW?LL&?]4?^XN+$5RT)U.39[_QJB3Q#<9WN;19E>;6S]B_,G._956J MQKS[R//Y(]]=Y\HY'@U9Q5N7!XBE13>#'KO L$V^N M\TE_A^9BY+]^Z4<_:*N41% T ?(3IKFN/WFA$H7N,B-YCH],+QK M+8!C57+64V]36\R5![=]FM+G-J1Y[OD&H"J.[5L+Y/!C^RHIJNE*R@>C@ G) M29:!!,AE.H!)Q 6.=!?&EOQ.EN1&=_>/2_7WS.X[I.:W$6YEC9]=P@B1S$M" ME,GH*P 0=(YXZ9XB2&"EM9+6EM%@G;<;-:MX0,UWGWK8H6Z5U-!4D6$'11&O M_WA]-D-";:8AHT>:39:(Q*%O&G1ICR6C]I0[43WWX>;I3UFK>\JRXCO:#@T\ M^W#V<@;#H_<;95:$0<+-AVJ&SKT,Q%FGHW0.9%A0Z9IABS>?^905M8]X.BEF MW'YXF^5,!6TH826U2H(H@QZ!$ZY35)3R)&/MK+@G,56O4Z>M:T6MW=>[#1V] M+VFB93Q/U6#1TJ=V$1ZZ'_JA D(\6Z-$*H-,/! IO2662T=B1+M;4^7K9PL> M-2#$N XB)$F85:7WB,/U4MQ]!]EF&DKTBPW@CB,\CH9%WD;T+T\W7>-8//^L8(\KW54C3G30K!L%:>.^:X<7]Z&Q@+D7K MB%*QA!I*DVC:IGRYS&F4GD>[D:X??-135W5=67;2;'#9?6^G5+X<0>I/2J[. M]=RJD&A2E)'DI"I3*BGQ+"JBJ1CTIW*K&K:[]PE=A/ V7]*APGE@ M6.0R1,)-D'@V:4HL$TB&&'S,Z#[G7#OX<-1P7DP"WS&KB8?2^\V)N7W[,&K259R$,%ZEI%W):I$GXCN^B!2_]5SWZ4X;:ME-I4%&[EW(X9GN+TSQ"- M9^[ )J J)G2M!7+XA*[]=;2L\$H"/ICVC5599PK$4(,>FPV4.)L]<8!'LHD* MQ&8AL<>E]7MRN0ZD]&WDVH$G/ ,V[P0>LDD\X MP4V[6;">I"[94NZ9D.9$XCE/+,<_0$7@(KG$JU<*UL+^''E76Z6/,*#76T@, M["*DUV,'#^HM+NMG6.]G6.]G6.]G6.]T;/.?8;W'$^#Y&=;[&=;[&=;[&=9[ MAF&]GW&21^2O_HR3_(R3_(R3;!@G>0]MKA_:\&V/L%EW[J8TX!M365.H5_W!%2YQ]J\^S/[5'FE159^_?WRE.W%4BKV<#2?]5)[:_P:?(%Z- M<(TPGM;#0IK6RUX#/,_SB:)S:#>O@^-.!06)Y%!Z]VM1!LQ*=+ZHEDY3"#K7 M[EA8"_O>S>OB%TA7 SC/>R*:^JT0LPZ!X_DBT)B5,0ABO2MIC<(FQ0S+F5>6 M9-T5'"I>=!3N+G5 /I[RCQV)JJ2'%S]6?T#KWC&#OEV9=R^U"41RD5$>HC1O M1:/?<&U-]6X)'2[G6'&R8Y)TL3[UD9"E \]]-;+W_G)>E;,)OHY*61_"=J2R MUL="AHU(NJ])P'*1'#F>8J&,P/5^TZOAW/X M"$%=W:V:551!\!W$HV:S*>=]TD!ZG4,FW 5*)*69> &,1"==&9X;3?5I0G< MG)C>=Q?NP8Z7C7?-L\O2C: '3+,HF20V2.2L3H&X(#EAF3H;>)+>/++(P!3X M8V'6@1W:PRO](,W3W@Z_P6Q83'_XOAG^X4?_A$EQ9VZ_P_NW4]OI.?L'&O=? M7J6 XJH'WQ S UB%WF.YQI-EN)XE%HPE)H40A?; 9>W3XEY ^^Z0JSY\ZB-G M)X6,-A+@&4U#EGCI;NF( \%*.PQ@H?:X]K5@#A60JZ?[Q4VICIP?2\!LMH8? MYW\-(;UO)A_!XX[[XV:1T\P&X:WF61!C#9IY"0T*"\P3QBA-(8&@KC:#-@)V MK"!6)0XL&MK5==&%&_80R%O6YR90.PHR;0'S./&F#I2]+9WVU-21R:4D<\)Z M09BAC$A< F>(^0L10;F='+^U$CU0&CI<7%J&P55;[H&_^\?,!C,?591H.\:&;$675F@3K&D 1P/#QG3RQ][>*>L,^DW5417NYG:V>B_(/EY5S<$ MS9(2)+1^I(N1>/0L2<@(A IMV>)XB'7=YV]]ZHFJ<&?!=;"E3X?7W9A)I2M7 MG(V'%[YP<-TY0L?3;.V-YDZ0XA6$R5:+NK,,:FQI M:8AO:@@.[7]\T;QB0'SD@?N@F?!QHVVJ'J93X-PQU7209,5-@F8O_6CTHS^\ M:)?CA^EZ:4V^^:6.XX5;83A,+'%WL1PDSDB]$,CQ7)I*HKGM&9Z_EBKB-)Z_ MD"4SJ?:<@R/%&36$B LU1)3=6[JL2JB?$1%82CI[Y77M;,%''F?<1O>;QQFW MD?/3BC-ZS[74TI D'%J\4FIBHW>$@M5&L^Q3J%U=_43CC%MQ8*.,?Z#@XM7 MPW&+\, ]^>WPSB+O&0!X,!YDE29Q@DET&H5 M$!X@2FM4YGJS5O_W/>5QA["VTDW3A6!KQPKNAD"Y8,H1ER$1:&HES5A&I MDG9<6!!QLZCD$XHL[ZS3W477P1%P/OD"H[-9626D6X[F#%]@$))*)? :+6Y? MP1/O0)$@I&%9:25B[?R0AS"='B\ZT48'+05WB'7.(DW1@M*@(K$2MRG)G2 ^ MJT20^ER@$Y@BKTVCG<$^MDCA/N[S831VD'S!:X!_@!]?C5K'?/SIZO+2CWXT M>394RP_>#L?HR<]>FO87DY_$OO&^&HSOX;MX;M*R! E/$""WPO5&R M](O() K&\;"U5JO::=Q?W_./H_;&$6&^/(GI7?KOHNCCBE$=G+4,G*7,4J7(. MW:4,Q H5$J!,E:H=EU^'Y5B!U",QH^E 0QWX0JMPS0N(-D#646AU/:KC1%+K M:&\#2NPA^L.2 X)G#I$0E3,Z[IYJM,^!$<]-3F@W.P.U.R(IN.C,"A*4YH0:@\L7/-6W.N_# M%N=9UA)Z!P6XU^-XER,VV7M\/JZ6@:2(S.22=RB)Y=$K14,*HOJ] MR5HT)T.&2@+O8&^X-K%>_+C^\G_V880/^?+C'7R#0;LQECZ%@0I*'--H/U%F M2'!H[H?DQV$85<&=I;QSMZS34^MA%H#;,NP*:(UZKG<+S-V;)<3<6O';GD4? K0>LXD=' MK6VTU"6EW@Z_7DW&K038[-0&F:Q.41/A.$-\-A&O$"3XJ*A Y>=D\NG\1UTQ3,B9ZKJRM'=I= ^69F\\5 M]+-,&[$O;3Z/_'"<870SQ:!MW[WJ!O0S?N1X]8_F\<@-UM*1.5US'4>RMFL0 MI'EDVNU@HZNZ)FF,\8QG(@W@FDR*)-C2D<-):\%://!K#R][_$Q]R'9_[$3= M1JD=$/2/9@BS_+7:,[@:C]XM&MFH#Q(H4NZ*PW%6,T)<(D02/0Q M!NUU2*'VU=E*(,^8+OLKIHL;MF;TM1GYR4)]\[S=:K2XKN")A&*B"G1%K,T6 M87J//W(RF]I]N.X%]*S94TM1'<3)__ST>_,-1L.RV#E05$L1VMD%H#1@O 29 MTQQESI%D5MQ056;.FXU&Q&Y%MW5HGC6KJJAHF3RR1K))+RH: M@\&-5,=BO$DDL*1;NUW#LPFL^^^?Z@+7L\MF-.G_%Z27S7C2KKP7M*+>6$K05J.ER7.9HFDMB=+;I",P8VO[ M7]MB?,Z75X-2J?;[J!F/_T29^4%9P.^HEA>0FS*>Z'N/ M^IR=1#DEW(:)#.AY>L_Q,$X:&$TBZU1]Y$D-X#^9>DC-=V#_[[J(TI7M9A$) MC$TT*Z*%Q_,_L4""E.4/*D,PB28:'PE][P#_2=]#:KX#MV%Q$;?;>-U>3H]I MCT8H!1(3TRBID(@5@1'#K4H\!Y"Q]MWXIMA^DK"R_BIZ&&TW@F+F+N14%U]L M17[M'?.DYR#[:*(F/D,H;4T8?A70/)8T& $,I%Z(DZQI^; C@.=(K(,I;)ED MJH8;NQGLGHM2 F4<'>Z2S$]1-)Z'2)157&;DCTFU[RLW1_<<>=>Q#I?9I@_4 M/:#&>*'-/KBC:OZ##!"J2T#A4N*%<5WHE7Y MCD6@$221JLRZC$80M!JC##9U>YK_Z@;GQZ),[L-9-I"=\<>R+0!U)^- M4JLI>Y^!3#MHZM@#F:R*G%-%*/?XIGF>T<6RF8@8;1D2+"6O?05S=%+5&!?BT@L!P[/!H/FKE,_CWU_B2=]OY\7\ W\9FIQ[ MV49O7,G,DR47&?]&@I?HRDMC6%(^)UI[I]D'[U./G.QC_!],SP=/0EAQ@=(3 M.=,\3V=GC*_H&^?9=6*>HW?^0'1#,YN_7<&PX"6"&A M7"E .8Y%CGB,*DXH[DF&.]!&U\Y*>QC5WK9^_ +I:@#G>>VSIBXUM=8Z9SB) M*99T0X]OAW.9T"1-!,N2A=JKWQ3;H:)KE3FR9-5WH8K'$A%;NZ07/TJJ:^L2 M:<>C$3D1ID417I#$1L>("MD*7)ESMO9!N@&L8T7#NJ%#TZU:.O @UZ\>/V#> M & #B!V%N#: =YS05G75;DJ=/?5R) I9<,P :+3Y3$;7& T_KU0DP8'T.NF8 M9>WKI:-1YX$ UF-@SC;JJ#W?YYT/IL<]<$Z'$;5EWTFX^O+KU01&BVQ5(2E# M01'ME,;E"EY&5G/")9KU(*62JG[ >B64TZ-##9E73*=O]ZWSG/L1KA'AJM]< MC5#05R.8H1/:"(F''5&B7#$'X9&H!O]J#-4"_X]YL=%1\."C3D?C'8BV@T3T METU;:QF+C-\.4187(QA?MU[F/D>!SE;(IK1>CIYX'VBYM@/\$5.>U;Z%N _/ MZ7"CNO0[*$Y].XS-)7R:^$E[9KV[W?M=9PH\"D5\B'AP.9E(8.!*^,?XTMW9 M+@X%W)L8]\ YZ:!%+35T4(.U!MK<'=X 7$=ABGN!'2= 44V-F]%C#QUT8&C> M#[+,S>71.J*<-;C/24Y<%)28,DXQ.VZ@>G[$$0CR0!CB./S81O0=\.(CC $_ ML,Q^>%5:D3;MGOGZ^U<4VMP^2D%IFA(GPD@C!\$0- MQ.10ID_$,D159Y)4B=H%2H%6O[W;!N ID:<[S1PR--[F1?0XTTD$(0E:::6E M54#3V^)FJU0V:-^%17013;43>WX*_@Z@MB?OB7P M=0"MV)'=T[K+]OMK%].C,>&YG!PQG.,+Y0Q#STT:E),('I?!O:E=ZU +^\E1 M[BA*/>3>]1XFO62X%MQ$HIB(1&K'IEUEC/7.2\#_Y=I&TGUX3HY$U83?@1=^ MF]4])9APF3$B5,JE*V,F@2-G8W3!<%5R[6OWX[G]_)-3_,["71NJK9DI^6G2 MQ'\&/RYM "Z+H=7BK%'YO.$G[Y\1NE6:$TKE O V:0 Q1.RY"UK7S*/9'72^+\D$L MXW5@9O,H? ;).">&H@RE5?AF*IO1^^#*2- AN-JS/:J!/U0>YH%9NCY/\Y#* M?BR)G%/X\S0@*;D,D0JB+2W7]1R]5U_N9S@(SG#_U]7C"G< '/^>XZ <6#3D M=]9%%U6C.POB9AG#5(R66R5PFZRIJ]KE#M9SG(N6/6BR-(CVD>CXJ? W6Z8C M8Z%D,>#;S4IC(+"64,>2TW4:UM3-4SXK6WP[356SA M%V3SW!D+AE%.B? >B,Q%3%1XPO%XX3'*9#;,4%W[B"/43!]=?4UUV7<0JWV- M7FSS Z#U'V>07%".@?3$,*#HG_-$;''Y!?7 I:-,JMKQ^Q4PGC%E:BFG@P/O M#J3SKT5 \\Q+G2P7R1+F/"O#DQAQR@LB@L8=6%&(U1.@UX+YR9U*BNH@SOH1 MQI-1/TX@M=#^1,V,/W[ZY=J^X;V M?C*IHL(JYMVVI^K'3V=C/TP(9GXQGM$<"2XGXH0IK3NM(H(-*N>NC@:)E!F5%]$S =A8'N #E._&9GM:Q6[QXR[< *O0M*&ZW! M&4VRE;BQ.86@&-5X!*E$30Q1F-K^R@$4_$"@HQO];B/*PX73VHT*]S+<[\Z' M<.T(:1'*H"DILB(2=ZF2S9N)MCHH;86ALGHCU,WA'=YHZ675Y?7E[%<9QU&]O;\\NFRM<%HJ6JQP\2:6UOTQ. M$I_18T\Q6&^4-O@V;[Y+=X+QV;#X,>FZ@^N4G:7Z_JJH:Q9 &)]=3;XTH](G MO><5UPP"([$4 $J>);$:%#$FXTN)?\VNNBU;>Q'/AMV/@P8=!'!V7M!T(6_' MXRM(;X4]5%_"3SP=3?P=9$+<, MGY?^:W_B!U.4I1G)Z!ND-\WHS55IDU=@EYD)/>4R1[,H$(Z'")$9WSMK#+Z! MWE%-M4\\UVZ8OC7(9\?);M6XS+N]9U6OEE!+:M OF_:J=@PS5L;?VZ0_K=_7F:S MOV\F_P=+>;9D?5Q MT&*9[^9H@:[7W[_V1]/.*5.[(G%NC0J12*IYR=(N 6VKB-*425KZ3(K : MX)\=GX^C]F7^VJ.Y1NT?LXR2Z5)8SWK&I0V6.(BT=.OW>.P4B\4PA_+5,>8# M96CMA/]YLO@8RE\FLCO:1GQ[+1_[%U\FXUE V5] CWIT\"1-1&>P^(H"D, $ M)U2ORK&V>WRI&'/<,53PXK4D, MK@SS<8SX6):JO8Y>*V.K;Z8'6=BS8_7CH\N*EV+OV[#N5GG]2=-_=#[Y J// M7_QPOO)@J8Z"&A)YF7'DA2,6RG:@1TFK%2_4P?HP MKO[N[*RLWIMQHZ=UU:]Q^Z56ZN&X$0MGU@M^=9YO>#9U^ H#;XU>I]QJD<&3 M*+R=5H5[23TQ3CD13!)9=M8,HLX2ZG5WK -L6E+AC0S!,HZ"S!$/0:F(+2/M MK31!FLRT<]4;97:QD$-U?3PFK]>W@#P6(QY+.\C[LOZ5XXJ#*I.=K"MU:(+8 M#.A3X])"REIJ(2HS_%$781V-*UL49&VCLX/7V6P"[F=!UM9JW*K@9A<=')PH MF4,&'1CAH$6QXC/:PY029\%$+FB6]GD79'7'CVU$W\D W_'D/'_R@^O2'L=H M2CX)8M"W(]*H1 +/B:1DD[!&62%J]'*/@9I>.?YNLZ6KM<(C DT/#5U4*HN/-0N8SCU7M9;Z7KC7M;;**IV"X[ECK@F M9F=%GJL%XV MPY(:B&M?U2;[PW6;; K,2(A A.<:W0\3B.,QHJ,3I!9*BI0V&[&Q_;.?.W6;K&AQ?G<^HKP0,8YA%32KCI&91$X)*@]Q,UUU9YJ;;ETNI' M_:1.35UT4,J^:D)(B<,K45)ZLD-W.#%+@J= HG<",1G*:>TAQJ<[OJ6:V;*# MHM$M8E$JF2)9&=$1L6/' X]]H[*G#IHXL M*[JZ!1V(2&K#3I?2R!@>FZ[\%/O67-XM]N]L0[#SP5:V5W*5:,FEZ# MF">,;0!CFX2'391:_V5\V%;90_B+ZMM#***MH:5HNB+?H M8#F7A'$0W(:MO8^MP#6&2GW];2.PRGJ;-3.>#X7U+@'GE"0E/9ZYP:%#3"U) M(0K-I(MLL_*_!S1WYZ&'.PGW$GM30V9=M.B_"N-^ZOO1CY*E/3L@6F9&[JG, M+I$04\ 3FC+BF+1$2$F33-9&7KWF MRMW=!&%7B84/HCM.FF E=2Z2I!M==)$ ^##2%(-"((*H*$L1$0W$4HD[II=" M.*V]==4SY(_$E@>2\XY&EFU44#N0,?7]VD*@LXL1M 'HV0'H06DN&2-"&TUD M]D \-Y1PSX3,RJD8-YO=OOX91[B4KJR.93]Z;UEV84R4]4X;I;^ZNAE#-.UI M?;NKS^OO> ;WQY!Z95YL#- V34G33+Z@GC\=W#IU MJYO##?G=(+%C827C>=?^?T!IY0?I[!N,_ 7,?]X.$^IIIRDPCWMN+&G2/G,2 M/.-X^BO=I3)E W(JV=!'K+;/@$$;?I2;\,@[CH MCRX'E_X2Y2*:__2#J_ED]?&;9G0]SB52%BGX3)SGZ 1 4L0R&PA8*[/V3ND-G9\- M'G9*ZJTBT"[FX]QG9;^'O]H?C7N99:D8[B-6B$ADR3%VWEJ2&=JZ1/66.=*B#BB-R%IEF'Z;H$ M-J*K^]Z/ILV2]JGBV>+C*U3W[+J82E4_;1?U6R!N&"6B88F5A W'T5!(*1*? MD&"!4B>I=I96[^FT%LR^Q\;B!T\3';C3C)4Z-$8+M8TVQ*:L2.(AX;=9YK[V MU>U*((>J^*FCZ\4C8G_9'KO>I\U_ C]X/2Y=W4KCM1BO+J\&9;#-*_@Z@MB? M]GB#ZX'VY_G#J/D*HUD^O@P.DL8U9@.X6I4UP<-1$)5B:0+)N&0;7;$\E-FW M#\ACI1I5X$=S##W53@3= /CT1GV.>':=O@GFFNF_.^(\0J[PX:BP)0&KZ?&Q M<- KFIT5AB1%T=SG*J%AF2E)FD9@TLG(['S'6WGQX[V?7(UPQ3??GM)=R6BIH8J(A)R7>.Z7R'0F(4G.&*=10^W\ MD\W1/7VKJ&.-=- 6]B[2&ET7N)L[\Z.LC#O@^B M2$IR'O'X9%F4F_ RST%:8FB@1N ?7/.GSI0',J\? 5&VT4(GDU 27 [[N3_M M:O3[E1_YX03F%4TI0N(\,*)BB6]8(XD-&HCE62FN,J6L]N3V^Q$=/FQ<37E+ M@U"J2;X#,^7\:WN;-;QX!WX,[_H^] ?]R8\>6"^E,/@&A-(]'U^)Z(^=45?&[:[_S1I&OB M]G#E %*B4YI>:79I!ZQD8P,:+?YDHWG50H"5X2#Q&R<$[%ZO= *X&"*6EIXXH41EN8\F49SXP0QVO?A-X#YY3(4(UF7?0 M.?8.21N$6'*=VEUK_+EY :_ZXZ_EYO$\][QF2@:A2,H6CZW *+$^<,(XY)BD M8T[6O@C?&-RI,*4;;720![W@1IW%.+KR@Y=^-/J!WVJSMU]>C48E;H3H4X'>EC;5[T@1*9%H7533[3NJ=T MFM:TT=(ZSVY*+$E=DA4U)$^DI))88RAA1I5$5H4N:^V>OP?.;I*6E>"-(DPD MARN,>+X&7?KY6!5UR$*KVC&O1YK=M(VN-\MNVD:VQ\YN6K>2-AQL@,680!$E M2^0OQ]*E*T;"LDHA2T%#KMW>>Q6.QW4+MY5V'^#+UE+N(.:QM./.^EUN@*JC MJ[;5B(YSR[:_QAZ@P![B/AP9@O%)2X[N%PVEJZPJ+3%8)BR 9>-CVU$_@\$@L95*>-8[+(C5$Q"H#/E@/(2L!?$!F\(FLU1 M&"VD#YN5W3_\K./['[NHI.E.GEUPO41BL#P@>?Y37\< M_>#_@!_U#.-2N8"KJ%YAN3O:$Z5/5_JJ?8(LP"Z! MN0^^GPJN\V%)A/R,/P>?)[CU,6\%5SF0J(OE;$N8SMI /.)+VGFK7-SH*-GB MH4^='IT*>>UM6LV(UBL(DQHU>"L_9_^HU,/P*L6=RH/>#L?HUK?7'=>L4(RB MWJTB(5A16C,($D3F1+,H*)1Q>;1V3&8-E'V/G+L?._6;<5^*+AI%T+K!O2D& M28(1D63/061CI1*UITRO@'&H>%,-'2\>#/M*];'$FNZNH_6FJ+:1&6&(UB&4 M.8**^ B4:".!@I19T=I9X,LHCA5GVENO]_)D:_EV$%:XB^C6P-%-<'4495J' MZ3AQIGUU=B\%]A3X(0D1,B0+NI0[05NN$HA30I- <_9*2AT7IST_,2(\$&LZ M% ^VD7-M3^'M<-A\\Y.K\;O&#Z\G2VN0(N.Y:*8M0]!S\3P207'78RSKM%@C MO<8C6/'AA[?\ZXB]J2BSVLFS=_"\Z8_&D]('*'Z99W8;JB((KXD2#+&!BL1E M@XXIA.B5,NCW;#:M[8$'G9QN]Y1EI^_J)T"+,-T%%[27WB9)9,H(3GE.G&0H M!*&32%:B04NW5_2*)YV59B>U=\.+"8PNR\H_X[^9GC^1.>42(QF-4CQ_ M*".!4T%RR,IE%DIWR>J92LLX3L4ZWUO&!]#[W%C< %5GY9:K$!VKTG)?C3U M@3W$W4DYY6ITP$VVRI*4.2.2E[E?>"X1YB@'[+"(\D J=HYV0"Q3$DT;/-!X*@-I:PPO//HP MV%K'^.[2JUBVLCB3<1,8IS<$=BOAKQDBNHOD:O==N@4G, 7:X!%B@K!$VN!) MVP\FF_CT8? UM#?-@*KK+>[ TUU$(GKB)X@;Z=&H2U@ S6$:QUB MH#X:!A4T]TB&P&XE]K5#8+>16>4#<)9.<3W3E@,'%HD5%H]CFTK=APAX)*") MYZ528;,\EX>4=_NA3U!Y.\NL TMUUNCX'^7"?C@Y'WTL\ZRFVXHSGJ8LB): MI[I4GGAJ$G'*J)Q!2$-K)[*M!?/4K9VZTNZ@4',EL)FUO@FTCL(7]\ Z3@RC MD@(WH<4>TC_4/C%OMV<<3308!.8-D<8[1"AS2\:)<1Z-$0H4S1*?"9YI+N-QQIU=:/*QR47&W8<< M;1[ _II8>XVQAQ@[2'9>./A@=-G+RK$HN")"XEJEC**D7R<2DH 0K :^.&RL M=N(9HCCV[=6[+C+0MI5NY_I^X^-\>J&0#J*"@-:.+47=*A#/=")0 K:<9L9, M[;X,Z["(#BN'%T6[PW" M H5NIMMH3[__.4];P;4%V<']Y%UT;X=E7NEX\M%/X%/ILIQFXVC\!?2\RS[' MB(=:,B6HI)&-91)FA"BIE6"HK]V[;W-T3YLH'6NC@[9.;X??$%E!^9]^U"]> M\&VTY6+G=4GI'_?Q)Z^'N)SI<+,>%Q;M&,Z(R)!*@@>:O: UX8D;D$FYH&O? M=>X(]308=0@]=1!\N"N*%W[<'W_Z.@*?SH?S=13\K"^"Z&< MD\$H*IC!LS353J'9%-MI$*@3351L$+7BC)TSO-1OO1W^1W^8>DS&G$JF+WC@ M1'*K<;A46=,_"A%;MTDQ805#"\HX M@^OFJ21ULTRDC:)4_P5C-\MW?O!1)ZSKW<2YK.R=Y]:VZ%[[T>#'1_@ZKX\ M)7;U8O\<^LMF-.G_%Z17_7%LHQM,:9X];B5"^%QV%D"#(3DB6-(J"9=9]1Y8 M#X)ZVJ3H1O8K(DM[!Q=O8RI@9_.-7W__BKX(]+11,?J4B:5.E6'IN#-EHXGU MFG'T;85=C"[M38W[$9T&+RI*?04I*@P3F9H?,SP%8D^SS 6:&*4N!Z9A#L>T M*YL:%SHXYSN(%RS!. WU[RO?%3KO,/[X.J-#61I&W+)86%!"H/=!N'..2"45 ML2)0PA!H3"5*T?&%TP, 3X,GW>ED!8/VCD2NO(>=A]G;U'!4 8Q?^L$ THL? M\TO5V2^6T0@Q4L5*%^1HB4R1XAM '0I.6FJC5\'7[L2T)^338-DA];:"=]WD M1[W^CB]&?PP?1OT(US^\!LUZ*C$M1.5. M0$^88U5UM()9^X4R5T)^X_NCMJ=Z3SO@,G%%LBP]VSW/:*/Q0, KKO$G*)_- MBH+O?\[35G]M0:Y0<@=MZ3]->P#]#LW%R'_]TH]^X(>I[4OV$;[!\ K>#G,S MNFPO:%XVPW( 3V]K/O;'_]RCZU>=!^_?)JP# 53J*[;TL!M^!A.DUYSA9F&1 M1\ZA^Y2\)=HS<"KCN91J-]]:CV;O,VWQDZ?YS6 Q=!I;6LJ+']?%NSD84"%Y8H"75@OE M_&0HHJ2=S8FBJD-MG_T>.,"8TX8'3DC&-_ZU>+W!H:CQ4+W , M9FPA]BX8<36>-)>E[>X"Q%G&.PAE0^(.#U=>]DI=4DI<0H\?W0!TS@2MGMSS M *0CE!G44M\B+2K*OH/L\Q5OPPL8QB^7?O3/]I4 ZR-#5XV(,C%;9K3#/-.9 M:/31A38Q2UU[RMM#F$[;TMA=_!VD+2_CFZ.;O1J;X#N4S;& [=$8'GMH]$&Z M5%#'(4R019S,H$?'62#113Z=DQQ*4)D+RV-TSD&JW23U.'39WA@Y(%NVT4(7 MK9K\ ,:SB-.'49.N8AN/G+=6\* ,M*D3N633 "561$%2RBK[J$RTM0,^]P)Z M!";)7OI;;.943?@=6"5GL4V?07P1^M_**7O=,-8S5V:<.IX=D1'_<,:4#@XT M>JN-S;EVA&P=EA/C0Q615^]/\W^;T=R G@XMLSIZ$3.0:*-"-%P0'\IH[>@L MU9QEK38Z.!YL4K/XY!,P.BN(M'('L-*1]CS?P32C\B:@*O8#6POD\-W!]M50 MTY5X*[_##=J2J).NF MDJ!J-\B?8WDQP^(2^.S $)OQZ))E))>3&DT"2UUV0J%BU%9*>W%B2MM%4%V] M:2]G6'@9W>@Y)T)F3Z2C!15ZDC08D8+7.7BSE=)>GIC2=A%4Q4#;'2ROYC%A M99(KXUJ9*JF>$5'YB%1B-FB7<:%6;-;(9^T9INPBJHNEZ!\OK&1;TKY ^ M+A)0"1?%4O&3*"[*TTBJ-I5YW,LO\^PX.$J-6OKJ6@97I(4 M"2FBJ9S0,@8/EAF]E=)^/S&E[2*HV@7DH_[=+)LLX&Y"Q]\,DK;15"U"\'G6-[.C2(($)DTQ+<=<@%=41]>![! M%=6[;A*Z=Q7ZVAC9T0I,RIR>=_UOD,[&8YB,PX^;?W8V G^HAN@KO^^; MX-H[,2-^@70UP*U\II+Q&WS32P.[T= /;BXJAFE!0;,V_9J%G%4D-B1=+-A M?-) E##<@8+D=.U*W_T0'ZKXQU(@<[,CO.J/)Z-^N&HUU]ZA M<1HCSYYH55)K8[3$0FBM#\DRQ4-#UDYV7X_F6/D#AZ1$TXEJ.L@\6XUL?C>^ M ;:.4EKOPW6<=-9:.MR(&GLHX- DB893R1@C.=-2NUY&0&D3"1BMJ%$I)U7[ MC#L\.1Y(7CT&-[:1>\V[U9(;-_K1^_-3+PM=]&"^<>&-]I%*0V)0KOB1'(^_&>KIJ*@IZ M[8:_8W3GSH8-,?UV]I#X<_'@X)K-RXR^?,]5V3#=*OOO)6X59MD%9 M*SCRQ8_@A4Q?7SYY'F&O4TB964*ITT9(BKP4%2!V)Q- M=MXKS3>+_:]]Q!'.C0X9U7!R@O&837OKHTU1?!3'63CGZ */6 M.1E&>-D,B[?2>B[+]/HPIU=/TW)M[ Q!][64UR8\'B)GJ%:1 [..4]@L:7/[ M9Y\P+3I61.VLIUMPVY6??RUR&7]X<3YGM4>[@',M,C R-# Y,S!?;&%B+GAM;-2]:7/D.)(V M^'U^!;;7;+?;3*CB 5ZU,_.:\JK-=[,RTS*57>]8VEH8+DKL#D6H24J5FE^_ M (\(QL6 (T"J]D-E22$2[OX@W $X_/CW__'C?HF>9%D5Z]5__,7_R?L+DBN^ M%L7J]C_^\NWF'4[_\C_^\]_^[=__-XS_UZLO']";-7^\EZL:O2XEK:5 ?Q3U M':KO)/I]7?ZS>*+H\Y+6^;J\Q_@_F]=>KQ^>R^+VKD:!%Y#^L?ZOY2])Z*6! M%W(_L"!C<21CG,B<8Y*E'&<__OCCIQ^L7/ZT+F]_ M#CPO_+E_^B_=XS\.GO\C;)[VLRS[N?GKYM&J./:@&M;_^7_]]N$KOY/W%!>K MJJ8KK@E4Q2]5\^&'-:=U@_I9OM#))_1ON'\,ZX^P'^#0_^E')?[RG_^&4 M' MN5[*+S)'^O_?OKP_23+[63_Q\TK>ZKG]+,MB+;[6M*P_4":7BOMFM/KY0?[' M7ZKB_F$I^\_N2ID?'W99ECNC:BXSS:4?:R[_]U/$?KZ ?4?\UH>\.F"N$?>C M*Q[',/WHC-T;92'D] P/R%S,KL2 MRFK]6/)VA51\Z=U!R^I_?OOIZT^(:MK/J-J0_O>?MQ),@^SRSX#7$@;55[3E M!@W9070E4,\0VG*$OK<\_;\G\5SS'>I+O:M8E_N(K+D+1+:*7"E(&CAR6K$& MDV[XG_4F[V>YK*O^$ZP_:;3Y$@Y^/O@279>]Y+3D9^:J>^)GOE:;L(<:[TQ; M7J[OG4%4KYU]_]H)5:S_!:U+(4NU/3\"PX$N?7J0FL;J]H-4>\(/!67%LAG] M,WW67%1O'N4UJ^J2\GH1B"3+XRC&(4\95GOH%&<\#7"4RY3X2HU8A)]IH6X0N^* MBM,E^B])2_0;K?4W]1E][_ET:)=LX'%DD$"D9[5$-J#LFR"K,>QLS[7XQV-5 M-X/>K+](+62QE.H8\G[%U_?RP[I2G[^FU=WGKWE= M/#7<;;3+CSFE)$[5R9^GF$2)CUD<,RQ9&"5AF$5YG"V4C65K4RLU!9L0C1TR M:ZRX Z:U@I8]VT@=2M%2L:P_U3]SQ3AZ5/RB8H76&S6G&Y9_@9G"22;5S&2^ M]$3!3.O>#&WX18IAU'*,_JIY_IO^LV8;]7PC]HS^^JV=L[\-;/.6_4EL[I3X M.K+-D[ XJPV?$N1]6S\I+;LUX5>YOBWIPUW!KTNU 'U8JX6H>)+B6NU#ZJU! M" FEG$09#C.]$XVR'#./^MA+*6=^('WB2<#^!K++'R4RL2IH6+E;XH:4&6S9/ &.V3%XN+DRO-O2N MFGMS?:#K:%ZA7\OUB.S@E7!<-$ZE&\DJ[=>X&O.'^\?E_KBJYGC;RNUIBZ+_Y9";]]?R7Q=RAOZ8R$#/V-Y M0G$L>*+60>YAF@J)I?!\YBO[,[8(Y(Y4PNV(>NT_9$$>:.M3' MZV8:##T9LZ%J96@T.X-KIRNTX1(-:PBQ:M#)X5+ MZ%QY)9SP-*\;PB6,!WX'IX/#K"H7/ZK%Z\>J7M_+\FVW,4YBDN41C3$-9* V M.FF 6:"CHY(P9HN)PZ8_,W)D%KQ?03C6GRLM!KS-/1=V:Q,F/<]L9B]!F[ MG51SI?5Z7=4WVOCME>X*:=I&'HX\(5:C?V9@P+Y!19K0:'XP\]5*L::$'>BM_,M/ 0]''=>XB@8"K<".+2R?Z2>:/:%(E M^4^WZZ>?U3NM$JD?MKIS.-(LVG)2@%X_3C]@MUSIFS?]W]M_/19/:IN\JJLO M4HU<<+4UUG^X7HG=#P9/ME'&[U=4?N(GL:]#W??:(5"O53HK[U9%4?[ MGIF9GW4[]3(3L[]+>R$N;$]F.L[T>.SA8S#- N"E(:44@F+]+/@8O) OKW(VTU4+?2,!\?7]/PW*6;0LR$L7'D;HCSI M0=(:(6>'3#@',Q] K2$Z/)S:#V7A26YC5OYON12=+_OS>EGPYZT6R5R=5@/I M8R(YQ\1C'+.8I>J?D+'04_8KB(U=R^>H37S [4*K-'VD&$": X!O]BQ6!FYH MEPC ;,LQX='WEKR1X; !."]=@F,G3L;].V .;9-A1OU=)\=9#[7MZD\.[YP MXY?@_K>;DNIMW=?G>[96"D@3&;"(XRQ+U<9*@8C5;HI@/R6<466]@M W];_M MC#RQ>>IHH9:8N0MN5_KS+CAKF6 &QU C/Q?J5+E316\4.QDN]K>5\M1.[%THM"G(VY+DOM'&GR:KHP! /] M/S?&U'O[Y1+U*\Z0N)F&GP5@7*M=R@[Y MJMI%I>>E\5RAI^JG09ZHN8X:(71>5UV# [S&,<4%?7?JT(-*;J701@1F4VR( MN$,%![T'5_2/Z]5'N08NKCLO3:RZBA;^^/838/7<%>F\"EI+ ].U7A#'Z^%1 M[JWT97>DV13CJ !##3C^@.4Y](Z6\A6MI!B:OL'2^>IY^TA7I^/Z#UJ*YI^_ MRTIO=]LK/7\19;F,LCC%44Y33!CEF&;JIS"+HCR(/9]0(^_.%,Q-O/ ?'=R2OKS^Q0'@L,LT1F9T7=-WM$VYHQP5AN: M4V/.MK4Y(]1PDW/N40LOFE;:ZO5R7@-\T0@B[>QI5S[:RD M=JZUT\/.YU@[*]J.6^W\TQ8A+I_RO.!2!P<^-&OK2KQ[+%=%K2:R.ZWZ(N-) MR!D.3J1,L4]]$01!S+DPJK%B1FYB-6[I-U'=#0--,'#>LP"([CB/ MV[@2NT<#ILP=$&]W@-A0MTG./(\((.#%*3)V$2^7(@0+@C$6>#0*YOPH\X7! M&$NT$P=C_I9E2>3Z3I;JK'%?M*7Q/FRNIF,OY=3C 4Y)PC!A>8"S.,BQI(E/ MA9=Q+@-0_>-3E*8V<9HN&A"^X$[_-%IF[@TG& -FYWX\!K%YT1S59#X))UY MJP^?$_>@U/#9%^#GA\_T^>\Z>Z&YVE=L;S>=IE],PU&F^WHJXNBI0@/R@ZVS MXZ\J4%BK?;3)^+-MJ '"#G?6D-'IG5)X\VZ6R_5NU_JU?5] M;7KR/3/,Q(N*IHX:\JBACP8,H"]2+<\K='V_?EP9EB

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�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σ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end XML 87 cdxs-20240930_htm.xml IDEA: XBRL DOCUMENT 0001200375 2024-01-01 2024-09-30 0001200375 2024-10-28 0001200375 2024-09-30 0001200375 2023-12-31 0001200375 us-gaap:ProductMember 2024-07-01 2024-09-30 0001200375 us-gaap:ProductMember 2023-07-01 2023-09-30 0001200375 us-gaap:ProductMember 2024-01-01 2024-09-30 0001200375 us-gaap:ProductMember 2023-01-01 2023-09-30 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2024-07-01 2024-09-30 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2023-07-01 2023-09-30 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2024-01-01 2024-09-30 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2023-01-01 2023-09-30 0001200375 2024-07-01 2024-09-30 0001200375 2023-07-01 2023-09-30 0001200375 2023-01-01 2023-09-30 0001200375 us-gaap:CommonStockMember 2024-06-30 0001200375 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001200375 us-gaap:RetainedEarningsMember 2024-06-30 0001200375 2024-06-30 0001200375 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001200375 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001200375 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001200375 us-gaap:CommonStockMember 2024-09-30 0001200375 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001200375 us-gaap:RetainedEarningsMember 2024-09-30 0001200375 us-gaap:CommonStockMember 2023-06-30 0001200375 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001200375 us-gaap:RetainedEarningsMember 2023-06-30 0001200375 2023-06-30 0001200375 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001200375 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001200375 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001200375 us-gaap:CommonStockMember 2023-09-30 0001200375 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001200375 us-gaap:RetainedEarningsMember 2023-09-30 0001200375 2023-09-30 0001200375 us-gaap:CommonStockMember 2023-12-31 0001200375 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001200375 us-gaap:RetainedEarningsMember 2023-12-31 0001200375 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001200375 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001200375 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001200375 us-gaap:CommonStockMember 2022-12-31 0001200375 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001200375 us-gaap:RetainedEarningsMember 2022-12-31 0001200375 2022-12-31 0001200375 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001200375 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001200375 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001200375 2022-01-01 2022-12-31 0001200375 2023-01-01 2023-12-31 0001200375 srt:AmericasMember 2024-07-01 2024-09-30 0001200375 srt:AmericasMember 2023-07-01 2023-09-30 0001200375 srt:AmericasMember 2024-01-01 2024-09-30 0001200375 srt:AmericasMember 2023-01-01 2023-09-30 0001200375 us-gaap:EMEAMember 2024-07-01 2024-09-30 0001200375 us-gaap:EMEAMember 2023-07-01 2023-09-30 0001200375 us-gaap:EMEAMember 2024-01-01 2024-09-30 0001200375 us-gaap:EMEAMember 2023-01-01 2023-09-30 0001200375 cdxs:APACMember 2024-07-01 2024-09-30 0001200375 cdxs:APACMember 2023-07-01 2023-09-30 0001200375 cdxs:APACMember 2024-01-01 2024-09-30 0001200375 cdxs:APACMember 2023-01-01 2023-09-30 0001200375 cdxs:ShortTermUnbilledReceivablesMember 2024-09-30 0001200375 cdxs:LongTermUnbilledReceivablesMember 2024-09-30 0001200375 cdxs:ShortTermUnbilledReceivablesMember 2023-12-31 0001200375 cdxs:LongTermUnbilledReceivablesMember 2023-12-31 0001200375 us-gaap:ProductMember 2024-10-01 2024-09-30 0001200375 us-gaap:ProductMember 2025-01-01 2024-09-30 0001200375 us-gaap:ProductMember 2026-01-01 2024-09-30 0001200375 us-gaap:ProductMember 2027-01-01 2024-09-30 0001200375 us-gaap:ProductMember 2024-09-30 0001200375 us-gaap:StockCompensationPlanMember 2024-07-01 2024-09-30 0001200375 us-gaap:StockCompensationPlanMember 2023-07-01 2023-09-30 0001200375 us-gaap:StockCompensationPlanMember 2024-01-01 2024-09-30 0001200375 us-gaap:StockCompensationPlanMember 2023-01-01 2023-09-30 0001200375 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001200375 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001200375 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001200375 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001200375 cdxs:SeqWellMember 2023-07-01 2023-09-30 0001200375 cdxs:SeqWellMember 2023-01-01 2023-09-30 0001200375 cdxs:ArzedaMember 2023-01-01 2023-09-30 0001200375 cdxs:ArzedaMember 2023-07-01 2023-09-30 0001200375 cdxs:MolecularAssembliesIncMember 2024-09-30 0001200375 cdxs:MolecularAssembliesIncMember 2023-12-31 0001200375 cdxs:SeqWellMember 2024-09-30 0001200375 cdxs:SeqWellMember 2023-12-31 0001200375 us-gaap:OtherAggregatedInvestmentsMember 2024-09-30 0001200375 us-gaap:OtherAggregatedInvestmentsMember 2023-12-31 0001200375 us-gaap:CashAndCashEquivalentsMember 2024-09-30 0001200375 us-gaap:ShortTermInvestmentsMember 2024-09-30 0001200375 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-09-30 0001200375 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-09-30 0001200375 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-09-30 0001200375 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-09-30 0001200375 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-09-30 0001200375 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-09-30 0001200375 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001200375 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001200375 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001200375 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001200375 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001200375 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001200375 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2024-09-30 0001200375 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2024-09-30 0001200375 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2024-09-30 0001200375 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001200375 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001200375 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001200375 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001200375 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001200375 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001200375 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001200375 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001200375 us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0001200375 us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001200375 us-gaap:ConvertibleDebtMember 2023-07-01 2023-09-30 0001200375 us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001200375 cdxs:LaboratoryEquipmentMember 2024-09-30 0001200375 cdxs:LaboratoryEquipmentMember 2023-12-31 0001200375 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001200375 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001200375 us-gaap:ComputerEquipmentMember 2024-09-30 0001200375 us-gaap:ComputerEquipmentMember 2023-12-31 0001200375 cdxs:OfficeEquipmentAndFurnitureMember 2024-09-30 0001200375 cdxs:OfficeEquipmentAndFurnitureMember 2023-12-31 0001200375 us-gaap:ConstructionInProgressMember 2024-09-30 0001200375 us-gaap:ConstructionInProgressMember 2023-12-31 0001200375 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001200375 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001200375 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001200375 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001200375 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001200375 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001200375 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001200375 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001200375 cdxs:A2024InducementPlanMember 2024-08-31 0001200375 us-gaap:EmployeeStockMember 2023-06-01 2023-06-30 0001200375 us-gaap:EmployeeStockMember 2023-06-30 0001200375 us-gaap:EmployeeStockMember 2024-07-01 2024-09-30 0001200375 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001200375 us-gaap:EmployeeStockMember 2024-09-30 0001200375 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001200375 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001200375 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-09-30 0001200375 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-01-31 0001200375 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-01-31 0001200375 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-01-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001200375 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001200375 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001200375 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001200375 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001200375 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001200375 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001200375 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001200375 cdxs:RSAsandRSUsMember 2024-07-01 2024-09-30 0001200375 cdxs:RSAsandRSUsMember 2023-07-01 2023-09-30 0001200375 cdxs:RSAsandRSUsMember 2024-01-01 2024-09-30 0001200375 cdxs:RSAsandRSUsMember 2023-01-01 2023-09-30 0001200375 cdxs:PerformanceContingentRestrictedStockUnitsPSUMember 2024-07-01 2024-09-30 0001200375 cdxs:PerformanceContingentRestrictedStockUnitsPSUMember 2023-07-01 2023-09-30 0001200375 cdxs:PerformanceContingentRestrictedStockUnitsPSUMember 2024-01-01 2024-09-30 0001200375 cdxs:PerformanceContingentRestrictedStockUnitsPSUMember 2023-01-01 2023-09-30 0001200375 cdxs:PerformanceBasedOptionsPBOsMember 2024-07-01 2024-09-30 0001200375 cdxs:PerformanceBasedOptionsPBOsMember 2023-07-01 2023-09-30 0001200375 cdxs:PerformanceBasedOptionsPBOsMember 2024-01-01 2024-09-30 0001200375 cdxs:PerformanceBasedOptionsPBOsMember 2023-01-01 2023-09-30 0001200375 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0001200375 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001200375 us-gaap:EmployeeStockOptionMember 2024-09-30 0001200375 cdxs:RSAsandRSUsMember 2024-09-30 0001200375 2023-02-27 0001200375 cdxs:PiperSandlerCoMember 2021-05-01 2021-05-31 0001200375 srt:MaximumMember cdxs:PiperSandlerCoMember 2021-05-31 0001200375 cdxs:PiperSandlerCoMember 2024-07-01 2024-09-30 0001200375 cdxs:PiperSandlerCoMember 2024-01-01 2024-09-30 0001200375 cdxs:PiperSandlerCoMember 2023-07-01 2023-09-30 0001200375 cdxs:PiperSandlerCoMember 2023-01-01 2023-09-30 0001200375 cdxs:CantorSalesAgreementMember 2024-05-02 2024-05-02 0001200375 cdxs:CantorSalesAgreementMember 2024-05-02 0001200375 cdxs:CantorMember 2024-07-01 2024-09-30 0001200375 cdxs:CantorMember 2024-01-01 2024-09-30 0001200375 cdxs:CantorMember 2024-09-30 0001200375 cdxs:SanCarlosMember 2023-10-01 0001200375 cdxs:SanCarlosMember 2023-10-01 2023-10-01 0001200375 cdxs:SanCarlosMember 2023-07-01 2023-09-30 0001200375 cdxs:SanCarlosMember 2023-10-01 2023-12-31 0001200375 cdxs:FacilityMaintenanceAgreementMember 2024-09-30 0001200375 us-gaap:IndemnificationGuaranteeMember 2024-09-30 0001200375 cdxs:InnovatusLoanMember us-gaap:SecuredDebtMember 2024-02-13 2024-02-13 0001200375 cdxs:InnovatusLoanMember us-gaap:SecuredDebtMember 2024-02-13 0001200375 cdxs:InnovatusLoanFirstTrancheMember us-gaap:SecuredDebtMember 2024-02-13 0001200375 cdxs:InnovatusLoanSecondTrancheMember us-gaap:SecuredDebtMember 2024-02-13 0001200375 2024-02-13 0001200375 srt:MaximumMember cdxs:InnovatusLoanMember us-gaap:SecuredDebtMember 2024-02-13 0001200375 srt:MinimumMember cdxs:InnovatusLoanMember us-gaap:SecuredDebtMember 2024-02-13 0001200375 cdxs:InnovatusLoanMember us-gaap:SecuredDebtMember 2024-07-01 2024-09-30 0001200375 cdxs:InnovatusLoanMember us-gaap:SecuredDebtMember 2024-01-01 2024-09-30 0001200375 cdxs:InnovatusLoanMember us-gaap:SecuredDebtMember 2024-09-30 0001200375 cdxs:InnovatusLoanWarrantsMember us-gaap:SecuredDebtMember 2024-02-13 0001200375 cdxs:CustomerAMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001200375 cdxs:CustomerAMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001200375 cdxs:CustomerAMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001200375 cdxs:CustomerBMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001200375 cdxs:CustomerBMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001200375 cdxs:CustomerCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001200375 cdxs:CustomerDMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001200375 cdxs:CustomerEMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001200375 cdxs:CustomerFMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001200375 cdxs:CustomerGMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001200375 cdxs:CustomerHMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001200375 cdxs:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001200375 cdxs:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001200375 cdxs:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001200375 cdxs:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001200375 cdxs:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001200375 cdxs:CustomerIMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001200375 cdxs:CustomerJMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001200375 cdxs:CustomerKMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001200375 country:US 2024-09-30 0001200375 country:US 2023-12-31 shares iso4217:USD iso4217:USD shares cdxs:segment pure cdxs:tranche 0001200375 false 2024 Q3 --12-31 P3M P1Y P1Y http://fasb.org/us-gaap/2024#PrimeRateMember http://fasb.org/us-gaap/2024#PrimeRateMember 10-Q true 2024-09-30 false 001-34705 Codexis, Inc. DE 71-0872999 200 Penobscot Drive Redwood City CA 94063 650 421-8100 Common Stock, par value $0.0001 per share CDXS NASDAQ Yes Yes Accelerated Filer true false false 81377855 37452000 65116000 514000 519000 52803000 0 9721000 10036000 3424000 815000 3460000 9142000 16605000 19993000 65000 65000 16540000 19928000 2103000 2685000 3490000 5218000 112902000 93466000 1062000 1062000 5790000 9700000 10772000 13137000 13266000 15487000 2463000 2463000 1928000 1246000 148183000 136561000 4212000 5947000 10320000 11246000 6505000 4735000 4081000 3781000 10011000 10121000 35129000 35830000 610000 640000 9134000 12243000 28631000 0 1279000 1233000 74783000 49946000 0.0001 0.0001 5000000 5000000 0 0 0 0 0 0 0.0001 0.0001 200000000 200000000 81376000 81376000 69905000 69905000 8000 7000 625696000 584138000 126000 0 -552430000 -497530000 73400000 86615000 148183000 136561000 11158000 5395000 26968000 24807000 1675000 3882000 10917000 18775000 12833000 9277000 37885000 43582000 4317000 2249000 12634000 9947000 11505000 13662000 34164000 47651000 13568000 12302000 42100000 41066000 0 3140000 0 3284000 0 9984000 165000 9984000 29390000 41337000 89063000 111932000 -16557000 -32060000 -51178000 -68350000 849000 1056000 2730000 3266000 -4922000 -3895000 -6421000 -3930000 -20630000 -34899000 -54869000 -69014000 10000 9000 31000 34000 -20640000 -34908000 -54900000 -69048000 -0.29 -0.29 -0.50 -0.50 -0.78 -0.78 -1.02 -1.02 72032000 72032000 69466000 69466000 70759000 70759000 67670000 67670000 -20640000 -34908000 -54900000 -69048000 149000 0 126000 0 -20491000 -34908000 -54774000 -69048000 70914000 7000 593253000 -23000 -531790000 61447000 22000 1584000 10440000 1000 29735000 29736000 2708000 2708000 -20640000 -20640000 149000 149000 81376000 8000 625696000 126000 -552430000 73400000 69804000 6000 579555000 0 -455430000 124131000 23000 2283000 2283000 -34908000 -34908000 69827000 6000 581838000 0 -490338000 91506000 69905000 7000 584138000 0 -497530000 86615000 73000 143000 143000 834000 859000 859000 124000 260000 260000 1584000 10440000 1000 29735000 29736000 10561000 10561000 -54900000 -54900000 126000 126000 81376000 8000 625696000 126000 -552430000 73400000 65811000 6000 566081000 0 -421290000 144797000 214000 422000 422000 787000 721000 3080000 7931000 7931000 7808000 7808000 65000 404000 404000 -69048000 -69048000 69827000 6000 581838000 0 -490338000 91506000 -54900000 -69048000 3737000 4302000 2364000 3647000 10561000 7808000 165000 9984000 3910000 3875000 0 187000 611000 0 -1009000 0 11000 -3000 -2818000 -21580000 -582000 276000 -1417000 252000 -1339000 -105000 -1334000 7269000 -3064000 -4384000 -140000 -11273000 -32942000 -41601000 2531000 4798000 84000 27000 72643000 0 19000000 0 1973000 0 0 1191000 -54117000 -5962000 281000 422000 525000 0 31320000 8652000 1615000 503000 29521000 0 642000 0 0 404000 59390000 8167000 -27669000 -39396000 66697000 116026000 39028000 76630000 1633000 28000 17000 193000 249000 159000 37452000 74577000 1576000 2053000 39028000 76630000 52800000 90300000 Description of Business<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to the unaudited condensed consolidated financial statements, the “Company,” “Codexis,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins leveraging our proprietary CodeEvolver</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directed evolution technology platform.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our Chief Executive Officer (“CEO”), our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment. Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocates resources based on the consolidated results of operations. We believe that these changes better align internal resources to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of December 31, 2023. Comparative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.</span></div> 2 1 2 Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024 and 2023, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2023.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2024 and results of operations for the interim periods presented. The interim results are not necessarily indicative of the results for any future interim period or for the entire year.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify all marketable debt securities that have effective maturities of three months or less from the date of purchase as cash equivalents and those with effective maturities of greater than three months as short-term investment securities in the condensed consolidated balance sheets. We determine the appropriate classification of our short-term investments at the time of purchase and reevaluate such designation at each balance sheet date. We have classified and accounted for our short-term investments as available-for-sale. After consideration of our risk versus reward objectives, as well as our liquidity requirements, we may sell these debt securities prior to their effective maturities. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry these short-term investments at fair value, and report the unrealized gains and losses, net of taxes, as a component of stockholders’ equity, except for the changes in allowance for expected credit losses, which are included in “Interest and other expense, net” in the unaudited condensed consolidated statements of operations. We determine any realized gains or losses on the sale of short-term investments on a specific identification method, and we record such gains and losses as a component of interest income.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are reviewed periodically for allowances for credit losses and impairment. When evaluating the investments, the Company reviews factors such as the extent to which the fair value of the security is less than the amortized cost basis, adverse conditions specifically related to the security, the financial condition of the issuer, the Company’s intent to sell, and whether it would be more likely than not that the Company would be required to sell the investments before the recovery of the amortized cost basis.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the carrying values of long-lived assets, which include property and equipment and right-of-use assets, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with the future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies assets as held for sale when the following conditions are met: (i) management has committed to a plan to sell, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to identify a buyer, (iv) it is probable that a sale will occur within one year, (v) the assets are actively marketed for sale at a reasonable price in relation to their current fair value, and (vi) there is a low likelihood of significant changes to the plan or that the plan will be withdrawn. If all of the criteria are met as of the balance sheet date, the assets are presented separately in the consolidated balance sheet as held for sale at the lower of the carrying amount or fair value less costs to sell. The assets are then no longer depreciated or amortized while classified as held for sale. There were no assets classified as held for sale as of September 30, 2024 and December 31, 2023.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2024, that are of significance or potential significance to us.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2024-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements - Amendments to Remove References to the Concepts Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU amends the FASB Accounting Standard Codification (the “ASC”) to remove references to various concepts statements and impacts a variety of topics in the ASC. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, FASB issued ASU No. 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU require public companies, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, FASB issued ASU No. 2023-07,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The standard should be applied retrospectively to all prior periods presented in the financial statements. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, FASB issued ASU No. 2023-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU are intended to amend certain disclosure and presentation requirements for a variety of topics within the ASC. These amendments align the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, as announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.</span></div> <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024 and 2023, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2023.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2024 and results of operations for the interim periods presented. The interim results are not necessarily indicative of the results for any future interim period or for the entire year.</span></div>The unaudited condensed consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</span></div> <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify all marketable debt securities that have effective maturities of three months or less from the date of purchase as cash equivalents and those with effective maturities of greater than three months as short-term investment securities in the condensed consolidated balance sheets. We determine the appropriate classification of our short-term investments at the time of purchase and reevaluate such designation at each balance sheet date. We have classified and accounted for our short-term investments as available-for-sale. After consideration of our risk versus reward objectives, as well as our liquidity requirements, we may sell these debt securities prior to their effective maturities. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry these short-term investments at fair value, and report the unrealized gains and losses, net of taxes, as a component of stockholders’ equity, except for the changes in allowance for expected credit losses, which are included in “Interest and other expense, net” in the unaudited condensed consolidated statements of operations. We determine any realized gains or losses on the sale of short-term investments on a specific identification method, and we record such gains and losses as a component of interest income.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are reviewed periodically for allowances for credit losses and impairment. When evaluating the investments, the Company reviews factors such as the extent to which the fair value of the security is less than the amortized cost basis, adverse conditions specifically related to the security, the financial condition of the issuer, the Company’s intent to sell, and whether it would be more likely than not that the Company would be required to sell the investments before the recovery of the amortized cost basis.</span></div> <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>We evaluate the carrying values of long-lived assets, which include property and equipment and right-of-use assets, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with the future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div>The Company classifies assets as held for sale when the following conditions are met: (i) management has committed to a plan to sell, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to identify a buyer, (iv) it is probable that a sale will occur within one year, (v) the assets are actively marketed for sale at a reasonable price in relation to their current fair value, and (vi) there is a low likelihood of significant changes to the plan or that the plan will be withdrawn. If all of the criteria are met as of the balance sheet date, the assets are presented separately in the consolidated balance sheet as held for sale at the lower of the carrying amount or fair value less costs to sell. The assets are then no longer depreciated or amortized while classified as held for sale. <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2024, that are of significance or potential significance to us.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2024-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements - Amendments to Remove References to the Concepts Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU amends the FASB Accounting Standard Codification (the “ASC”) to remove references to various concepts statements and impacts a variety of topics in the ASC. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, FASB issued ASU No. 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU require public companies, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, FASB issued ASU No. 2023-07,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The standard should be applied retrospectively to all prior periods presented in the financial statements. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, FASB issued ASU No. 2023-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU are intended to amend certain disclosure and presentation requirements for a variety of topics within the ASC. These amendments align the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, as announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. We are currently evaluating the effects of the standard on our consolidated financial statements and related disclosures.</span></div> Revenue Recognition<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about disaggregated revenue from contracts with customers by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eographic regions. The geographic regions that are tracked are the Americas (United States, Canada, and Latin America), EMEA (Europe, Middle East, and Africa), and APAC (Australia, New Zealand, Southeast Asia, and China).</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disaggregated information is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary geographical markets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,885 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,582 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities: deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no asset impairment charges related to financial assets in the three and nine months ended September 30, 2024 and 2023.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in contract assets was primarily due to increases in product revenue from contracts subject to over time revenue recognition. The decrease in unbilled receivables was primarily due to the timing of billings. The decrease in deferred revenue was primarily due to the timing of recognition of revenue.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we have </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of short-term unbilled receivables presented as unbilled receivables within current assets and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of long-term unbilled receivables that is included within the other non-current assets line item in the condensed consolidated balance sheets. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of short-term unbilled receivables presented as unbilled receivables within current assets and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of long-term unbilled receivables that is included within the other non-current assets line item in the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following revenues (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the period for:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in contract liabilities at the beginning of the period:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied from new activities in the period - contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,885 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,582 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2024.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balances in the table below a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2024 (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remainder of 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027 and Thereafter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div> <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about disaggregated revenue from contracts with customers by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eographic regions. The geographic regions that are tracked are the Americas (United States, Canada, and Latin America), EMEA (Europe, Middle East, and Africa), and APAC (Australia, New Zealand, Southeast Asia, and China).</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disaggregated information is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary geographical markets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,885 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,582 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 1534000 4278000 9823000 10798000 2229000 3191000 6768000 14630000 9070000 1808000 21294000 18154000 12833000 9277000 37885000 43582000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities: deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following revenues (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the period for:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in contract liabilities at the beginning of the period:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied from new activities in the period - contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,885 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,582 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 3424000 815000 4793000 9904000 10621000 10761000 0 0 3500000 1300000 9100000 800000 0 1303000 475000 9111000 146000 1018000 -446000 4238000 12687000 6956000 37856000 30233000 12833000 9277000 37885000 43582000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2024.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balances in the table below a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2024 (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remainder of 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027 and Thereafter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div> 9981000 140000 140000 360000 10621000 N<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">et Loss per S</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">hare</span><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding, less restricted stock awards (“RSAs”) subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock shares outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common stock shares had been issued for other dilutive securities. For all periods presented, diluted and basic net loss per share are identical since potential common stock shares are excluded from the calculation, as their effect was anti-dilutive.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Dilutive Securities</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In periods of net loss, the weighted average number of shares outstanding, prior to the application of the treasury stock method, excludes potentially dilutive securities from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under the Equity Incentive Plan and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,355</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,355</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pertains to the warrants issued in connection with the Innovatus Loan. For additional information, see Note 11, “Debt.”</span></div> <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under the Equity Incentive Plan and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,355</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,355</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pertains to the warrants issued in connection with the Innovatus Loan. For additional information, see Note 11, “Debt.”</span></div> 12931000 8873000 12931000 8873000 424000 0 424000 0 13355000 8873000 13355000 8873000 Investments in Non-Marketable Securities<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Marketable Equity Securities</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-marketable equity securities are investments in privately held companies without readily determinable market value and primarily relate to our investments in Molecular Assemblies, Inc. (“MAI”) and seqWell, Inc. (“seqWell”). These investments are accounted for under the measurement alternative and are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes for identical or similar securities of the same issuer. Non-marketable equity securities are measured at fair value on a non-recurring basis and classified within Level 2 in the fair value hierarchy when we estimate the fair value of these investments using the observable transaction price paid by third party investors for the same or similar security of the same issuers. The fair value of non-marketable equity securities are classified within Level 3 when we estimate fair value using unobservable inputs such as when we remeasure due to impairment and we use discount rates, market data of comparable companies, and rights and obligations of the securities the Company holds, among others. We adjust the carrying value of non-marketable equity securities which have been remeasured during the period and recognize resulting gains or losses as a component of interest and other expense, net in the unaudited condensed consolidated statements of operations.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, we recognized an impairment charge of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is presented within interest and other expense, net in the condensed consolidated statements of operations. This adjustment is related to the write-down of our investment in MAI to its related fair value as determined based on valuation methods using the latest observed transaction price of MAI’s preferred stock securities to be issued during the fourth quarter of 2024 and adjusted for the rights and obligations of the preferred stock securities the Company holds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no remeasurement event for our investments in seqWell and other non-marketable equity securities that occurred during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2024. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, we recognized an impairment charge of $3.9 million and included this as an adjustment to the carrying value of our investments in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> seqWell and Arzeda Corp. (“Arzeda”). This adjustment, which is presented within interest and other expense, net in the condensed consolidated statements of operations, is related to the write-down of the carrying value of our investments in seqWell by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in Arzeda by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their estimated fair values as determined based on valuation methods using the recent transaction price of similar p</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">referred stock securities issued by the investees and adjusted for the rights and obligations of the preferred stock securities the Company holds. We recognized no realized gains or losses during the three and nine months ended September 30, 2024 and 2023. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table presents the carrying value of our non-marketable equity securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAI</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">seqWell</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments in non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-marketable equity securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,790 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 3900000 3900000 3900000 3900000 3000000.0 3000000.0 900000 900000 0 0 0 0 The following table presents the carrying value of our non-marketable equity securities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAI</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">seqWell</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments in non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-marketable equity securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,790 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table> 2783000 6693000 2625000 2625000 382000 382000 5790000 9700000 Fair Value Measurements<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company’s cash, cash equivalents, and short-term investments by significant investment category as of September 30, 2024 and December 31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,803 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,803 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,255 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,452 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,803 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments uses inputs that are either directly or indirectly observable for the asset through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We limit the credit risk associated with our cash equivalents and short-term investments by placing them with banks and institutions we believe are highly credit-worthy and investing in highly-rated investments. As of September 30, 2024, and December 31, 2023, the contractual maturity of all investments held was less than one year. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024 and 2023, we did not recognize any significant credit losses nor other-than-temporary impairment losses on our short-term investments.</span></div> <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company’s cash, cash equivalents, and short-term investments by significant investment category as of September 30, 2024 and December 31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,803 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,803 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,255 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,452 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,803 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments uses inputs that are either directly or indirectly observable for the asset through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term Investments</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 7359000 7359000 7359000 0 30093000 0 0 30093000 30093000 0 8416000 7000 0 8423000 0 8423000 8723000 14000 2000 8735000 0 8735000 1983000 9000 0 1992000 0 1992000 33555000 98000 0 33653000 0 33653000 52677000 128000 2000 52803000 0 52803000 90129000 128000 2000 90255000 37452000 52803000 8742000 8742000 8742000 0 56374000 0 0 56374000 56374000 0 65116000 0 0 65116000 65116000 0 0 0 0 0 0 0 0 0 Balance Sheets Details<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Inventories</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, prepaid expenses and other current assets consisted of prepaid expenses of $3.2 million and other current assets of $0.3 million. As of December 31, 2023, prepaid expenses and other current assets consisted of prepaid expenses of $4.6 million and other current assets of $0.6 million.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,989 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,487 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the unaudited condensed consolidated statements of operations was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Accrued Liabilities</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued purchases </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and outside service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,505 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,735 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Inventories</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 0 108000 36000 7000 2067000 2570000 2103000 2685000 3200000 300000 4600000 600000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,989 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,487 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the unaudited condensed consolidated statements of operations was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 36468000 37216000 12086000 11912000 2675000 2565000 1131000 1469000 1629000 1636000 53989000 54798000 40723000 39311000 13266000 15487000 965000 1121000 3017000 3606000 219000 236000 658000 696000 1184000 1357000 3675000 4302000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued purchases </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and outside service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,505 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,735 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 3291000 1402000 2810000 2330000 404000 1003000 6505000 4735000 Stock-based Compensation<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, our board of directors (the “Board”) approved the 2024 Employment Inducement Award Plan (the “2024 Inducement Plan”) which provides for the grant of non-qualified stock options, RSAs, restricted stock units (“RSUs”), and performance awards to eligible employees with respect to an aggregate of up to 1,000,000 shares of our common stock. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Board approved an employee stock purchase plan (as may be amended from time to time, the “ESPP”) which became effective upon approval at the Annual Meeting in June 2023. The ESPP allows eligible employees of the Company to purchase shares of our common stock through payroll deductions. Offering periods are generally</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over a 24-month period and begin in May and November of each year. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The per share purchase price will be the lower of 85% of the closing trading price per share of our common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date. Participant purchases are limited to a maximum of $25,000 of fair value of our stock per calendar year. The Company is authorized to grant up to 2,000,000 shares of common stock under the ESPP. The first offering period of the ESPP commenced in December 2023. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, nil and 123,889 shares of our common stock were purchased under the ESPP, respectively. As of September 30, 2024, 1,876,111 shares of common stock were available for future issuance under the ESPP. We recognized $0.1 million and $0.2 million of stock-based compensation expenses related to the ESPP for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the total unrecognized stock-based compensation expense, net of expected forfeitures, related to the ESPP was $0.6 million and is expected to be recognized over the remaining offering period.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees generally have a maximum term of ten years and vest over four years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. In January 2024, the Board approved the grants of stock options with a vesting term over three years from the date of grant, of which 33% vest at the end of one year, and 67% vest monthly over the remaining two years.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units (“RSUs”)</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also grant employees RSUs, which generally vest over either a period with 33% of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. We may grant RSUs with different vesting terms from time to time.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,561 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-contingent restricted stock units (“PSUs”)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance based options (“PBOs”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,561 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2024, we entered into an Advisory Services Agreement with a former executive of the Company. Pursuant to the advisory agreement, the exercise period for the former executive’s vested stock options and performance-based options was also extended. The modification resulted in a stock-based compensation expense of $2.0 million recognized in selling, general and administrative expenses during the nine months ended September 30, 2024.</span></div>As of September 30, 2024, unrecognized stock-based compensation expense, net of expected forfeitures, was $12.0 million related to unvested stock options, and $5.0 million related to unvested RSUs and RSAs. Stock-based compensation expense for these awards will be recognized through 2028. 1000000 P24M 0.85 0.85 25000 2000000 0 123889 1876111 100000 200000 600000 P10Y P4Y 0.25 P1Y 0.75 P3Y P3Y 0.33 P1Y 0.67 P2Y 0.33 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,561 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 93000 60000 309000 272000 690000 450000 2151000 1978000 1925000 1773000 8101000 5558000 2708000 2283000 10561000 7808000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-contingent restricted stock units (“PSUs”)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance based options (“PBOs”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,561 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1506000 1017000 5137000 3035000 1109000 942000 3578000 3441000 0 292000 247000 1408000 0 32000 1357000 -76000 93000 0 242000 0 2708000 2283000 10561000 7808000 2000000 12000000.0 5000000.0 Capital Stock<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exercise of Options</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024 and September 30, 2023, we issued 72,856 and 214,284 shares, respectively, upon option exercises at a weighted-average exercise price of $1.97 per share, with net cash proceeds of $0.1 million and $0.4 million, respectively.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Agreements</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we filed a Registration Statement on Form S-3 with the SEC (the “2021 Registration Statement”), that automatically became effective upon its filing, under which we were permitted to sell common stock, preferred stock, debt securities, warrants, purchase contracts, and units from time to time in one or more offerings. On February 27, 2023, we filed a post-effective amendment to the 2021 Registration Statement. Pursuant to that post-effective amendment, we registered an aggregate $200.0 million of securities. In May 2021, we entered into an Equity Distribution Agreement (“EDA”) with Piper Sandler &amp; Co (“PSC”), under which PSC, as our exclusive agent, at our discretion and at such times that we determined from time to time, may have sold over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock. Under the terms of the EDA, PSC was permitted to sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”).</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were not required to sell any shares at any time during the term of the EDA. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2024, we terminated the EDA.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No shares of our common stock were issued and sold pursuant to the EDA during the three and nine months ended September 30, 2024. During the three and nine months ended September 30, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nil</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 3,079,421 shares of our common stock, respectively, were issued and sold pursuant to the EDA and we received gross proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nil</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $8.7 million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nil</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $7.9 million in net proceeds after PSC's commissions and direct offering expenses of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nil</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $0.7 million, respectively. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2024, we entered into a Controlled Equity Offering℠ Sales Agreement (the “Cantor Sales Agreement”) with Cantor Fitzgerald &amp; Co., as sales agent (“Cantor”), under which Cantor, at our discretion and at such times that we may determine from time to time, may sell up to a maximum of $75.0 million of shares of our common stock. Under the terms of the Cantor Sales Agreement, Cantor may sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act. On May 2, 2024, we filed a registration statement on Form S-3 registering the offer and sale of these shares under the Securities Act which became effective on May 14, 2024. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the Cantor Sales Agreement.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,440,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of our common stock were issued and sold pursuant to the Cantor Sales Agreement and we received gross proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$29.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net proceeds after Cantor’s commissions and direct offering expenses of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, $43.7 million remained available for sale under the Cantor Sales Agreement.</span></div> 72856 214284 1.97 1.97 100000 400000 200000000 P3Y 50000000 0 0 0 3079421 0 8700000 0 7900000 0 700000 75000000 0.030 10440000 10440000 31300000 31300000 29700000 29700000 1600000 1600000 43700000 Commitments and Contingencies<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease and other information</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into operating leases primarily for office and laboratory space. Lease cost amounts included in the measurement of lease obligations and other information related to non-cancellable operating leases were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Company had no variable lease costs.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cash paid </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands):</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining 3 months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of operating lease liabilities as shown within the unaudited condensed consolidated balance sheets (in thousands):</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease obligations - Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations - Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, we announced our plan to consolidate operations from our previous San Carlos facility to our headquarters in Redwood City. On September 1, 2023, the Company entered into an Assignment and Assumption of Lease (the “Assignment Agreement”) with Vaxcyte, Inc. (“Vaxcyte”) to assign to Vaxcyte all of the Company’s right, title and interest in, under and to the San Carlos facility and the Lease Agreement, dated as of January 29, 2021. On September 6, 2023, the Company, Vaxcyte and ARE-San Francisco No. 63, LLC (“ARE”) entered into a Consent to Assignment and First Amendment pursuant to which ARE consented to the Assignment Agreement and the assignment by the Company and the assumption by Vaxcyte of the Company’s interest as tenant in the lease. The effective date of the assignment was October 1, 2023.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Assignment Agreement, the Company remeasured the lease obligation for the San Carlos facility to its present value of $3.1 million and wrote off the remaining lease liability of $19.6 million and the corresponding right of use asset balance. Simultaneously, the Company determined that indicators of impairment existed because the lease assignment impacts the utilization of the related right of use assets and leasehold improvements in the San Carlos facility, and therefore performed a recoverability test by estimating future undiscounted net cash flows expected to be generated from the use of these assets. As there were no substantial future cash inflows associated with these assets, the carrying values of these assets were deemed unrecoverable. As a result, during the third quarter of 2023, the Company recognized a non-cash impairment charge of $7.7 million, of which $4.7 million was related to leasehold improvements and $3.0 million for the right of use assets, presented within the asset impairment and other charges line item in the condensed consolidated statements of operations, for the three and nine months ended September 30, 2023. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the plan, the Company entered into agreements to sell certain laboratory equipment previously located in the San Carlos facility through an asset auction and as part of the lease assignment of the San Carlos facility to Vaxcyte. These certain items of laboratory equipment met the assets held for sale criteria and were sold during the fourth quarter of 2023. Using a fair value estimate based of Level 3 inputs in the fair value hierarchy, the Company determined that the carrying value of these assets exceeds fair value less costs to sell, which resulted in a write-down of $1.5 million, presented within the asset impairment and other charges line item in the consolidated statements of operations for the three and nine months ended September 30, 2023.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes. Commitments under service agreements are typically subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 (Remaining 3 Months)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025 and Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility maintenance agreement</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be involved in legal actions in the ordinary course of business, including inquiries and proceedings concerning business practices and intellectual property infringement, employee relations and other claims. We will recognize a loss contingency in the condensed consolidated financial statements when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. We will disclose any loss contingencies that do not meet both conditions if there is a reasonable possibility that a material loss may have been incurred. Gain contingencies are not recorded until they are realized. We are not currently a party to any material pending litigation or other material legal proceedings that management believes could have a material adverse effect on our financial statements.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented.</span></div> Lease cost amounts included in the measurement of lease obligations and other information related to non-cancellable operating leases were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Company had no variable lease costs.</span><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cash paid </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands):</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1032000 1618000 3097000 5278000 0 0 0 0 P3Y1M6D 0.066 3542000 5668000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining 3 months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of operating lease liabilities as shown within the unaudited condensed consolidated balance sheets (in thousands):</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease obligations - Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations - Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 1184000 4868000 5014000 2533000 760000 318000 14677000 1462000 13215000 4081000 9134000 13215000 3100000 19600000 7700000 4700000 3000000.0 1500000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 (Remaining 3 Months)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025 and Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility maintenance agreement</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 281000 281000 0 0 Debt<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovatus Loan Agreement</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2024 (the “Closing Date”), we entered into a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">five</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-year term loan and security agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP (“Innovatus”), an affiliate of Innovatus Capital Partners, LLC, for an aggregate principal amount of up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and with a maturity date of February 13, 2029 (the “Innovatus Loan”). The Innovatus Loan consists of two tranches, of which the first tranche of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was funded on February 13, 2024. We will be eligible to draw down the second tranche of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon achievement of certain milestones including pre-specified revenue thresholds. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The floating per annum interest rate of the Innovatus Loan is equal to </span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sum of (a) the greater of (i) prime rate published in the Money Rates section of the Wall Street Journal and (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-770">7.50</span>%</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, plus (b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-771">3.25</span>%; provided that, at the election of the Company, up to 2.0% of such rate shall be payable in-kind until the third anniversary of the closing date. The Company is required to make monthly interest-only payments through February 1, 2027, after which the Company is required to make monthly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. 2.0% of the interest is payable in-kind for the first three years of the term by increasing the principal balance. Prepayments of the loan, in whole or in part, will be subject to an early prepayment fee which ranges between 3.0% and 1.0% and declines each year until the third anniversary date of the Closing Date, after which no prepayment fee is required. The Company is also required to pay an exit fee upon any payment or prepayment equal to 3.0% of the aggregate principal amount of the tranches funded under the Innovatus Loan.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Innovatus Loan contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and net product revenue, with the latter beginning with the period ended September 30, 2024. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Innovatus Loan is secured by perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company's intellectual property.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Innovatus Loan, we recorded a debt discount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and capitalized debt issuance costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.6 million</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The discount and issuance costs will be amortized over the life of the Innovatus Loan. Interest expense for the Innovatus Loan for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2024</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 million and $2.5 million respectively,</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is inclusive of non-cash amortization of the debt discount, debt issuance costs, payable in-kind interest, and accretion of final payment. The carrying amount of the Innovatus Loan approximates fair value given its recent issuance and the interest rate is based on the current prime rate. The effective interest rate for the Innovatus Loan was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5%</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with entering into the Innovatus Loan, we entered into a Warrant Agreement with Innovatus on February 13, 2024 and issued to Innovatus a warrant to purchase an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424,028</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of the Company’s common stock at an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.83</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share. The warrants may be exercised on a cashless basis, and are immediately exercisable through the 10th anniversary of the issuance date. At the time of issuance, the Company determined the estimated fair value of the warrants of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9 million</span><span style="background-color:#ffffff;color:#1e1d1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using the Black-Scholes model. As the warrants represent a freestanding equity instrument, the Company recorded the fair value of the warrants in additional paid-in capital during the first quarter of 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the amortization of the debt discount and issuance costs utilizing the effective interest method. Long-term debt consisted of the following at September 30, 2024 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: payment in-kind interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: amortized exit fee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments under the Innovatus Loan are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: amortized exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: uncapitalized payment in-kind interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P5Y 40000000.0 2 30000000.0 10000000.0 0.0750 0.0325 0.020 0.020 P3Y 0.030 0.010 0.030 1300000 600000 1000000.0 2500000 0.135 424028 2.83 900000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the amortization of the debt discount and issuance costs utilizing the effective interest method. Long-term debt consisted of the following at September 30, 2024 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: payment in-kind interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: amortized exit fee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30000000 332000 87000 1208000 580000 28631000 <div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments under the Innovatus Loan are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: amortized exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: uncapitalized payment in-kind interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 13264000 15917000 2653000 31834000 87000 1502000 1208000 580000 28631000 Segment, Geographical and Other Revenue Information<div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our CEO, our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocated resources based on the consolidated results of operations. We believe that these changes better align internal resources and external go to market activities in order to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December 31, 2023. Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the restructuring of our business, the Company determined that a triggering event had occurred that required an interim goodwill impairment test during the third quarter of 2023. The fair value estimate used in the interim goodwill impairment test was primarily based on Level 3 inputs in the fair value hierarchy. Based on the results of the impairment evaluation, the Company determined that the goodwill within the Novel Biotherapeutics reporting unit was impaired, which resulted in a non-cash impairment charge of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to write off all of the associated goodwill. The impairment charge is recorded within asset impairment and other charges in the condensed consolidated statements of operation for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that each accounted for 10% or more of our total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Total Revenues for the</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer F</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer G</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer H</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">* Percentage was less than 10%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Accounts Receivables as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer I</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer J</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">* Percentage was less than 10% </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable long-lived assets by location was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> <div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our CEO, our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocated resources based on the consolidated results of operations. We believe that these changes better align internal resources and external go to market activities in order to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December 31, 2023. Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.</span></div> 2 1 2 800000 800000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that each accounted for 10% or more of our total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Total Revenues for the</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer E</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer F</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer G</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer H</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">* Percentage was less than 10%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Accounts Receivables as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer I</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer J</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">* Percentage was less than 10% </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div> 0.18 0.17 0.10 0.17 0.10 0.11 0.11 0.15 0.20 0.16 0.10 0.12 0.21 0.12 0.15 0.13 0.15 0.12 0.21 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable long-lived assets by location was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 24277000 28624000 false false false false